0001293971-24-00004010-Q bluebird bio, Inc. 20240913202409131637131637141637140 0001293971-24-000040 10-Q 82 20240331 20240913 20240913 bluebird bio, Inc. 0001293971 2836 000000000 DE 1231 10-Q 34 001-35966 241298281 455 GRAND UNION BOULEVARD SOMERVILLE MA 02145 339-499-9300 455 GRAND UNION BOULEVARD SOMERVILLE MA 02145 Genetix Pharmaceuticals Inc 20040616 10-Q 1 blue-20240331.htm 10-Q blue-
20240331false2024Q1000129397112/31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesblue:trancheblue:segmentxbrli:pureblue:room00012939712024-01-012024-03-3100012939712024-09-1100012939712024-03-3100012939712023-12-3100012939712023-01-012023-03-310001293971us-gaap:CommonStockMember2023-12-310001293971us-gaap:AdditionalPaidInCapitalMember2023-12-31000129397 1us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001293971us-gaap:RetainedEarningsMember2023-12-310001293971us-gaap:CommonStockMember2024-01-012024-03-310001293971us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001293971us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001293971us-gaap:RetainedEarningsMember2024-01-012024-03-310001293971us-gaap:CommonStockMember2024-03-310001293971us-gaap:AdditionalPaidInCapitalMember2024-03-310001293971us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001293971us-gaap:RetainedEarningsMember2024-03-310001293971us-gaap:CommonStockMember2022-12-310001293971us-gaap:AdditionalPaidInCapitalMember2022-12-310001293971us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001293971us-gaap:RetainedEarningsMember2022-12-3100012939712022-12-310001293971us-gaap:CommonStockMember2023-01-012023-03-310001293971us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001293971us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001293971us-gaap:RetainedEarningsMember2023-01-012023-03-310001293971us-gaap:CommonStockMember2023-03-310001293971us-gaap:AdditionalPaidInCapitalMember2023-03-310001293971us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001293971us-gaap:RetainedEarningsMember2023-03-3100012939712023-03-310001293971us-gaap:PrivatePlacementMember2024-01-012024-03-310001293971us-gaap:PrivatePlacementMember2023-01-012023-03-310001293971blue:PublicOfferingMember2024-01-012024-03-310001293971blue:PublicOfferingMember2023-01-012023-03-310001293971blue:AtTheMarketOfferingMember2023-08-012023-08-310001293971blue:AtTheMarketOfferingMember2024-01-012024-03-310001293971blue:DecemberUnderwritingAgreementMember2023-12-012023-12-310001293971blue:TermLoanMember2024-03-012024-03-310001293971blue:TermLoanMember2024-03-310001293971blue:ZYNTEGLOMember2024-01-012024-03-310001293971blue:ZYNTEGLOMember2023-01-012023-03-310001293971blue:SKYSONAMember2024-01-012024-03-310001293971blue:SKYSONAMember2023-01-012023-03-310001293971us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberblue:SixIndividualCustomersMember2024-01-012024-03-310001293971us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberblue:OneIndividualCustomerMember2023-01-012023-03-310001293971us-gaap:FairValueMeasurementsRecurringMember2024-03-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-03-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-03-310001293971us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-03-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-03-310001293971us-gaap:FairValueMeasurementsRecurringMember2023-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310001293971us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310001293971blue:BeneficialInterestMember2023-12-310001293971blue:BeneficialInterestMember2024-01-012024-03-310001293971blue:BeneficialInterestMember2024-03-310001293971us-gaap:SecuredDebtMemberblue:TermLoanFacilityMemberus-gaap:LineOfCreditMember2024-03-150001293971us-gaap:SecuredDebtMemberblue:TermLoanFacilityMemberus-gaap:LineOfCreditMember2024-03-152024-03-150001293971us-gaap:SecuredDebtMemberblue:TermLoanFacilityTrancheThreeMemberus-gaap:LineOfCreditMember2024-03-150001293971us-gaap:SecuredDebtMemberblue:TermLoanFacilityTrancheTwoMemberus-gaap:LineOfCreditMember2024-03-150001293971us-gaap:SecuredDebtMemberblue:TermLoanFacilityTrancheFourMemberus-gaap:LineOfCreditMember2024-03-150001293971us-gaap:SecuredDebtMemberblue:TermLoanFacilityMemberus-gaap:PrimeRateMemberus-gaap:LineOfCreditMember2024-03-152024-03-150001293971us-gaap:SecuredDebtMemberblue:TermLoanFacilityMemberblue:PrimeFloorRateMemberus-gaap:LineOfCreditMember2024-03-152024-03-150001293971us-gaap:SecuredDebtMemberblue:TermLoanFacilityMemberblue:PaidInKindMemberus-gaap:LineOfCreditMember2024-03-150001293971us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2024-03-150001293971us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2024-03-152024-03-150001293971blue:TheWarrantsMember2024-03-150001293971blue:TheWarrantsMember2024-03-310001293971blue:TheWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2024-03-150001293971blue:TheWarrantsMemberus-gaap:MeasurementInputOptionVolatilityMember2024-03-150001293971blue:TheWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-03-150001293971blue:DrugProductManufacturingFacilityMember2024-01-012024-03-310001293971blue:DrugSubstanceManufacturingFacilityMember2024-01-012024-03-310001293971blue:QualityTestingFacilityMember2024-01-310001293971blue:JanuaryUnderwritingAgreementMember2023-01-182023-01-180001293971blue:JanuaryUnderwritingAgreementMember2023-01-180001293971us-gaap:OverAllotmentOptionMember2023-01-182023-01-180001293971blue:JanuaryUnderwritingAgreementMember2023-01-232023-01-230001293971blue:DecemberUnderwritingAgreementMember2023-12-192023-12-190001293971blue:DecemberUnderwritingAgreementMember2023-12-190001293971us-gaap:OverAllotmentOptionMember2023-12-192023-12-190001293971blue:DecemberUnderwritingAgreementMember2023-12-222023-12-220001293971blue:A2023IncentiveAwardPlanMember2024-03-310001293971blue:EmployeeAndNonEmployeeStockOptionMember2024-01-012024-03-310001293971blue:EmployeeAndNonEmployeeStockOptionMember2023-01-012023-03-310001293971us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001293971us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001293971blue:EmployeeStockPurchasePlanAndOtherMember2024-01-012024-03-310001293971blue:EmployeeStockPurchasePlanAndOtherMember2023-01-012023-03-310001293971us-gaap:CostOfSalesMember2024-01-012024-03-310001293971us-gaap:CostOfSalesMember2023-01-012023-03-310001293971us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001293971us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001293971us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001293971us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001293971us-gaap:RestrictedStockUnitsRSUMember2023-12-310001293971us-gaap:RestrictedStockUnitsRSUMember2024-03-310001293971blue:EmployeeStockPurchasePlanAndOtherMember2013-06-300001293971blue:EmployeeStockPurchasePlanAndOtherMember2021-06-300001293971srt:MaximumMemberblue:EmployeeStockPurchasePlanAndOtherMember2023-01-012023-03-310001293971us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001293971us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001293971us-gaap:WarrantMember2024-01-012024-03-310001293971blue:EmployeeStockPurchasePlanAndOtherMember2024-01-012024-03-310001293971srt:ScenarioPreviouslyReportedMember2023-01-012023-03-310001293971srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberblue:ErrorCorrectionEmbeddedLeasesMember2023-01-012023-03-310001293971srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:ErrorCorrectionOtherMember2023-01-012023-03-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:CommonStockMember2022-12-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:AdditionalPaidInCapitalMember2022-12-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2022-12-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:CommonStockMember2023-01-012023-03-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2023-01-012023-03-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:CommonStockMember2023-03-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:AdditionalPaidInCapitalMember2023-03-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2023-03-310001293971srt:ScenarioPreviouslyReportedMember2023-03-310001293971blue:ErrorCorrectionEmbeddedLeasesMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:CommonStockMember2022-12-310001293971blue:ErrorCorrectionEmbeddedLeasesMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2022-12-310001293971blue:ErrorCorrectionEmbeddedLeasesMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001293971blue:ErrorCorrectionEmbeddedLeasesMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:RetainedEarningsMember2022-12-310001293971srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberblue:ErrorCorrectionEmbeddedLeasesMember2022-12-310001293971blue:ErrorCorrectionEmbeddedLeasesMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:RetainedEarningsMember2023-01-012023-03-310001293971blue:ErrorCorrectionEmbeddedLeasesMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:CommonStockMember2023-03-310001293971blue:ErrorCorrectionEmbeddedLeasesMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2023-03-310001293971blue:ErrorCorrectionEmbeddedLeasesMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001293971blue:ErrorCorrectionEmbeddedLeasesMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:RetainedEarningsMember2023-03-310001293971srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberblue:ErrorCorrectionEmbeddedLeasesMember2023-03-310001293971us-gaap:ErrorCorrectionOtherMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:CommonStockMember2022-12-310001293971us-gaap:ErrorCorrectionOtherMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2022-12-310001293971us-gaap:ErrorCorrectionOtherMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001293971us-gaap:ErrorCorrectionOtherMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:RetainedEarningsMember2022-12-310001293971srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:ErrorCorrectionOtherMember2022-12-310001293971us-gaap:ErrorCorrectionOtherMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:RetainedEarningsMember2023-01-012023-03-310001293971us-gaap:ErrorCorrectionOtherMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:CommonStockMember2023-03-310001293971us-gaap:ErrorCorrectionOtherMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2023-03-310001293971us-gaap:ErrorCorrectionOtherMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001293971us-gaap:ErrorCorrectionOtherMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:RetainedEarningsMember2023-03-310001293971srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:ErrorCorrectionOtherMember2023-03-310001293971srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberblue:ErrorCorrectionLeasesMember2023-01-012023-03-310001293971srt:ScenarioPreviouslyReportedMemberus-gaap:PrivatePlacementMember2023-01-012023-03-310001293971blue:ErrorCorrectionEmbeddedLeasesMemberus-gaap:PrivatePlacementMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2023-01-012023-03-310001293971us-gaap:ErrorCorrectionOtherMemberus-gaap:PrivatePlacementMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2023-01-012023-03-310001293971srt:ScenarioPreviouslyReportedMemberblue:PublicOfferingMember2023-01-012023-03-310001293971blue:ErrorCorrectionEmbeddedLeasesMemberblue:PublicOfferingMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2023-01-012023-03-310001293971us-gaap:ErrorCorrectionOtherMemberblue:PublicOfferingMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2023-01-012023-03-310001293971blue:DebtInstrumentAvailabilityTrancheTwoMemberus-gaap:SecuredDebtMemberblue:TermLoanFacilityMemberus-gaap:LineOfCreditMember2024-03-150001293971blue:DebtInstrumentAvailabilityTrancheThreeMemberus-gaap:SecuredDebtMemberblue:TermLoanFacilityMemberus-gaap:LineOfCreditMember2024-03-150001293971blue:DebtInstrumentAvailabilityTrancheFourMemberus-gaap:SecuredDebtMemberblue:TermLoanFacilityMemberus-gaap:LineOfCreditMember2024-03-150001293971us-gaap:SubsequentEventMemberus-gaap:SecuredDebtMemberblue:TermLoanFacilityTrancheTwoMemberus-gaap:LineOfCreditMember2024-08-130001293971us-gaap:SubsequentEventMemberus-gaap:SecuredDebtMemberblue:TermLoanFacilityTrancheTwoMemberus-gaap:LineOfCreditMember2024-08-132024-08-130001293971us-gaap:SubsequentEventMemberus-gaap:SecuredDebtMemberblue:TermLoanFacilityTrancheThreeMemberus-gaap:LineOfCreditMember2024-08-130001293971us-gaap:SubsequentEventMemberblue:TermLoanFacilityTrancheThreeMemberus-gaap:LineOfCreditMemberblue:ProceedsReceivedDecember202024Memberus-gaap:SecuredDebtMember2024-08-132024-08-130001293971us-gaap:SubsequentEventMemberblue:TermLoanFacilityTrancheThreeMemberus-gaap:LineOfCreditMemberblue:ProceedsReceivedJune302025Memberus-gaap:SecuredDebtMember2024-08-132024-08-130001293971us-gaap:SubsequentEventMemberus-gaap:SecuredDebtMemberblue:TermLoanFacilityTrancheThreeMemberus-gaap:LineOfCreditMember2024-08-132024-08-130001293971us-gaap:SubsequentEventMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2024-08-130001293971blue:TheWarrantsMemberus-gaap:SubsequentEventMember2024-08-132024-08-130001293971blue:TheWarrantsMemberus-gaap:SubsequentEventMember2024-08-13

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, DC 20549

FORMÂ 10-Q

(Mark One)â˜’QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2024ORâ˜TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromÂ Â

toÂ Â Â Â

equivalents$212,047Â $239,045Â Restricted cash included in other current assets3,866Â 1,417Â 5Table of ContentsRestricted cash included in restricted cash and other non-current assets47,998Â 43,937Â Total cash, cash equivalents and restricted cash$263,911Â $284,399Â Supplemental cash flow disclosures from investing and financing activities:Purchases of property, plant and equipment included in accounts payable and accrued expensesâ€”Â 189Â Offering expenses included in accounts payable and accrued expensesâ€”Â 523Â Priority review voucher expenses accrued or in accounts payableâ€”Â 43Â Right-of-use assets obtained in exchange for financial lease liabilities38,669Â (214)Beneficiary interest obtained in transferred invoices1,680Â â€”Â Derecognition of due to factor liabilities15,120Â â€”Â Cash paid during the period for income taxes1Â 2Â See accompanying notes to unaudited condensed consolidated financial statements.6Table of Contentsbluebird bio, Inc.Notes to Condensed Consolidated Financial Statements(unaudited)1. Description of the businessbluebird bio, Inc. (the â€œCompanyâ€ or â€œbluebirdâ€) was incorporated in Delaware on AprilÂ 16, 1992, and is headquartered in Somerville, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, and commercialization of its approved products, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates, provide selling, general and administrative support for these operations and market and commercially manufacture and distribute its approved products.The Companyâ€™s programs in severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel) as a treatment for Î²-thalassemia; LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel) as a treatment for sickle cell disease ("SCD"); and SKYSONA (elivaldogene autotemcel, also known as eli-cel) as a treatment for cerebral adrenoleukodystrophy ("CALD"). On August 17, 2022, ZYNTEGLO was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adult and pediatric patients with ÃŸ-thalassemia who require regular red blood cell transfusions. On September 16, 2022, the FDA granted Accelerated Approval of SKYSONA to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active CALD. On December 8, 2023, LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease and with a history of vaso-occlusive-events. In August 2023, the Company entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Companyâ€™s common stock up to $125.0Â million, from time to time, through an â€œat the marketâ€ equity offering program under which Jefferies will act as sales agent. As of March 31, 2024, the Company has made no sales pursuant to the Sales Agreement.In December 2023, the Company entered into an underwriting agreement (the â€œUnderwriting Agreementâ€) with Goldman Sachs & Co. LLC ("Goldman") and J.P. Morgan Securities LLC, to sell 83.3 million shares of the Company's common stock. The Company received net proceeds of approximately $118.1Â million. In March 2024, the Company entered into a five-year term loan facility agreement with Hercules Capital, Inc. to secure debt financing for up to $175Â million, available in four tranches. This is described in Note 8, Term Loan Debt, in the Notes to Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q.Since its inception, the Company has incurred significant operating losses and negative operating cash flows. As of March 31, 2024, the Company had an accumulated deficit of $4.3Â billion. During the three months ended March 31, 2024, the Company incurred a net loss of $69.8 million and used $74.7 million of cash in operations. As of March 31, 2024, the Company had cash and cash equivalents of $212.0 million. In accordance with Accounting Standards Codification (â€œASCâ€) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date the financial statements are issued.This evaluation initially does not take into consideration the potential mitigating effect of managementâ€™s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Companyâ€™s ability to continue as a going concern. The mitigating effect of managementâ€™s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entityâ€™s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.The Company's history of recurring operating losses and negative operating cash flows, its expectation to generate operating losses and negative operating cash flows, and the need for additional funding to support its planned operations raise substantial doubt regarding the Companyâ€™s ability to continue as a going concern for a period of one year after the date that these consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include controlling spending, executing on commercial launch plans, and exploring additional financing options. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that 7Table of Contentssubstantial doubt exists about the Companyâ€™s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements. The Company has based the estimated cash needs on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects. Along with the Company's revenue from product sales, the Company expects to finance its future cash needs through the issuance of equity, or debt, or other alternative means. If the Company is unable to obtain funding on a timely basis, or if revenues from product sales are less than it has projected, the Company may be required to further revise its business plan and strategy, which may result in the Company significantly curtailing, delaying or discontinuing one or more of its research or development programs or the commercialization of any products or may result in the Company being unable to expand its operations or otherwise capitalize on its business opportunities. As a result, the Company's business, financial condition and results of operations could be materially affected. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.2. Basis of presentation, principles of consolidation and significant accounting policiesBasis of presentationThe accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the Accounting Standard Codification (â€œASCâ€) and Accounting Standards Updates (â€œASUsâ€) of the Financial Accounting Standards Board (â€œFASBâ€). Certain information and footnote disclosures normally included in the Companyâ€™s annual financial statements have been condensed or omitted. These condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Companyâ€™s financial position and results of operations for the interim periods ended MarchÂ 31, 2024 and 2023.The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended DecemberÂ 31, 2023, and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023, filed with the Securities and Exchange Commission (the â€œSECâ€) on SeptemberÂ 13, 2024 (the "2023 Annual Report on Form 10-K").Amounts reported are computed based on thousands, except percentages, per share amounts, or as otherwise noted.Â As a result, certain totals may not sum due to rounding.The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company views its operations and manages its business in one operating segment.Restatement of Previously Issued Financial StatementsAs previously disclosed in the Company's 2023 Annual Report Form 10-K filed with the SEC on SeptemberÂ 13, 2024, the Company is restating its previously issued unaudited condensed consolidated financial information for the first quarter ended March 31, 2023 due to multiple prior period misstatements. The accompanying condensed consolidated financial information as of and for the quarter ended March 31, 2023 have been restated in this Quarterly Report on Form 10-Q (see Note 15: Restatement of Previously Issued Financial Statements). In addition, the Company has corrected the accompanying footnotes in connection with the restatement.Significant accounting policiesThe significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended MarchÂ 31, 2024 are consistent with those discussed in Note 3 to the consolidated financial statements included in the Companyâ€™s 2023 Annual Report on Form 10-K.8Table of ContentsReclassification of Prior Year PresentationCertain prior year amounts have been reclassified to conform to the current year presentation. Specifically, interest expense has been reclassified from interest income to interest expense in the consolidated statement of operations and comprehensive (loss) income. These reclassifications had no effect on the reported results of operations.Use of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates and judgments are used in the following areas, among others: the alternative future use of assets used in research and development activities, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, gross-to-net revenue calculations, stock-based compensation expense, accrued expenses, income taxes, the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements, and the assessment of the likelihood and magnitude of losses that may be sustained upon resolution of contingencies.InventoryInventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Companyâ€™s consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used to produce clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product. Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product which has been produced for the treatment of specific patients, that are owned by the Company until infusion. Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on-hand and firm purchase commitments as well as remaining shelf life of on-hand inventories. The Company writes down its inventory that is in excess, obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue in the Companyâ€™s consolidated statements of operations and comprehensive loss.Revenue recognitionUnder ASC Topic 606, Revenue from Contracts with Customers (â€œTopic 606â€), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.9Table of ContentsOnce a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customerâ€™s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.Â The Company assesses whether each promised good or service is distinct to identify the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)Â the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entityâ€™s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).Â Â The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (â€œSSPâ€) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the adjustment period.In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed each of its revenue generating arrangements to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.Product revenue In 2022, the Company received approval of ZYNTEGLO and SKYSONA from the FDA. In 2023, the Company received approval of LYFGENIA from the FDA. The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. The Company uses Specialty Distributors ("SD") and Specialty Pharmacies ("SP") to deliver product to the Qualified Treatment Centers ("QTC"). Revenue is only recognized when the performance obligation is satisfied. The Company recognizes revenue upon infusion to the patient. To determine whether a significant reversal will occur in future periods, the Company will assess both the likelihood and magnitude of any such potential reversal of revenue. Gross product revenue is reduced by outcomes-based rebates, other rebates and distributor fees.Rebates expenseRebates are based on contractual arrangements or statutory requirements and include amounts due to Medicaid agencies and third-party payers. These amounts may vary by product and payer. Rebates are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. The Company assesses and updates estimates each reporting period to reflect actual claims and other current information. Rebates that

are payable to Medicaid agencies and third-party payers are recorded in accrued expenses and other current liabilities on the Company's consolidated balance sheets. 10Table of ContentsDistributor fees The Company pays distribution fees to SDs and SPs in connection with the sales of our product. These distributor fees are based on a contractually determined fixed percentage of sales. Other revenue In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, Revenue Recognition Not-for-Profit Entities, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In 2023, the Company ceased further research work and is in the process of winding down such collaboration.Recent accounting pronouncementsIn November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 â€“ Segment Reporting. This update is effective beginning with the Companyâ€™s 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Companyâ€™s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact to its income tax disclosures. In March 2024, the FASB issued ASU 2024-01, Compensation-Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards. This update clarifies the scope of "Profit Interest" and similar awards and adds an illustrative example to the existing ASC 718 standard that includes four fact patterns to demonstrate how an entity should apply the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic 718. The amendments in this ASU are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for interim and annual financial statements not yet issued or made available for issuance. The amendments in this ASU should be applied either (1) retrospectively to all prior periods presented in the financial statements or (2) prospectively to profits interest and similar awards granted or modified on or after the date at which the entity first applies the amendments. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures.In March 2024, the FASB issued ASU 2024-02 "Codification Improvementsâ€”Amendments to Remove References to the Concepts Statements", which removes various references to concepts statements from the FASB Accounting Standards Codification. This ASU is effective for the Company beginning in the first quarter of fiscal year 2026, with early adoption permitted. The Company expects the new guidance will have an immaterial impact on its consolidated financial statements and intends to adopt the guidance when it becomes effective in the first quarter of fiscal year 2026.11Table of Contents3. Product revenue and reservesFor the three months ended MarchÂ 31, 2024 and 2023, the Company recorded $18.6Â million and $2.3Â million, respectively, of product revenue. Product revenue by therapy represents: For the three months ended March 31,20242023ZYNTEGLO$18,561Â $â€”Â SKYSONAâ€”Â 2,296Â Total product revenue, net$18,561Â $2,296Â Six individual customers accounted for 100% of product revenue for the three months ended MarchÂ 31, 2024 and one individual customer accounted for 100% of product revenue for the three months ended MarchÂ 31, 2023. The Company considers there to be revenue concentration risks for customers that represent product revenues that exceed 10% of total product revenue. The concentration of the Companyâ€™s product revenue within a particular customer may have a material adverse effect on the Companyâ€™s revenue and results of operations if sales with the respective customer experience difficulties. All product revenue during the three months ended MarchÂ 31, 2024 and 2023 were within the United States.The following table summarizes an analysis of the change in reserves for gross to net deductions for the periods indicated: TotalBalance at December 31, 2023$5,365Â Provision for rebates3,780Â Payments/creditsâ€”Â Balance at March 31, 2024$9,145Â 4. Fair value measurementsThe following table sets forth the Companyâ€™s assets and liabilities that are measured at fair value on a recurring basis as of MarchÂ 31, 2024 and DecemberÂ 31, 2023 (in thousands):DescriptionTotalQuotedprices inactivemarkets(Level 1)Significantotherobservableinputs(Level 2)Significantunobservableinputs(Level 3)March 31, 2024Assets:Cash and cash equivalents$212,047Â $212,047Â $â€”Â $â€”Â Marketable securities:U.S. government agency securities and treasuriesâ€”Â â€”Â â€”Â â€”Â Due from factor:Beneficiary interest in factored invoices1,120Â â€”Â â€”Â 1,120Â Total$213,167Â $212,047Â $â€”Â $1,120Â December 31, 2023Assets:Cash and cash equivalents$221,755Â $221,755Â $â€”Â $â€”Â Marketable securities:U.S. government agency securities and treasuriesâ€”Â â€”Â â€”Â â€”Â Receivables and other current assets:Beneficiary interest in factored invoices560Â â€”Â â€”Â 560Â Total$222,315Â $221,755Â $â€”Â $560Â 12Table of ContentsCash and cash equivalentsThe Company considers all highly liquid securities with original final maturities of 90 days or less from the date of purchase to be cash equivalents. As of MarchÂ 31, 2024 and DecemberÂ 31, 2023, cash and cash equivalents comprise funds in cash and money market accounts held at multiple banking and asset management institutions.Marketable securitiesMarketable securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities and treasuries, corporate bonds, and commercial paper. The Company estimates the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts. At MarchÂ 31, 2024 and DecemberÂ 31, 2023, the balance in the Companyâ€™s accumulated other comprehensive loss was composed primarily of activity related to the Companyâ€™s available-for-sale debt securities. There were no and $0.1 million of realized losses recognized on the sale or maturity of available-for-sale debt securities during the three months ended MarchÂ 31, 2024 and 2023, respectively.Accrued interest receivable on the Company's available-for-sale debt securities totaled $0.3 million and $0.3Â million as of MarchÂ 31, 2024 and DecemberÂ 31, 2023, respectively. No accrued interest receivable was written off during the three months ended MarchÂ 31, 2024 or 2023.Factoring agreementDue from factor classified as Level 3 within the valuation hierarchy consists of beneficiary interest in transferred invoices. The Company estimates the fair value of the beneficiary interest based on the estimated cash flows after applying counterparty and credit risk adjustments associated with the factoring agent and distributors, respectively. As of MarchÂ 31, 2024, no adjustment to the beneficiary interest in invoices sold was deemed an unobservable input and was determined based from ongoing credit evaluations and historical experience with aging of such invoices, among other factors. A significant change to this input could result in a significantly lower or higher fair value measurement.The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the three months ended MarchÂ 31, 2024: For the three months endedMarch 31,2024Level 3 financial assets, beginning of period$560Â Beneficiary interest obtained in transferred invoices1,680Â Proceeds from previously transferred invoices(1,120)Level 3 financial assets, end of period$1,120Â 13Table of Contents5. InventoryInventory, net, consists of the following (in thousands):As of March 31, 2024As of December 31, 2023Raw materials$3,177Â $2,329Â Work in progress22,146Â 17,375Â Finished goods4,982Â 3,215Â Inventory$30,305Â $22,919Â Raw materials inventory consists of completed materials purchased directly from third party suppliers. Work in progress inventory consists of materials manufactured at contract manufacturing organizations ("CMOs") that are either partially completed, fully manufactured but are pending quality acceptance, or completed meeting quality acceptance standards to be used in the manufacture of drug product and drug products that are either partially completed or fully manufactured but are pending quality acceptance. Finished goods are completed and quality approved drug products that are either awaiting shipment, in-transit or delivered to a qualified treatment center, but have not yet been infused in a patient. 6. Factoring agreementThe company sells rights to future revenues associated with invoices issued upon delivery of drug product to QTCs. The upfront payments are treated as a short-term liability, presented as due to factor on our consolidated balance sheets until the right to consideration from the customer is deemed unconditional. The remaining invoice amount payable to the Company at infusion is considered a beneficial interest in the factored invoice and represents the extent of our continued involvement in the sale of invoices.Due to FactorFor the three months ending MarchÂ 31, 2024, the Company collected $15.1Â million in cash receipts prior to an unconditional right to consideration and derecognized $15.1Â million of due to factor amounts as a result of patient drug product infusions. Amounts presented as due to factor on the consolidated balance sheets would be subject to payment based on the repurchase requirements that exist prior to the infusion date in the factoring agreement. Due from FactorFor the three months ending MarchÂ 31, 2024, the company obtained $1.6Â million of beneficiary interest in invoices and collected $1.1Â million in cash receipts. Uncollected amounts presented as due from factor on the consolidated balance sheets are net of accrued fees of $0.1Â million. The maximum loss exposure is $1.1Â million at MarchÂ 31, 2024. The total loss from the sale of customer invoices is estimated on the patient infusion date of the drug product and was $0.3Â million for the three months ending MarchÂ 31, 2024. In addition to the loss from the sale of invoices the Company has incurred $0.4Â million in servicing fees. 7. Accrued expenses and other current liabilitiesAccrued expenses and other current liabilities consist of the following (in thousands):As of March 31, 2024As of December 31, 2023Accrued CMO and CRO costs$22,481Â $24,824Â Accrued employee compensation10,876Â 19,972Â Accrued goods and services5,453Â 8,391Â Accrued rebates9,194Â 5,365Â Accrued professional fees7,090Â 2,531Â Accrued refund liabilityâ€”Â 5,600Â Other9,002Â 6,505Â Total accrued expenses and other current liabilities$64,096Â $73,188Â 14Table of Contents8. Term loan debt2024 Term LoanOn March 15, 2024 (the â€œEffective Dateâ€), the Company entered into a Loan and Security Agreement (the â€œLSAâ€) and a Warrant Agreement (the â€œWarrant Agreementâ€) with Hercules Capital and funds managed by Hercules Capital (collectively, â€œHerculesâ€ or â€œthe lendersâ€). Under the terms of the LSA, the Company may borrow up to an aggregate principal amount of $175.0Â million over the term of the agreement, in four separate tranches (the â€œTerm Loansâ€) dependent on the achievement of certain milestones. On the Effective Date, the Company drew down the initial $75.0Â million of gross proceeds (â€œInitial Loanâ€), and paid initial debt issuance costs of $3.5Â million, inclusive of legal fees of approximately $2.7Â million and the original issuance discount (â€œOIDâ€) of $0.8Â million, or 1% of the drawn amount, in accordance with the terms of the LSA. Additional amounts are available to borrow in two separate $25.0Â million tranches based on the Company meeting certain pre-defined milestone achievements associated with cell collection from LYFGENIA patients (35 patients on or before September 30, 2024 or 55 patients on or before December 31, 2024) (â€œTranche 2â€) and compliance with a gross profit metric (no later than the period ending June 30, 2025) (â€œTranche 3â€). Additionally, the Company may request up to an additional $50.0Â million through December 15, 2026 from Hercules (â€œTranche 4â€). The lenders have no obligation to fund any amounts under Tranche 4 as funding is conditioned on approval by the lendersâ€™ investment committee.The Term Loans bear both cash interest and paid-in-kind interest (â€œPIKâ€). The cash interest is due on the first business day of each month (â€œPayment Dateâ€) and will be equal to the WSJ prime rate (â€œprime rateâ€) plus 1.45% (floored at 9.95%). The PIK interest is fixed at 2.45% and is to be capitalized and added to the outstanding principal on each Payment Date. Unless prepaid by the Company at their discretion, subject to certain prepayment penalties and conditions, the Term Loans are repayable in monthly interest-only payments until April 1, 2027, or April 1, 2028, if the Company has achieved, no later than December 31, 2026, certain financial metrics (the â€œPerformance Milestoneâ€). After the expiration of the interest-only payment period, the Term Loans are repayable in equal monthly payments of principal and accrued interest until maturity. The Term Loans will mature on April 1, 2029.The 2024 Term Loan is collateralized by substantially all the Companyâ€™s assets. In addition to other covenants, the 2024 Term Loan contains affirmative covenants as well as certain financial covenants, including a minimum cash coverage requirement of 40% of the outstanding principal of the term loan and a minimum net product revenue requirement that commences with the quarter ending September 30, 2024. The Company was in compliance with the minimum cash coverage covenant as of March 31, 2024, but the Company projects that it will not maintain its minimum cash coverage requirement within the next 12 months (see the Company's going concern assessment in Note 1, Description of the business). As such, the term loan is presented as a current liability as of March 31, 2024. The Company also issued warrants under the Warrant Agreement for the right to purchase shares of the Companyâ€™s common stock to Hercules, with the number of shares to be based on the amounts borrowed under the LSA (the â€œWarrantsâ€). The Warrants are exercisable for a number of shares of common stock equal to the quotient of (i.) 5% times the aggregate original principal of amounts drawn under the LSA divided by (ii.) the exercise price of $1.45 per share. As of March 31, 2024, the Company had issued 2.6Â million warrants associated with the Initial Loan (â€œInitial Warrantsâ€) to purchase common stock at an exercise price of $1.45 per share and a contractual life of 7 years from the Effective Date. The Warrants have been recorded at their relative fair value using the Black-Scholes option-pricing model and the following assumptions: no dividend yield, expected volatility of 81.1%, risk free rate of 4.3%, and expected term of 7 years, equal to the life of the warrant. The relative fair value allocated to the initial warrants was $2.7Â million, which was classified as additional-paid-in-capital and recorded as a debt discount which will be amortized, together with debt issuance costs, to interest expense using the effective interest method over the life of the loan at an effective interest rate of 15.7%. For the period ended March 31, 2024, the Company recorded approximately $0.5Â million in interest expense associated with the Term Loans, inclusive of amounts related to the Warrants.Refer to Note 16, Subsequent Events, for further discussion on the amendments to the LSA and the Warrant Agreement subsequent to the three months ended March 31, 2024.9. LeasesThe Company leases certain office and laboratory space, primarily located in Somerville, Massachusetts.Â Additionally, the Company has embedded leases through its agreements with CMOs and a contract testing organization ("CTO") in both the United States and internationally. Except as described below, there have been no material changes in lease obligations from those disclosed in Note 11 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K.15Table of ContentsEmbedded leasesPeriodically, throughout the three months ended March 31, 2024, the Company amended several of its embedded contract manufacturing leases, some of which were accounted for as lease modifications under ASC 842. The lease modifications primarily relate to the execution of new statements of work with the vendors or the extension of contractual terms.As it relates to embedded leases related to drug product manufacturing and quality testing, the Company increased its finance lease right-of-use assets in the amount of $28.3 million.As it relates to embedded leases related to drug substance manufacturing, the Company decreased its finance lease right-of-use assets in the amount of $3.8 million.The following paragraphs describe the significant lease modifications to the Companyâ€™s embedded contract manufacturing leases.Embedded Leases â€“ Drug Substance ManufacturingIn March 2024, the Company extended its embedded lease for the manufacturing of vector and is obligated under the defined production schedule through May 2024.Embedded Leases â€“ Drug Product ManufacturingIn January 2024, the Company amended its lease agreement with a CMO to expand into two additional controlled environment rooms, both designated for the Company's exclusive use during the term of the agreement. Pursuant to the amended agreement, the Company is obligated to pay a monthly fixed fee for each additional space in addition to fees based on committed production levels through the remaining lease term, which ends in February 2025. The fixed portion of the fee is included as part of the Companyâ€™s lease liability.Embedded Leases â€“ Quality TestingIn January 2024, the Company entered into a Reserved Capacity Agreement with a CTO that provides clinical development services. The Reserved Capacity Agreement amended the Companyâ€™s existing master contract services agreement with the CTO and provides for legally binding minimum purchase commitments with step decreases throughout its three-year contract term in six-month increments. The Company included the â€œfirmâ€ legally binding portion of the forecast through 2026 as part of its fixed minimum lease liability. 16Table of ContentsSummary of all lease costs recognized under ASC 842The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Companyâ€™s operating and finance leases for the three months ended MarchÂ 31, 2024 and 2023 (in thousands):For the three months ended March 31,20242023(As Restated)Finance leasesInterest expense$4,347Â $4,267Â Amortization expense14,328Â 5,216Â Total fixed finance lease cost$18,675Â $9,483Â Operating leasesFixed lease cost 9,486Â 11,470Â Total fixed operating lease cost9,486Â 11,470Â Variable lease cost6,043Â 6,862Â Short-term lease cost76Â 52Â Total lease cost$34,280Â $27,867Â Operating sublease income$10,346Â $10,108Â Cash paid in the

measurement of lease liabilitiesOperating cash flows used for operating leases2,844Â 6,361Â Operating cash flows used for finance leases1,411Â 3,352Â Financing cash flows for finance leases22,210Â 15,280Â Other informationWeighted average remaining lease term - finance leasesÂ 1.42 years2.30 yearsWeighted average discount rate - finance leases14.45Â %15.13Â %Weighted average remaining lease term - operating leasesÂ 6.75 years7.59 yearsWeighted average discount rate - operating leases7.00Â %7.04Â %As of MarchÂ 31, 2024, future minimum commitments under ASC 842 under the Companyâ€™s leases were as follows (in thousands):Operating LeasesFinancing LeasesRemaining Lease PaymentsRemainder of 202428,492Â 102,277Â 202537,084Â 41,270Â 202635,719Â 3,422Â 202736,742Â 2,548Â 202837,795Â 1,043Â 2029 and thereafter81,986Â â€”Â Total257,818Â 150,560Â Less: Imputed Interest(52,772)(10,259)Present Value of Lease Liabilities$205,046Â $140,301Â 17Table of Contents10. Commitments and contingenciesLease commitmentsThe Company leases certain office and laboratory space and has embedded leases at CMOs and a CTO. As of MarchÂ 31, 2024, the Company has commitments arising from a forward starting lease that had not yet commenced related to an embedded equipment lease with a CMO. This lease is expected to commence in 2025 with an initial lease term of three years. Fixed commitments under this contract approximate $56.8Â million. The following table presents the non-cancelable contractual obligations arising from this arrangement as of the three months ended MarchÂ 31, 2024 (in thousands):FuturecommitmentRemainder of 2024$â€”Â 202513,763Â 202617,858Â 202717,858Â 20287,310Â 2029 and thereafterâ€”Â Total purchase commitments$56,789Â Refer to Note 9, Leases, for further information on the terms of these lease agreements.LitigationFrom time to time, the Company is party to various claims and complaints arising in the ordinary course of business, including securities class action litigation and intellectual property litigation. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Companyâ€™s business partners. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is generally unlimited. Accruals for loss contingencies are recognized when a loss is probable, and the amount of such loss can be reasonably estimated. The Company has not accrued for a loss for any matter described below as a loss is not probable and a loss, or a range of loss, is not reasonably estimable. The Company also indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and by-laws. The term of the indemnification period lasts as long as such officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations.There have been no material changes in claims and complaints from those disclosed in Note 12 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K.11. EquityOn January 18, 2023, the Company entered into an underwriting agreement (the â€œJanuary Underwriting Agreementâ€) with Goldman and J.P. Morgan Securities LLC in connection with the public offering, issuance, and sale by the Company of 20.0Â million shares of the Companyâ€™s common stock at a public offering price of $6.00 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 and a related prospectus supplement filed with the Securities and Exchange Commission. Under the terms of the January Underwriting Agreement, the Company also granted the underwriters an option exercisable for 30 days to purchase up to an additional 3.0Â million shares of common stock at the public offering price, less underwriting discounts and commissions, which the underwriters exercised in full. The offering closed on January 23, 2023. The Company received aggregate net proceeds of $130.5Â million.18Table of ContentsIn August 2023, the Company entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Companyâ€™s common stock up to $125.0Â million, from time to time, through an â€œat the marketâ€ equity offering program under which Jefferies will act as sales agent. As of March 31, 2024, the Company has made no sales pursuant to the Sales Agreement.On December 19, 2023, the Company entered into an underwriting agreement (the â€œDecember Underwriting Agreementâ€) with Goldman and J.P. Morgan Securities LLC, in connection with the public offering, issuance, and sale by the Company of 83.3 million shares of the Companyâ€™s common stock at a public offering price of $1.50 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 and a related prospectus supplement filed with the Securities and Exchange Commission. Under the terms of the December Underwriting Agreement, the Company also granted the underwriters an option exercisable for 30 days to purchase up to an additional 12.5 million shares of common stock at the public offering price, less underwriting discounts and commissions, which option was not exercised. The offering closed on December 22, 2023. The Company received aggregate net proceeds of $118.1Â million. 12. Stock-based compensationIn June 2023, the Companyâ€™s stockholders approved the bluebird bio, Inc. 2023 Incentive Award Plan (the â€œ2023 Planâ€), which replaced the 2013 Stock Option and Incentive Plan (â€œ2013 Planâ€). Following approval of the 2023 Plan, no further awards will be granted under the 2013 Plan. As of MarchÂ 31, 2024, the total number of shares of common stock available for issuance under the 2023 Plan was approximately 2.1Â million.Stock-based compensation expense The Company recognized stock-based compensation expense totaling $3.8 million and $5.4 million during the three months ended MarchÂ 31, 2024 and 2023, respectively. Stock-based compensation expense recognized by award type is included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):For the three months ended March 31,20242023Stock options$1,230Â $1,723Â Restricted stock units2,451Â 3,668Â Employee stock purchase plan and other80Â â€”Â $3,761Â $5,391Â 19Table of ContentsStock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):Â For the three months ended March 31,20242023Cost of product revenue491Â 103Â Selling, general and administrative2,335Â 2,361Â Research and development935Â 2,927Â $3,761Â $5,391Â During the three months ended MarchÂ 31, 2024 and 2023, the Company had $0.3Â million and $0.5 million of stock compensation expense that was capitalized into inventory. Stock optionsThe following table summarizes the stock option activity under the Companyâ€™s equity award plans excluding awards held by employees of 2seventy bio:Shares(in thousands)Weighted-averageexercise priceper shareOutstanding at December 31, 20234,227Â $14.16Â Granted2,572Â $1.56Â Exercisedâ€”Â $â€”Â Canceled, forfeited, or expired(229)$16.55Â Outstanding at March 31, 20246,570Â $9.16Â Exercisable at March 31, 20241,871Â $22.75Â Vested and expected to vest at March 31, 20246,570Â $9.16Â During the three months ended MarchÂ 31, 2024, no stock options were exercised.Restricted stock unitsThe following table summarizes the restricted stock unit activity under the Companyâ€™s equity award plans excluding awards held by employees of 2seventy bio:Shares(in thousands)Weighted-averagegrant datefair valueUnvested at December 31, 20234,207Â $6.08Â Granted2,177Â $1.56Â Vested(785)$7.14Â Forfeited(205)$4.41Â Unvested at March 31, 20245,394Â $4.16Â Employee stock purchase planIn JuneÂ 2013, the Company's board of directors adopted its 2013 Employee Stock Purchase Plan (â€œ2013 ESPPâ€), which authorized the initial issuance of up to a total of 0.2 million shares of the Companyâ€™s common stock to participating employees. In June 2021, the Company amended the 2013 ESPP to authorize an additional 1.4Â million shares of the Companyâ€™s common stock available to participating employees. During each of the three months ended MarchÂ 31, 2024 and 2023, no shares and less than 0.1Â million shares, respectively, of common stock were issued under the 2013 ESPP.20Table of Contents13. Income taxesDeferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Companyâ€™s otherwise recognizable net deferred tax assets. The tax benefit recognized during the three months ended MarchÂ 31, 2024 was $0.0Â million due to the full valuation allowance.14. Net loss per shareThe following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):For the three months endedMarch 31,2024Outstanding stock options(1)7,903Â Restricted stock units(1)5,449Â Warrants2,586Â ESPP shares and other84Â 16,022Â (1) Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.Net loss per share for the three months ended MarchÂ 31, 2024 was $0.36. During the three months ended March 31, 2023, the Company had net income of $18.9 million. Basic weighted-average common shares outstanding were 102.9 million, the effect of dilutive securities was 0.4 million, and diluted weighted-average common shares outstanding were 103.3 million. Basic earnings per share and diluted earnings per share were both $0.18.21Table of Contents15. Restatement of Previously Issued Financial StatementsAs further described below, as well as in Note 2 - Basis of Presentation, the Company identified several prior period misstatements that impacted its unaudited quarterly condensed consolidated financial statements for the quarter ended MarchÂ 31, 2023. Such restated and unaudited quarterly financial data and the related impacted amounts were presented in the Company's Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.As part of the restatement, the Company recorded adjustments to correct the material misstatements related to accounting for embedded leases and other immaterial errors. The following tables present the restated unaudited Condensed Consolidated Financial Information for the quarter ended MarchÂ 31, 2023.Consolidated Statements of Operations and Comprehensive LossFor the three months ended March 31, 2023As Previously ReportedAdjustments to Embedded LeasesOther AdjustmentsAs RestatedRevenue:Product revenue, net$2,296Â $â€”Â $â€”Â $2,296Â Other revenue85Â â€”Â â€”Â 85Â Total revenues2,381Â â€”Â â€”Â 2,381Â Cost of product revenue3,376Â 2,136Â â€”Â 5,512Â Gross margin(995)(2,136)â€”Â (3,131)Operating expenses:Research and development46,144Â (4,516)(41)41,587Â Selling, general and administrative37,354Â 113Â â€”Â 37,467Â Total operating expenses83,498Â (4,403)(41)79,054Â Gain from sale of priority review voucher, net92,930Â â€”Â â€”Â 92,930Â Income from operations8,437Â 2,267Â 41Â 10,745Â Interest income2,828Â â€”Â â€”Â 2,828Â Interest expense(3)(4,267)â€”Â (4,270)Other income, net9,978Â (351)â€”Â 9,627Â Income before income taxes21,240Â (2,351)41Â 18,930Â Income tax (expense) benefitâ€”Â â€”Â â€”Â â€”Â Net income 21,240Â (2,351)41Â 18,930Â Net income per share - basic (1)$0.21Â (0.02)â€”Â $0.18Â Net income per share - diluted (1)$0.21Â (0.02)â€”Â $0.18Â Weighted-average number of common shares usedin computing net income per share - basic:102,920Â 102,920Â 102,920Â 102,920Â Weighted-average number of common shares usedin computing net income per share - diluted:103,303Â 103,303Â 103,303Â 103,303Â Other comprehensive income:Other comprehensive income, net of tax(benefit) expense of $0.0Â million for the three months ended March 31, 2023984Â â€”Â â€”Â 984Â Total other comprehensive income984Â â€”Â â€”Â 984Â Comprehensive income$22,224Â $(2,351)$41Â $19,914Â (1) Due to differences in rounding to the nearest cent per basic or diluted share, totals may not equal the sum of the line items.22Table of ContentsStatements of Changes in Stockholders' Equity:Common stockAdditionalpaid-incapitalAccumulatedothercomprehensive(loss) incomeAccumulateddeficitTotalstockholders'equitySharesAmountAs Previously ReportedBalances at December 31, 202282,923Â $830Â $4,186,086Â $(4,070)$(3,986,503)$196,343Â Vesting of restricted stock382Â 3Â (198)â€”Â â€”Â (195)Exercise of stock options3Â â€”Â 7Â â€”Â â€”Â 7Â Purchase of shares under ESPP62Â 1Â 226Â â€”Â â€”Â 227Â Issuance of common stock for privateequity placement23,000Â 230Â 130,061Â â€”Â â€”Â 130,291Â Issuance of unrestricted stock awards tosettle accrued employee compensationStock-based compensationâ€”Â â€”Â 5,843Â â€”Â â€”Â 5,843Â Other comprehensive incomeâ€”Â â€”Â â€”Â 984Â â€”Â 984Â Net incomeâ€”Â â€”Â â€”Â â€”Â 21,240Â 21,240Â Balances at March 31, 2023106,370Â $1,064Â $4,322,025Â $(3,086)$(3,965,263)$354,740Â Adjustments to Embedded LeasesBalances at December 31, 2022$â€”Â $â€”Â $â€”Â $â€”Â $(59,700)$(59,700)Vesting of restricted stockâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Exercise of stock optionsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Purchase of shares under ESPPâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of common stock for private equity placementâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of unrestricted stock awards to settle accrued employee compensationStock-based compensationâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Net incomeâ€”Â â€”Â â€”Â â€”Â (2,351)(2,351)Balances at March 31, 2023â€”Â $â€”Â $â€”Â $â€”Â $(62,051)$(62,051)Other AdjustmentsBalances at December 31, 2022â€”Â â€”Â (98)â€”Â (2,212)(2,310)Vesting of restrictedstockâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Exercise of stock optionsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Purchase of shares under ESPPâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of common stock for private equity placementâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of unrestricted stock awards to settle accrued employee compensationStock-based compensationâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Net incomeâ€”Â â€”Â â€”Â â€”Â 41Â 41Â Balances at March 31, 2023â€”Â $â€”Â (98)â€”Â $(2,171)$(2,269)As RestatedBalances at December 31, 202282,923Â 830Â 4,185,988Â (4,070)(4,048,415)134,333Â Vesting of restricted stock382Â 3Â (198)â€”Â â€”Â (195)Exercise of stock options3Â â€”Â 7Â â€”Â â€”Â 7Â 23Table of ContentsPurchase of shares under ESPP62Â 1Â 226Â â€”Â â€”Â 227Â Issuance of common stock for privateequity placement23,000Â 230Â 130,061Â â€”Â â€”Â 130,291Â Issuance of unrestricted stock awards to settle accrued employee compensationStock-based compensationâ€”Â â€”Â 5,843Â â€”Â â€”Â 5,843Â Other comprehensive incomeâ€”Â â€”Â â€”Â 984Â â€”Â 984Â Net incomeâ€”Â â€”Â â€”Â â€”Â 18,930Â 18,930Â Balances at March 31, 2023106,370Â $1,064Â $4,321,927Â $(3,086)$(4,029,485)$290,420Â 24Table of ContentsConsolidated Statement of Cash FlowsFor the three months ended March 31,2023As Previously ReportedAdjustments to Embedded LeasesOther AdjustmentsAs RestatedCash flows from operating activities:Net income $21,240Â $(2,351)$41Â $18,930Â Adjustments to reconcile net income to net cash used in operatingÂ Â Â activities:Depreciation and amortization1,082Â 5,131Â (41)6,172Â Stock-based compensation expense5,391Â â€”Â â€”Â 5,391Â Noncash research and development expense (finance lease)â€”Â 1,441Â â€”Â 1,441Â Noncash operating lease expenseâ€”Â 7,423Â â€”Â 7,423Â Gain from sale of priority review voucher(92,930)â€”Â â€”Â (92,930)Excess inventory reserve228Â â€”Â 2,355Â 2,583Â Other non-cash items237Â â€”Â â€”Â 237Â Gain on foreign currency exchange ratesâ€”Â (108)â€”Â (108)Changes in operating assets and liabilities:Prepaid expenses and other assets(9,335)2,846Â 2,800Â (3,689)Inventory(3,586)610Â (2,355)(5,331)Operating right of use assets11,829Â (11,829)â€”Â â€”Â Accounts payable(6,443)7,703Â â€”Â 1,260Â Accrued expenses and other liabilities(9,065)1,859Â â€”Â (7,206)Accrued interest payable under finance leaseâ€”Â 915Â â€”Â 915Â Operating lease liabilities(8,001)1,640Â â€”Â (6,361)Deferred revenue2,715Â â€”Â (2,800)(85)Net cash used in operating activities(86,638)15,280Â â€”Â (71,358)Cash flows from investing activities:Purchase of property, plant and equipment(232)â€”Â â€”Â (232)Purchases of marketable securities(19,610)â€”Â â€”Â (19,610)Proceeds from maturities of marketable securities4,021Â â€”Â â€”Â 4,021Â Proceeds from sales of marketable securities5,853Â â€”Â â€”Â 5,853Â Purchase of intangible assets(868)â€”Â â€”Â (868)Proceeds from sale of priority review voucher92,972Â â€”Â â€”Â 92,972Â Net cash provided by investing activities82,136Â â€”Â â€”Â 82,136Â Cash flows from financing activities:Proceeds from exercise of stock options and ESPP contributions7Â â€”Â â€”Â 7Â Proceeds from vesting of restricted stock(196)â€”Â â€”Â (196)Principal payments on finance leaseâ€”Â (15,280)â€”Â (15,280)Proceeds from the secondary public offering, net of issuance costs130,645Â â€”Â â€”Â 130,645Â Net cash provided by financing activities130,456Â (15,280)â€”Â 115,176Â Increase in cash, cash equivalents and restricted cash125,954Â â€”Â â€”Â 125,954Â Cash, cash equivalents and restricted cash at beginning of year158,445Â â€”Â â€”Â 158,445Â Cash, cash equivalents and restricted cash at end of year$284,399Â $â€”Â $â€”Â $284,399Â Reconciliation of cash, cash equivalents and restricted cash:Cash and cash equivalents$239,045Â $â€”Â $â€”Â $239,045Â Restricted cash included in receivables and other current assets1,417Â â€”Â â€”Â 1,417Â Restricted cash included in restricted cash and other non-current assets43,937Â â€”Â â€”Â 43,937Â Total cash, cash equivalents and restricted cash$284,399Â $â€”Â $â€”Â $284,399Â Supplemental cash flow disclosures:Purchases of property, plant and equipment included in accountsÂ Â payable and accrued expenses189Â â€”Â â€”Â 189Â Offering expenses included in accounts payable and accrued expenses523Â â€”Â â€”Â 523Â Priority review voucher expenses accrued or in AP43Â â€”Â â€”Â 43Â Right-of-use assets obtained in exchange for finance lease liabilitiesâ€”Â (214)â€”Â (214)Cash paid during the period for income taxes2Â â€”Â â€”Â 2Â 25Table of Contents16. Subsequent events Term Loan DebtAs previously disclosed in Note 8, Term loan debt, on March 15, 2024, the Company entered into a five-year term loan facility agreement with Hercules Capital, Inc. ("Hercules") to secure debt financing for up to $175Â million, available in four tranches. The first tranche in an amount equal to $75Â million was drawn at the time of closing (the "Initial Loan"). The Company may draw upon two additional tranches of $25Â million each, subject to satisfaction of certain conditions, including achievement of commercial milestones. The facility also provides a fourth tranche of $50Â million, available at the sole discretion of Hercules, until December 15, 2026.The Loan and Security Agreement ("LSA")

requires the Company to comply with customary affirmative and negative covenants, including, among other things, a requirement to deliver annual financial statements within 90 days of each fiscal year and quarterly financial statements within 45 days of each fiscal quarter. A failure to comply with these covenants, or failure to obtain a waiver for any non-compliance, would result in an event of default under the LSA and would allow Hercules to accelerate repayment of the debt, which could materially and adversely affect the business, results of operations and financial condition of the Company. On April 30, 2024, July 9, 2024, August 13, 2024, and August 29, 2024 the Company and Hercules entered into amendments to the LSA providing for revised monthly financial reporting metrics for each month through September 30, 2024 and extension of the deadlines by which the Company must provide certain annual and quarterly financial statements.On August 13, 2024, the Company and Hercules entered into a third amendment to the LSA (the â€œThird Amendmentâ€), pursuant to which the parties agreed to, among other things, revised terms for the availability of the second and third tranches of funding under the LSA. In accordance with the Third Amendment, the Company may draw the second tranche of $25.0Â million during the period commencing on the date the Company has (x) received at least $75.0Â million in gross cash proceeds from qualified financing transactions by December 20, 2024 and (y) completed patient starts (cell collections) for at least 50 LYFGENIA patients by March 31, 2025 or 70 LYFGENIA patients by June 30, 2025 (collectively, the â€œTranche 2 Milestoneâ€) and ending on the earlier of (i) the date that is 30 days immediately following achievement of the Tranche 2 Milestone and (ii) July 31, 2025. The Company may draw the third tranche of $25.0Â million during the period commencing on the date the Company has (x) received at least $100.0Â million in gross cash proceeds from qualified financing transactions by December 20, 2024 or at least $125.0Â million by June 30, 2025 and (y) completed 70 drug product deliveries within a given six-month period ending no later than December 31, 2025, at least 40 of which are for LYFGENIA (collectively, the â€œTranche 3 Milestoneâ€) and ending on the earlier of (i) the date that is 30 days immediately following the date the Company achieves the Tranche 3 Milestone and (ii) December 31, 2025. Additionally, the Company and Hercules agreed to increase the minimum cash coverage requirement from 40% to 45% of the outstanding principal of the term loan.Additionally, in connection with entry into the LSA, the Company issued to the lenders warrants to purchase that number of shares of the Companyâ€™s common stock equal to five percent of the Initial Loan, or $3.75Â million, divided by the volume-weighted average price (â€œVWAPâ€) of the Companyâ€™s common stock for the ten-day period preceding March 15, 2024 (the â€œInitial Warrantsâ€). The Company agreed to issue additional common stock warrants to the lenders at the closings of future tranches of funding under the LSA, if any, to purchase that number of shares of common stock equal to five percent of the applicable loan divided by the VWAP of the Companyâ€™s common stock for the ten-day period preceding March 15, 2024 (together with the Initial Warrants, the â€œWarrantsâ€). On August 13, 2024, in connection with the Third Amendment, the Company agreed to amend the exercise price of the Warrants to purchase shares of the Companyâ€™s common stock from $1.45 per share to the lesser of the VWAP of the Companyâ€™s common stock for the ten-day period preceding August 13, 2024, and the price per share of the Companyâ€™s first equity financing event within six months of August 13, 2024. The amendment does not impact the number of shares the lenders may purchase pursuant to the Warrants. 26Table of ContentsItemÂ 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following information should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission, or the SEC, on SeptemberÂ 13, 2024 (the "2023 Annual Report on Form 10-K").The Company restated the consolidated financial statements for the year ended December 31, 2022 presented in its 2023 Annual Report on Form 10-K. In addition, the Company restated its unaudited quarterly financial data for the period ended March 31, 2023. Such restated unaudited quarterly financial data and related impacted amounts were presented in the Company's 2023 Annual Report on Form 10-K. The following discussion gives effect to the restatement of our unaudited interim consolidated financial statements for the three months ended March 31, 2023. See the related discussion in Note 2, "Basis of presentation, principles of consolidation and significant accounting policies" of the Notes to Unaudited Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.Except for the historical information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be deemed to be forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. In this Quarterly Report on Form 10-Q, words such as â€œmay,â€ â€œexpect,â€ â€œanticipate,â€ â€œestimate,â€ â€œintend,â€ â€œplan,â€ and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.Our actual results and the timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods.The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under Part II, ItemÂ 1A. Risk Factors.We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.Overview We are a biotechnology company committed to researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on our proprietary lentiviral vector (â€œLVVâ€) gene addition platform. We currently market three gene therapies in the U.S.: ZYNTEGLOâ„¢ (betibeglogene autotemcel, also known as beti-cel), SKYSONAâ„¢ (elivaldogene autotemcel, also known as eli-cel), which were approved by the U.S. Food and Drug Administration (the â€œFDAâ€) in 2022, and LYFGENIAâ„¢ (lovotibeglogene autotemcel, also known as lovo-cel), which received approval from the FDA in December 2023.The FDA approved ZYNTEGLO for the treatment of adult and pediatric patients with ÃŸ-thalassemia who require regular red blood cell transfusions on August 17, 2022. The FDA granted accelerated approval of SKYSONA to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (â€œCALDâ€) on September 16, 2022. On December 8, 2023, LYFGENIA, was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease (â€œSCDâ€) and a history of vaso-occlusive-events.We are focusing our development and commercialization efforts in the U.S. market. We have obtained the withdrawal of the marketing authorization for beti-cel and eli-cel in the European Union, which became effective in 2022 and 2021, respectively. We are continuing the long-term follow-up of patients previously enrolled within the clinical trial programs in Europe as planned but do not intend to initiate any new clinical trials in Europe for Î²-thalassemia, CALD or SCD. 27Table of ContentsSince our inception in 1992, we have devoted substantially all of our resources to our development and commercialization efforts relating to our products and product candidates, including activities to manufacture products and product candidates in compliance with good manufacturing practices (â€œGMPâ€) to conduct clinical studies of our product candidates, to provide selling, general and administrative support for these operations, to market, commercially manufacture and distribute our approved products and to protect our intellectual property. We have funded our operations primarily through the sale of common stock in our public offerings, issuance of warrants, the sale of two Rare Pediatric Disease Priority Review Vouchers ("PRVs"), debt financing agreements and through collaborations. In August 2022 and September 2022 we received the two PRVs under an FDA program intended to encourage the development of treatments for rare pediatric diseases. In the fourth quarter of 2022, we sold our first PRV for aggregate net proceeds of $102.0Â million. In the first quarter of 2023, we sold our second PRV for aggregate net proceeds of $92.9Â million, inclusive of additional legal costs incurred.In the first quarter of 2023, we sold 23.0 million shares of common stock (inclusive of shares sold pursuant to an option to the underwriters in connection with the offering) through an underwritten public offering at a price of $6.00 per share for aggregate net proceeds of $130.5Â million, inclusive of additional offering costs incurred. In the fourth quarter of 2023, we sold 83.3Â million shares of common stock through an underwritten public offering at a price of $1.50 per share for aggregate net proceeds of $118.1Â million, after deducting for offering costs.In March 2024, we entered into a five-year term loan facility agreement with Hercules Capital, Inc. to secure debt financing for up to $175.0 million, available in four tranches, based on amendments executed through August 2024.As of MarchÂ 31, 2024, we had cash and cash equivalents of approximately $212.0 million. Absent the sale of our PRVs, we have never been profitable and have incurred net losses in each year since inception. Our net loss was $69.8 million for the three months ended MarchÂ 31, 2024 and our accumulated deficit was $4.3Â billion as of MarchÂ 31, 2024. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations. We expect to continue to incur significant expenses and operating losses for the foreseeable future, if and as we:â€¢fund activities related to the commercialization of ZYNTEGLO, SKYSONA, and LYFGENIA in the United States; â€¢scale our manufacturing capabilities in support of the commercialization of ZYNTEGLO, SKYSONA, and LYFGENIA;â€¢conduct clinical studies; andâ€¢continue research and development-related activities for severe genetic diseases.Because of the numerous risks and uncertainties associated with product development and commercialization, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. We may not be able to generate substantial revenue from the sale of our products, and we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. Until we reach profitability, if ever, we expect to continue to seek to fund our operations through public or private equity or debt financings, strategic collaborations, or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our business.Business updateWe had cash and cash equivalents of approximately $212.0 million as of MarchÂ 31, 2024. We will continue to generate operating losses and negative operating cash flows for the foreseeable future as we continue to commercialize ZYNTEGLO, SKYSONA, and LYFGENIA and we will require the need for additional funding to support our planned operations before becoming profitable.Based on our current forecasts, and assuming we implement planned cost-saving initiatives, we expect our existing cash and cash equivalents will enable us to fund our operations and maintain compliance with the minimum cash requirements of the Loan Agreement with Hercules Capital, Inc. into the first quarter of 2025. Not accounting for the minimum cash requirements of the Loan Agreement, we expect our existing cash and cash equivalents will enable us to fund our operations into the second quarter of 2025.28Table of ContentsWe have based this estimate on assumptions of revenues and operating costs that may prove to be wrong. Our cash runway estimate does not include use of our restricted cash, which as of MarchÂ 31, 2024 was $51.9 million. The restricted cash was unavailable for use as of MarchÂ 31, 2024, and we believe at least $48.0 million of this restricted cash is unlikely to be released in the near term. In addition, our future net product revenues will depend upon the demand for our products, the size of the markets, our ability to timely scale our manufacturing capabilities to meet market demand, our ability to achieve sufficient market acceptance, reimbursement from third-party payers, adequate market share in those markets and the performance of drug product subject to outcome-based programs. As a result, we could deplete our capital resources sooner than we currently expect. If, for any reason, our revenues or our expenses differ materially from our assumptions or we utilize our cash more quickly than anticipated, or if we are unable to obtain funding on a timely basis, we may be required to revise our business plan and strategy, which may result in bluebird failing to achieve profitability, significantly curtailing, delaying or discontinuing the commercialization of any products or may result in bluebird being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial condition, and results of operations could be materially affected.The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Financial operations overviewProduct revenueOur revenues were derived from product revenues associated with the sale of SKYSONA and ZYNTEGLO in the United States.Other revenueWe have recognized an immaterial amount of revenue associated with grants.Cost of product revenueCost of product revenue includes costs associated with the sale of SKYSONA and ZYNTEGLO in the United States.Selling, general and administrative expensesSelling, general and administrative expenses consist primarily of salaries and related costs for personnel, including stock-based compensation and travel expenses for our employees in executive, operational, finance, legal, business development, commercial, information technology, and human resource functions. Other selling, general and administrative expenses include facility-related costs, professional fees for accounting, tax, legal and consulting services, directorsâ€™ fees and expenses associated with obtaining and maintaining patents. These expenses include lease expense related to 50 Binney Street and 100 Binney Street; however, sublease income is presented in other income, net.We anticipate that our selling, general and administrative expenses, including payroll and sales and marketing expenses, may continue to increase in the future relative to current levels as we continue commercialization activities for ZYNTEGLO, SKYSONA, and LYFGENIA in the United States. Research and development expensesResearch and development expenses consist primarily of costs incurred for the development of our product candidates, which include:â€¢employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;â€¢expenses incurred under agreements with contract research organizations (â€œCROsâ€) and clinical sites that conduct our clinical studies;â€¢expenses, including amortization of right-of-use assets when used in research and development, incurred under agreements with contract manufacturing organizations (â€œCMOsâ€) related to pre-commercial manufacturing activities;â€¢facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, information technology, insurance, and other supplies in support of research and development activities;â€¢costs associated with our research platform and preclinical activities;29Table of Contentsâ€¢milestones and upfront license payments; andâ€¢costs associated with our regulatory, quality assurance and quality control operations.Research and development costs including those under executory contracts and variable costs related to arrangements that contain a lease are expensed as incurred. Right-of-use assets related to arrangements with CMOs and contract testing organizations (â€œCTOsâ€) that contain a lease under ASC 842 but have no alternative future use under ASC 730 are immediately expensed to research and development expense at commencement or upon a modification until commercialization is achieved. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites. We cannot determine with certainty the duration and completion costs of the current or future clinical studies of our products or to what extent we will generate revenues from the commercialization and sale of our approved products. The duration, costs, and timing of clinical studies and development of our products will depend on a variety of factors, any of which could affect our research and development expenses, including:â€¢the scope, rate of progress, and expense of our ongoing as well as any additional clinical studies and other research and development activities we undertake;â€¢future clinical study results;â€¢uncertainties in clinical study enrollment rates;â€¢new manufacturing processes or protocols that we may choose to or be required to implement in the manufacture of our LVV or drug product;â€¢regulatory feedback on requirements for regulatory approval, as well as changing standards for regulatory approval; andâ€¢the timing and receipt of any regulatory approvals. We plan to continue to incur research and development expenses for the foreseeable future as we continue to conduct research activities for our platform technology. We expect our research and development expenses to decrease in conjunction with an increase in commercial activities and selling, general and administrative expense due to the approvals of ZYNTEGLO, SKYSONA, and LYFGENIA. Our research and development expenses include expenses associated with the following activities: â€¢the long-term follow-up protocol associated with the clinical studies of ZYNTEGLO, and a postmarketing study for the same; â€¢the long-term follow-up protocol associated with the clinical studies of SKYSONA, and a postmarketing study for the same;â€¢HGB-210, the long-term follow-up protocol associated with the clinical studies of LYFGENIA, and a postmarketing study for the same;â€¢research and development activities for our platform technology; andâ€¢the manufacture of clinical study materials in support of our clinical studies.Our direct research and development expenses consist principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical studies, and costs related to acquiring and manufacturing clinical study materials. We allocate salary

and benefit costs that are directly related to specific programs. We do not allocate personnel-related discretionary bonus or stock-based compensation costs, laboratory and related expenses, certain license and other collaboration costs, depreciation or other indirect costs that are deployed across multiple projects under development and, as such, the costs are separately classified as other research and development expenses in the table below:30Table of ContentsFor thethree months ended March 31,20242023(in thousands)(As Restated)ZYNTEGLO (beti-cel)$1,889Â $2,644Â LYFGENIA (lovo-cel)7,085Â 17,635Â SKYSONA (eli-cel)469Â 3,692Â Preclinical programs33Â 309Â Total direct research and development expense9,476Â 24,280Â Employee-and contractor-related expenses7,831Â 6,954Â Stock-based compensation expense935Â 2,927Â License and other related expensesâ€”Â 87Â Laboratory and other expenses1,785Â 732Â Facility expenses5,045Â 6,607Â Total other research and development expenses15,596Â 17,307Â Total research and development expense$25,072Â $41,587Â Gain from sale of priority review voucher, netGain from sale of priority review voucher, net consists of gain from the sale of our priority review vouchers. In the first quarter of 2023, we sold our PRV for aggregate net proceeds of $92.9 million. We received the PRV in September 2022 under an FDA program intended to encourage the development of treatments for rare pediatric diseases. Interest incomeInterest income consists primarily of interest income earned on investments.Interest expenseInterest expense consists primarily of interest expense associated with finance lease arrangements and long-term debt.Other income, netOther income, net consists primarily of sublease income, gains and losses on disposal of fixed assets, and gains and losses on foreign currency transactions.Critical accounting policies and significant judgements and estimatesOur managementâ€™s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies. During the three months ended MarchÂ 31, 2024, there were no material changes to our critical accounting policies as reported in our 2023 Annual Report on Form 10-K, except as otherwise described in Note 2, Basis of presentation, principles of consolidation and significant accounting policies, in the Notes to Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q.31Table of ContentsResults of OperationsComparison of the three months ended MarchÂ 31, 2024 and 2023:For the three months endedMarch 31,20242023Change(in thousands)(As Restated)Revenue:Product revenue, net$18,561Â $2,296Â $16,265Â Other revenue12Â 85Â (73)Total revenues18,573Â 2,381Â 16,192Â Cost of product revenue25,864Â 5,512Â 20,352Â Gross margin(7,291)(3,131)(4,160)Operating expenses:Selling, general and administrative46,329Â 37,467Â 8,862Â Research and development25,072Â 41,587Â (16,515)Total operating expenses71,401Â 79,054Â (7,653)Gain from sale of priority review voucher, netâ€”Â 92,930Â (92,930)(Loss) income from operations(78,692)10,745Â (89,437)Interest income2,579Â 2,828Â (249)Interest expense(4,856)(4,270)(586)Other income, net11,165Â 9,627Â 1,538Â (Loss) Income before income taxes(69,804)18,930Â (88,734)Income tax (expense) benefitâ€”Â â€”Â Â€”Â Net (loss) income$(69,804)$18,930Â $(88,734)Revenues. Total revenue was $18.6 million for the three months ended MarchÂ 31, 2024, compared to $2.4 million for the three months ended MarchÂ 31, 2023. The increase of $16.2 million was primarily attributable to increased product sales during 2024.Cost of product revenue. Cost of product revenue was $25.9 million for the three months ended MarchÂ 31, 2024, compared to $5.5 million for the three months ended MarchÂ 31, 2023. The increase is primarily attributable to increased product sales during 2024. Selling, general and administrative expenses. Selling, general and administrative expenses were $46.3 million for the three months ended MarchÂ 31, 2024, compared to $37.5 million for the three months ended MarchÂ 31, 2023. The net increase of $8.8 million was primarily attributable to the following: â€¢$5.0 million of increased net employee compensation, benefit, and other headcount-related expenses, driven by increased headcount in selling, general and administrative costs in 2024; andâ€¢$3.8 million of increased professional fees driven by increased legal and accounting advisory fees.Research and development expenses. Research and development expenses were $25.1 million for the three months ended MarchÂ 31, 2024, compared to $41.6 million for the three months ended MarchÂ 31, 2023. The net decrease of $16.5 million was primarily attributable to the following:â€¢$5.0 million of decreased manufacturing costs primarily driven by material production for all commercial products now being included in inventory and cost of product revenue;â€¢$4.3 million of decreased net employee compensation, benefit, and other headcount related expenses, including a decrease of $2.0 million in stock-based compensation expense, driven by related expenses being included in inventory and cost of product revenue for our commercial products;â€¢$3.4 million of decreased clinical subject treatment costs;32Table of Contentsâ€¢$2.5 million of decreased consulting fees; and â€¢$2.3 million of decreased information technology and facility-related costs primarily driven by information technology and facility-related expenses now being included in inventory and cost of product revenue. These decreased costs were partially offset by the following:â€¢$1.6 million of increased costs related to lab expenses driven by an increase in lab consumables.Gain from sale of priority review voucher, net. The decrease in gain from sale of priority review voucher, net was related to the sale of a priority review voucher in the first quarter of 2023.Interest income. The decrease in interest income was primarily related to higher cash balances in interest bearing accounts in the first quarter of 2023 compared to the first quarter of 2024.Interest expense. The increase in interest expense was primarily due to interest expense associated with finance lease arrangements and long-term debt.Other income, net. The increase in other income, net was primarily related to gains and losses on foreign currency transactions.Liquidity and Capital ResourcesAs of MarchÂ 31, 2024, we had cash and cash equivalents of approximately $212.0 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. As of MarchÂ 31, 2024, our funds are primarily held in U.S. government agency securities and treasuries, and money market accounts with maturities at date of purchase of 90 days or less.We have incurred losses and cumulative negative cash flows from operations since our inception in April 1992, and as of MarchÂ 31, 2024, we had an accumulated deficit of $4.3 billion. We expect our research and development expenses to decrease in conjunction with an increase in commercial activities and selling, general and administrative expense due to the commercialization of ZYNTEGLO, SKYSONA, and LYFGENIA.Based on our current forecasts, and assuming we implement planned cost-saving initiatives, we expect our existing cash and cash equivalents will enable us to fund our operations and maintain compliance with the minimum cash requirements of the Loan Agreement with Hercules Capital, Inc. into the first quarter of 2025. Not accounting for the minimum cash requirements of the Loan Agreement, we expect our existing cash and cash equivalents will enable us to fund our operations into the second quarter of 2025.We have based this estimate on assumptions of revenues and operating costs that may prove to be wrong. Our cash runway estimate does not include use of our restricted cash of $51.9 million, which was unavailable for use as of MarchÂ 31, 2024, and we believe at least $48.0Â million of this restricted cash is unlikely to be released in the near term. In addition, our future net product revenues will depend upon the demand for our products, the size of the markets, our ability to timely scale our manufacturing capabilities to meet market demand, our ability to achieve sufficient market acceptance, reimbursement from third-party payers, adequate market share in those markets and the performance of drug product subject to outcome-based programs. As a result, we could deplete our capital resources sooner than we currently expect. If, for any reason, our revenues or our expenses differ materially from our assumptions or we utilize our cash more quickly than anticipated, or if we are unable to obtain funding on a timely basis we may be required to revise our business plan and strategy, which may result in bluebird failing to achieve profitability, significantly curtailing, delaying or discontinuing one or more of our research or development programs or the commercialization of any products or may result in bluebird being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial condition, and results of operations could be materially affected.We have funded our operations principally from the sale of common stock in public offerings, the Loan Agreement, and the sale of the two PRVs. The following is a summary of recent financing transactions:â€¢In the first quarter of 2023, we sold our second PRV for aggregate net proceeds of $92.9 million.33Table of Contentsâ€¢In the first quarter of 2023, we sold 23.0 million shares of common stock (inclusive of shares sold pursuant to an option to the underwriters in connection with the offering) in an underwritten public offering at a price of $6.00 per share for aggregate net proceeds of $130.5 million.â€¢In August 2023, we entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of our common stock up to $125.0 million, from time to time, through an â€œat the marketâ€ equity offering program under which Jefferies will act as sales agent. As of MarchÂ 31, 2024, we have made no sales pursuant to the Sales Agreement.â€¢In December 2023, we sold 83.3 million shares of common stock in an underwritten public offering at a price of $1.50 per share for aggregate net proceeds of $118.1 million. â€¢In March 2024, we entered into the Loan Agreement for up to $175.0 million in debt financing.Sources of LiquidityCash FlowsThe following table summarizes our cash flow activity:For the three months ended March 31,20242023(in thousands)(As Restated)Net cash used in operating activities$(74,676)$(71,358)Net cash (used in) provided by investing activities(655)82,136Â Net cash provided by financing activities64,645Â 115,176Â Net (decrease) increase in cash, cash equivalents and restricted cash$(10,686)$125,954Â Operating Activities. The $3.3 million increase in cash used in operating activities for the three months ended MarchÂ 31, 2024 compared to the three months ended MarchÂ 31, 2023 was primarily due to the increase in net loss of $88.7 million, a decrease in net working capital of $9.0 million, a change in non-cash items including excess inventory reserves of $2.5 million, offset by no adjustments for the gain from the sale of priority review voucher of $92.9 million, which was sold in 2023, and by non-cash items including a change in depreciation and amortization expense of $9.3 million.Investing Activities. The $82.8 million decrease in cash provided by investing activities for the three months ended MarchÂ 31, 2024 compared to the three months ended MarchÂ 31, 2023 was primarily due to no proceeds from sale of priority review voucher, compared to $93.0 million in proceeds from sale of priority review voucher during the three months ended MarchÂ 31, 2023. Financing Activities. The $50.5 million decrease in cash provided by financing activities for the three months ended MarchÂ 31, 2024 compared to the three months ended MarchÂ 31, 2023 was primarily due to no proceeds from the secondary public offering, compared to $130.6 million in proceeds from the secondary public offering, net of paid offering costs during the three months ended MarchÂ 31, 2023, offset by the proceeds from the issuance of debt of $71.3 million during the three months ended March 31, 2024.Contractual Obligations and CommitmentsExcept as discussed in Note 9, Leases, and Note 10, Commitments and contingencies, in the Notes to Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes to our contractual obligations and commitments as included in our 2023 Annual Report on Form 10-K. ItemÂ 3. Quantitative and Qualitative Disclosures About Market RisksWe are exposed to market risk related to changes in interest rates. As of MarchÂ 31, 2024 and DecemberÂ 31, 2023, we had cash and cash equivalents of $212.0 million and $221.8 million, respectively, primarily invested in U.S. government agency securities and treasuries, corporate bonds, commercial paper, equity securities, and money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. 34Table of ContentsItemÂ 4. Controls and ProceduresLimitations on Effectiveness of Controls and ProceduresIn designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.Evaluation of Disclosure Controls and ProceduresOur management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13(a)- 15(e) and 15(d)- 15(e) under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€)), as of March 31, 2024, the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weakness in our internal control over financial reporting described below.In connection with the Companyâ€™s preparation of its financial statements and the restatement (as further described within Note 2, Restatement of Previously Issued Financial Statements to the consolidated financial statements appearing in the Annual Report on Form 10-K filed September 13, 2024), the Company identified a material weakness in its internal controls over financial reporting, which failed to prevent or detect the identified misstatements requiring restatement. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Companyâ€™s annual or interim financial statements will not be prevented or detected on a timely basis.Our management concluded that a material weakness existed as of December 31, 2023, and in prior periods, with respect to the design and operating effectiveness of the Companyâ€™s controls over the accounting for arrangements that contain a lease. Specifically, the Company did not: (i) design controls to properly apply the Company's accounting policy to combine lease and non-lease components in lease arrangements, including embedded leases, (ii) operate controls to review the identification of leases and lease elements and accounting for lease arrangements, including embedded leases and lease modifications, by individuals with appropriate knowledge and competency, and (iii) operate controls to review the accounting for embedded leases with contract manufacturing organizations and contract testing organizations by individuals with appropriate knowledge and competency to determine the appropriate lease classification, presentation and commencement date.This material weakness resulted in the restatement of the Companyâ€™s consolidated financial statements as of and for the year ended December 31, 2022, and the unaudited condensed consolidated financial information for each of the first three quarters of 2023 and 2022. Additionally, the material weakness could result in misstatements to the Companyâ€™s accounts and disclosures that would result in a material misstatement of the annual or interim consolidated financial statements that would not be prevented or detected.Remediation PlanOur management is committed to maintaining a strong internal control environment. In response to the identified material weakness above, management intends to take comprehensive actions to remediate the material weakness in internal control over financial reporting, including:â€¢reassess and enhance the design of existing internal controls over lease accounting and design and implement new or modified internal controls to ensure that financial statement assertion level risks (e.g. valuation, completeness, accuracy, presentation and disclosure) related to leases are addressed;â€¢strengthen the lease accounting technical knowledge and experience within the Company's accounting function to enhance the oversight of the processes related to accounting for leases and arrangements that could contain embedded leases or lease modifications;35Table of Contentsâ€¢conduct training for individuals responsible for performing and reviewing the accounting and presentation for leases and arrangements with contract manufacturing and contract testing organizations which could contain embedded leases or modifications.The remediation plan, when finalized, is expected to include a number of enhanced activities that reflect a continuation of activities the Company has started to undertake during the 2023 financial close process. We believe that the actions outlined above, when fully implemented, will remediate the material weakness. The material weakness will not be considered remediated, however, until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We may also conclude that additional measures may be required to remediate the material weakness in our internal control over financial reporting, which may necessitate additional implementation and evaluation time. We will continue to assess the effectiveness of our internal control over financial reporting and take steps to remediate the material weakness expeditiously.Changes in Internal Control over Financial ReportingOther than the changes associated with the material weakness and corresponding remediation procedures described above, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13(a)-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, during the first quarter of 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 36Table of ContentsPART II. OTHER INFORMATIONItemÂ 1. Legal ProceedingsIn the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements, employment and other matters. The outcome of these proceedings and claims cannot be predicted with certainty. We believe no governmental proceedings are pending or, to our knowledge, contemplated against us. We are not a party to any material proceedings in which any director, member of senior management or affiliate of ours is either a party adverse to us or our subsidiaries or has a material interest adverse to us or our subsidiaries.On October 21, 2021,

San Rocco Therapeutics, LLC, formerly known as Errant Gene Therapeutics, LLC, filed a complaint against us in the United States District Court for the District of Delaware for alleged infringement of U.S. Patent Nos. 7,541,179 and 8,058,061. The term of U.S. Patent No. 8,058,061 already expired on November 25, 2022, and U.S. Patent No. 7,541,179 will expire on May 13, 2024. The allegations relate to our use of the BB305 lentiviral vector, including in connection with the beti-cel program and seeks injunctive relief and money damages. On February 21, 2022, the parties stipulated to amend the case caption, in light of the plaintiffâ€™s name change, from Errant Gene Therapeutics, LLC to San Rocco Therapeutics, LLC ("SRT"). The Court granted this stipulation and, accordingly, the case is now captioned, San Rocco Therapeutics, LLC v. bluebird bio, Inc. and Third Rock Ventures, LLC, C.A. No. 21-1478-RGA. On April 6, 2022, weâ€”along with Third Rock Ventures, LLCâ€”filed a motion seeking various relief including to stay the proceedings and compel arbitration on two threshold issues, which we argued warranted complete dismissal of the action as a matter of law, regardless of the merits of SRTâ€™s underlying infringement claims. On July 26, 2022, the Court granted our request to stay the proceedings and issued an Order compelling the parties to arbitrate the threshold issues we raised. On February 7, 2023, the Arbitrator issued a final award finding in favor of SRT on both threshold issues, thereby enabling SRT to pursue its claims for alleged infringement. On March 1, 2023, the parties jointly stipulated, subject to the approval of the United States District Court for the District of Delaware, to lift the stay.â€¯ The Court lifted the stay on March 2, 2023, and on March 31, 2023, we filed our answer to SRT's complaint with counterclaims asserting that we do not infringe the patents-in-suit and that the patents-in-suit are invalid. Also, on April 22, 2024, the Patent Trial & Appeal Board of the U.S. PTO found that our two petitions for inter partes review did not show by a preponderance of the evidence that the challenged claims of the patents-in-suit are unpatentable, and we filed notices of appeal with the U.S. Court of Appeals for the Federal Circuit on June 21, 2024. Our opening brief is currently due on October 7, 2024, SRT's responsive brief is due November 13, 2024, and our reply brief is due December 4, 2024. We have requested an extension of the opening brief until December 6, 2024, which will adjust the responsive and reply brief deadlines if granted. On June 17, 2024, the Court entered a claim construction order in bluebird's favor. On July 17, 2024, the Court granted our request for leave to file a case-dispositive motion for summary judgment of noninfringement, and on July 25, 2024, the Court ordered a stay of discovery pending a decision on the summary judgment motion. On August 1, 2024, we filed our motion for summary judgment of noninfringement, SRT filed an opposition on September 3, 2024, and our reply is currently due September 17, 2024. We plan to vigorously defend against SRT's claims in this action. On April 27, 2023, SRT filed another complaint against us (as well as against Mr. Nick Leschly, Mr. Mitchell Finer, Mr. Philip Reilly, Third Rock Ventures LLC, and 2Seventy Bio, Inc.) in the United States District Court for the District of Massachusetts. This complaint alleges civil violations of the Federal Racketeer Influenced and Corrupt Organizations Act, violations of Mass. Gen. Laws ch. 93A, Â§ 11, and fraudulent inducement of SRT into a release provision in a November 2020 confidential settlement agreement we executed with, inter alia, SRT. The allegations relate to our use of the BB305 lentiviral vector, including in connection with the beti-cel program, and SRT seeks declaratory relief and money damages. On July 3, 2023, we (in conjunction with the other defendants) moved to dismiss all claims with prejudice brought by SRT in its Complaint for failure to state a claim upon which relief may be granted. On August 7, 2023, SRT filed an amended complaint, adding Craig Thompson as a defendant, and adding additional claims of alleged antitrust violations under federal and state law. The case is now captioned San Rocco Therapeutics, LLC v. Nick Leschly, Mitchell Finer, Philip Reilly, Craig Thompson, Third Rock Ventures LLC, bluebird bio, Inc. and 2Seventy Bio, Inc., C.A. No. 1:23-cv-10919-ADB. On September 18, 2023, we (in conjunction with the non-Thompson defendants), moved to dismiss with prejudice once again. SRT filed an opposition to that motion on October 12, 2023. On October 24, 2023, we filed a motion for leave to file a reply brief, which was granted on October 30, 2023. SRT filed a sur-reply brief on November 2, 2023. The motion to dismiss remains pending and we plan to vigorously defend against SRTâ€™s claims in this action.On April 15, 2024, SRT filed a Demand for Arbitration with the American Arbitration Association, accusing us of breaching a November 2020 confidential settlement agreement by initiating a proceeding before the Patent Trial & Appeal Board (PTAB) of the United States Patent & Trademark Office in October 2022, asserting invalidity of two patents licensed to SRT. SRT seeks reimbursement of its costs and fees, including attorneyâ€™s fees, incurred in the PTAB proceeding, totaling approximately $1.5 million. On August 26, 2024, the parties submitted their respective opening dispositive briefs, which remain 37Table of Contentspending. We believe SRTâ€™s breach claim has no merit and intend to vigorously defend against it.On March 28, 2024, a class action lawsuit captioned Garry Gill v. bluebird bio, Inc. et al., Case No. 1:24-cv-10803-PBS, was filed against us in the United States District Court for the District of Massachusetts. An amended complaint was filed on August 15, 2024. The amended complaint purports to assert claims against us and certain of our current and former officers pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, on behalf of a putative class of investors who purchased or otherwise acquired the Companyâ€™s shares between April 24, 2023 and December 8, 2023 (the â€œclass periodâ€). Plaintiff seeks to recover damages allegedly caused by purported misstatements and omissions regarding (i) whether the Company could obtain FDA approval for the lovo-cel BLA without a black box warning for hematologic malignancies; and (ii) whether the Company would be granted a priority review voucher by the FDA in connection with the BLA, which it could sell in order to strengthen its financial position. The amended complaint claims these alleged statements and omissions operated to artificially inflate the price paid for our common stock during the class period. On September 2, 2024, the Court entered the partiesâ€™ stipulated schedule for briefing a motion to dismiss the amended complaint: the opening brief in support of a motion to dismiss is due October 11, 2024; the opposition brief is due December 5, 2024; and a reply brief in further support of a motion to dismiss is due December 20, 2024. We intend to vigorously defend against the claims in this action. On June 27, 2024, a shareholder derivative lawsuit captioned Å imaitis v. Obenshain et al., Case No. 1:24-cv-11674-PBS, was filed nominally on our behalf against certain current and former members of Company management and the Board of Directors in the United States District Court for the District of Massachusetts. The complaint purports to assert derivative claims pursuant to Sections 10(b), 14(a), and 21D of the Securities Exchange Act of 1934, as well as for breach of fiduciary duties, unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control. Plaintiff seeks to recover damages on our behalf allegedly caused by purported materially false and misleading public statements and omissions, including in the April 28, 2023 proxy statement, regarding (i) whether the Company could obtain FDA approval for the lovo-cel BLA without a black box warning for hematologic malignancies; and (ii) whether the Company would be granted a priority review voucher by the FDA in connection with the BLA, which it could sell in order to strengthen its financial position. The complaint claims these allegedly misleading statements and omissions operated to artificially inflate the Companyâ€™s common stock price during the relevant time period. To support its derivative claims, the complaint alleges that a legally required pre-suit demand on the Board would be futile and should be excused. On July 25, 2024, the case was consolidated with Syracuse v. Obenshain et al., Case No. 1:24-cv-11752 (D. Mass. July 8, 2024). The consolidated actions were recaptioned In re bluebird bio, Inc. Stockholder Derivative Litigation, Case No. 1:24-cv-11674-PBS. Parties must submit a scheduling order to the Court by September 23, 2024. On July 8, 2024, a shareholder derivative lawsuit captioned Syracuse v. Obenshain et al., Case No. 1:24-cv-11752-PBS, was filed nominally on our behalf against certain current and former members of Company management and the Board of Directors in the United States District Court for the District of Massachusetts. The complaint purports to assert derivative claims against pursuant to Section 14(a) of the Securities Exchange Act of 1934, as well as for breach of fiduciary duties, gross mismanagement, waste of corporate assets, and unjust enrichment. Plaintiff seeks to recover damages on our behalf allegedly caused by purported materially false and misleading public statements and omissions, including in the April 28, 2023 proxy statement, regarding (i) whether the Company could obtain FDA approval for the lovo-cel BLA without a black box warning for hematologic malignancies; and (ii) whether the Company would be granted a priority review voucher by the FDA in connection with the BLA, which it could sell in order to strengthen its financial position. The complaint claims these allegedly misleading statements and omissions operated to artificially inflate the Companyâ€™s common stock price during the relevant time period. To support its derivative claims, the complaint alleges that a legally required pre-suit demand on the Board would be futile and should be excused. On July 25, 2024, the case was consolidated with Å imaitis v. Obenshain et al., Case No. 24-cv-11674 (D. Mass. July 27, 2024). The consolidated actions were recaptioned In re bluebird bio, Inc. Stockholder Derivative Litigation, Case No. 1:24-cv-11674-PBS. Parties must submit a scheduling order to the Court by September 23, 2024. ItemÂ 1A. Risk FactorsAn investment in shares of our common stock involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report on Form 10-Q, including our financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment.38Table of ContentsWe have incurred significant losses since our inception and we may not achieve our goal of becoming profitable in the timeframe we expect, or at all.We have incurred significant net losses since our inception in 1992, including net losses from continuing operations of $211.9 million for the year ended December 31, 2023. As of December 31, 2023, we had an accumulated deficit of $4.3 billion. To date, we have devoted significant financial resources to building our commercial infrastructure and research and development, including our clinical and preclinical development activities. We will continue to incur net losses for the foreseeable future and we may not become profitable on the timeline we anticipate, or at all. To date, we have financed our operations primarily through our loan agreement with Hercules Capital, Inc., the sale of equity securities and priority review vouchers, and, to a lesser extent, through collaboration agreements and grants from governmental agencies and charitable foundations. We did not generate material revenues from the sale of ZYNTEGLO in the European Union and are just beginning to recognize revenue from our approved products in the U.S. given the treatment cycle time, in which revenue is recognized upon infusion. Our future revenues will depend upon the size of any markets in which our products have received approval, and our ability to achieve sufficient market acceptance, reimbursement from third-party payers and adequate market share for our products in those markets. We anticipate that our expenses may increase substantially, we may continue to incur operating losses, and we may not generate profit if and as we: â€¢grow our capabilities to support our commercialization efforts for ZYNTEGLO, SKYSONA and LYFGENIA, including continuing to establish a sales, marketing and distribution infrastructure in the United States; â€¢obtain, build and expand manufacturing capacity, including capacity at third-party manufacturers; â€¢attract and retain skilled personnel; â€¢initiate additional research, preclinical, clinical or other programs as we seek to identify and validate additional product candidates;â€¢continue our ongoing and planned clinical development of ZYNTEGLO, SKYSONA and LYFGENIA, including completion of the HGB-210 clinical trial and long-term follow-up studies;â€¢acquire or in-license other product candidates and technologies; â€¢maintain, protect and expand our intellectual property portfolio; â€¢incur expenses for legal, accounting, and other professional services in connection with the restatement of our consolidated financial statements;â€¢defend against lawsuits, including patent or stockholder litigation; and â€¢experience any delays or encounter issues with any of the above.The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. Further, there is no assurance that we will ever achieve profitability. In addition, in any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our commercial programs, product development efforts or other operations.Based on our current business plan as of the date hereof, management has concluded that there is substantial doubt regarding our ability to continue as a going concern. See Part I, Item 2 â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Liquidity and Capital Resourcesâ€ of this Quarterly Report on Form 10-Q for a discussion 39Table of Contentsof our expected cash runway. Accordingly, we will need to raise additional funding in order to execute on our current business plans and strategy, including prior to becoming profitable or generating free cash flow.We cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity, traditional debt or other debt-like arrangements, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. See also "Risk Factors â€“ â€œOur existing and any future indebtedness could adversely affect our ability to operate our businessâ€. We could also be required to seek funds through arrangements with collaborative partners or otherwise, which may require us to relinquish rights to some of our technologies or products or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. In addition, our efforts to raise additional funding may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our products. Furthermore, as a result of the restatement of our consolidated financial statements for the year ended December 31, 2022 and the quarterly periods in the years ended December 31, 2022 and 2023, we were delayed in filing our Annual Report on Form 10-K and this Quarterly Report on Form 10-Q and we have not yet filed our Quarterly Report on Form 10-Q for the period ended June 30, 2024. As a result, we will not be eligible to sell securities under our existing shelf registration statement on Form S-3 or file a new Form S-3 until we have filed in a timely manner all required reports in accordance with the requirements of Form S-3. See "Risk Factor â€” The restatement of our consolidated financial statements for the year ended December 31, 2022 and the quarterly periods in the years ended December 31, 2022 and 2023 has subjected us to a number of additional risks and uncertainties, including increased possibility of legal proceedings". Our inability to use Form S-3 could make it more difficult and costly for us to obtain funding through a sale of securities.Moreover, as a result of recent volatile market conditions, the cost and availability of capital has been and may continue to be adversely affected. Lenders and institutional investors may reduce, and in some cases, cease to provide credit to businesses and consumers. Continued turbulence in the U.S. market and economy may adversely affect our liquidity and financial condition, including our ability to access the capital markets to meet liquidity needs. In addition, we maintain the majority of our cash and cash equivalents in accounts with major financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.If we are unable to obtain funding on a timely basis, or if revenues from collaboration arrangements or product sales are less than we have projected, we may be required to further revise our business plan and strategy, which may result in us significantly curtailing, delaying or discontinuing the commercialization of any current or future products or may result in our being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial condition and results of operations could be materially affected.Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome. Any such adverse events may require us to halt or delay further clinical development of our products or any future product candidates or to suspend or cease commercialization, and the commercial potential of our products and any such future product candidates may be materially and negatively impacted.Adverse events or other undesirable side effects caused by our products or any future product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay, denial or withdrawal of regulatory approval by the FDA or other comparable foreign regulatory authorities. A potentially significant risk in any gene therapy product using viral vectors that can integrate into the genome is that the vector will insert in or near cancer-causing genes, leading to the proliferation of certain cellular clones that could cause cancer in the patient, known as insertional oncogenesis. For instance, multiple patients with CALD treated with eli-cel (now SKYSONA) in our clinical studies have been diagnosed with myelodysplastic syndrome (â€œMDSâ€), or acute myeloid leukemia ("AML"), likely mediated byâ€¯Lenti-Dâ€¯LVV insertion. SKYSONAâ€™s label includes a boxed warning for the known risk of hematologic malignancy and, accordingly, we expect additional cases to arise over time. In April 2024, the boxed warning was revised to include updated information on hematologic malignancies diagnosed in our clinical study patients, as well as other updates to monitoring procedures and alternative treatment options. We continue to closely monitor potential cases of hematologic malignancy in patients treated with 40Table of ContentsSKYSONA and we are communicating regularly with treating physicians and regulatory authorities. We cannot make assurances that additional patients treated with SKYSONA, ZYNTEGLO or LYFGENIA in the

clinical or commercial setting will not be diagnosed with hematologic malignancy.Moreover, in December 2021, the FDA placed the lovo-cel clinical development program under a partial clinical hold for patients under the age of 18. The hold related to a case of persistent anemia in an adolescent patient with two Î±-globin gene deletions (â^'Î±3.7/â^'Î±3.7), also known as alpha-thalassemia trait, who was treated with lovo-cel. In December 2022, the FDA lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovo-cel for SCD. Notwithstanding the lifting of this partial clinical hold, additional adverse events or new data or analyses regarding previously reported events may indicate significant safety issues, and the FDA could potentially impose or reimpose a clinical hold in the future on studies evaluating lovo-cel. Moreover, laboratory results following gene therapy can be difficult to interpret, resulting in different or changing diagnoses by treating physicians. For instance, on January 31, 2023, we received a physician diagnosis of MDS in a patient treated with lovo-cel, in response to lab results obtained through routine monitoring of the same adolescent patient with two Î±-globin gene deletions subject to the partial clinical hold noted above. Consistent with established safety protocols, the information was reviewed by an independent Data Monitoring Committee which concluded that available evidence did not support a diagnosis of MDS and additional data would be needed to confirm such diagnosis, and that lovo-cel clinical studies should continue. Test results received since the investigatorâ€™s initial report (including integration site analysis) demonstrated no evidence of insertional oncogenesis and as of August 27, 2024, the patient remained clinically stable with stable laboratory results and was not undergoing treatment for an MDS diagnosis. Study investigators and the FDA were informed and we will continue to monitor additional analyses as further test results are received.Furthermore, treatment with our products and any future product candidates involves or may involve chemotherapy or myeloablative treatments, which can cause side effects or adverse events that may impact the perception of the potential benefits of our products and any future product candidates. For instance, MDS leading to AML is a known risk of certain myeloablative regimens. Accordingly, it is possible that the events of MDS and AML previously reported in our HGB-206 clinical study of lovo-cel in SCD were caused by underlying SCD, transplant procedure, and stress on the bone marrow following drug product infusion in connection with the lovo-cel treatment. The product label for LYFGENIA includes a boxed warning for the known risk of hematologic malignancy. Additionally, the procedures associated with the administration or collection of cells for ZYNTEGLO, SKYSONA, or LYFGENIA, could potentially cause other adverse events that have not yet been predicted. The inclusion of patients with significant underlying medical problems in our clinical studies may result in deaths, or other adverse medical events, due to other therapies or medications that such patients may be using, or the progression of their disease.Moreover, patients treated with our therapies, including lovo-cel, have exhibited persistent oligoclonality, which we define as two consecutive instances of (i) any LVV insertion site observed at >=10% relative frequency, or (ii) two or more insertion sites observed at >= to 5% relative frequency, as measured by integration site analysis. Based on our clinical protocols, we increase monitoring of patients who exhibit persistent oligoclonality. It is not clear at this time whether persistent oligoclonality represents an increased risk of developing hematologic malignancy in the future, but it is a criterion used by the FDA to evaluate the safety of gene therapies over time.Additionally, there is the potential risk of other delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material. The FDA has stated that LVVs possess characteristics that may pose high risks of delayed adverse events. If any such adverse events occur, including insertional oncogenesis, further advancement of our ongoing and future clinical studies and other development efforts could be halted or delayed, and we may be unable to commercialize our approved products in the manner we expect, or at all. It is possible that upon occurrence or recurrence of any of these events, the FDA may place one or more of our programs on hold, impose requirements that result in delays for regulatory approvals for our products or any future product candidates, require the implementation of risk evaluation or mitigation strategies, or may cause us to cease commercialization of our approved products. If any of these were to occur, the commercial potential of our programs may be materially and negatively impacted. Although ZYNTEGLO, SKYSONA and LYFGENIA have been approved by the FDA, serious safety events may result in an approved product being removed from the market or its market opportunity being significantly reduced. For instance, it is possible that as we commercialize our products, conduct long-term follow-up, or test any future product candidates in larger, longer and more extensive clinical trials, or as use of these products or any future products becomes more widespread, illnesses, injuries, discomforts and other adverse events that were observed in previous trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects (that may or may not be related to our 41Table of Contentsproducts or any future product candidate) are only detectable after investigational products are tested in large-scale clinical trials or, in some cases, after they are made available to patients on a commercial scale following approval. Other patients receiving our products may develop hematologic malignancies in the future, which may negatively impact the commercial prospects of our products and any future product candidates. We or others may later identify undesirable side effects or adverse events caused by such products, or side effects or adverse events could accumulate over time, and a number of potentially significant negative consequences could result, including but not limited to: â€¢regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution; â€¢regulatory authorities may require additional warnings on the label, including â€œboxedâ€ warnings, or issue safety alerts, "Dear Healthcare Provider" or "Dear Doctor" letters, press releases or other communications containing warnings or other safety information about the product; â€¢we may be required to change the way the product is administered or conduct additional clinical trials or post-marketing studies; â€¢we may be required to create a risk evaluation and mitigation strategy, or REMS which could include elements to assure safe use, or a medication guide outlining the risks of such side effects for distribution to patients; â€¢we may be subject to fines, injunctions or the imposition of criminal penalties; â€¢patients and/or treating physicians could perceive the risk of undesirable side effects or adverse events caused by the product to exceed its potential benefit and choose not to use the product;â€¢we could choose to remove such product from the market;â€¢we could be sued and held liable for harm caused to patients; and â€¢our reputation may suffer. Any of these events could impair our ability to develop or commercialize our products or any future product candidates, and their commercial potential may be materially and negatively impacted.We rely on complex, single-source supply chains for SKYSONA, ZYNTEGLO, and LYFGENIA, respectively. The manufacture, testing and delivery of LVV and drug products present significant challenges for us, and we may not be able to produce our vector and drug products at the quality, quantities, or timing needed to support our clinical programs and commercialization.We rely on third parties to manufacture the LVV and the drug product for ZYNTEGLO, SKYSONA and LYFGENIA. The manufacture of LVV and drug products is complex and requires significant expertise. Even with the relevant experience and expertise, manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production, managing the transition from clinical manufacturing to manufacturing in the commercial setting, and ensuring that the product meets required specifications. These problems include difficulties with production costs and yields, quality control, quality assurance testing, operator error, scarcity of qualified manufacturing and quality control testing personnel, shortages of any production raw materials as well as compliance with strictly enforced federal, state and foreign regulations. Further, the transition from clinical to commercial manufacturing is complex and has resulted in, and may continue to result in, lower operational success rates due to, among other things, tighter specifications and higher regulatory standards associated with commercial products. We cannot make any assurances that these problems will not occur in the future, or that we will be able to resolve or address in a timely manner or with available funds problems that occur. Because of this complexity, transitioning production of either LVV or drug products to backup or second source manufacturing requires a lengthy technology transfer process and regulatory review and approval, which often takes significant time and may require additional significant financial expenditures. We currently have only one manufacturer of final drug product and one manufacturer of LVV for both ZYNTEGLO and SKYSONA and, separately, one manufacturer of final drug product and one manufacturer of LVV for LYFGENIA; 42Table of Contentsaccordingly, any significant disruption or change in our supplier relationships could harm our business. For instance, we have recently provided notice to our manufacturer of LVV for ZYNTEGLO and SKYSONA that we intend to wind down production as we explore alternative manufacturing methods and plans for LVV used in these products. Further, we have experienced challenges in manufacturing adherent LVV, which is currently used in ZYNTEGLO and SKYSONA. As a result of these events, or other difficulties related to our manufacturing relationships and processes, we may be unable to meet our manufacturing forecasts. Any inability to meet our manufacturing forecasts could impact the ongoing commercialization of these drug products, and hinder our ability to meet our financial goals. Further, we source key materials from third parties, either directly through agreements with suppliers or indirectly through our manufacturers who have agreements with suppliers. There are a small number of suppliers for certain key materials that are used to manufacture SKYSONA, ZYNTEGLO, and LYFGENIA. Such suppliers may not sell these key materials to us or to our manufacturers at the times we need them or on commercially reasonable terms. We do not control the process for acquisition of all key materials and shortages may occur for reasons beyond our control.We continue to advance plans to make additional investment in manufacturing to expand capacity and, to date, we have secured adequate commercial-scale drug product manufacturing capacity in order to meet our near-term sales forecasts for ZYNTEGLO, SKYSONA and LYFGENIA, including recent approval to double our manufacturing capacity for ZYNTEGLO and SKYSONA; however, any plans to further expand our manufacturing capacity are subject to FDA approval, which we may not receive in connection with any planned expansions. If we fail to secure adequate capacity to manufacture our drug products or LVV used in the manufacture of our drug products in accordance with our forecasts we may be unable to execute on our commercialization plans on the timing that we expect, or at all. The actual cost to manufacture our LVV and drug products could be greater than we expect and could materially and adversely affect the commercial viability of SKYSONA, ZYNTEGLO, or LYFGENIA. If we or our third-party manufacturers are unable to produce the necessary quantities of LVV and drug product, or in compliance with GMP or other pertinent regulatory requirements, and within our planned time frame and cost parameters, including due to reduced operational success rates as a result of the transition to commercial manufacturing, the development and commercialization of our products and future product candidates may be materially harmed, result in delays in our plans or increased capital expenditures. Additionally, since the hematopoietic stem cells ("HSCs") used as starting material for our products have a limited window of stability following procurement from a patient, we have initially established transduction facilities in areas that we believe can adequately service patients from regions where we are commercializing SKYSONA, ZYNTEGLO, and LYFGENIA. However, we cannot ensure that such facilities will enable us to produce and deliver drug product in a timely manner; any issues with production and delivery of drug product could have a material adverse effect on our successful commercialization or further development of our products or any future product candidates. Moreover, establishing additional facilities in appropriate regions may be financially impractical or impeded by technical, quality, or regulatory issues related to these new sites and we may also run into technical or scientific issues related to transfer of our transduction process or other developmental issues that we may be unable to resolve in a timely manner or with available funds. Changes in our manufacturing processes may cause delays in our clinical development and commercialization plans.The manufacturing processes for our LVV and our drug products are complex. We explore improvements to our manufacturing processes on a continual basis, as we evaluate clinical and manufacturing data and based on discussions with regulatory authorities. In some circumstances, changes in the manufacturing process may require us to perform additional comparability studies, collect additional data from patients, submit additional regulatory filings, or comply with additional requirements, which may lead to delays in our clinical development and commercialization plans. Such changes may require regulatory review and approval including reaching agreement with the FDA on an acceptable comparability data package. The FDA may require us to conduct additional clinical studies, collect additional data, develop additional assays, or modify product specifications relating to such comparability analysis and, therefore, the proposed change may not be approved in a timely manner, if at all. Any such requests or delays may impact our commercialization plans and may require substantial additional funds.Risks related to commercialization We have limited experience as a commercial company and the marketing and sale of ZYNTEGLO, SKYSONA and LYFGENIA may be unsuccessful or less successful than anticipated.We have limited experience as a commercial company as we recently launched our three FDA-approved products, ZYNTEGLO, SKYSONA and LYFGENIA. Consequently, there is limited information about our ability to overcome many of 43Table of Contentsthe risks and uncertainties encountered by companies commercializing products in the biopharmaceutical industry in the U.S. To execute our business plan, we will need to successfully: â€¢sustain adequate pricing and reimbursement for ZYNTEGLO, SKYSONA and LYFGENIA across all U.S. payer segments; â€¢establish and maintain, in the regions where we hope to treat patients, relationships with qualified treatment centers who will be treating the patients who receive ZYNTEGLO, SKYSONA, and LYFGENIA;â€¢manage our manufacturing capabilities and supply chain operations in the coordination and delivery of drug product to patients at qualified treatment centers;â€¢manage our spending as we engage in commercialization efforts; â€¢manage the patient uptake process for each of our products, including with respect to overall timing and potential barriers such as clinical assessment periods and payer approval processes; andâ€¢initiate, develop and maintain successful strategic alliances. If we are not successful in accomplishing these objectives, we may not be able to effectively commercialize ZYNTEGLO, SKYSONA or LYFGENIA, raise capital, expand our business, or continue our operations. For instance, the phasing of LYFGENIA patient starts has affected the timing of our revenue expectations. If we are unable to meet our forecasts, our business may suffer.The commercial success of ZYNTEGLO, SKYSONA and LYFGENIA will depend upon the degree of market acceptance by physicians, patients, payers and other stakeholders. The commercial success of ZYNTEGLO, SKYSONA, and LYFGENIA will depend in part on the medical community, patients, and third-party or governmental payers accepting gene therapy products in general, and ZYNTEGLO, SKYSONA, and LYFGENIA, in particular, as medically useful, cost effective, and safe. ZYNTEGLO, SKYSONA, and LYFGENIA may not gain market acceptance by physicians, patients, payers and other stakeholders. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable and our future business prospects will be adversely impacted. The degree of market acceptance of ZYNTEGLO, SKYSONA, and LYFGENIA will depend on a number of factors, including: â€¢our ability to compete with alternative treatments, including other approved gene therapies for similar indications, including with respect to potential and perceived efficacy and other potential advantages;â€¢the prevalence and severity of any side effects, including any limitations or warnings contained in a productâ€™s approved labeling; for instance, each of the LYFGENIA and SKYSONA product labels includes a boxed warning for the risk of hematologic malignancy; â€¢the prevalence and severity of any side effects resulting from the chemotherapy and myeloablative treatments associated with the procedure by which our products are administered, including the possible prejudicial effects that chemotherapy can have on fertility; â€¢relative convenience and ease of administration, including patientsâ€™ willingness and ability to travel to qualified treatment centers within our network; â€¢given the complexity of manufacturing product and the reduced operational success rates in connection with the transition to commercial manufacturing, the perception or possibility that issues may continue to arise in the supply of product which could delay treatment;â€¢the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; 44Table of Contentsâ€¢the strength of marketing and distribution support and timing of market introduction of competitive products; â€¢the pricing of our products, including in comparison to competitors; â€¢publicity concerning our products, or competing products and treatments; â€¢sufficient insurance coverage or reimbursement;â€¢the possible occurrence of adverse clinical findings or decreased effectiveness of a product or product candidate over time identified during continued monitoring and evaluation of patients; and â€¢the mix of private and governmental payer coverage, which can impact both the total reimbursement for the drug and the time-to-reimbursement, and the conditions to coverage imposed by the various payers, including non-preferred or exclusion decisions in favor of our competitor.Even if a product displays a favorable efficacy and safety profile in clinical studies, market acceptance of the product will not be known until some period after it is launched. Our efforts to educate the medical community and payers on the benefits of our products may require significant resources and may never be successful. Our efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors. Any of these factors may cause ZYNTEGLO, SKYSONA, or LYFGENIA to be unsuccessful or less successful than anticipated. If the market opportunities for our commercial products or any future product candidates are smaller than we believe they are, and if we are not able to successfully identify patients and achieve significant market share, our revenues may be adversely affected and our business may suffer.Our platform focuses on treatments for severe genetic diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our products or any future product candidates we may develop, are based on estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients

may turn out to be lower or more difficult to identify than expected. Additionally, the potentially addressable patient populations for our products or any future product candidates may be limited or may not be amenable to treatment with such products or product candidates. For instance, each of the SKYSONA and LYFGENIA product labels includes a boxed warning for the risk of hematologic malignancy, which may impact market opportunity. Any of these factors may negatively affect our ability to generate revenues from sales of our products as forecasted and our ability to achieve and maintain profitability and, as a consequence, our business may suffer. We have limited sales and distribution experience and limited capabilities for marketing and market access. Although we have invested and expect to continue to invest significant financial and management resources, if we are unable to establish and maintain these commercial capabilities and infrastructure, or to enter into agreements with third parties to market and sell our products, we may be unable to generate sufficient revenue to sustain our business. We have limited prior sales or distribution experience and limited capabilities for marketing and market access, and we did not generate meaningful product sales following the commercial launch of ZYNTEGLO following marketing approval in Europe. To successfully commercialize ZYNTEGLO, SKYSONA, and LYFGENIA, we will need to further develop these capabilities. We may need to expand our infrastructure to further support commercial operations in the United States, either on our own or with others. Commercializing an autologous gene therapy is resource-intensive and has required, and will continue to require, substantial investment in commercial capabilities. We are competing with companies that currently have extensive and well-funded marketing and sales operations. Without significant commercial experience as a company or the support of a third party to perform these functions, including marketing and sales functions, we may be unable to compete successfully against these more established companies. Furthermore, a significant proportion of the patient populations for ZYNTEGLO, SKYSONA, and LYFGENIA lies outside of the United States. We currently expect to focus our operations and efforts on markets in the United States and will need to rely heavily on third parties for commercializing any products in geographies outside of the United States, if at all. We may enter into collaborations with third parties to utilize their mature marketing and distribution capabilities, but we may be unable 45Table of Contentsto enter into agreements on favorable terms, if at all. If we do not enter into collaboration arrangements with third parties to pursue regulatory authorization or commercialization of our programs for markets outside of the United States, or if our future collaborative partners do not commit sufficient resources to such efforts, we may be unable to generate sufficient revenue to sustain our business. We may encounter challenges with engaging or coordinating with qualified treatment centers needed for the ongoing commercialization of ZYNTEGLO, SKYSONA and LYFGENIA. Our commercial strategy is to engage apheresis and transplant centers as qualified treatment centers for the collection of patient HSCs and infusion of the drug product once manufactured. To ensure that the qualified treatment centers are prepared to collect patient HSCs and to ship them to our transduction facilities in accordance with our specifications and regulatory requirements, we train and conduct quality assessments of each center as part of engagement. These qualified treatment centers are the first and last points on our complex supply chain to reach patients in the commercial setting. We may encounter challenges or delays in engaging and interacting with our qualified treatment centers, and such challenges could impact a qualified treatment centerâ€™s willingness and ability to administer our products. Furthermore, we may fail to manage the logistics of collecting and shipping patient material to the manufacturing site and shipping the drug product back to the patient. Logistical and shipment delays and problems caused by us, our third-party vendors, and other factors not in our control, such as weather, could prevent or delay the manufacture of or delivery of drug product to patients. If our qualified treatment centers fail to perform satisfactorily, we may suffer reputational, operational, and business harm. Additionally, delays with infusion at the qualified treatment centers, due to, for instance, the patient's schedule or health condition or such centerâ€™s capacity or the availability of manufacturing slots at our CMOs, or due to the need for multiple cell collections, could result in a patient becoming medically ineligible for our treatment or selecting an alternative treatment, the drug product becoming unusable and loss of medical coverage, which would have a material adverse effect on commercial sales. These delays may also impact our relationship with our qualified treatment center network. Any failure in our engagement or interaction with our qualified treatment centers due to delays in treatment or complications related to manufacturing, among other things, may limit patient access to our therapies and, accordingly, have a material adverse effect on our commercial forecasts and business.We are required to maintain a complex chain of identity and chain of custody with respect to patient material as it moves through the manufacturing process, from the qualified treatment center to the transduction facility, and back to the patient. Failure to maintain chain of identity and chain of custody could result in adverse patient outcomes, loss of product or regulatory action.The insurance coverage and reimbursement status of newly-approved products in the United States is uncertain. Due to the novel nature of our technology and the potential for our products to offer lifetime therapeutic benefit in a single administration, we face unique and additional challenges in obtaining adequate coverage and reimbursement for our products. Failure to obtain or maintain adequate coverage and reimbursement for any new or current product, including to the extent that payers 'non-prefer' any or all of our therapies to our competitors, could limit our ability to market those products and decrease our ability to generate revenue.â€˜The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford healthcare, and especially expensive medicines, such as gene therapy products. Sales of our products depend substantially on the extent to which our products are covered by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or are reimbursed by government health administration authorities, private health coverage insurers and other payers. There is no assurance that payers will be willing to, or continue to, reimburse providers at the company-established list price or that reimbursement levels that payers will be willing to pay will be sufficient. Moreover, given that our therapies are generally administered in the inpatient care setting, it is important that our products are either reimbursed as a separate item from the underlying services incurred during the patientâ€™s hospitalization or that, if reimbursement for our therapies is â€œbundledâ€ with reimbursement for the hospital stay, the bundled payment rate adequately reflects the price of our therapy. We cannot assure you that payers will agree to either â€œseparate reimbursementâ€ or an appropriate bundled payment rate. Accordingly, the estimation of potential revenues is complex and it is difficult to predict what payers will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products.â€˜In the U.S., regional Medicare Administrative Contractors (â€œMACsâ€) are responsible for making a determination with regard to whether a new therapy meets the federal standard of â€œreasonable and necessaryâ€ such that it is covered and reimbursed by Medicare. For the Medicaid program, each State Medicaid Agency is responsible for establishing coverage 46Table of Contentscriteria, billing policies, and reimbursement rates for FDA-approved drugs. Reimbursement methodologies in Medicare and Medicaid can vary based on the type of therapeutic agent and setting of care, and for Medicaid, the reimbursement methodologies also vary by state. There is uncertainty with this process both in terms of the timing of the decision-making process and the coverage decision itself. We anticipate that Medicaid coverage will be significant for the potential patient population for our products. On the other hand, we anticipate that Medicare coverage will be less significant, given that only a small percentage of our patient population may be Medicare eligible. We expect these patients may be dually eligible for Medicare and Medicaid based on meeting federally-established disability standards, in which case Medicare serves as the primary payer and Medicaid as the secondary payer for any service not otherwise covered by Medicare that is covered under a State's Medicaid program. Moreover, increasing efforts by governmental and third-party payers to cap or reduce healthcare costs may cause such payers to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for ZYNTEGLO, SKYSONA, or LYFGENIA. The reimbursement policies of reinsurers, stop-loss carriers, and self-insured employers, including those that exclude coverage for gene therapies, could negatively impact our ability to market our therapies. We expect to experience pricing pressures in connection with the sale of our products due to greater scrutiny on list prices and total prescription drug spending across all payer channels as well as additional legislative changes at the state and federal level; moreover, public pressure from payers or negative public opinion regarding our list prices could affect the perception of our company and the value or cost-effectiveness of our therapies, which could impact our ability to successfully market our products. Further, net prices for drugs may be reduced by mandatory discounts or rebates required by government or private payers. As a result, increasingly high barriers are being erected to the entry of new products, often in the form of limiting the patient population for whom a new therapy is deemed â€œmedically necessary.â€â€˜â€˜Even if coverage is provided, the amount payers are willing to reimburse may not be sufficient.Furthermore, because a provider is responsible for costs associated not just with obtaining our medicines but also with the underlying hospital stay in which the administration of our therapies occurs, the pricing and reimbursement dynamics that impact patient access are not entirely within our control as providers and payers negotiate separately for the cost of the associated items and services, decisions in which we cannot and do not play a role. These services include the collection of HSCs from the patient, followed by chemotherapy and myeloablative treatments, and inpatient hospital stay following drug product infusion. If our customers are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our products will be adversely affected.â€˜We have entered into and continue to engage with payers across all channels around outcomes-based contracts for ZYNTEGLO and LYFGENIA. In the event that a payer opts for the outcomes-based contract, we will need to reserve a certain portion of revenue from each sale to account for the potential that a rebate will be owed if the pre-established outcome metric is not achieved over a designated period of time, which differs depending on the product and the agreement, following drug product administration. The amount of revenue reserved for a potential rebate depends on the product and payer type; for instance, our outcomes-based contract for ZYNTEGLO could require us to remit up to 80% of the cost of the therapy to a payer based on patient outcomes achieved. In the event that rebates are due under these contracts, we may be required to adjust revenue previously recognized. Despite our efforts to engage with CMS and work with experts to ensure all of our payer contracting efforts comply with relevant federal and state regulations, including government price reporting obligations, given the complexity of these arrangements, it is not possible to completely mitigate the risk that our interpretation differs from that of the regulatory authorities such that we may not be able to satisfy the compliance requirements, which may result in significant fines and liability. â€˜Collectively, these factors could affect our ability to successfully commercialize our products and generate or recognize revenues, which would adversely impact our business, financial condition, results of operations and prospects.â€˜ Risks related to the research and development of our products and any future product candidates We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are more advanced, safer or more effective than ours, which may adversely affect our financial condition and our ability to successfully develop and commercialize ZYNTEGLO, SKYSONA and LYFGENIA. We are engaged in the development and commercialization of gene therapies for severe genetic diseases, which is a competitive and rapidly changing field. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff, more experienced manufacturing capabilities, or more established commercial infrastructure. For instance, the FDA has 47Table of Contentsapproved a gene therapy for the treatment of sickle cell disease and beta thalassemia from Vertex Pharmaceuticals, Inc., which does not have a boxed warning and has a lower wholesale acquisition cost in the United States than that of LYFGENIA and ZYNTEGLO. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective, safer, or less costly than any products that we may develop, or achieve patent protection, marketing approval, product commercialization and market penetration earlier than us. Additionally, technologies developed by our competitors may render our products or any future product candidates uneconomical or obsolete. As a result of any of these factors, we may not be successful in marketing our products against competitors. Finally, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitorsâ€™ products. The availability of our competitorsâ€™ products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our products and any future product candidates.In order to obtain and maintain marketing approval from regulatory authorities for the commercialization of our products and future product candidates, we must conduct extensive clinical studies to demonstrate the safety, purity and potency, and/or efficacy, of the product candidates in humans. Clinical testing is expensive, time-consuming and uncertain as to outcome. There is a high failure rate for therapies proceeding through clinical studies. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical studies even after achieving promising results in earlier stage clinical studies. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development of our products and product candidates include:â€¢inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;â€¢delays or failure in obtaining regulatory authorization to commence a trial; â€¢delays in reaching agreement on acceptable terms with prospective contract research organizations (â€œCROsâ€), and clinical trial sites, and QTCs participating in post-approval registry studies, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; â€¢delays in identifying, recruiting and training suitable clinical investigators; â€¢delays in obtaining required IRB or ethics committee approvals at each clinical trial and/or QTC registry site; â€¢delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our future product candidates for use in clinical trials or the inability to do any of the foregoing; â€¢insufficient or inadequate supply or quality of drug product or other materials necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;â€¢imposition of a clinical hold by regulatory agencies, including after review of an IND or amendment or equivalent foreign application or amendment, as a result of a new safety finding that presents unreasonable risk to clinical trial participants or after an inspection of our clinical study operations or study sites or due to unforeseen safety issues; â€¢failure by our CROs, other third parties or us to adhere to clinical trial protocols or failure to perform in accordance with the FDAâ€™s or any other regulatory authorityâ€™s good clinical practice requirements (â€œGCPsâ€) or applicable regulatory guidelines in other countries; 48Table of Contentsâ€¢occurrence of adverse events associated with the product or product candidate that are viewed to outweigh its potential benefits, or occurrence of adverse events in trial of the same class of agents conducted by other companies, particularly due to the fact that we are required to follow patients in our clinical and registry studies for an extended period of time (up to 15 years); â€¢changes to the clinical trial protocols;â€¢clinical sites deviating from trial protocol or dropping out of a trial;â€¢changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; â€¢selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data;â€¢the cost of clinical trials of our products or future product candidates being greater than we anticipate; â€¢clinical trials of our products or future product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates; â€¢transfer of manufacturing processes to larger-scale facilities operated by a CMO and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; or â€¢changes in regulatory requirements and guidance that require amending or submitting new clinical protocols. Clinical trials must be conducted in accordance with the FDA and other applicable regulatory authoritiesâ€™ legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions where the clinical trials are conducted. Further, conducting clinical trials in foreign countries, as we may do for our products or any future product candidates, presents additional risks that may delay completion of clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the

denial of marketing approval of one or more of our products or product candidates.Delays in the completion of any clinical trial of our products or product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence or continue product sales and generate product revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.49Table of ContentsWe depend on enrollment of patients in our registry studies to complete required post marketing studies for our products, and on enrollment of patients in any future clinical trials we may conduct. If we experience delays or difficulties enrolling in our registry studies or any future clinical trials, our research and development efforts, business, financial condition, and results of operations could be materially adversely affected.Successful and timely completion of clinical trials, including additional trials that the FDA may require we complete prior to or as part of approval of our products or future product candidates, will require that we enroll a sufficient number of patient candidates. For instance, we are required to conduct long-term observational registry studies evaluating the safety of ZYNTEGLO, SKYSONA and LYFGENIA. These registry studies and other trials we may decide to conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, patient withdrawal or adverse events. These types of developments could cause us to delay the study or halt further development. If we are unable to complete required registry studies or any other post-marketing requirements under the terms specified by the FDA, we could be subject to FDA enforcement action, including restrictions on our ability to sell our products, misbranding charges and civil monetary penalties. Additionally, any future clinical trials we may conduct could compete with other clinical trials that are in the same therapeutic areas as any future product candidates, and this competition could reduce the number and types of patients available to us, as some patients who might have opted to enroll in our trials or to receive our commercial therapies may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators and clinical trial sites for the patient populations we pursue may be limited, we may conduct one or more future clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. In addition, there may be limited patient pools from which to draw for clinical studies. In addition to the rarity of some diseases, the eligibility criteria of future clinical studies may further limit the pool of available study participants as we may require that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a study.Patient enrollment depends on many factors, including:â€¢the size and nature of the patient population; â€¢the severity of the disease under investigation; â€¢eligibility criteria for the trial;â€¢the proximity of patients to clinical sites; â€¢the design of the clinical protocol;â€¢the ability to obtain and maintain patient consents; â€¢the ability to recruit clinical trial investigators with the appropriate competencies and experience; â€¢the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion;â€¢the availability of competing clinical trials; â€¢the availability of new drugs approved for the indication the clinical trial is investigating; and â€¢cliniciansâ€™ and patientsâ€™ perceptions as to the potential advantages of the drug being studied in relation to other available therapies. These factors may make it difficult for us to enroll enough patients to complete our registry studies or any future clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial may increase our costs, slow down our development process and could delay, or potentially jeopardize, our ability to obtain and maintain required regulatory approvals, commercialize our products or any future product candidates and generate revenue. 50Table of ContentsData from our clinical trials that we announce or publish from time to time may change as more patient data become available either through long-term patient follow-up and/or as such data are audited and verified, which could result in material changes to clinical and safety profiles for our products. From time to time, we may disclose top-line, interim or preliminary data from our clinical trials. Such data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. In addition, the clinical trials evaluating our products, and likely those evaluating any future product candidates, generally require that we continue to monitor and evaluate safety and efficacy in patients over an extended period of time following treatment, including for up to fifteen years for some studies, which may result in changes to the safety or efficacy profile over time. Changes in the efficacy and safety profile of our products or any future product candidates over time could significantly harm our business prospects including resulting in volatility in the price of our common stock.Additionally, preliminary or top-line data are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Interim data from clinical trials that we may conduct are further subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, the top-line, interim or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Further, disclosure of such data by us or by our competitors could also result in volatility in the price of our common stock. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our Company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If others, including regulatory authorities, disagree with the conclusions reached with respect to such information and assessments, our ability to obtain approval for, and commercialize, our products and any future product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.Although we have received accelerated approval from the FDA for SKYSONA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained. In September 2022, SKYSONA received accelerated approval from the FDA and we may in the future seek accelerated approval for one or more future product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsorâ€™s agreement to conduct, in a diligent manner, one or more additional confirmatory studies to verify and describe the drugâ€™s clinical benefit. If such post-approval studies fail to confirm the drugâ€™s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of the drug on an expedited basis. For example, we agreed to provide confirmatory long-term clinical data to the FDA as a condition of the SKYSONA accelerated approval, and continued approval for the approved indication will be contingent upon verification of clinical benefit with confirmatory clinical data. Moreover, certain payers, including state Medicaid agencies, may scrutinize therapies that reach the market through accelerated approval, which can lead to delays in broader access after approval and require additional company resources to address any concerns.51Table of ContentsIn addition, in December 2022, President Biden signed an omnibus appropriations bill to fund the U.S. government through fiscal year 2023. Included in the omnibus bill is the Food and Drug Omnibus Reform Act of 2022, which among other things, provided FDA new statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these provisions, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted.We did not receive a priority review voucher in connection with the FDA approval of LYFGENIA. Although we are pursuing the Formal Dispute Resolution process with the FDA, there is no guarantee that we will be successful or receive the voucher.In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a â€œrare pediatric diseaseâ€ that meets certain criteria may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval. We obtained a rare pediatric disease designation for lovo-cel for the treatment of SCD and in October 2023, we entered into an agreement to sell a priority review voucher, if received by March 31, 2024, for $103.0 million. However, upon FDA approval of LYFGENIA in December 2023, we did not receive a priority review voucher. We are pursuing the Formal Dispute Resolution process with the FDA to dispute this decision; however, the FDA dispute process is uncertain and there is no guarantee that we will receive the voucher. Moreover, the dispute process is time consuming and may result in substantial costs and distraction to our management. Because we did not receive a priority review voucher by March 31, 2024, the outside date under our previously announced sale agreement has passed and the buyer has the right to terminate the agreement at any time.Our biological products may face competition sooner than anticipated. The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (â€œBPCIAâ€), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or â€œbiosimilarâ€ product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. The 12-year exclusivity blocks the submission and approval of biosimilars under the abbreviated pathway only. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsorâ€™s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. This exclusivity is only available to the â€œfirst licensureâ€ of the reference biological product. If a biological product has a related structure to a previously licensed product from the same sponsor, it may not qualify as a first licensure. If LYFGENIA and ZYNTEGLO are considered to have a related structure, it is possible that LYFGENIA will not be granted its own 12-year exclusivity period and accordingly would be protected under ZYNTEGLO's 12-year exclusivity period. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace factors that are still developing. This may further incentivize the development of competing versions or our products under the full BLA pathway rather than the biosimilars pathway. Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our products and any future product candidates or adversely affect our ability to conduct our business or obtain and maintain marketing approvals for our products and any future product candidates.Public perception may be influenced by claims that gene therapy, including gene editing technologies, is unsafe or unethical, and research activities and adverse events in the field, even if not ultimately attributable to us or our products or any future product candidates, could result in increased governmental regulation, unfavorable public perception, challenges in recruiting patients to participate in our clinical studies, potential regulatory delays in the testing or approval of our products or any future product candidates, stricter labeling requirements for our approved products, and a decrease in demand for any such 52Table of Contentsproduct. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our products or any future product candidates or reduce demand for any approved products. Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could negatively impact our business.The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDAâ€™s or foreign regulatory authoritiesâ€™ ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDAâ€™s or foreign regulatory authoritiesâ€™ ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA may also slow the time necessary for new drugs, medical devices and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Separately, in response to the global COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations any resurgence of the virus or emergence of new variants may lead to inspectional or administrative delays. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.A Regenerative Medicine Advanced Therapy designation by the FDA, even if granted for any future product candidate, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that such future product candidate will receive marketing approval.We have obtained Regenerative Medicine Advanced Therapy (â€œRMATâ€) designation for LYFGENIA for the treatment of SCD, and we may seek additional RMAT designations for our future product candidates. A biological product candidate is eligible for RMAT designation if: (1) it meets the definition of a regenerative medicine therapy, which the FDA defines as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) the candidate is intended to treat, modify, reverse, or cure a serious disease or condition; and (3) preliminary clinical evidence indicates that the candidate has the potential to address unmet medical needs for such disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review of BLAs. Product candidates granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or through reliance upon data obtained from a meaningful number of sites, including through expansion to a sufficient number of sites, as appropriate. RMAT-designated product candidates that receive accelerated approval may, as appropriate, be able to fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence (such as electronic health records); through the collection of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the therapy.RMAT designation is within the sole discretion of the FDA. Accordingly, even if we believe one of our future product candidates meets the criteria for RMAT designation, the FDA may disagree and instead determine not to make such designation. RMAT

designation does not change the standards for product approval, and there is no assurance that such designation or eligibility for such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the RMAT designation. Additionally, RMAT designation can be revoked if the product candidate fails to meet the qualifications as clinical data continue to emerge.We have obtained orphan drug designation for our products, but we may be unable to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our product revenue, if any, to be reduced. We have obtained orphan drug exclusivity for certain diseases or conditions for LYFGENIA, ZYNTEGLO and SKYSONA. Under the Orphan Drug Act, the FDA may designate a biological product as an orphan drug if it is intended to 53Table of Contentstreat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Orphan drug designation must be requested before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, waivers from certain pediatric clinical trial requirements, and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. In addition, if a product candidate receives the first FDA approval for the disease or condition for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same disease or condition for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our collaborators seek approval for a disease or condition broader than the orphan designated disease or condition and may be lost if the FDA later determines that the request for designation was materially defective.Even if we obtain orphan drug designation for a future product candidate, we may not be the first to obtain marketing approval for any particular orphan disease or condition due to the uncertainties associated with developing pharmaceutical products. Further, we have received orphan drug exclusivity from the FDA for ZYNTEGLO for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusions; for SKYSONA for the slowing of progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy; and for LYFGENIA for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events. These orphan drug exclusivities, and any exclusivities we may obtain in the future may not effectively protect the product from competition because different drugs can be approved for the same disease or condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. Risks related to our reliance on third parties We rely on third parties to conduct some or all aspects of our LVV production, drug product manufacturing, and testing, and these third parties may not perform satisfactorily. We do not independently conduct all aspects of our LVV production, drug product manufacturing, and testing. We currently rely, and expect to continue to rely, on third parties with respect to these items, including manufacturing and testing in the commercial context. Our reliance on these third parties for manufacturing, testing, research and development activities reduces our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for products that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical studies are conducted in accordance with the study plan and protocols, and that our LVV and drug products are manufactured in accordance with GMP as applied in the relevant jurisdictions. If these third parties do not successfully carry out their contractual duties, including as a result of insolvency, meet expected deadlines, conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, or manufacture our LVV and drug products in accordance with GMP, we will not be able to support commercialization of SKYSONA, ZYNTEGLO and LYFGENIA. Many of our agreements with these third parties contain termination provisions that allow these third parties to terminate their relationships with us at any time. If we need to enter into alternative arrangements, our product development and commercialization activities could be delayed. Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the products ourselves, including:â€¢the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, including the inability to negotiate favorable terms to increase capacity to meet future forecasted demand; 54Table of Contentsâ€¢reduced control as a result of using third-party manufacturers for all aspects of manufacturing activities; â€¢the risk that these activities are not conducted in accordance with our study plans and protocols, including the potential for failed product batches that have resulted, and may in the future result, in delays in treatment of patients; â€¢termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; and â€¢disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including, for example, the bankruptcy or financial condition of the manufacturer or supplier. We may be forced to manufacture LVV and drug product ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different manufacturer, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills required to manufacture our LVV or future product candidates may be unique or proprietary to the original manufacturer, and we may have difficulty or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. Any of these events could lead to clinical study delays or impact our ability to obtain required regulatory approvals or successfully commercialize our products or any future product candidates. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production.We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our products, or those we may use for any future product candidates, are subject to extensive regulation. Some components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our products or any future product candidates that may not be detectable in final product testing. We or our contract manufacturers must adhere to the FDAâ€™s or other regulatorâ€™s good laboratory practices (â€œGLPâ€), and GMP regulations enforced by the FDA or other regulator through facilities inspection programs. Some of our contract manufacturers, particularly those we use for the commercial production of LYFGENIA, have not previously produced a commercially-approved product and therefore have not previously obtained the requisite FDA or other regulatory approvals to do so. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors may be required to successfully complete a pre-approval inspection for compliance with GMPs and other applicable regulations as a condition of certain regulatory approvals. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not successfully complete any required inspections, it is possible FDA or other marketing approvals may be delayed, prevented or otherwise adversely affected.The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third-party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.Further, any plans to expand our manufacturing capacity are subject to the review and approval of regulatory authorities and there is no guarantee that we will receive such approval on the timelines we anticipate. Delays in our expansion of manufacturing capacity could affect our ability to meet demand and could materially harm our business.If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other regulators can impose regulatory sanctions including, among other things, refusal to approve a pending application for a biologic product, or 55Table of Contentsrevocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed.Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. The number of manufacturers with the necessary manufacturing capabilities is limited. In addition, an alternative manufacturer would need to be qualified through a BLA supplement or similar regulatory submission which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.These factors could cause the delay of clinical studies, regulatory submissions, required approvals or commercialization of our products or any future product candidates, cause us to incur higher costs and prevent us from successfully commercializing our products or any future product candidates. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies or commercial production may be delayed and we could lose potential revenues. We rely on third parties to conduct, supervise and monitor our clinical studies, and if these third parties perform in an unsatisfactory manner, it may harm our business.We rely on CROs and clinical study sites to ensure our clinical studies are conducted properly and on time. While we will have agreements governing their activities, we will have limited influence over their actual performance. We will control only certain aspects of our CROsâ€™ activities. Nevertheless, we will be responsible for ensuring that each of our clinical studies is conducted in accordance with the applicable protocol and in accordance with applicable GCPs, GLPs and other legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with the FDAâ€™s and other regulatory authoritiesâ€™ GCPs for conducting, recording and reporting the results of clinical studies to assure that the data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical study participants are protected. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our future clinical studies may be deemed unreliable and the FDA and other regulatory authorities may require us to perform additional clinical studies before approving any marketing applications.If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical studies may be extended, delayed or terminated, and we may not be able to successfully commercialize our products or any future product candidates. As a result, our financial results and the commercial prospects for our products or any future product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.Because we rely on third parties to manufacture our vectors and our drug products, and because we collaborate with various organizations and academic institutions on the advancement of our gene therapy platform, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitorâ€™s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.In addition, these agreements typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided 56Table of Contentsthat we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitorâ€™s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. Risks related to our financial condition and capital requirements We have not generated material revenue from product sales and may never be profitable. Our ability to generate revenues and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully commercialize ZYNTEGLO, SKYSONA and LYFGENIA and other potential future product candidates (if and when approved). Our ability to generate revenues from product sales depends heavily on our success in: â€¢developing a sustainable, commercial-scale, reproducible, and transferable manufacturing process for our vectors and drug products; â€¢establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products and services to support clinical development for our product candidates and commercial demand for our approved products; â€¢launching and commercializing our approved products with a sustainable field-based team and marketing and distribution infrastructure; â€¢obtaining sufficient pricing and reimbursement for our approved products from private and governmental payers; â€¢obtaining market acceptance and adoption of our approved products and gene therapy as a viable treatment option; â€¢addressing any competing technological and market developments;â€¢completing research and preclinical and clinical development of future product candidates; â€¢seeking and obtaining regulatory and marketing approvals for future product candidates for which we complete clinical studies; â€¢negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; and â€¢maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how. We expect to continue to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase, which costs may increase further as competitors enter the market. Even if we are able to generate material product revenues, we may not become profitable and may need to obtain additional funding to continue operations.If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements are incorrect, our actual results may vary from those reflected in our projections and accruals. Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions 57Table of Contentsunderlying them, will be correct. We may be incorrect in our assumptions regarding the applicability of drug pricing programs and rebates that may be applicable to our products and future product candidates, which may result in our under- or over-estimating our anticipated product revenues especially as applicable laws and regulations governing pricing evolve over time. In addition, to the extent payment for our products and future product candidates is subject to outcomes-based arrangements over time, as it is for ZYNTEGLO and LYFGENIA, the total payments received from product sales may vary, our cash collection of future payments and revenue assumptions from product sales will be at risk, and the timing of revenue recognition will not correspond to the timing of cash collection. Further, from time to time we issue financial guidance relating to our expectations for our cash, cash equivalents,

and marketable securities available for operations, which guidance is based on estimates and the judgment of management. Moreover, our future net product revenues will depend upon the size of the markets in which the products have received approval, the ability to manufacture and deliver drug product to patients, the ability of such products to achieve sufficient market acceptance, reimbursement from third-party payers, adequate market share in those markets and performance of the drug product subject to outcome-based programs. If, for any reason, our expenses differ materially from our guidance or we utilize our cash more quickly than anticipated, we may have to adjust our publicly announced financial guidance. If we fail to meet, or if we are required to change or update any element of, our publicly disclosed financial guidance or other expectations about our business, including with respect to revenue generation, our stock price could decline. Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance. Our operating results are difficult to predict and will likely fluctuate from quarter to quarter and year to year. We expect that revenues from product sales will be difficult to predict from period to period, given the absence of significant historical sales data for ZYNTEGLO, SKYSONA, and LYFGENIA. Further, changes in our operations, such as undertaking of additional programs, or business activities, or entry into strategic transactions, including potential future acquisitions of products, technologies or businesses may also cause significant fluctuations in our expenses.The cumulative effects of these factors, further exacerbated by the impact of the ongoing volatility in macro-economic conditions, will likely result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. Our existing and any future indebtedness could adversely affect our ability to operate our business. On March 15, 2024, we entered into a Loan and Security Agreement, by and among the Company, the several banks and other financial institutions or entities party thereto, as lenders (the â€œLenderâ€), and Hercules Capital, Inc., as administrative agent and collateral agent, which we amended on April 30, 2024, July 9, 2024, August 13, 2024 and August 29, 2024 (as amended, the "LSA"). The LSA provides a secured term loan facility of up to $175.0 million (collectively, the â€œTerm Loansâ€), consisting of: (a) an initial tranche of term loans in an aggregate amount of $75.0 million, which was funded at closing (the â€œInitial Loanâ€); (b) an additional tranche of term loans in an aggregate amount of $25.0 million, which will be available, subject to customary terms and conditions, during the period commencing on the date the Company has (x) received at least $75.0 million in gross cash proceeds from qualified financing transactions by December 20, 2024 and (y) completed patient starts (cell collections) for at least 50 LYFGENIA patients by March 31, 2025 or 70 LYFGENIA patients by June 30, 2025 (the â€œTranche 2 Milestoneâ€) and ending on the earlier of (i) the date that is 30 days immediately following achievement of the Tranche 2 Milestone and (ii) July 31, 2025; (c) an additional tranche of term loans in an aggregate amount of $25.0 million, which will be available, subject to customary terms and conditions, during the period commencing on the date the Company has (x) received at least $100.0 million in gross cash proceeds from qualified financing transactions by December 20, 2024 or at least $125.0 million by June 30, 2025 and (y) completed 70 drug product deliveries within a given six-month period ending no later than December 31, 2025, at least 40 of which are for LYFGENIA (the â€œTranche 3 Milestoneâ€) and ending on the earlier of (i) the date that is 30 days immediately following the date the Company achieves the Tranche 3 Milestone and (ii) December 31, 2025; and (d) an additional tranche of term loans of $50.0 million, available in the sole discretion of the lenders, and subject to customary terms and conditions, until December 15, 2026. Although our entry into the LSA and receipt of funds thereunder 58Table of Contentsextends our cash runway, our outstanding indebtedness, including any additional indebtedness beyond our borrowings under the LSA, combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:â€¢requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund working capital, capital expenditures, product candidate development and other general corporate purposes; â€¢increasing our vulnerability to adverse changes in general economic, industry and market conditions; â€¢subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing; â€¢limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and â€¢placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. The Term Loans are secured by a lien on substantially all of our assets. We intend to satisfy our current and future debt service obligations with our then-existing cash and cash equivalents. However, we may not have sufficient funds, and may be unable to arrange for additional financing, to pay the amounts due under the LSA or any other debt instruments. Failure to make payments or comply with other covenants under the LSA or such other debt instruments could result in an event of default and acceleration of amounts due. Other events of default under the LSA include, among others: (i) the occurrence of any event that the Lender interprets as a material adverse effect (including potentially with respect to our declining cash position or negative data results), (ii) a change in control as delineated under the Loan Agreement, and (iii) breaches of covenants in the LSA, including, among others, a minimum liquidity requirement and a covenant that requires us to meet certain revenue levels; if we do not meet our projections, we may be unable to satisfy these covenants. Upon the occurrence and continuance of an event of default, the Lender has the right to require us to repay the Term Loans immediately, which we would be unable to do given our current cash position. Any declaration by the Lender of an event of default would significantly harm our business and prospects and could cause the price of our common stock to decline or force us to discontinue our operations immediately. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility. Amounts under our factoring arrangement are subject to terms that may adversely affect our operations and financial condition.We entered into an accounts receivable factoring agreement in December 2023. The factoring agreement provides for us to have access to up to $100.0 million on a revolving basis, measured by the outstanding balance of purchased accounts from time to time. Upon receipt of the upfront purchase price for any purchased accounts, we will have sold and assigned all of our rights in such purchased accounts and all proceeds thereof. The buyer has the right to require that we repurchase any purchased account that was ineligible as of the date of purchase or with respect to which any account debtor asserts a dispute that is not resolved by the related due date. The buyer does not have recourse to us for the insolvency or other credit risk of the account debtors. We have granted the buyer a security interest in the purchased accounts, and proceeds thereof, as more fully described in the agreement, in order to perfect the buyerâ€™s ownership interest in the purchased accounts and secure the payment and performance of all our obligations to the buyer under the agreement. If the buyer demands repurchase and we fail to do so, or if we cause or permit any other event of default as defined in the agreement, or fail to comply with covenants set forth in the agreement, we would be subject to additional expenses and lose access to this agreement to fund further accounts receivable. Such results could have a material adverse effect on our operations and financial condition.Risks related to our business operations Our future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel.We are highly dependent on our executive team and key employees, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are â€œat willâ€ employees. Recruiting and retaining other 59Table of Contentsqualified employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and our turnover rate has been high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, our financial condition has made it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive, key employee, consultant or advisor may impede the progress of our research, development and commercialization objectives. Our products remain subject to regulatory scrutiny.For any regulatory approvals that we have or may receive, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products and/or any future product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as ongoing compliance with cGMPs and GCPs for any clinical trials that we may conduct. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. Even though we have obtained regulatory approval in the U.S. for ZYNTEGLO, SKYSONA and LYFGENIA, any regulatory approvals we receive will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of such product, and such approvals may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA typically advises that patients treated with integrating gene therapy undergo follow-up observations for potential adverse events for a 15-year period. Furthermore, we have agreed to provide confirmatory long-term clinical data to the FDA as a condition of the SKYSONA accelerated approval, and continued approval for the approved indication will be contingent upon verification and description of clinical benefit in a confirmatory trial. If our confirmatory trials fail to adequately verify or describe the anticipated clinical benefit of SKYSONA, or if we fail to conduct such trials in a timely manner, the FDA could withdraw its approval for SKYSONA on an expedited basis.Additionally, the holder of an approved BLA is obligated to monitor and report adverse events. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. We have experienced interruptions in clinical programs due to safety concerns arising from our SKYSONA and LYFGENIA programs, and we can make no assurance that we will not experience interruptions in any clinical studies, marketing or other commercialization activities in the future, whether due to safety concerns in any approved or investigational products, or due to events arising from programs that utilize technologies similar to or related to ours. In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with good manufacturing practices ("GMP") and adherence to commitments made in the BLA. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we fail to comply with applicable regulatory requirements following marketing approval for a product, a regulatory agency may: â€¢issue a warning letter asserting that we are in violation of the law; â€¢seek an injunction or impose civil or criminal penalties or monetary fines; â€¢suspend or withdraw marketing approval; â€¢suspend any ongoing clinical studies; â€¢refuse to approve a pending marketing application, such as a BLA or supplements to a BLA submitted by us; â€¢seize product; or 60Table of Contentsâ€¢refuse to allow us to enter into supply contracts, including government contracts. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any approved product and generate revenues. The FDAâ€™s and other regulatory authoritiesâ€™ policies may change and additional government regulations may be promulgated that could prevent, limit or delay marketing authorization of any future product candidates we develop. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs and biologics. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval that the FDA grants is limited to those specific diseases and indications for which a product is deemed to be safe, pure and potent, or effective, by the FDA. For example, the current FDA-approved indication for ZYNTEGLO is limited to the treatment of adult and pediatric patients with Î²-thalassemia who require regular red blood cell transfusions; the FDA-approved indication for SKYSONA is limited to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active CALD, which is defined to include to asymptomatic or mildly symptomatic (neurologic function score, NFS â‰¤ 1) boys who have gadolinium enhancement on brain magnetic resonance imaging and Loes scores of 0.5-9; and the FDA-approved indication for LYFGENIA is limited to the treatment of sickle cell disease in patients ages 12 and older who have a history of VOEs. While physicians in the United States may choose, and are generally permitted, to prescribe drugs for uses that are not described in the productâ€™s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to manufacture and promote any products will be narrowly limited to those indications that are specifically approved by the FDA. If we are found to have manufactured and promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of any of our products, we could become subject to significant liability, which would materially adversely affect our business and financial condition.We are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws and false claims laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties, reputational harm, and diminished profits and future earnings. In the United States, the research, manufacturing, distribution, sale, and promotion of drugs and biologic products are subject to regulation by various federal, state, and local authorities in addition to FDA, including CMS, other divisions of the HHS, (e.g., the Office of Inspector General), the United States Department of Justice offices of the United States Attorney, the Federal Trade Commission and state and local governments. Our operations are directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations. These laws apply to, among other things, our sales, marketing, patient services and educational programs and include the following:â€¢the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs or other federal healthcare programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, 61Table of Contentspurchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution;â€¢the federal civil and criminal false claims laws, including the False Claims Act, or FCA, and civil monetary penalty laws, which prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;â€¢HIPAA, which created federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payer (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statutes or specific intent to violate them;â€¢the

Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Childrenâ€™s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;â€¢federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; andâ€¢analogous or related foreign, state or local laws and regulations, including anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.State and federal regulatory and enforcement agencies continue actively to investigate violations of health care laws and regulations, and the United States Congress continues to strengthen the arsenal of enforcement tools. Most recently, the Bipartisan Budget Act of 2018 increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the Anti-Kickback Statute. Enforcement agencies also continue to pursue novel theories of liability under these laws. In particular, government agencies have recently increased regulatory scrutiny and enforcement activity with respect to programs supported or sponsored by pharmaceutical companies, including reimbursement and co-pay support, funding of independent charitable foundations and other programs that offer benefits for patients. Several investigations into these programs have resulted in significant civil and criminal settlements. In addition, in July 2024, the Office of Inspector General (OIG) issued two negative opinions to pharmaceutical companies seeking to offer fertility support for gene therapy patients insured by Medicaid and other federal healthcare programs. OIG stated that it lacked data to conclude that the fertility support programs would pose a sufficiently low risk of fraud and abuse under the federal Anti-Kickback Statute to grant prospective immunity.62Table of ContentsBecause of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert the attention of our management from operating our business. Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition.In the U.S., HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their implementing regulations (collectively, "HIPAA"), imposes requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data), which are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. Certain states have also adopted comparable privacy and security laws and regulations, which govern the privacy, processing and protection of health-related and other personal information. For example, California enacted the California Consumer Privacy Act ("CCPA") which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. While there is currently an exception for certain clinical trial data, as currently written, the CCPA may impact our business activities. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has increased the likelihood of, and risks associated with data breach litigation. Further, the California Privacy Rights Act (â€œCPRAâ€) generally went into effect on January 1, 2023, and significantly amends the CCPA. It imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may also be required. Similar laws have passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.Furthermore, the Federal Trade Commission (â€œFTCâ€) has authority to initiate enforcement actions against entities that make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5(a) of the FTC Act. For example, according to the FTC, failing to take appropriate steps to keep consumersâ€™ personal information secure can constitute unfair acts or practices in or affecting commerce in violation of 63Table of ContentsSection 5(a) of the Federal Trade Commission Act. The FTC expects a companyâ€™s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. The FTC and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive, including by. regulating the presentation of website content.We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, in Europe, the European Union General Data Protection Regulation (â€œGDPRâ€) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area (â€œEEAâ€). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to â‚¬20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA, and the United States remains uncertain. Case law from the Court of Justice of the European Union (â€œCJEUâ€) states that reliance on the standard contractual clauses (â€œSCCsâ€) - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (â€œDPFâ€), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.Since the beginning of 2021, after the end of the transition period following the United Kingdomâ€™s departure from the European Union, we are also subject to the United Kingdom data protection regime, which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to Â£17.5 million or 4% of a noncompliant companyâ€™s global annual revenue for the preceding financial year, whichever is greater. On October 12, 2023, the United Kingdom Extension to the DPF came into effect (as approved by the United Kingdom Government), as a data transfer mechanism from the United Kingdom to U.S. entities self-certified under the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.We participate in governmental programs that impose extensive drug price reporting and payment obligations on pharmaceutical manufacturers. Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program (the â€œMDRPâ€), as a condition of federal funds being made available for our covered outpatient drugs under Medicaid and certain drugs or biologicals under Medicare Part B, we pay a rebate to state Medicaid programs for each unit of our covered outpatient drugs dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid rebates are based on pricing data that we report on a monthly and quarterly basis to CMS, the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the Average Manufacturer Price (â€œAMPâ€) for each drug and, in the case of innovator products, best price. In connection with Medicare Part B, a pharmaceutical manufacturer must provide CMS with average sales price (â€œASPâ€) information for certain drugs or biologicals on a quarterly basis. ASP is calculated based on a statutorily defined formula, as well as regulations and interpretations of the statute by CMS. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. If we fail to provide information on a timely basis or are found to have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, in which case payment would not be available for our covered outpatient drugs under Medicaid or, if applicable, Medicare Part B.Federal law requires that any company that participates in the MDRP also participate in the 340B program in order for federal funds to be available for the manufacturerâ€™s drugs under Medicaid and Medicare Part B. The 340B program is 64Table of Contentsadministered by HRSA and requires us, as a participating manufacturer, to agree to charge statutorily defined covered entities no more than the 340B "ceiling price" for our covered outpatient drugs when used in an outpatient setting.. To date, bluebirdâ€™s therapies have been administered in the inpatient setting exclusively and we anticipate that most patients will continue to receive bluebirdâ€™s therapies in an inpatient setting. However, in the event that patients are treated in an outpatient setting, the 340B â€œceiling priceâ€ requirement may apply to these transactions if otherwise eligible under 340B legal standards. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low income patients. A drug that is designated for a rare disease or condition by the Secretary of Health and Human Services is not subject to the 340B ceiling price requirement with regard to the following types of covered entities: rural referral centers, sole community hospitals, critical access hospitals, and free standing cancer hospitals. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We must report 340B ceiling prices to the HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized a revised administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if enacted, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, we must also participate in the VA/FSS pricing program. Under the VA/FSS program, we must report the Non-FAMP for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If we fail to provide timely information or are found to have knowingly submitted false information, we may be subject to civil monetary penalties.Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and states may impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts, which can change and evolve over time. Such pricing calculations and reporting, along with any necessary restatements and recalculations, could increase our costs for complying with the laws and regulations governing the MDRP and other governmental programs, and under the MDRP could result in an overage or undercharge in Medicaid rebate liability for past quarters. Price recalculations under the MDRP also may affect the ceiling price at which we are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B, if applicable, for our covered outpatient drugs. Pursuant to the Inflation Reduction Act of 2022 (the â€œIRAâ€), the AMP figures we report will also be used to compute rebates under Medicare Part D triggered by price increases that outpace inflation. We cannot assure you that our submissions will not be found to be incomplete or incorrect.We face potential product

liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our products or product candidates harm patients, or is perceived to harm patients even when such harm 65Table of Contentsis unrelated to our products or product candidates, our marketing approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims. The use of products and product candidates in clinical studies and the sale of products for which we have obtained marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients participating in clinical trials, consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products and any future product candidates. There is a risk that our products and any future product candidates may induce adverse events. For instance, each of the LYFGENIA and SKYSONA product labels includes a boxed warning for the risk of hematologic malignancy. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:â€¢impairment of our business reputation;â€¢withdrawal of clinical study participants; â€¢costs due to related litigation;â€¢distraction of managementâ€™s attention from our primary business;â€¢substantial monetary awards to patients or other claimants;â€¢the inability to develop our product candidates or commercialize any approved product; andâ€¢decreased demand for any approved product. We carry product liability insurance and we believe our product liability insurance coverage is sufficient in light of our current clinical programs and approved products; however, we may not be able to maintain insurance coverage at commercially reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.Patients with the diseases targeted by our products and product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our products and product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain marketing approval for any approved product, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products and product candidates the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our marketing approval process in other countries, or impact and limit the type of marketing approval our product candidates may receive or our approved products maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations. The increasing focus on environmental sustainability and social initiatives could increase our costs, harm our reputation and adversely impact our financial results.There has been increasing public focus by investors, patients, environmental activists, the media and governmental and nongovernmental organizations on a variety of environmental, social and other sustainability matters. We may experience pressure to make commitments relating to sustainability matters that affect us, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. If we are not effective in addressing environmental, social and other sustainability matters affecting our business, or setting and meeting relevant sustainability goals, our reputation and financial results may suffer. In addition, even if we are effective at addressing such concerns, we may experience increased costs as a result of executing upon our sustainability goals that may not be offset by any benefit to our reputation, which could have an adverse impact on our business and financial condition.66Table of ContentsIn addition, this emphasis on environmental and social matters has resulted in the adoption of new laws and regulations, including new reporting requirements, and may result in the adoption of additional laws and regulations in the future. New reporting requirements may be particularly difficult or expensive to comply with and, if we fail to comply, we may be required to issue financial restatements, suffer harm to our reputation or otherwise have our business be adversely impacted. Such ESG matters may also impact our suppliers or patients, which may adversely impact our business, financial condition and results of operations.In addition, this emphasis on environmental, social and other sustainability matters has resulted and may result in the adoption of new laws and regulations, including new reporting requirements. If we fail to comply with new laws, regulations or reporting requirements, our reputation and business could be adversely impacted.Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. The United States has enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell products for which we have obtained marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; (iv) additional record-keeping requirements; or (v) directly or indirectly limit the net price of sales to federal healthcare programs that form a substantial portion of our business. If any such changes were to be imposed, they could adversely affect the operation of our business. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payers have attempted to control costs by limiting coverage and the level of reimbursement for particular medical products and services, implementing reductions in Medicare and other healthcare funding and applying new payment methodologies. For example, in March 2010, the Affordable Care Act ("ACA") was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended manufacturer Medicaid rebate obligations to utilization by individuals enrolled in Medicaid managed care plans; established a Medicare Part D coverage gap discount program (to be replaced by a new program in 2025, as discussed below); subjected drug manufacturers to new annual fees based on pharmaceutical companiesâ€™ share of sales to federal healthcare programs; imposed a new federal excise tax on the sale of certain medical devices; created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011, among other things, led to reductions of Medicare payments to providers, which will remain in effect through 2032 unless additional Congressional action is taken. More recently, in March 2021, President Biden signed into law the American Rescue Plan Act of 2021, which eliminated the statutory cap on the Medicaid drug rebate beginning January 1, 2024. The rebate was previously capped at 100% of a drugâ€™s AMP.Most significantly, in August 2022, President Biden signed the Inflation Reduction Act of 2022 ("IRA") into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap (with resulting prices for the initial ten drugs first effective in 2026); imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. HHS has issued and will continue to issue and update guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.67Table of ContentsIn addition, the Center for Medicare and Medicaid Innovation initiated the Cell and Gene Therapy (â€œCGTâ€) Access Model in 2023. This voluntary payment model is designed to test whether a CMS-led approach to developing and administering outcomes-based agreements (OBAs) for cell and gene therapies would improve Medicaid beneficiariesâ€™ access to innovative treatment. If CMS proceeds with implementing the CGT model as currently anticipated, states may begin to participate in the model in 2025. The possible impact of the CGT model is uncertain.At the U.S. state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or provider reimbursement constraints, patient out-of-pocket cost caps for certain classes of therapy, discounts, restrictions on certain product access, marketing cost disclosure and other transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private third-party payers. There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products and any future product candidates. Such reforms could have an adverse effect on anticipated revenue from products and any future product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop such future product candidates. Our information technology systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of any future product candidatesâ€™ development programs and activities related to our approved products and have a material adverse effect on our reputation, business, financial condition or results of operations. We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business, including our mobile and web-based applications, our e-commerce platform and our enterprise software. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, clinical trial data, and personal information (collectively, â€œConfidential Informationâ€) of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information.Our information technology systems and those of our current or future third-party collaborators, service providers, contractors and consultants may fail and are vulnerable to attack, damage and interruption from computer viruses and malware (e.g. ransomware), misconfigurations, â€œbugsâ€ or other vulnerabilities, malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organizations, or persons with access to systems inside our organization. Attacks on information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and they are being conducted by increasingly sophisticated and organized groups and individuals with a wide range of motives and expertise. The prevalent use of mobile devices and unauthorized applications also increases the risk of data security incidents. As a result of the continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. There can also be no assurance that our and our current or future third-party collaboratorsâ€™, service providersâ€™, contractorsâ€™ and consultantsâ€™ cybersecurity risk management program and processes, including policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information.68Table of ContentsWe and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if we were to experience a system failure, accident or security breach that causes interruptions in our operations or the operations of third-party collaborators, service providers, contractors and consultants, it could result in significant reputational, financial, legal, regulatory, business or operational harm. For example, the loss of clinical trial data for any future product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or our products and any future product candidates, or inappropriate disclosure of Confidential Information, we could incur liabilities and the further development of any future product candidates could be delayed. In addition, we rely on third-party service providers for management of the manufacture and delivery of drug product to patients in the commercial context, including for chain of identity and chain of custody. We also rely on third-party service providers for aspects of our internal control over financial reporting and such service providers may experience a material system failure or fail to carry out their obligations in other respects, which may impact our ability to produce accurate and timely financial statements, thus harming our operating results, our ability to operate our business, and our investorsâ€™ view of us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to material failures, security breaches, cyberattacks and other related breaches.Any failure or perceived failure by us or any third-party collaborators, service providers, contractors or consultants to comply with our privacy, confidentiality, data security or similar obligations to third parties, or any data security incidents or other security breaches that result in the unauthorized access, release or transfer of sensitive information, including personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation or public statements against us. These events could cause third parties to lose trust in us or could result in claims by third parties asserting that we have breached our privacy, confidentiality, data security or similar obligations, any of which could have a material adverse effect on our reputation, business, financial condition or results of operations. While we have implemented data security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or data security incidents. Further, our insurance coverage may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.Risks related to the separation of our oncology programs and portfolio We may incur operational difficulties or be exposed to claims and liabilities as a result of the separation of 2seventy bio.On November 4, 2021, we distributed all of the outstanding shares of 2seventy bio, Inc. ("2seventy") common stock to our stockholders in connection with the separation of our oncology programs and portfolio. In connection with the distribution, we entered into a separation agreement and various other agreements (including a tax matters agreement, an employee matters agreement, transition services agreements and an intellectual property license agreement). These agreements govern the separation and distribution and the relationship between us and 2seventy going forward, including with respect to the assignment and assumption of assets and liabilities and potential tax-related losses associated with the separation and distribution. They also provide for the performance of services by each company for the benefit of the other for a period of time. As a result of the separation, we remain contractually liable in connection with certain agreements transferred to 2seventy; for instance, we may be liable in the event of a breach by 2seventy of an assigned lease agreement, which could result in material expenses. Although the separation agreement provides for indemnification obligations designed to make 2seventy financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation, we cannot guarantee that 2seventy will be able to satisfy its indemnification obligations, including as related to the lease agreement. It is also possible that a court would disregard the allocation agreed to between us and 2seventy and require us to assume responsibility for obligations allocated to 2seventy. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation agreement may not be sufficient to fully cover all of these liabilities and

obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to 2seventy, including those related to assets or liabilities allocated to us, may be significant. These risks could negatively affect our business, financial condition or results of operations. 69Table of ContentsIf the distribution of shares of 2seventy, together with certain related transactions, does not qualify as a transaction that is generally tax-free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.The completion of the distribution of shares of 2seventy was conditioned upon, among other things, our receipt of a private letter ruling from the U.S. Internal Revenue Service (the "IRS"), and an opinion from Goodwin Procter LLP, both satisfactory to our board of directors and both continuing to be valid, together confirming that the distribution, together with certain related transactions, generally is tax-free for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the U.S. Internal Revenue Code of 1986, as amended (the "Code"). We have received a favorable private letter ruling from the IRS addressing one significant issue of the qualification of the distribution under Section 355 of the Code. However, the private letter ruling does not address the remaining issues that are relevant to determining whether the distribution, together with certain related transactions, qualifies as a transaction that is generally tax-free for U.S. federal income tax purposes. This can include events that occur following the distribution such as subsequent public offerings by us or 2seventy or share sales to persons that engaged in negotiations over share purchases prior to the distribution. Subsequent tax opinions have been obtained by us and 2seventy in connection with certain post-distribution sales of 2seventy's shares. The IRS private letter ruling, the opinion of Goodwin Procter LLP and tax opinions related to certain subsequent post-distribution sales of 2seventy shares were based, among other things, on various facts and assumptions, as well as certain representations, statements and undertakings from us and 2seventy (including those relating to the past and future conduct of us and 2seventy) and were subject to certain caveats. If any of these facts, assumptions, representations, statements or undertakings is, or becomes, inaccurate or incomplete, or if we or 2seventy breach any of our respective covenants relating to the separation, the IRS private letter ruling and tax opinion may be invalid. Moreover, the opinion is not binding on the IRS or any courts. Accordingly, notwithstanding receipt of the IRS private letter ruling and an opinion of Goodwin Procter LLP at the time of the distribution, the IRS could determine that the distribution and certain related transactions should be treated as taxable transactions for U.S. federal income tax purposes.If the distribution, together with certain related transactions, were to fail to qualify as a transaction that is generally tax-free under Sections 355 and 368(a)(1)(D) of the Code, in general, for U.S. federal income tax purposes, we would recognize taxable gain as if we have sold 2seventyâ€™s distributed common stock in a taxable sale for its fair market value and our stockholders who receive shares of 2seventy common stock in the distribution would be subject to tax as if they had received a taxable distribution equal to the fair market value of such shares.In connection with the distribution, we and 2seventy entered into a tax matters agreement pursuant to which each party is responsible for certain liabilities and obligations following the distribution. In general, under the terms of the tax matters agreement, if the distribution, together with certain related transactions, were to fail to qualify as a transaction that is generally tax-free for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Code, and if and to the extent that such failure results from a prohibited change of control in us under Section 355(e) of the Code, or an acquisition of our stock or assets or certain actions, omissions or failures to act, by us, then we will bear any resulting taxes, interest, penalties and other costs. If and to the extent that such failure results from a prohibited change of control in 2seventy under Section 355(e) of the Code or an acquisition of 2seventy stock or assets or certain actions by 2seventy, then 2seventy will be obligated to indemnify us for any resulting taxes, interest, penalties and other costs, including any reductions in our net operating loss carryforwards or other tax assets. If such failure does not result from a prohibited change of control in us or 2seventy under Section 355(e) of the Code and both we and 2seventy are responsible for such failure, liability will be shared according to relative fault. If neither we nor 2seventy is responsible for such failure, we will bear any resulting taxes, interest, penalties and other costs. Risks related to our intellectual property If we are unable to obtain or protect intellectual property rights related to our products, we may not be able to compete effectively in our markets.We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our products. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our products in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our products, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our products or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.70Table of ContentsIf the patent applications we hold or have in-licensed with respect to our programs or our products fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our products, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize our current and future products. Several patent applications covering our products have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any future product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product or product candidate under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by a third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available however the life of a patent, and the protection it affords, is limited. Even if patents covering our products are obtained, once the patent life has expired for a product, we may be open to competition from generic medications.In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, and information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDAâ€™s disclosure policies may change in the future, if at all.Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex parte reexaminations, post-grant review, and inter partes review proceedings before the U.S. Patent and Trademark Office (â€œU.S. PTOâ€) and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products may be subject to claims of infringement of the patent rights of third parties.71Table of ContentsThird parties have asserted and in the future may assert that we are employing their proprietary technology without authorization. For example, as discussed in Part II, Item 1, â€œLegal Proceedingsâ€, San Rocco Therapeutics, LLC, formerly known as Errant Gene Therapeutics, LLC has alleged that our use of the BB305 lentiviral vector, including in connection with the beti-cel program infringes U.S. Patent Nos. 7,541,179 and 8,058,061, and seeks equitable, injunctive and monetary relief, including royalties, treble damages, attorney fees and costs. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe.In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our products, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further commercialize one or more of our products. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneyâ€™s fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.We may not be successful in obtaining or maintaining necessary rights to gene therapy product components and processes for our programs through acquisitions and in-licenses.Presently we have rights to the intellectual property, through licenses from third parties and under patents that we own, to manufacture and commercialize our products. Because our programs may involve additional technologies that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. For instance, we may elect to leverage advancements in complementary technologies such as in reduced toxicity conditioning or in stem cell mobilization. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or clinical development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institutionâ€™s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. Pursuant to an intellectual 72Table of Contentsproperty license agreement with 2seventy, we granted sublicenses to 2seventy to certain existing license agreements. If we fail to comply with our obligations under these agreements, we or 2seventy materially breach these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.We may need to obtain licenses from third parties to advance the development of future product candidates or allow commercialization of our products, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected products or product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our approved products, or future products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.In many cases, patent prosecution of our licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including:â€¢the scope of rights granted under the license agreement and other interpretation-related issues;â€¢the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;â€¢the sublicensing of patent and other rights under our collaborative development relationships;â€¢our diligence obligations under the license agreement and what activities satisfy those diligence obligations;â€¢the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; andâ€¢the priority of invention of patented technology.If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected approved products or product candidates.We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be

expensive, time-consuming and unsuccessful.Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the 73Table of Contentsvalidity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our products and product candidates. Such a loss of patent protection would have a material adverse impact on our business.Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employeeâ€™s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We have had in the past, and we may also have in the future, ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our products and product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the U.S. PTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The U.S. PTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.74Table of ContentsChanges in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our potential products.As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.We may not be able to protect our intellectual property rights throughout the world.Filing, prosecuting and defending patents on our products and any future product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.Risks related to ownership of our common stockThe market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above the price at which you purchase them.Companies trading in the stock market in general, and The Nasdaq Global Select Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and biotechnology and pharmaceutical industry factors, such as the recent volatility and disruption experienced in the global economy and rising interest and inflation rates, may negatively affect the market price of our common stock, regardless of our actual operating performance.The market price of our common stock has been volatile in the past, and may continue to be volatile for the foreseeable future. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:â€¢adverse results or delays in preclinical or clinical studies;â€¢reports of adverse events, either from patients participating in our clinical trials or in connection with sales of our commercial products or other gene therapy products in the market;â€¢inability to obtain additional funding;75Table of Contentsâ€¢failure to successfully manage and sustain the commercial launch of ZYNTEGLO, SKYSONA or LYFGENIA, including failure to manage our supply chain operations in the coordination and delivery of drug product to patients at qualified treatment centers;â€¢failure to obtain sufficient pricing and reimbursement for ZYNTEGLO, SKYSONA or LYFGENIA from private and governmental payers;â€¢failure to obtain market acceptance and adoption of ZYNTEGLO, SKYSONA or LYFGENIA;â€¢failure to maintain our existing strategic collaborations or enter into new collaborations;â€¢failure by us or our licensors and strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights;â€¢changes in laws or regulations applicable to future products;â€¢inability to obtain adequate product supply for ZYNTEGLO, SKYSONA or LYFGENIA, or the inability to do so at acceptable prices;â€¢adverse regulatory decisions;â€¢announcements of clinical trial results or progress in the development of programs by our competitors, and the introduction of new products, services or technologies by our competitors;â€¢failure to meet or exceed financial projections we may provide to the public;â€¢failure to meet or exceed the financial projections of the investment community;â€¢the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;â€¢announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partner or our competitors;â€¢disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;â€¢additions or departures of key scientific or management personnel;â€¢significant lawsuits, including patent or stockholder litigation;â€¢changes in the market valuations of similar companies;â€¢global macroeconomic conditions, including as impacted by geopolitical conflicts and war;â€¢sales of our common stock by us or our stockholders in the future; andâ€¢trading volume of our common stock.76Table of ContentsThe restatement of our consolidated financial statements for the year ended December 31, 2022 and the quarterly periods in the years ended December 31, 2022 and 2023 has subjected us to a number of additional risks and uncertainties, including increased possibility of legal proceedings.As discussed elsewhere in this Quarterly Report, our management determined that our consolidated financial statements for the year ended December 31, 2022 and the quarterly periods in the years ended December 31, 2022 and 2023 should be restated due to errors relating to our accounting for lease arrangements, including embedded leases, and the application of our accounting policy for the treatment of non-lease components in lease arrangements, including embedded leases. The restatement of our consolidated financial statements has caused us to incur substantial expenses for legal, accounting, and other professional services and has diverted our managementâ€™s attention from our business and could continue to do so. As a result of the restatement, we were delayed in filing our Annual Report on Form 10-K and this Quarterly Report on Form 10-Q, and we have not yet filed our Quarterly Report on Form 10-Q for the period ended June 30, 2024. There can be no assurance that we will be able to timely file our required reports for future periods. In addition, as a result of the restatement, investors may lose confidence in our financial reporting, the price of our common stock could decline and we may be subject to litigation or regulatory enforcement actions.We have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls.A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a companyâ€™s annual or interim financial statements will not be prevented or detected on a timely basis. We identified a material weakness in our internal controls related to our accounting for lease arrangements, including embedded leases, and the application of our accounting policy for the treatment of non-lease components in lease agreements, including embedded leases. The material weakness resulted in the restatement of the Company's previously issued consolidated financial statements for the year ended December 31, 2022 and the quarterly periods in the years ended December 31, 2022 and 2023. As a result of the material weakness, our management concluded that our internal control over financial reporting was not effective as of December 31, 2023. Additionally, the material weakness in our internal control over financial reporting has resulted in our management concluding that our disclosure controls and procedures were not effective as of December 31, 2023.Our management, under the oversight of the Audit Committee of our Board of Directors and in consultation with outside advisors, has begun evaluating and implementing measures designed to remediate the material weakness. Management intends to implement enhancements to its internal control over financial reporting, which are expected to include refinements and enhancements to the complement of personnel, design and operation of its controls related to the accounting for, and identification of, leases. The Company intends to begin to implement these enhancements to the design of its controls during 2024. However, this material weakness will not be considered remediated until management designs and implements effective controls that operate for a sufficient period of time and management has concluded, through testing, that these controls are effective. The Company will monitor the effectiveness of the remediation plan and will refine the remediation plan, as needed. Until remediated, the material weakness could result in future errors to the Companyâ€™s financial statements.In addition, we cannot assure you that the measures we are taking will be sufficient to remediate the material weakness or avoid the identification of additional material weaknesses in the future. Our failure to implement and maintain effective internal control over financial reporting could result in the identification of additional errors in our consolidated financial statements that could result in a further restatement of our financial statements and could cause us to fail to meet our periodic reporting obligations, any of which could diminish investor confidence in us, cause a decline in the price of our common stock and subject us to litigation or regulatory enforcement actions.There can be no assurance that we will be able to comply with the continued listing standards of Nasdaq.On April 24, 2024, we received a notification from the listing qualifications department of Nasdaq indicating that as a result of the untimely filing of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, we were not in compliance with the requirements for continued listing under Listing Rule 5250(c)(1) (the â€œListing Ruleâ€), which requires listed companies to timely file all required periodic financial reports with the SEC. On July 15, 2024, Nasdaq granted us a grace period of 180 calendar days from the due date of the Form 10-K, or until October 14, 2024, in which to regain compliance with the Listing Rule. On August 20, 2024, we received additional notifications from Nasdaq with respect to the untimely filing of our Quarterly Reports on Form 10-Q for the three-month periods ended March 31, 2024 and June 30, 2024. In order to regain compliance with the Listing Rule, we must file our Annual Report and both Quarterly Reports by October 14, 2024. We have filed our Form 10-K and this Form 10-Q for the three months ended March 31, 2024; however, we have not yet filed our Form 10-Q for the quarter ended June 30, 2024.77Table of ContentsIf we fail to comply with the Listing Rule by October 14, 2024, our common stock could be delisted from Nasdaq. The delisting of our common stock from Nasdaq may make it more difficult for us to raise capital on favorable terms in the future. Such a delisting would likely lead to a limited amount of analyst coverage, have a negative effect on the price of our common stock and impair our stockholdersâ€™ ability to sell or purchase our common stock. In addition, a delisting could cause our stock to be deemed a â€œpenny stock,â€ which would require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities. There can be no assurance that we will come back into compliance with the Listing Rule or that we will not receive future notifications regarding noncompliance with any of the requirements for continued listing on Nasdaq.Actual or potential sales of our common stock by our employees, including our executive officers, pursuant to pre-arranged stock trading plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual or potential sales by such persons could be viewed negatively by other investors.In accordance with the guidelines specified under Rule 10b5-1 of the Securities

Exchange Act of 1934, as amended, and our policies regarding stock transactions, a number of our employees, including executive officers and members of our board of directors, have adopted and may continue to adopt stock trading plans pursuant to which they have arranged to sell shares of our common stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Actual or potential sales of our common stock by such persons could cause the price of our common stock to fall or prevent it from increasing for numerous reasons.Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.Pursuant to our 2023 Incentive Award Plan (the "2023 Plan") we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The 2023 Plan authorizes the issuance of up to 5.2 million shares. We also make equity grants to certain new employees joining the Company pursuant to an inducement plan, and our compensation committee may elect to increase the number of shares available for future grant under the inducement plan without stockholder approval. We also have an Employee Stock Purchase Plan and any shares of common stock purchased pursuant to that plan will also cause dilution.We may be subject to litigation, which may result in substantial costs and a diversion of management's attention and resources, which could harm our business.In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities, and we have in the past litigated class action complaints in the United States District Court for the District of Massachusetts and for the District of Delaware, filed by purported stockholders against us and certain of our directors and officers. For instance, on March 28, 2024, a class action lawsuit captioned Garry Gill v. bluebird bio, Inc. et al., Case No. 1:24-cv-10803-PBS, was filed against us in the United States District Court for the District of Massachusetts and we may face additional securities class action litigation in the future. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years, and we expect to experience continued stock price volatility. Separately, two purported bluebird shareholders, derivatively and purportedly on behalf of bluebird, have each filed a shareholder derivative action in the United States District Court for the District of Massachusetts against our directors and certain members of management alleging, among other things, breaches of their fiduciary duties. Defending against our current and any future litigation could result in substantial costs and a diversion of managementâ€™s attention and resources, which could harm our business.We are also a party to litigation and subject to claims incident to the ordinary course of business. For instance, as discussed in Part II, Item 1, â€œLegal Proceedingsâ€, San Rocco Therapeutics, LLC, has filed a complaint against us in the United States District Court for the District of Massachusetts, alleging, among other things, civil violations of the Federal Racketeer Influenced and Corrupt Organizations Act, and antitrust violations under state and federal law and seeking declaratory relief and money damages. Although we believe that these claims have no merit, the outcome of litigation is inherently unpredictable. 78Table of ContentsAn adverse result in any litigation could materially harm our financial condition, reputation and business. Regardless of the outcome, litigation can have an adverse impact on us because of defense costs, diversion of management resources and other factors.Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.Under Sections 382 and 383 of the Code, if a corporation undergoes an â€œownership change,â€ generally defined as a cumulative change of greater than 50% (by value) in its equity ownership over a three-year period, the corporationâ€™s ability to use its pre-change net operating loss carryforwards ("NOLs") and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income and taxes may be limited. We have completed several financings since our inception, which we believe have resulted in shifts in our equity ownership. We completed a study through December 2023 confirming no ownership changes have occurred since our initial public offering in 2013. We may have experienced ownership changes since December 2023, and we may also experience ownership changes in the future as a result of subsequent shifts in our equity ownership, some of which are outside our control. There is a significant likelihood that we will experience an ownership change as a result of future equity offerings, although whether we experience an ownership change will depend on the specific facts that apply at the time of any offering. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-change NOLs or other pre-change tax attributes if we undergo a future ownership change. Accordingly, if we earn net taxable income, our ability to use our pre-change NOLs and other pre-change tax attributes to offset U.S. federal taxable income may be subject to limitations, which could potentially result in significant increased future tax liability to us, which could materially adversely affect our profitability and cash position. In addition, at the state level, there may be periods during which the use of NOLs and other pre-change tax attributes is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.We do not intend to pay cash dividends on our common stock so any returns will be limited to the value of our stock.We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.Provisions in our amended and restated certificate of incorporation and by-laws, as well as provisions of Delaware law, could make it more difficult for a third-party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.Our amended and restated certificate of incorporation, amended and restated by-laws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and by-laws, include provisions that:â€¢authorize â€œblank checkâ€ preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;â€¢create a classified board of directors whose members serve staggered three-year terms;â€¢specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, our chief executive officer or our president;â€¢prohibit stockholder action by written consent;â€¢establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;â€¢provide that our directors may be removed only for cause;â€¢provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;â€¢specify that no stockholder is permitted to cumulate votes at any election of directors;79Table of Contentsâ€¢expressly authorize our board of directors to modify, alter or repeal our amended and restated by-laws; andâ€¢require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated by-laws.These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.Any provision of our amended and restated certificate of incorporation or amended and restated by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.Our amended and restated certificate of incorporation and amended and restated by-laws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us.Our amended and restated certificate of incorporation and amended and restated by-laws specify that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders, other than suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) or any other claim for which the federal courts have exclusive jurisdiction and any action that the Court of Chancery of the State of Delaware has dismissed for lack of subject matter jurisdiction, which may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated by-laws also specify that, unless we consent in writing to the selection of an alternate forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the â€œSecurities Actâ€). Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation and amended and restated by-laws described above.We believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes or federal judges experienced in resolving Securities Act disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees, and agents as it may limit any stockholderâ€™s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees, or agents and result in increased costs for stockholders to bring a claim. The enforceability of similar choice of forum provisions in other companiesâ€™ certificates of incorporation and by-laws has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation and amended and restated by-laws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation or amended and restated by-laws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations.Changes in tax law and regulations could adversely affect our business, financial condition and results of operations.New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future earnings. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. Generally, future changes in applicable tax laws and regulations, or their interpretation and application, potentially with retroactive effect, could have an adverse effect on our business, financial conditions and results of operations. We are unable to predict whether such changes will occur and, if so, the ultimate impact on our business. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.80Table of ContentsUnstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.The global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates, geopolitical conflicts and war, and uncertainty about economic stability. If the equity and credit markets continue to deteriorate or the United States enters a recession, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. In addition, there is a risk that one or more of our CROs, suppliers or other third-party providers may not survive an economic downturn or recession. As a result, our business, results of operations and price of our common stock may be adversely affected. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity SecuritiesNoneItem 3. Defaults Upon Senior SecuritiesNoneItem 4. Mine Safety DisclosuresNoneItemÂ 5. Other Information(a)Â Â Â Â None.(b)Â Â Â Â None.(c)Â Â Â Â During the quarter ended March 31, 2024, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified, or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K.ItemÂ 6. ExhibitsThe exhibits filed as part of this Quarterly Report on Form 10-Q are set forth in the Exhibit Index below, which is incorporated herein by reference.81Table of ContentsExhibit IndexIncorporated by ReferenceExhibitNumberExhibit TitleFormFile no.ExhibitFiling Date2.1*Separation Agreement, dated as of November 3, 2021, by and between the Registrant and 2seventy bio, Inc.8-K001-359662.1November 4, 20212.2*Asset Purchase Agreement, dated as of November 29, 2022, by and between bluebird bio, Inc. and argenx BV8-K001-359662.1November 30, 20222.3*Asset Purchase Agreement, dated as of January 5, 2023, by and between bluebird bio, Inc. and Bristol-Myers Squibb Company8-K001-359662.1January 6, 20232.4*Asset Purchase Agreement, dated as of October 26, 2023, by and between bluebird bio, Inc. and Novartis Pharma AG8-K001-359662.1October 30, 20233.1Amended and Restated Certificate of Incorporation of the Registrant8-K001-359663.1June 24, 20133.2Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant8-K001-359663.1June 20, 20233.3Amended and Restated By-laws of the Registrant8-K001-359663.1December 18, 20234.1Specimen Common Stock CertificateS-1/A333-1886054.1June 4, 20134.2**Form of Warrant Agreement8-K001-359664.1August 14, 20244.3Form of Warrant Agreement Amendment8-K001-359664.2August 14, 202410.1**â€ Loan and Security Agreement, dated as of March 15, 2024, between the Registrant, as Borrower, and Hercules Capital, Inc. as Lender8-K001-3596610.1May 2, 202431.1Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.â€”â€”â€”Filed herewith31.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.â€”â€”â€”Filed herewith32.1Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.â€”â€”â€”FurnishedÂ herewith101.INSInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)Filed herewith101.SCHInline XBRL Taxonomy Extension Schema Document.â€”â€”â€”Filed herewith101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.â€”â€”â€”Filed herewith101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.â€”â€”â€”Filed herewith101.LABInline XBRL Taxonomy Extension Label Linkbase Document.â€”â€”â€”Filed herewith101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.â€”â€”â€”Filed herewith104Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)â€”â€”â€”Filed herewith*Â Â Â Â Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant will furnish copies of any such schedules and exhibits to the SEC upon request.**Â Â Â Â Exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant will furnish copies of any such exhibits to the SEC upon request.â€ Â Â Â Â Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC.82Table of Contents83Table of ContentsSIGNATURESPursuant to the requirements of SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.bluebird bio, Inc.Date: September 13, 2024By:/s/ Andrew ObenshainAndrew ObenshainPresident, Chief Executive Officer and Director(Principal Executive Officer and Duly Authorized Officer)Date: September 13, 2024By:/s/ O. James SterlingO. James SterlingChief Financial Officer(Principal Financial Officer and Principal Accounting Officer)84 EX-31.1 2 blue-20240331xex3111.htm EX-31,1 DocumentExhibit 31.1CERTIFICATIONSI, Andrew Obenshain, certify that:1. I have reviewed this Quarterly Report on Form 10-Q of bluebird bio, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness

of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: September 13, 2024By:/s/ Andrew ObenshainAndrew ObenshainPresident and Chief Executive Officer(Principal Executive Officer) EX-31.2 3 blue-20240331xex3121.htm EX-31.2 DocumentExhibit 31.2CERTIFICATIONSI, O. James Sterling, certify that:1. I have reviewed this Quarterly Report on Form 10-Q of bluebird bio, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: September 13, 2024By:/s/ O. James SterlingO. James SterlingChief Financial Officer (Principal Financial Officer and Principal Accounting Officer) EX-32.1 4 blue-20240331xex3211.htm EX-32.1 DocumentExhibit 32.1CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q of bluebird bio, Inc. (the â€œCompanyâ€) for the period ended MarchÂ 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. SectionÂ 1350, that to his knowledge:(1) the Report fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: September 13, 2024By:/s/ Andrew ObenshainAndrew ObenshainPresident, Chief Executive Officer and Director (Principal Executive Officer and Duly Authorized Signer)Date: September 13, 2024By:/s/ O. James SterlingO. James SterlingChief Financial Officer(Principal Financial Officer, Principal Accounting Officer and Duly Authorized Signer) EX-101.SCH 5 blue-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Description of the business link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Product revenue and reserves link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Factoring agreement link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Accrued expenses and other current liabilities link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Term loan debt link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Net loss per share link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Restatement of Previously Issued Financial Statements link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Product revenue and reserves (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Accrued expenses and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Commitment and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Net loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Restatement of Previously Issued Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Description of the business (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Product revenue and reserves - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Product revenue and reserves - Summary of Product Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Product revenue and reserves - Rebate Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Fair value measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Fair value measurements - Factoring Agreement Reconciliation of Beginning and Ending Balances (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Factoring agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Leases - Summary of Operating Lease Costs and Other Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases - Schedule of Future Minimum Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases - Schedule of Future Minimum Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Commitments and contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Term loan debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Stock-based compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Stock-based compensation - Summary of Stock Option Activity Under Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stock-based compensation - Summary of Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Net loss per share - Anti-dilutive shares (Detail) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Net loss per share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Restatement of Previously Issued Financial Statements - Schedule of Operations and Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Restatement of Previously Issued Financial Statements - Schedule of Changes in Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Restatement of Previously Issued Financial Statements - Schedule of Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 blue-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 blue-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 blue-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Inclusive of Shares Pursuant to Over Allotment Option Granted Over-Allotment Option [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Summary of Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Statistical Measurement Statistical Measurement [Domain] Line of credit Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Award Type Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Unvested balance at beginning of period (in shares) Unvested balance at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Operating right of use assets Lessee, Increase (Decrease) In Operating Lease, Right-of-Use Asset Lessee, Increase (Decrease) In Operating Lease, Right-of-Use Asset MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Vesting of restricted stock units (in shares) Stock Issued During Period Shares Vesting Of Restricted Stock Units Stock issued during period shares vesting of restricted stock units. Level 3 financial assets, beginning of period Level 3 financial assets, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Commitments and contingencies (Note 10) Commitments and Contingencies As Previously Reported Previously Reported [Member] Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Insider Trading Policies and Procedures [Line Items] Exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Interest receivable, write-offs Interest Receivable, Write-Off Interest Receivable, Write-Off Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Equity Equity [Text Block] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Income taxes Income Tax Disclosure [Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Term Loan Term Loan [Member] Term Loan January Underwriting Agreement January Underwriting Agreement [Member] January Underwriting Agreement Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and outstanding at MarchÂ 31, 2024 and DecemberÂ 31, 2023 Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted- average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Canceled, forfeited, or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Derecognition of due to factor liabilities Beneficial Interest, Amount Derecognized Beneficial Interest, Amount Derecognized Net (loss) income per share - diluted (in dollars per share) Diluted EPS (in dollars per share) Net income per share - diluted (in dollars per share) Earnings Per Share, Diluted Term Loan Facility Tranche Three Term Loan Facility Tranche Three [Member] Term Loan Facility Tranche Three PEO Total Compensation Amount PEO Total Compensation Amount Accrued refund liability Customer Refund Liability, Current Vested and expected to vest at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Increase (decrease) in finance lease right of use asset Increase (Decrease) In Right-Of-Use Asset Obtained In Exchange For Finance Lease Liability Increase (Decrease) In Right-Of-Use Asset Obtained In Exchange For Finance Lease Liability Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Line of Credit Line of Credit [Member] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Other comprehensive income (loss), tax Other comprehensive income, net of tax (benefit) expense of $0.0Â million for the three months ended March 31, 2023 Other Comprehensive Income (Loss), Tax Net (loss) income Net (loss) income Net (loss) income Net (loss) income Net income Net Income (Loss) Attributable to Parent Remainder of 2024 Unrecorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year Proceeds from previously transferred invoices Fair Value, Measurement with Unobservable Inputs

Reconciliation, Recurring Basis, Asset, Proceeds From Transferred Invoices Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Proceeds From Transferred Invoices Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2026 Finance Lease, Liability, to be Paid, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Accrued interest payable under finance lease Increase (Decrease) Accrued Interest Payable Under Finance Lease Increase (Decrease) Accrued Interest Payable Under Finance Lease Due from factor Factoring Agreement Receivable, Current Factoring Agreement Receivable, Current Period immediately following achievement Debt Instrument, Covenant, Period Immediately Following Achievement Debt Instrument, Covenant, Period Immediately Following Achievement Liabilities and Stockholdersâ€™ Equity Liabilities and Equity [Abstract] The Warrants The Warrants [Member] The Warrants Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Exercise of stock options (in shares) Stock option share exercised (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Executive Category: Executive Category [Axis] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] SKYSONA SKYSONA [Member] SKYSONA Beneficiary interest obtained in transferred invoices Beneficiary Interest Obtained In Transferred Invoices Beneficiary Interest Obtained In Transferred Invoices Shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Quoted prices in active markets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name 2027 Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three Issuance of warrants Adjustments to Additional Paid in Capital, Warrant Issued Goodwill Goodwill Equity Components Equity Components [Axis] Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Number of shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Value of warrants issued in relation to debt Class Of Warrant Or Right, Value Of Warrants Issued In Relation To Debt Class Of Warrant Or Right, Value Of Warrants Issued In Relation To Debt Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Annual financial statement delivery period Debt Instrument, Covenant, Annual Financial Statement Delivery, Maximum Period Debt Instrument, Covenant, Annual Financial Statement Delivery, Maximum Period Selling, general and administrative Selling, General and Administrative Expenses [Member] Measurement Frequency Measurement Frequency [Axis] Warrants Warrant [Member] Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Basis of presentation, principles of consolidation and significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Cash receipts collected Factoring Agreement, Cash Receipts Collected Factoring Agreement, Cash Receipts Collected Restricted stock units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt instrument term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Payments of debt issuance costs Payments of Debt Issuance Costs Employee stock purchase plan and other Employee stock purchase plan and other ESPP shares and other Employee Stock Purchase Plan And Other [Member] Employee stock purchase plan. Contract with Customer, Refund Liability [Roll Forward] Contract with Customer, Refund Liability [Roll Forward] Contract with Customer, Refund Liability Beneficial Interest Beneficial Interest [Member] Beneficial Interest Income Statement Location Income Statement Location [Axis] Line of Credit Facility [Table] Line of Credit Facility [Table] Schedule of Future Minimum Commitments Under Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Shares of common stock sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Payables and Accruals [Abstract] Payables and Accruals [Abstract] Total revenues Total revenues Revenues Risk Free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Product and Service Product and Service [Domain] Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Term Loan Facility Tranche Four Term Loan Facility Tranche Four [Member] Term Loan Facility Tranche Four Lease, Cost Lease, Cost [Table Text Block] Inventory Increase (Decrease) in Inventories Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type Award Type [Axis] Due to factor Factoring Agreement Payable, Current Factoring Agreement Payable, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Supplemental cash flow disclosures from investing and financing activities: Noncash Investing and Financing Items [Abstract] Interest expense Interest expense Interest Expense Purchases of property, plant and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Common shares reserved for future issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Trading Arrangement: Trading Arrangement [Axis] Less: Imputed Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Number of additional controlled environment rooms Number of Additional Controlled Environment Rooms Number of Additional Controlled Environment Rooms Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Original issue discount Debt Instrument, Unamortized Discount Operating lease liability, current portion Operating Lease, Liability, Current Prepaid expenses Prepaid Expense, Current 2029 and thereafter Unrecorded Unconditional Purchase Obligation, to be Paid, After Year Four Unrecorded Unconditional Purchase Obligation, to be Paid, After Year Four Number of warrants issued as a percentage of debt Class Of Warrant Or Right, Number Of Warrants Issued As A Percentage Of Debt Class Of Warrant Or Right, Number Of Warrants Issued As A Percentage Of Debt Interest expense Finance Lease, Interest Expense Purchase of shares under ESPP (in shares) Purchase of common stock under employee stock purchase plan (ESPP) (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Beneficiary interest obtained in transferred invoices Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Beneficiary Interest Obtained From Transferred Invoices Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Beneficiary Interest Obtained From Transferred Invoices Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Other revenue Revenue Not from Contract with Customer Beneficiary interest obtained in transferred invoices Beneficiary Interest Obtained Beneficiary Interest Obtained Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Common stock price per share (in dollars per share) Sale of Stock, Price Per Share Private Placement Private Placement [Member] Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease cost Variable Lease, Cost Debt Instrument Availability, Tranche Four Debt Instrument Availability, Tranche Four [Member] Debt Instrument Availability, Tranche Four Fixed lease cost Operating Lease, Cost Common stock, shares issued (in shares) Common Stock, Shares, Issued Summary of Restricted Common Stock Awards Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Gross margin Gross margin Gross Profit Security Exchange Name Security Exchange Name Paid In Kind Paid In Kind [Member] Paid In Kind Total Assets, Fair Value Disclosure Balance at December 31, 2023 Balance at March 31, 2024 Contract With Customer, Rebate Liability, Current Contract With Customer, Rebate Liability, Current Proceeds from stock offering Sale of Stock, Consideration Received on Transaction Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Outstanding stock options Employee Stock Option Share-Based Payment Arrangement, Option [Member] Prime Floor Rate Prime Floor Rate [Member] Prime Floor Rate Total operating expenses Total operating expenses Costs and Expenses Maximum Maximum [Member] Comprehensive (loss) income Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type 2028 Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four Error Correction, Leases Error Correction, Leases [Member] Error Correction, Leases Restatement of Previously Issued Financial Statements Error Correction [Text Block] Tabular List, Table Tabular List [Table Text Block] Value of shares available for issue in transaction Sale Of Stock, Value Of Shares Available For Issue In Transaction Sale Of Stock, Value Of Shares Available For Issue In Transaction Short-term lease cost Short-Term Lease, Cost Entity Address, Address Line One Entity Address, Address Line One Term Loan Facility Tranche Two Term Loan Facility Tranche Two [Member] Term Loan Facility Tranche Two Inventory Inventory, Policy [Policy Text Block] Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Drug Product Manufacturing Facility Drug Product Manufacturing Facility [Member] Drug Product Manufacturing Facility 2027 Finance Lease, Liability, to be Paid, Year Three Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Stock-based compensation Share-Based Payment Arrangement [Text Block] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Other non-cash items Other non-cash items Other Noncash Income (Expense) Purchases of marketable securities Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale 2025 Finance Lease, Liability, to be Paid, Year One Weighted- average exercise price per share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Subsequent Event Subsequent Event [Member] Customer Concentration Risk Customer Concentration Risk [Member] Restricted cash included in restricted cash and other non-current assets Restricted Cash, Noncurrent Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Title of 12(b) Security Title of 12(b) Security Vesting of restricted stock units Stock Issued During Period Value Vesting Of Restricted Stock Units Stock issued during period value vesting of restricted stock units. Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Operating sublease income Sublease Income Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Unvested balance at beginning of period (in dollars per share) Unvested balance at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Number of tranches Debt Instrument, Number of Tranches Debt Instrument, Number of Tranches Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventory Inventory Inventory, Net Total lease cost Lease, Cost Amount capitalized Share-Based Payment Arrangement, Amount Capitalized Statistical Measurement Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Interest receivable Interest Receivable Term loan debt Long-Term Debt [Text Block] Total Shareholder Return Amount Total Shareholder Return Amount Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Excess inventory reserve Inventory, Excess Valuation Reserves Inventory, Excess Valuation Reserves Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Number of tranches Number of Tranches Number of Tranches Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue recognition Revenue from Contract with Customer [Policy Text Block] Error Correction, Type [Axis] Error Correction, Type [Axis] Debt covenant, minimum gross cash proceeds Debt Instrument, Covenant, Draw Requirement, Minimum Gross Cash Proceeds Debt Instrument, Covenant, Draw Requirement, Minimum Gross Cash Proceeds Debt amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Total Finance Lease, Liability, to be Paid Accrued rebates Accrued Rebates, Current Accrued Rebates, Current Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Operating cash flows used for operating leases Operating Lease, Payments Summary of Stock-Based Compensation Expense by Award Type Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance, shares (in shares) Common Stock, Shares, Outstanding Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale PEO PEO [Member] Offering expenses included in accounts payable and accrued expenses Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Factoring agreement Factoring Agreements [Text Block] Factoring Agreements Asset Class [Domain] Asset Class [Domain] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock Sale of Stock [Axis] Finance leases Finance Lease, Liability [Abstract] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash receipts collected prior to consideration Factoring Agreement, Cash Receipts Collected Prior To Consideration Factoring Agreement, Cash Receipts Collected Prior To Consideration Customer [Domain] Customer [Domain] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Corrections to Impacted Financial Statements Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Present Value of Lease Liabilities Operating Lease, Liability Measurement Input Type [Domain] Measurement Input Type [Domain] Remainder of 2024 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Credit Facility Credit Facility [Axis] Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Debt Covenant Terms [Domain] Debt Covenant Terms [Domain] Debt Covenant Terms [Domain] Prepaid expenses and other assets Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated other comprehensive (loss) income AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Proceeds Received June 30, 2025 Proceeds Received June 30, 2025 [Member] Proceeds Received June 30, 2025 Increase in shares authorized (in shares) Share-based Compensation Arrangement By Share-based Payment Award, Increase In Shares Authorized Share-based Compensation Arrangement By Share-based Payment Award, Increase In Shares

Authorized Measurement Frequency Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] 2025 Unrecorded Unconditional Purchase Obligation, to be Paid, Year One Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] 2029 and thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Debt Disclosure [Abstract] Property, Plant and Equipment, Type Long-Lived Tangible Asset [Domain] Accrued professional fees Accrued Professional Fees Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock, $0.01 par value, 250,000 shares authorized; 193,583 and 192,772 shares issued and outstanding at MarchÂ 31, 2024 and DecemberÂ 31, 2023, respectively Common Stock, Value, Issued Expected Volatility Measurement Input, Option Volatility [Member] Purchase commitments Total purchase commitments Unrecorded Unconditional Purchase Obligation Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Principal payments on finance leasesÂ Financing cash flows for finance leases Finance Lease, Principal Payments Schedule of Future Minimum Commitments Under Financing Leases Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Cash paid in the measurement of lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date PEO Name PEO Name Expected Dividend Rate Measurement Input, Expected Dividend Rate [Member] Concentration risk, percentage Concentration Risk, Percentage Proceeds from sale of priority review voucher Proceeds from Sales of Assets, Investing Activities Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value U.S. government agency securities and treasuries US Treasury and Government [Member] Restricted cash included in other current assets Restricted Cash, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding 2028 Finance Lease, Liability, to be Paid, Year Four 2026 Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Proceeds from the transfer of invoices Proceeds from Other Debt Other Other Accrued Liabilities, Current Description of the business Nature of Operations [Text Block] Debt Covenant Terms [Axis] Debt Covenant Terms [Axis] Debt Covenant Terms PIK interest Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Operating lease liabilities Increase Decrease In Operating Lease Liabilities Increase (decrease) in operating lease liabilities. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] One Individual Customer One Individual Customer [Member] One Individual Customer Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Attributable to Parent Cash, cash equivalents and marketable securities Investments and Cash Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Financing Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Total fixed finance lease cost Finance Lease, Cost Finance Lease, Cost Concentration Risk Type [Axis] Concentration Risk Type [Axis] Debt covenant, product delivery period Debt Instrument, Covenant, Product Delivery Period Debt Instrument, Covenant, Product Delivery Period Restatement [Domain] Revision of Prior Period [Domain] Subsequent Events [Abstract] Warrants and rights outstanding, measurement input Warrants and Rights Outstanding, Measurement Input Purchase of intangible assets Payments to Acquire Intangible Assets ZYNTEGLO ZYNTEGLO [Member] ZYNTEGLO Property, Plant and Equipment, Type Long-Lived Tangible Asset [Axis] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Debt issuance costs, net Debt Issuance Costs, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Beneficiary interest in factored invoices Beneficial Interest, Fair Value Disclosure Beneficial Interest, Fair Value Disclosure Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Due to factor, value derecognized Factoring Agreement Payable, Current, Derecognized Factoring Agreement Payable, Current, Derecognized Document Fiscal Period Focus Document Fiscal Period Focus 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities Antidilutive Securities [Axis] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common stock Common Shares Common Stock [Member] Noncash research and development expense (finance lease) Noncash, Research And Development Expense, Finance Lease Noncash, Research And Development Expense, Finance Lease Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service Product and Service [Axis] Net loss per share Earnings Per Share [Text Block] Income Statement Location Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Lease period Lessee, Operating Lease, Term of Contract Offering expenses included in accounts payable and accrued expenses Offering Expenses Included In Accounts Payable And Accrued Expenses Offering Expenses Included In Accounts Payable And Accrued Expenses Property, plant and equipment, net Property, Plant and Equipment, Net Receivables [Abstract] Summary of Stock Option Activity Under Plan Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Gain on foreign currency exchange rates Gain (Loss), Foreign Currency Transaction, before Tax Provision for rebates Provision For Contract With Customer, Rebate Liability Provision For Contract With Customer, Rebate Liability Debt issuance costs, gross Debt Issuance Costs, Gross Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Summary Of Contract With Customer, Refund Liability Summary Of Contract With Customer, Refund Liability [Table Text Block] Summary Of Contract With Customer, Refund Liability Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated deficit Retained Earnings [Member] Term loan debt Long-Term Debt, Current Maturities Drug Substance Manufacturing Facility Drug Substance Manufacturing Facility [Member] Drug Substance Manufacturing Facility At The Market Offering At The Market Offering [Member] At The Market Offering Schedule of Stock-Based Compensation Expense by Classification Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholdersâ€™ equity Liabilities and Equity Restricted cash and other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net (loss) income per share - basic (in dollars per share) Basic EPS (In dollars per share) Net income per share - basic (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Purchase of shares under ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Accounting Policies [Abstract] Payments/credits Contract With Customer Payments, Rebate Liability Contract With Customer Payments, Rebate Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock Sale of Stock [Domain] Gain from sale of priority review voucher, net Gain from sale of priority review voucher Gain (Loss) on Disposition of Assets Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Warrants and rights outstanding, contractual term (in years) Warrants and Rights Outstanding, Term Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Number of securities called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Revision of Prior Period, Error Correction, Adjustment Revision of Prior Period, Error Correction, Adjustment [Member] Debt Instrument Availability [Axis] Debt Instrument Availability [Axis] Debt Instrument Availability Option to purchase additional shares, exercise period Sale Of Stock, Option To Purchase Additional Shares, Exercise Period Sale Of Stock, Option To Purchase Additional Shares, Exercise Period Cash paid during the period for income taxes Income Taxes Paid Consolidation Consolidation, Policy [Policy Text Block] Proceeds from the issuance of debt, net of fees paid to lender Proceeds from Issuance of Debt Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Discount percentage Debt Instrument, Unamortized Discount, Percent Debt Instrument, Unamortized Discount, Percent Accrued CMO and CRO costs Accrued Clinical And Contract Research Organization Costs Current Accrued clinical and contract research organization costs current. Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Minimum cash coverage as a percentage of outstanding principal Debt Instrument, Covenant, Minimum Cash Coverage As A Percentage Of Outstanding Principal Debt Instrument, Covenant, Minimum Cash Coverage As A Percentage Of Outstanding Principal Accrued expenses and other current liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Uncollectable amounts, net of accrued fees Factoring Agreement Receivable, Uncollectable Amounts, Net Of Accrued Fees Factoring Agreement Receivable, Uncollectable Amounts, Net Of Accrued Fees Right-of-use assets obtained in exchange for financial lease liabilities Right-Of-Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement Right-Of-Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Adjustments to reconcile net (loss) income to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Debt Instrument Availability, Tranche Two Debt Instrument Availability, Tranche Two [Member] Debt Instrument Availability, Tranche Two All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Accrued goods and services Accrued Goods and Services, Current Accrued Goods and Services, Current Compensation Amount Outstanding Recovery Compensation Amount Servicing fees Factoring Agreement, Servicing Fees Factoring Agreement, Servicing Fees Additional paid-in capital Additional Paid in Capital Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 2029 and thereafter Finance Lease, Liability, to be Paid, After Year Four Finance Lease, Liability, to be Paid, After Year Four Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Non-cancelable Contractual Obligations Long-Term Purchase Commitment [Table Text Block] Present Value of Lease Liabilities Finance Lease, Liability Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Priority review voucher expenses accrued or in accounts payable Disposition Of Assets, Expenses Incurred During Noncash Or Partial Noncash Transaction Disposition Of Assets, Expenses Incurred During Noncash Or Partial Noncash Transaction Public Offering Public Offering [Member] Public Offering Insider Trading Arrangements [Line Items] (Loss) income before income taxes Income (Loss) Attributable to Parent, before Tax 2023 Incentive Award Plan 2023 Incentive Award Plan [Member] 2023 Incentive Award Plan Maximum loss exposure Factoring Agreement Receivable, Current, Net Of Uncollectible Factoring Agreement Receivable, Current, Net Of Uncollectible Accounting Changes and Error Corrections [Abstract] Entity Registrant Name Entity Registrant Name Noncash interest related to debt Noncash Interest Related to Debt Noncash Interest Related to Debt Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements December Underwriting Agreement December Underwriting Agreement [Member] December Underwriting Agreement Relative fair value allocated to the initial warrants Warrants and Rights Outstanding Adjustment to Compensation, Amount Adjustment to Compensation Amount Term Loan Facility Term Loan Facility [Member] Term Loan Facility Cost of product revenue Cost of Sales [Member] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Stock options Employee And Non Employee Stock Option [Member] Employee and non employee stock option. Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted average discount rate - finance leases Finance Lease, Weighted Average Discount Rate, Percent Financing lease liability, net of current portion Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Debt Instrument Availability [Domain] Debt Instrument Availability [Domain] Debt Instrument Availability [Domain] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax (expense) benefit Income tax expense (benefit) Income tax (expense) benefit Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Noncash operating lease expense Noncash Lease Expense Noncash Lease Expense Debt Instrument Availability, Tranche Three Debt Instrument Availability, Tranche Three [Member] Debt Instrument Availability, Tranche Three Accrued employee compensation Employee-related Liabilities, Current Fair value measurements Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Total other comprehensive (loss) income Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Issuance of common stock Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Inventory Inventory Disclosure [Text Block] Weighted average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Product revenue, net Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Quarterly financial statement delivery period Debt Instrument, Covenant, Quarterly Financial Statement Delivery, Maximum Period Debt Instrument, Covenant, Quarterly Financial Statement Delivery, Maximum Period Weighted average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Shares of common stock issued under plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Assets: Assets, Fair Value Disclosure [Abstract] Credit Facility Credit Facility [Domain] Variable rate Debt Instrument, Basis Spread on Variable Rate Loss on sale of invoice Factoring Agreement, Gain (Loss) On Sale Of Invoices Factoring Agreement, Gain (Loss) On Sale Of Invoices Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Weighted average remaining lease term - finance leases Finance Lease, Weighted Average Remaining Lease Term Receivables and other current assets Receivables And Other Current Assets Receivables and other current assets. Weighted-average number of common shares used in computing net (loss) income per share - diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted-average number of common shares used in computing net income per share - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Realized loss Debt Securities, Available-for-Sale, Realized Gain (Loss) Operating expenses: Operating Expenses [Abstract] Less: Imputed Interest Finance Lease, Liability, Undiscounted Excess Amount Product revenue and reserves Revenue from Contract with Customer [Text Block] Purchase of property, plant and equipment Purchase of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid-in Capital [Member] Weighted average price, period Class Of Warrant Or Right, Weighted Average Price,

Period Class Of Warrant Or Right, Weighted Average Price, Period Other information Lease, Cost [Abstract] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Restatement [Axis] Revision of Prior Period [Axis] Cover page. Cover [Abstract] Proceeds allocated to detachable warrants issued in conjunction with debt Proceeds from Issuance of Warrants Subsequent events Subsequent Events [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Operating cash flows used for finance leases Finance Lease, Interest Payment on Liability Other non-current liabilities Other Liabilities, Noncurrent Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Canceled, forfeited, or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Total Lessee, Operating Lease, Liability, to be Paid Operating leases Operating Lease, Liability [Abstract] Quality Testing Facility Quality Testing Facility [Member] Quality Testing Facility Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Prime Rate Prime Rate [Member] Amortization expense Finance Lease, Right-of-Use Asset, Amortization Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Number of additional tranches Debt Instrument, Number Of Additional Tranches Debt Instrument, Number Of Additional Tranches Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] (Decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Secured Debt Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Renewal term Lessee, Operating Lease, Renewal Term Marketable securities: Marketable Securities Equity Component Equity Component [Domain] Financing lease liability, current portion Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Work in progress Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-average number of common shares used in computing net (loss) income per share - basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted-average number of common shares used in computing net income per share - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] (Loss) income from operations Income from operations Operating Income (Loss) Six Individual Customers Six Individual Customers [Member] Six Individual Customers Reclassification of Prior Year Presentation Reclassification, Comparability Adjustment [Policy Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Other Adjustments Error Correction, Other [Member] Adjustments to Embedded Leases Error Correction, Embedded Leases [Member] Error Correction, Embedded Leases Revenue: Revenues [Abstract] Cost of product revenue Cost of Revenue Percentage of aggregate original principal Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Error Correction, Type [Domain] Error Correction, Type [Domain] Proceeds from exercise of stock options and ESPP contributions Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Proceeds Received December 20, 2024 Proceeds Received December 20, 2024 [Member] Proceeds Received December 20, 2024 Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Vested and expected to vest at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Proceeds from long-term lines of credit Proceeds from Long-Term Lines of Credit EX-101.PRE 9 blue-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover Page - shares 3 Months Ended Mar. 31, 2024 Sep. 11, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Mar. 31, 2024 Â Document Transition Report false Â Entity File Number 001-35966 Â Entity Registrant Name bluebird bio, Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 13-3680878 Â Entity Address, Address Line One 455 Grand Union Boulevard Â Entity Address, City or Town Somerville Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 02145 Â City Area Code 339 Â Local Phone Number 499-9300 Â Title of 12(b) Security Common Stock, $0.01 par value per share Â Trading Symbol BLUE Â Security Exchange Name NASDAQ Â Entity Current Reporting Status No Â Entity Interactive Data Current No Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 193,913,585 Amendment Flag false Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q1 Â Entity Central Index Key 0001293971 Â Current Fiscal Year End Date --12-31 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands Mar. 31, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 212,047 $ 221,755 Prepaid expenses 11,511 14,800 Inventory 30,305 22,919 Due from factor 970 560 Receivables and other current assets 16,768 21,651 Total current assets 271,601 281,685 Property, plant and equipment, net 90,366 65,936 Goodwill 5,646 5,646 Intangible assets, net 10,244 10,438 Operating lease right-of-use assets 195,209 201,113 Restricted cash and other non-current assets 58,417 54,343 Total assets 631,483 619,161 Current liabilities: Â Â Accounts payable 19,387 18,498 Due to factor 2,520 2,520 Accrued expenses and other current liabilities 64,096 73,188 Term loan debt 68,995 0 Operating lease liability, current portion 24,363 21,202 Financing lease liability, current portion 114,212 84,705 Total current liabilities 293,573 200,113 Operating lease liability, net of current portion 180,683 186,687 Financing lease liability, net of current portion 26,089 37,732 Other non-current liabilities 92 92 Total liabilities 500,437 424,624 Commitments and contingencies (Note 10) Stockholdersâ€™ equity: Â Â Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and outstanding at MarchÂ 31, 2024 and DecemberÂ 31, 2023 0 0 Common stock, $0.01 par value, 250,000 shares authorized; 193,583 and 192,772 shares issued and outstanding at MarchÂ 31, 2024 and DecemberÂ 31, 2023, respectively 1,913 1,905 Additional paid-in capital 4,461,373 4,454,756 Accumulated other comprehensive loss (2,108) (1,796) Accumulated deficit (4,330,132) (4,260,328) Total stockholdersâ€™ equity 131,046 194,537 Total liabilities and stockholdersâ€™ equity $ 631,483 $ 619,161 X - DefinitionFactoring Agreement Payable, Current + ReferencesNo definition available. + Details Name: blue_FactoringAgreementPayableCurrent Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFactoring Agreement Receivable, Current + ReferencesNo definition available. + Details Name: blue_FactoringAgreementReceivableCurrent Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionReceivables and other current assets. + ReferencesNo definition available. + Details Name: blue_ReceivablesAndOtherCurrentAssets Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance

Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-

02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares Mar. 31, 2024 Dec. 31, 2023 Stockholdersâ€™ equity: Â Â Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01 Preferred stock, shares authorized (in shares) 5,000,000 5,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.01 $ 0.01 Common stock, shares authorized (in shares) 250,000,000 250,000,000 Common stock, shares issued (in shares) 193,583,000 192,772,000 Common stock, shares outstanding (in shares) 193,583,000 192,772,000 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Revenue: Â Â Product revenue, net $ 18,561 $ 2,296 Other revenue 12 85 Total revenues 18,573 2,381 Cost of product revenue 25,864 5,512 Gross margin (7,291) (3,131) Operating expenses: Â Â Selling, general and administrative 46,329 37,467 Research and

development 25,072 41,587 Total operating expenses 71,401 79,054 Gain from sale of priority review voucher, net 0 92,930 (Loss) income from operations (78,692) 10,745 Interest income 2,579 2,828 Interest expense (4,856) (4,270) Other income, net 11,165 9,627 (Loss) income before income taxes (69,804) 18,930 Income tax (expense) benefit 0 0 Net (loss) income $ (69,804) $ 18,930 Net (loss) income per share - basic (in dollars per share) $ (0.36) $ 0.18 Net (loss) income per share - diluted (in dollars per share) $ (0.36) $ 0.18 Weighted-average number of common shares used in computing net (loss) income per share - basic (in shares) 193,151 102,920 Weighted-average number of common shares used in computing net (loss) income per share - diluted (in shares) 193,151 103,303 Other comprehensive (loss) income: Â Â Total other comprehensive (loss) income $ (312) $ 984 Comprehensive (loss) income $ (70,116) $ 19,914 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI

https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_IncomeLossAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new

knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) (Parenthetical) - USD ($) $ in Millions 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Income Statement [Abstract] Â Â Other comprehensive income (loss), tax $ 0.0 $ 0.0 X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands Total Common stock Additional paid-in capital Accumulated other comprehensive (loss) income Accumulated deficit Beginning balance (in shares) at Dec. 31, 2022 Â 82,923,000 Â Â Â Beginning balance at Dec. 31, 2022 $ 134,333 $ 830 $ 4,185,988 $ (4,070) $ (4,048,415) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Vesting of restricted stock units (in shares) Â 382,000 Â Â Â Vesting of restricted stock units (195) $ 3 (198) Â Â Exercise of stock options (in shares) Â 3,000 Â Â Â Exercise of stock options 7 Â 7 Â Â Purchase of shares under ESPP (in shares) Â 62,000 Â Â Â Purchase of shares under ESPP 227 $ 1 226 Â Â Issuance of common stock (in shares) Â 23,000,000 Â Â Â Issuance of common stock 130,291 $ 230 130,061 Â Â Stock-based compensation expense 5,843 Â 5,843 Â Â Other comprehensive (loss) income 984 Â Â 984 Â Net (loss) income 18,930 Â Â Â 18,930 Ending balance, shares (in shares) at Mar. 31, 2023 Â 106,370,000 Â Â Â Ending balance at Mar. 31, 2023 $ 290,420 $ 1,064 4,321,927 (3,086) (4,029,485) Beginning balance (in shares) at Dec. 31, 2023 192,772,000 192,772,000 Â Â Â Beginning balance at Dec. 31, 2023 $ 194,537 $ 1,905 4,454,756 (1,796) (4,260,328) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Vesting of restricted stock units (in shares) Â 811,000 Â Â Â Vesting of restricted stock units 0 $ 8 (8) Â Â Issuance of warrants $ 2,571 Â 2,571 Â Â Exercise of stock options (in shares) 0 Â Â Â Â Stock-based compensation expense $ 4,054 Â 4,054 Â Â Other comprehensive (loss) income (312) Â Â (312) Â Net (loss) income $ (69,804) Â Â Â (69,804) Ending balance, shares (in shares) at Mar. 31, 2024 193,583,000 193,583,000 Â Â Â Ending balance at Mar. 31, 2024 $ 131,046 $ 1,913 $ 4,461,373 $ (2,108) $ (4,330,132) X - DefinitionStock issued during period shares vesting of restricted stock units. + ReferencesNo definition available. + Details Name: blue_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits Namespace Prefix: blue_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value vesting of restricted stock units. + ReferencesNo definition available. + Details Name: blue_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards

Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic

505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Cash flows from operating activities: Â Â Net (loss) income $ (69,804) $ 18,930 Adjustments to reconcile net (loss) income to net cash used in operating activities: Â Â Depreciation and amortization 15,469 6,172 Stock-based compensation expense 3,761 5,391 Noncash research and development expense (finance lease) 0 1,441 Noncash operating lease expense 5,904 7,423 Gain from sale of priority review voucher 0 (92,930) Excess inventory reserve 91 2,583 Noncash interest related to debt 156 0 Other non-cash items (10) 237 Gain on foreign currency exchange rates (777) (108) Changes in operating assets and liabilities: Â Â Prepaid expenses and other assets (13,528) (3,689) Inventory (7,185) (5,331) Accounts payable 1,454 1,260 Accrued expenses and other liabilities (10,299) (7,206) Accrued interest payable under finance lease 2,936 915 Operating lease liabilities (2,844) (6,361) Deferred revenue 0 (85) Net cash used in operating activities (74,676) (71,358) Cash flows from investing activities: Â Â Purchase of property, plant and equipment (1,775) (232) Purchases of marketable securities 0 (19,610) Proceeds from maturities of marketable securities 0 4,021 Proceeds from sales of marketable securities 0 5,853 Cash receipts collected 1,120 0 Purchase of intangible assets 0 (868) Proceeds from sale of priority review voucher 0 92,972 Net cash (used in) provided by investing activities (655) 82,136 Cash flows from financing activities: Â Â Proceeds from the issuance of debt, net of fees paid to lender 71,316 0 Proceeds allocated to detachable warrants issued in conjunction with debt 2,669 0 Payments of debt issuance costs (2,250) 0 Proceeds from exercise of stock options and ESPP contributions 0 7 Proceeds from the transfer of invoices 15,120 0 Principal payments on finance leasesÂ (22,210) (15,280) Net cash provided by financing activities 64,645 115,176 (Decrease) increase in cash, cash equivalents and restricted cash (10,686) 125,954 Cash, cash equivalents and restricted cash at beginning of period 274,597 158,445 Cash, cash equivalents and restricted cash at end of period 263,911 284,399 Reconciliation of cash, cash equivalents and restricted cash: Â Â Cash and cash equivalents 212,047 239,045 Restricted cash included in other current assets 3,866 1,417 Restricted cash included in restricted cash and other non-current assets 47,998 43,937 Total cash, cash equivalents and restricted cash 263,911 284,399 Supplemental cash flow disclosures from investing and financing activities: Â Â Purchases of property, plant and equipment included in accounts payable and accrued expenses 0 189 Offering expenses included in accounts payable and accrued expenses 0 523 Priority review voucher expenses accrued or in accounts payable 0 43 Right-of-use assets obtained in exchange for financial lease liabilities 38,669 (214) Beneficiary interest obtained in transferred invoices 1,680 0 Derecognition of due to factor liabilities 15,120 0 Cash paid during the period for income taxes 1 2 Private Placement Â Â Cash flows from financing activities: Â Â Proceeds from issuance of common stock 0 (196) Public Offering Â Â Cash flows from financing activities: Â Â Proceeds from issuance of common stock $ 0 $ 130,645 X - DefinitionBeneficial Interest, Amount Derecognized + ReferencesNo definition available. + Details Name: blue_BeneficialInterestAmountDerecognized Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionBeneficiary Interest Obtained In Transferred Invoices + ReferencesNo definition available. + Details Name: blue_BeneficiaryInterestObtainedInTransferredInvoices Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposition Of Assets, Expenses Incurred During Noncash Or Partial Noncash Transaction + ReferencesNo definition available. + Details Name: blue_DispositionOfAssetsExpensesIncurredDuringNoncashOrPartialNoncashTransaction Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFactoring Agreement, Cash Receipts Collected + ReferencesNo definition available. + Details Name: blue_FactoringAgreementCashReceiptsCollected Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) Accrued Interest Payable Under Finance Lease + ReferencesNo definition available. + Details Name: blue_IncreaseDecreaseAccruedInterestPayableUnderFinanceLease Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in operating lease liabilities. + ReferencesNo definition available. + Details Name: blue_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInventory, Excess Valuation Reserves + ReferencesNo definition available. + Details Name: blue_InventoryExcessValuationReserves Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash Interest Related to Debt + ReferencesNo definition available. + Details Name: blue_NoncashInterestRelatedToDebt Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNoncash Lease Expense + ReferencesNo definition available. + Details Name: blue_NoncashLeaseExpense Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash, Research And Development Expense, Finance Lease + ReferencesNo definition available. + Details Name: blue_NoncashResearchAndDevelopmentExpenseFinanceLease Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOffering Expenses Included In Accounts Payable And Accrued Expenses + ReferencesNo definition available. + Details Name: blue_OfferingExpensesIncludedInAccountsPayableAndAccruedExpenses Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRight-Of-Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement + ReferencesNo definition available. + Details Name: blue_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -

URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -

Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from debt classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromOtherDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSalesOfAssetsInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=blue_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Description of the business 3 Months Ended Mar. 31, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Description of the business Description of the businessbluebird bio, Inc. (the â€œCompanyâ€ or â€œbluebirdâ€) was incorporated in Delaware on AprilÂ 16, 1992, and is headquartered in Somerville, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, and commercialization of its approved products, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates, provide selling, general and administrative support for these operations and market and commercially manufacture and distribute its approved products.The Companyâ€™s programs in severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel) as a treatment for Î²-thalassemia; LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel) as a treatment for sickle cell disease ("SCD"); and SKYSONA (elivaldogene autotemcel, also known as eli-cel) as a treatment for cerebral adrenoleukodystrophy ("CALD"). On August 17, 2022, ZYNTEGLO was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adult and pediatric patients with ÃŸ-thalassemia who require regular red blood cell transfusions. On September 16, 2022, the FDA granted Accelerated Approval of SKYSONA to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active CALD. On December 8, 2023, LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease and with a history of vaso-occlusive-events. In August 2023, the Company entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Companyâ€™s common stock up to $125.0Â million, from time to time, through an â€œat the marketâ€ equity offering program under which Jefferies will act as sales agent. As of March 31, 2024, the Company has made no sales pursuant to the Sales Agreement.In December 2023, the Company entered into an underwriting agreement (the â€œUnderwriting Agreementâ€) with Goldman Sachs & Co. LLC ("Goldman") and J.P. Morgan Securities LLC, to sell 83.3 million shares of the Company's common stock. The Company received net proceeds of approximately $118.1Â million. In March 2024, the Company entered into a five-year term loan facility agreement with Hercules Capital, Inc. to secure debt financing for up to $175Â million, available in four tranches. This is described in Note 8, Term Loan Debt, in the Notes to Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q.Since its inception, the Company has incurred significant operating losses and negative operating cash flows. As of March 31, 2024, the Company had an accumulated deficit of $4.3Â billion. During the three months ended March 31, 2024, the Company incurred a net loss of $69.8 million and used $74.7 million of cash in operations. As of March 31, 2024, the Company had cash and cash equivalents of $212.0 million. In accordance with Accounting Standards Codification (â€œASCâ€) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date the financial statements are issued.This evaluation initially does not take into consideration the potential mitigating effect of managementâ€™s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Companyâ€™s ability to continue as a going concern. The mitigating effect of managementâ€™s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entityâ€™s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.The Company's history of recurring operating losses and negative operating cash flows, its expectation to generate operating losses and negative operating cash flows, and the need for additional funding to support its planned operations raise substantial doubt regarding the Companyâ€™s ability to continue as a going concern for a period of one year after the date that these consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include controlling spending, executing on commercial launch plans, and exploring additional financing options. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Companyâ€™s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements. The Company has based the estimated cash needs on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects. Along with the Company's revenue from product sales, the Company expects to finance its future cash needs through the issuance of equity, or debt, or other alternative means. If the Company is unable to obtain funding on a timely basis, or if revenues from product sales are less than it has projected, the Company may be required to further revise its business plan and strategy, which may result in the Company significantly curtailing, delaying or discontinuing one or more of its research or development programs or the commercialization of any products or may result in the Company being unable to expand its operations or otherwise capitalize on its business opportunities. As a result, the Company's business, financial condition and results of operations could be materially affected. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org//275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of presentation, principles of consolidation and significant accounting policies 3 Months Ended Mar. 31, 2024 Accounting Policies [Abstract] Â Basis of presentation, principles of consolidation and significant accounting policies Basis of

presentation, principles of consolidation and significant accounting policiesBasis of presentationThe accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the Accounting Standard Codification (â€œASCâ€) and Accounting Standards Updates (â€œASUsâ€) of the Financial Accounting Standards Board (â€œFASBâ€). Certain information and footnote disclosures normally included in the Companyâ€™s annual financial statements have been condensed or omitted. These condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Companyâ€™s financial position and results of operations for the interim periods ended MarchÂ 31, 2024 and 2023.The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended DecemberÂ 31, 2023, and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023, filed with the Securities and Exchange Commission (the â€œSECâ€) on SeptemberÂ 13, 2024 (the "2023 Annual Report on Form 10-K").Amounts reported are computed based on thousands, except percentages, per share amounts, or as otherwise noted.Â As a result, certain totals may not sum due to rounding.The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company views its operations and manages its business in one operating segment.Restatement of Previously Issued Financial StatementsAs previously disclosed in the Company's 2023 Annual Report Form 10-K filed with the SEC on SeptemberÂ 13, 2024, the Company is restating its previously issued unaudited condensed consolidated financial information for the first quarter ended March 31, 2023 due to multiple prior period misstatements. The accompanying condensed consolidated financial information as of and for the quarter ended March 31, 2023 have been restated in this Quarterly Report on Form 10-Q (see Note 15: Restatement of Previously Issued Financial Statements). In addition, the Company has corrected the accompanying footnotes in connection with the restatement.Significant accounting policiesThe significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended MarchÂ 31, 2024 are consistent with those discussed in Note 3 to the consolidated financial statements included in the Companyâ€™s 2023 Annual Report on Form 10-K.Reclassification of Prior Year PresentationCertain prior year amounts have been reclassified to conform to the current year presentation. Specifically, interest expense has been reclassified from interest income to interest expense in the consolidated statement of operations and comprehensive (loss) income. These reclassifications had no effect on the reported results of operations.Use of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates and judgments are used in the following areas, among others: the alternative future use of assets used in research and development activities, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, gross-to-net revenue calculations, stock-based compensation expense, accrued expenses, income taxes, the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements, and the assessment of the likelihood and magnitude of losses that may be sustained upon resolution of contingencies.InventoryInventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Companyâ€™s consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used to produce clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product. Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product which has been produced for the treatment of specific patients, that are owned by the Company until infusion. Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on-hand and firm purchase commitments as well as remaining shelf life of on-hand inventories. The Company writes down its inventory that is in excess, obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue in the Companyâ€™s consolidated statements of operations and comprehensive loss.Revenue recognitionUnder ASC Topic 606, Revenue from Contracts with Customers (â€œTopic 606â€), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customerâ€™s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.Â The Company assesses whether each promised good or service is distinct to identify the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)Â the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entityâ€™s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).Â Â The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (â€œSSPâ€) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the adjustment period.In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed each of its revenue generating arrangements to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.Product revenue In 2022, the Company received approval of ZYNTEGLO and SKYSONA from the FDA. In 2023, the Company received approval of LYFGENIA from the FDA. The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. The Company uses Specialty Distributors ("SD") and Specialty Pharmacies ("SP") to deliver product to the Qualified Treatment Centers ("QTC"). Revenue is only recognized when the performance obligation is satisfied. The Company recognizes revenue upon infusion to the patient. To determine whether a significant reversal will occur in future periods, the Company will assess both the likelihood and magnitude of any such potential reversal of revenue. Gross product revenue is reduced by outcomes-based rebates, other rebates and distributor fees.Rebates expenseRebates are based on contractual arrangements or statutory requirements and include amounts due to Medicaid agencies and third-party payers. These amounts may vary by product and payer. Rebates are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. The Company assesses and updates estimates each reporting period to reflect actual claims and other current information. Rebates that are payable to Medicaid agencies and third-party payers are recorded in accrued expenses and other current liabilities on the Company's consolidated balance sheets. Distributor fees The Company pays distribution fees to SDs and SPs in connection with the sales of our product. These distributor fees are based on a contractually determined fixed percentage of sales. Other revenue In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, Revenue Recognition Not-for-Profit Entities, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In 2023, the Company ceased further research work and is in the process of winding down such collaboration.Recent accounting pronouncementsIn November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 â€“ Segment Reporting. This update is effective beginning with the Companyâ€™s 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Companyâ€™s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact to its income tax disclosures. In March 2024, the FASB issued ASU 2024-01, Compensation-Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards. This update clarifies the scope of "Profit Interest" and similar awards and adds an illustrative example to the existing ASC 718 standard that includes four fact patterns to demonstrate how an entity should apply the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic 718. The amendments in this ASU are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for interim and annual financial statements not yet issued or made available for issuance. The amendments in this ASU should be applied either (1) retrospectively to all prior periods presented in the financial statements or (2) prospectively to profits interest and similar awards granted or modified on or after the date at which the entity first applies the amendments. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures.In March 2024, the FASB issued ASU 2024-02 "Codification Improvementsâ€”Amendments to Remove References to the Concepts Statements", which removes various references to concepts statements from the FASB Accounting Standards Codification. This ASU is effective for the Company beginning in the first quarter of fiscal year 2026, with early adoption permitted. The Company expects the new guidance will have an immaterial impact on its consolidated financial statements and intends to adopt the guidance when it becomes effective in the first quarter of fiscal year 2026. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Product revenue and reserves 3 Months Ended Mar. 31, 2024 Revenue from Contract with Customer [Abstract] Â Product revenue and reserves Product revenue and reservesFor the three months ended MarchÂ 31, 2024 and 2023, the Company recorded $18.6Â million and $2.3Â million, respectively, of product revenue. Product revenue by therapy represents: For the three months ended March 31,20242023ZYNTEGLO$18,561Â $â€”Â SKYSONAâ€”Â 2,296Â Total product revenue, net$18,561Â $2,296Â Six individual customers accounted for 100% of product revenue for the three months ended MarchÂ 31, 2024 and one individual customer accounted for 100% of product revenue for the three months ended MarchÂ 31, 2023. The Company considers there to be revenue concentration risks for customers that represent product revenues that exceed 10% of total product revenue. The concentration of the Companyâ€™s product revenue within a particular customer may have a material adverse effect on the Companyâ€™s revenue and results of operations if sales with the respective customer experience difficulties. All product revenue during the three months ended MarchÂ 31, 2024 and 2023 were within the United States.The following table summarizes an analysis of the change in reserves for gross to net deductions for the periods indicated: TotalBalance at December 31, 2023$5,365Â Provision for rebates3,780Â Payments/creditsâ€”Â Balance at March 31, 2024$9,145Â X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to,

disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements 3 Months Ended Mar. 31, 2024 Fair Value Disclosures [Abstract] Â Fair value measurements Fair value measurementsThe following table sets forth the Companyâ€™s assets and liabilities that are measured at fair value on a recurring basis as of MarchÂ 31, 2024 and DecemberÂ 31, 2023 (in thousands):DescriptionTotalQuotedprices inactivemarkets(Level 1)Significantotherobservableinputs(Level 2)Significantunobservableinputs(Level 3)March 31, 2024Assets:Cash and cash equivalents$212,047Â $212,047Â $â€”Â $â€”Â Marketable securities:U.S. government agency securities and treasuriesâ€”Â â€”Â â€”Â â€”Â Due from factor:Beneficiary interest in factored invoices1,120Â â€”Â â€”Â 1,120Â Total$213,167Â $212,047Â $â€”Â $1,120Â December 31, 2023Assets:Cash and cash equivalents$221,755Â $221,755Â $â€”Â $â€”Â Marketable securities:U.S. government agency securities and treasuriesâ€”Â â€”Â â€”Â â€”Â Receivables and other current assets:Beneficiary interest in factored invoices560Â â€”Â â€”Â 560Â Total$222,315Â $221,755Â $â€”Â $560Â Cash and cash equivalentsThe Company considers all highly liquid securities with original final maturities of 90 days or less from the date of purchase to be cash equivalents. As of MarchÂ 31, 2024 and DecemberÂ 31, 2023, cash and cash equivalents comprise funds in cash and money market accounts held at multiple banking and asset management institutions.Marketable securitiesMarketable securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities and treasuries, corporate bonds, and commercial paper. The Company estimates the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts. At MarchÂ 31, 2024 and DecemberÂ 31, 2023, the balance in the Companyâ€™s accumulated other comprehensive loss was composed primarily of activity related to the Companyâ€™s available-for-sale debt securities. There were no and $0.1 million of realized losses recognized on the sale or maturity of available-for-sale debt securities during the three months ended MarchÂ 31, 2024 and 2023, respectively.Accrued interest receivable on the Company's available-for-sale debt securities totaled $0.3 million and $0.3Â million as of MarchÂ 31, 2024 and DecemberÂ 31, 2023, respectively. No accrued interest receivable was written off during the three months ended MarchÂ 31, 2024 or 2023.Factoring agreementDue from factor classified as Level 3 within the valuation hierarchy consists of beneficiary interest in transferred invoices. The Company estimates the fair value of the beneficiary interest based on the estimated cash flows after applying counterparty and credit risk adjustments associated with the factoring agent and distributors, respectively. As of MarchÂ 31, 2024, no adjustment to the beneficiary interest in invoices sold was deemed an unobservable input and was determined based from ongoing credit evaluations and historical experience with aging of such invoices, among other factors. A significant change to this input could result in a significantly lower or higher fair value measurement.The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the three months ended MarchÂ 31, 2024: For the three months endedMarch 31,2024Level 3 financial assets, beginning of period$560Â Beneficiary interest obtained in transferred invoices1,680Â Proceeds from previously transferred invoices(1,120)Level 3 financial assets, end of period$1,120Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory 3 Months Ended Mar. 31, 2024 Inventory Disclosure [Abstract] Â Inventory InventoryInventory, net, consists of the following (in thousands):As of March 31, 2024As of December 31, 2023Raw materials$3,177Â $2,329Â Work in progress22,146Â 17,375Â Finished goods4,982Â 3,215Â Inventory$30,305Â $22,919Â Raw materials inventory consists of completed materials purchased directly from third party suppliers. Work in progress inventory consists of materials manufactured at contract manufacturing organizations ("CMOs") that are either partially completed, fully manufactured but are pending quality acceptance, or completed meeting quality acceptance standards to be used in the manufacture of drug product and drug products that are either partially completed or fully manufactured but are pending quality acceptance. Finished goods are completed and quality approved drug products that are either awaiting shipment, in-transit or delivered to a qualified treatment center, but have not yet been infused in a patient. X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Factoring agreement 3 Months Ended Mar. 31, 2024 Receivables [Abstract] Â Factoring agreement Factoring agreementThe company sells rights to future revenues associated with invoices issued upon delivery of drug product to QTCs. The upfront payments are treated as a short-term liability, presented as due to factor on our consolidated balance sheets until the right to consideration from the customer is deemed unconditional. The remaining invoice amount payable to the Company at infusion is considered a beneficial interest in the factored invoice and represents the extent of our continued involvement in the sale of invoices.Due to FactorFor the three months ending MarchÂ 31, 2024, the Company collected $15.1Â million in cash receipts prior to an unconditional right to consideration and derecognized $15.1Â million of due to factor amounts as a result of patient drug product infusions. Amounts presented as due to factor on the consolidated balance sheets would be subject to payment based on the repurchase requirements that exist prior to the infusion date in the factoring agreement. Due from FactorFor the three months ending MarchÂ 31, 2024, the company obtained $1.6Â million of beneficiary interest in invoices and collected $1.1Â million in cash receipts. Uncollected amounts presented as due from factor on the consolidated balance sheets are net of accrued fees of $0.1Â million. The maximum loss exposure is $1.1Â million at MarchÂ 31, 2024. The total loss from the sale of customer invoices is estimated on the patient infusion date of the drug product and was $0.3Â million for the three months ending MarchÂ 31, 2024. In addition to the loss from the sale of invoices the Company has incurred $0.4Â million in servicing fees. X - DefinitionFactoring Agreements + ReferencesNo definition available. + Details Name: blue_FactoringAgreementsTextBlock Namespace Prefix: blue_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued expenses and other current liabilities 3 Months Ended Mar. 31, 2024 Payables and Accruals [Abstract] Â Accrued expenses and other current liabilities Accrued expenses and other current liabilitiesAccrued expenses and other current liabilities consist of the following (in thousands):As of March 31, 2024As of December 31, 2023Accrued CMO and CRO costs$22,481Â $24,824Â Accrued employee compensation10,876Â 19,972Â Accrued goods and services5,453Â 8,391Â Accrued rebates9,194Â 5,365Â Accrued professional fees7,090Â 2,531Â Accrued refund liabilityâ€”Â 5,600Â Other9,002Â 6,505Â Total accrued expenses and other current liabilities$64,096Â $73,188Â X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases 3 Months Ended Mar. 31, 2024 Leases [Abstract] Â Leases LeasesThe Company leases certain office and laboratory space, primarily located in Somerville, Massachusetts.Â Additionally, the Company has embedded leases through its agreements with CMOs and a contract testing organization ("CTO") in both the United States and internationally. Except as described below, there have been no material changes in lease obligations from those disclosed in Note 11 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K.Embedded leasesPeriodically, throughout the three months ended March 31, 2024, the Company amended several of its embedded contract manufacturing leases, some of which were accounted for as lease modifications under ASC 842. The lease modifications primarily relate to the execution of new statements of work with the vendors or the extension of contractual terms.As it relates to embedded leases related to drug product manufacturing and quality testing, the Company increased its finance lease right-of-use assets in the amount of $28.3 million.As it relates to embedded leases related to drug substance manufacturing, the Company decreased its finance lease right-of-use assets in the amount of $3.8 million.The following paragraphs describe the significant lease modifications to the Companyâ€™s embedded contract manufacturing leases.Embedded Leases â€“ Drug Substance ManufacturingIn March 2024, the Company extended its embedded lease for the manufacturing of vector and is obligated under the defined production schedule through May 2024.Embedded Leases â€“ Drug Product ManufacturingIn January 2024, the Company amended its lease agreement with a CMO to expand into two additional controlled environment rooms, both designated for the Company's exclusive use during the term of the agreement. Pursuant to the amended agreement, the Company is obligated to pay a monthly fixed fee for each additional space in addition to fees based on committed production levels through the remaining lease term, which ends in February 2025. The fixed portion of the fee is included as part of the Companyâ€™s lease liability.Embedded Leases â€“ Quality TestingIn January 2024, the Company entered into a Reserved Capacity Agreement with a CTO that provides clinical development services. The Reserved Capacity Agreement amended the Companyâ€™s existing master contract services agreement with the CTO and provides for legally binding minimum purchase commitments with step decreases throughout its three-year contract term in six-month increments. The Company included the â€œfirmâ€ legally binding portion of the forecast through 2026 as part of its fixed minimum lease liability. Summary of all lease costs recognized under ASC 842The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Companyâ€™s operating and finance leases for the three months ended MarchÂ 31, 2024 and 2023 (in thousands):For the three months ended March 31,20242023(As Restated)Finance leasesInterest expense$4,347Â $4,267Â Amortization expense14,328Â 5,216Â Total fixed finance lease cost$18,675Â $9,483Â Operating leasesFixed lease cost 9,486Â 11,470Â Total fixed operating lease cost9,486Â 11,470Â Variable lease cost6,043Â 6,862Â Short-term lease cost76Â 52Â Total lease cost$34,280Â $27,867Â Operating sublease income$10,346Â $10,108Â Cash paid in the measurement of lease liabilitiesOperating cash flows used for operating leases2,844Â 6,361Â Operating cash flows used for finance leases1,411Â 3,352Â Financing cash flows for finance leases22,210Â 15,280Â Other informationWeighted average remaining lease term - finance leasesÂ 1.42 years2.30 yearsWeighted average discount rate - finance leases14.45Â %15.13Â %Weighted average remaining lease term - operating leasesÂ 6.75 years7.59 yearsWeighted average discount rate - operating leases7.00Â %7.04Â %As of MarchÂ 31, 2024, future minimum commitments under ASC 842 under the Companyâ€™s leases were as follows (in thousands):Operating LeasesFinancing LeasesRemaining Lease PaymentsRemainder of 202428,492Â 102,277Â 202537,084Â 41,270Â 202635,719Â 3,422Â 202736,742Â 2,548Â 202837,795Â 1,043Â 2029 and thereafter81,986Â â€”Â Total257,818Â 150,560Â Less: Imputed Interest(52,772)(10,259)Present Value of Lease Liabilities$205,046Â $140,301Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies 3 Months Ended Mar. 31, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and contingencies Commitments and contingenciesLease commitmentsThe Company leases certain office and laboratory space and has embedded leases at CMOs and a CTO. As of MarchÂ 31, 2024, the Company has commitments arising from a forward starting lease that had not yet commenced related to an embedded equipment lease with a CMO. This lease is expected to commence in 2025 with an initial lease term of three years. Fixed commitments under this contract approximate $56.8Â million. The following table presents the non-cancelable contractual obligations arising from this arrangement as of the three months ended MarchÂ 31, 2024 (in

thousands):FuturecommitmentRemainder of 2024$â€”Â 202513,763Â 202617,858Â 202717,858Â 20287,310Â 2029 and thereafterâ€”Â Total purchase commitments$56,789Â Refer to Note 9, Leases, for further information on the terms of these lease agreements.LitigationFrom time to time, the Company is party to various claims and complaints arising in the ordinary course of business, including securities class action litigation and intellectual property litigation. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Companyâ€™s business partners. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is generally unlimited. Accruals for loss contingencies are recognized when a loss is probable, and the amount of such loss can be reasonably estimated. The Company has not accrued for a loss for any matter described below as a loss is not probable and a loss, or a range of loss, is not reasonably estimable. The Company also indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and by-laws. The term of the indemnification period lasts as long as such officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations.There have been no material changes in claims and complaints from those disclosed in Note 12 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Term loan debt 3 Months Ended Mar. 31, 2024 Debt Disclosure [Abstract] Â Term loan debt Term loan debt2024 Term LoanOn March 15, 2024 (the â€œEffective Dateâ€), the Company entered into a Loan and Security Agreement (the â€œLSAâ€) and a Warrant Agreement (the â€œWarrant Agreementâ€) with Hercules Capital and funds managed by Hercules Capital (collectively, â€œHerculesâ€ or â€œthe lendersâ€). Under the terms of the LSA, the Company may borrow up to an aggregate principal amount of $175.0Â million over the term of the agreement, in four separate tranches (the â€œTerm Loansâ€) dependent on the achievement of certain milestones. On the Effective Date, the Company drew down the initial $75.0Â million of gross proceeds (â€œInitial Loanâ€), and paid initial debt issuance costs of $3.5Â million, inclusive of legal fees of approximately $2.7Â million and the original issuance discount (â€œOIDâ€) of $0.8Â million, or 1% of the drawn amount, in accordance with the terms of the LSA. Additional amounts are available to borrow in two separate $25.0Â million tranches based on the Company meeting certain pre-defined milestone achievements associated with cell collection from LYFGENIA patients (35 patients on or before September 30, 2024 or 55 patients on or before December 31, 2024) (â€œTranche 2â€) and compliance with a gross profit metric (no later than the period ending June 30, 2025) (â€œTranche 3â€). Additionally, the Company may request up to an additional $50.0Â million through December 15, 2026 from Hercules (â€œTranche 4â€). The lenders have no obligation to fund any amounts under Tranche 4 as funding is conditioned on approval by the lendersâ€™ investment committee.The Term Loans bear both cash interest and paid-in-kind interest (â€œPIKâ€). The cash interest is due on the first business day of each month (â€œPayment Dateâ€) and will be equal to the WSJ prime rate (â€œprime rateâ€) plus 1.45% (floored at 9.95%). The PIK interest is fixed at 2.45% and is to be capitalized and added to the outstanding principal on each Payment Date. Unless prepaid by the Company at their discretion, subject to certain prepayment penalties and conditions, the Term Loans are repayable in monthly interest-only payments until April 1, 2027, or April 1, 2028, if the Company has achieved, no later than December 31, 2026, certain financial metrics (the â€œPerformance Milestoneâ€). After the expiration of the interest-only payment period, the Term Loans are repayable in equal monthly payments of principal and accrued interest until maturity. The Term Loans will mature on April 1, 2029.The 2024 Term Loan is collateralized by substantially all the Companyâ€™s assets. In addition to other covenants, the 2024 Term Loan contains affirmative covenants as well as certain financial covenants, including a minimum cash coverage requirement of 40% of the outstanding principal of the term loan and a minimum net product revenue requirement that commences with the quarter ending September 30, 2024. The Company was in compliance with the minimum cash coverage covenant as of March 31, 2024, but the Company projects that it will not maintain its minimum cash coverage requirement within the next 12 months (see the Company's going concern assessment in Note 1, Description of the business). As such, the term loan is presented as a current liability as of March 31, 2024. The Company also issued warrants under the Warrant Agreement for the right to purchase shares of the Companyâ€™s common stock to Hercules, with the number of shares to be based on the amounts borrowed under the LSA (the â€œWarrantsâ€). The Warrants are exercisable for a number of shares of common stock equal to the quotient of (i.) 5% times the aggregate original principal of amounts drawn under the LSA divided by (ii.) the exercise price of $1.45 per share. As of March 31, 2024, the Company had issued 2.6Â million warrants associated with the Initial Loan (â€œInitial Warrantsâ€) to purchase common stock at an exercise price of $1.45 per share and a contractual life of 7 years from the Effective Date. The Warrants have been recorded at their relative fair value using the Black-Scholes option-pricing model and the following assumptions: no dividend yield, expected volatility of 81.1%, risk free rate of 4.3%, and expected term of 7 years, equal to the life of the warrant. The relative fair value allocated to the initial warrants was $2.7Â million, which was classified as additional-paid-in-capital and recorded as a debt discount which will be amortized, together with debt issuance costs, to interest expense using the effective interest method over the life of the loan at an effective interest rate of 15.7%. For the period ended March 31, 2024, the Company recorded approximately $0.5Â million in interest expense associated with the Term Loans, inclusive of amounts related to the Warrants.Refer to Note 16, Subsequent Events, for further discussion on the amendments to the LSA and the Warrant Agreement subsequent to the three months ended March 31, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity 3 Months Ended Mar. 31, 2024 Equity [Abstract] Â Equity EquityOn January 18, 2023, the Company entered into an underwriting agreement (the â€œJanuary Underwriting Agreementâ€) with Goldman and J.P. Morgan Securities LLC in connection with the public offering, issuance, and sale by the Company of 20.0Â million shares of the Companyâ€™s common stock at a public offering price of $6.00 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 and a related prospectus supplement filed with the Securities and Exchange Commission. Under the terms of the January Underwriting Agreement, the Company also granted the underwriters an option exercisable for 30 days to purchase up to an additional 3.0Â million shares of common stock at the public offering price, less underwriting discounts and commissions, which the underwriters exercised in full. The offering closed on January 23, 2023. The Company received aggregate net proceeds of $130.5Â million.In August 2023, the Company entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Companyâ€™s common stock up to $125.0Â million, from time to time, through an â€œat the marketâ€ equity offering program under which Jefferies will act as sales agent. As of March 31, 2024, the Company has made no sales pursuant to the Sales Agreement.On December 19, 2023, the Company entered into an underwriting agreement (the â€œDecember Underwriting Agreementâ€) with Goldman and J.P. Morgan Securities LLC, in connection with the public offering, issuance, and sale by the Company of 83.3 million shares of the Companyâ€™s common stock at a public offering price of $1.50 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 and a related prospectus supplement filed with the Securities and Exchange Commission. Under the terms of the December Underwriting Agreement, the Company also granted the underwriters an option exercisable for 30 days to purchase up to an additional 12.5 million shares of common stock at the public offering price, less underwriting discounts and commissions, which option was not exercised. The offering closed on December 22, 2023. The Company received aggregate net proceeds of $118.1Â million. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation 3 Months Ended Mar. 31, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-based compensation Stock-based compensationIn June 2023, the Companyâ€™s stockholders approved the bluebird bio, Inc. 2023 Incentive Award Plan (the â€œ2023 Planâ€), which replaced the 2013 Stock Option and Incentive Plan (â€œ2013 Planâ€). Following approval of the 2023 Plan, no further awards will be granted under the 2013 Plan. As of MarchÂ 31, 2024, the total number of shares of common stock available for issuance under the 2023 Plan was approximately 2.1Â million.Stock-based compensation expense The Company recognized stock-based compensation expense totaling $3.8 million and $5.4 million during the three months ended MarchÂ 31, 2024 and 2023, respectively. Stock-based compensation expense recognized by award type is included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):For the three months ended March 31,20242023Stock options$1,230Â $1,723Â Restricted stock units2,451Â 3,668Â Employee stock purchase plan and other80Â â€”Â $3,761Â $5,391Â Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):Â For the three months ended March 31,20242023Cost of product revenue491Â 103Â Selling, general and administrative2,335Â 2,361Â Research and development935Â 2,927Â $3,761Â $5,391Â During the three months ended MarchÂ 31, 2024 and 2023, the Company had $0.3Â million and $0.5 million of stock compensation expense that was capitalized into inventory. Stock optionsThe following table summarizes the stock option activity under the Companyâ€™s equity award plans excluding awards held by employees of 2seventy bio:Shares(in thousands)Weighted-averageexercise priceper shareOutstanding at December 31, 20234,227Â $14.16Â Granted2,572Â $1.56Â Exercisedâ€”Â $â€”Â Canceled, forfeited, or expired(229)$16.55Â Outstanding at March 31, 20246,570Â $9.16Â Exercisable at March 31, 20241,871Â $22.75Â Vested and expected to vest at March 31, 20246,570Â $9.16Â During the three months ended MarchÂ 31, 2024, no stock options were exercised.Restricted stock unitsThe following table summarizes the restricted stock unit activity under the Companyâ€™s equity award plans excluding awards held by employees of 2seventy bio:Shares(in thousands)Weighted-averagegrant datefair valueUnvested at December 31, 20234,207Â $6.08Â Granted2,177Â $1.56Â Vested(785)$7.14Â Forfeited(205)$4.41Â Unvested at March 31, 20245,394Â $4.16Â Employee stock purchase planIn JuneÂ 2013, the Company's board of directors adopted its 2013 Employee Stock Purchase Plan (â€œ2013 ESPPâ€), which authorized the initial issuance of up to a total of 0.2 million shares of the Companyâ€™s common stock to participating employees. In June 2021, the Company amended the 2013 ESPP to authorize an additional 1.4Â million shares of the Companyâ€™s common stock available to participating employees. During each of the three months ended MarchÂ 31, 2024 and 2023, no shares and less than 0.1Â million shares, respectively, of common stock were issued under the 2013 ESPP. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718

-SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income taxes 3 Months Ended Mar. 31, 2024 Income Tax Disclosure [Abstract] Â Income taxes Income taxesDeferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Companyâ€™s otherwise recognizable net deferred tax assets. The tax benefit recognized during the three months ended MarchÂ 31, 2024 was $0.0Â million due to the full valuation allowance. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per share 3 Months Ended Mar. 31, 2024 Earnings Per Share [Abstract] Â Net loss per share Net loss per shareThe following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):For the three months endedMarch 31,2024Outstanding stock options(1)7,903Â Restricted stock units(1)5,449Â Warrants2,586Â ESPP shares and other84Â 16,022Â (1) Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.Net loss per share for the three months ended MarchÂ 31, 2024 was $0.36. During the three months ended March 31, 2023, the Company had net income of $18.9 million. Basic weighted-average common shares outstanding were 102.9 million, the effect of dilutive securities was 0.4 million, and diluted weighted-average common shares outstanding were 103.3 million. Basic earnings per share and diluted earnings per share were both $0.18. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restatement of Previously Issued Financial Statements 3 Months Ended Mar. 31, 2024 Accounting Changes and Error Corrections [Abstract] Â Restatement of Previously Issued Financial Statements Restatement of Previously Issued Financial StatementsAs further described below, as well as in Note 2 - Basis of Presentation, the Company identified several prior period misstatements that impacted its unaudited quarterly condensed consolidated financial statements for the quarter ended MarchÂ 31, 2023. Such restated and unaudited quarterly financial data and the related impacted amounts were presented in the Company's Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.As part of the restatement, the Company recorded adjustments to correct the material misstatements related to accounting for embedded leases and other immaterial errors. The following tables present the restated unaudited Condensed Consolidated Financial Information for the quarter ended MarchÂ 31, 2023.Consolidated Statements of Operations and Comprehensive LossFor the three months ended March 31, 2023As Previously ReportedAdjustments to Embedded LeasesOther AdjustmentsAs RestatedRevenue:Product revenue, net$2,296Â $â€”Â $â€”Â $2,296Â Other revenue85Â â€”Â â€”Â 85Â Total revenues2,381Â â€”Â â€”Â 2,381Â Cost of product revenue3,376Â 2,136Â â€”Â 5,512Â Gross margin(995)(2,136)â€”Â (3,131)Operating expenses:Research and development46,144Â (4,516)41,587Â Selling, general and administrative37,354Â 113Â â€”Â 37,467Â Total operating expenses83,498Â (4,403)(41)79,054Â Gain from sale of priority review voucher, net92,930Â â€”Â â€”Â 92,930Â Income from operations8,437Â 2,267Â 41Â 10,745Â Interest income2,828Â â€”Â â€”Â 2,828Â Interest expense(3)(4,267)â€”Â (4,270)Other income, net9,978Â (351)â€”Â 9,627Â Income before income taxes21,240Â (2,351)41Â 18,930Â Income tax (expense) benefitâ€”Â â€”Â â€”Â â€”Â Net income 21,240Â (2,351)41Â 18,930Â Net income per share - basic (1)$0.21Â (0.02)â€”Â $0.18Â Net income per share - diluted (1)$0.21Â (0.02)â€”Â $0.18Â Weighted-average number of common shares usedin computing net income per share - basic:102,920Â 102,920Â 102,920Â 102,920Â Weighted-average number of common shares usedin computing net income per share - diluted:103,303Â 103,303Â 103,303Â 103,303Â Other comprehensive income:Other comprehensive income, net of tax(benefit) expense of $0.0Â million for the three months ended March 31, 2023984Â â€”Â â€”Â 984Â Total other comprehensive income984Â â€”Â â€”Â 984Â Comprehensive income$22,224Â $(2,351)$41Â $19,914Â (1) Due to differences in rounding to the nearest cent per basic or diluted share, totals may not equal the sum of the line items.Statements of Changes in Stockholders' Equity:Common stockAdditionalpaid-incapitalAccumulatedothercomprehensive(loss) incomeAccumulateddeficitTotalstockholders'equitySharesAmountAs Previously ReportedBalances at December 31, 202282,923Â $830Â $4,186,086Â $(4,070)$(3,986,503)$196,343Â Vesting of restricted stock382Â 3Â (198)â€”Â â€”Â (195)Exercise of stock options3Â â€”Â 7Â â€”Â â€”Â 7Â Purchase of shares under ESPP62Â 1Â 226Â â€”Â â€”Â 227Â Issuance of common stock for privateequity placement23,000Â 230Â 130,061Â â€”Â â€”Â 130,291Â Issuance of unrestricted stock awards tosettle accrued employee compensationStock-based compensationâ€”Â â€”Â 5,843Â â€”Â â€”Â 5,843Â Other comprehensive incomeâ€”Â â€”Â â€”Â 984Â â€”Â 984Â Net incomeâ€”Â â€”Â â€”Â 21,240Â 21,240Â Balances at March 31, 2023106,370Â $1,064Â $4,322,025Â $(3,086)$(3,965,263)$354,740Â Adjustments to Embedded LeasesBalances at December 31, 2022$â€”Â $â€”Â $â€”Â $â€”Â $(59,700)$(59,700)Vesting of restricted stockâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Exercise of stock optionsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Purchase of shares under ESPPâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of common stock for private equity placementâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of unrestricted stock awards to settle accrued employee compensationStock-based compensationâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Net incomeâ€”Â â€”Â â€”Â â€”Â (2,351)(2,351)Balances at March 31, 2023â€”Â $â€”Â $â€”Â $â€”Â $(62,051)$(62,051)Other AdjustmentsBalances at December 31, 2022â€”Â â€”Â (98)â€”Â (2,212)(2,310)Vesting of restricted stockâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Exercise of stock optionsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Purchase of shares under ESPPâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of common stock for private equity placementâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of unrestricted stock awards to settle accrued employee compensationStock-based compensationâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Net incomeâ€”Â â€”Â â€”Â â€”Â 41Â 41Â Balances at March 31, 2023â€”Â $â€”Â (98)â€”Â $(2,171)$(2,269)As RestatedBalances at December 31, 202282,923Â 830Â 4,185,988Â (4,070)(4,048,415)134,333Â Vesting of restricted stock382Â 3Â (198)â€”Â â€”Â (195)Exercise of stock options3Â â€”Â 7Â â€”Â â€”Â 7Â Purchase of shares under ESPP62Â 1Â 226Â â€”Â â€”Â 227Â Issuance of common stock for privateequity placement23,000Â 230Â 130,061Â â€”Â â€”Â 130,291Â Issuance of unrestricted stock awards to settle accrued employee compensationStock-based compensationâ€”Â â€”Â 5,843Â â€”Â â€”Â 5,843Â Other comprehensive incomeâ€”Â â€”Â â€”Â 984Â â€”Â 984Â Net incomeâ€”Â â€”Â â€”Â â€”Â 18,930Â 18,930Â Balances at March 31, 2023106,370Â $1,064Â $4,321,927Â $(3,086)$(4,029,485)$290,420Â Consolidated Statement of Cash FlowsFor the three months ended March 31,2023As Previously ReportedAdjustments to Embedded LeasesOther AdjustmentsAs RestatedCash flows from operating activities:Net income $21,240Â $(2,351)$41Â $18,930Â Adjustments to reconcile net income to net cash used in operatingÂ Â Â activities:Depreciation and amortization1,082Â 5,131Â (41)6,172Â Stock-based compensation expense5,391Â â€”Â â€”Â 5,391Â Noncash research and development expense (finance lease)â€”Â 1,441Â â€”Â 1,441Â Noncash operating lease expenseâ€”Â 7,423Â â€”Â 7,423Â Gain from sale of priority review voucher(92,930)â€”Â â€”Â (92,930)Excess inventory reserve228Â â€”Â 2,355Â 2,583Â Other non-cash items237Â â€”Â â€”Â 237Â Gain on foreign currency exchange ratesâ€”Â (108)â€”Â (108)Changes in operating assets and liabilities:Prepaid expenses and other assets(9,335)2,846Â 2,800Â (3,689)Inventory(3,586)610Â (2,355)(5,331)Operating right of use assets11,829Â (11,829)â€”Â â€”Â Accounts payable(6,443)7,703Â â€”Â 1,260Â Accrued expenses and other liabilities(9,065)1,859Â â€”Â (7,206)Accrued interest payable under finance leaseâ€”Â 915Â â€”Â 915Â Operating lease liabilities(8,001)1,640Â â€”Â (6,361)Deferred revenue2,715Â â€”Â (2,800)(85)Net cash used in operating activities(86,638)15,280Â â€”Â (71,358)Cash flows from investing activities:Purchase of property, plant and equipment(232)â€”Â â€”Â (232)Purchases of marketable securities(19,610)â€”Â â€”Â (19,610)Proceeds from maturities of marketable securities4,021Â â€”Â â€”Â 4,021Â Proceeds from sales of marketable securities5,853Â â€”Â â€”Â 5,853Â Purchase of intangible assets(868)â€”Â â€”Â (868)Proceeds from sale of priority review voucher92,972Â â€”Â â€”Â 92,972Â Net cash provided by investing activities82,136Â â€”Â â€”Â 82,136Â Cash flows from financing activities:Proceeds from exercise of stock options and ESPP contributions7Â â€”Â â€”Â 7Â Proceeds from vesting of restricted stock(196)â€”Â â€”Â (196)Principal payments on finance leaseâ€”Â (15,280)â€”Â (15,280)Proceeds from the secondary public offering, net of issuance costs130,645Â â€”Â â€”Â 130,645Â Net cash provided by financing activities130,456Â (15,280)â€”Â 115,176Â Increase in cash, cash equivalents and restricted cash125,954Â â€”Â â€”Â 125,954Â Cash, cash equivalents and restricted cash at beginning of year158,445Â â€”Â â€”Â 158,445Â Cash, cash equivalents and restricted cash at end of year$284,399Â $â€”Â $â€”Â $284,399Â Reconciliation of cash, cash equivalents and restricted cash:Cash and cash equivalents$239,045Â $â€”Â $â€”Â $239,045Â Restricted cash included in receivables and other current assets1,417Â â€”Â â€”Â 1,417Â Restricted cash included in restricted cash and other non-current assets43,937Â â€”Â â€”Â 43,937Â Total cash, cash equivalents and restricted cash$284,399Â $â€”Â $â€”Â $284,399Â Supplemental cash flow disclosures:Purchases of property, plant and equipment included in accountsÂ Â payable and accrued expenses189Â â€”Â â€”Â 189Â Offering expenses included in accounts payable and accrued expenses523Â â€”Â â€”Â 523Â Priority review voucher expenses accrued or in AP43Â â€”Â â€”Â 43Â Right-of-use assets obtained in exchange for finance lease liabilitiesâ€”Â (214)â€”Â (214)Cash paid during the period for income taxes2Â â€”Â â€”Â 2Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting error correction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7 + Details Name: us-gaap_ErrorCorrectionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent events 3 Months Ended Mar. 31, 2024 Subsequent Events [Abstract] Â Subsequent events Subsequent events Term Loan DebtAs previously disclosed in Note 8, Term loan debt, on March 15, 2024, the Company entered into a five-year term loan facility agreement with Hercules Capital, Inc. ("Hercules") to secure debt financing for up to $175Â million, available in four tranches. The first tranche in an amount equal to $75Â million was drawn at the time of closing (the "Initial Loan"). The Company may draw upon two additional tranches of $25Â million each, subject to satisfaction of certain conditions, including achievement of commercial milestones. The facility also provides a fourth tranche of $50Â million, available at the sole discretion of Hercules, until December 15, 2026.The Loan and Security Agreement ("LSA") requires the Company to comply with customary affirmative and negative covenants, including, among other things, a requirement to deliver annual financial statements within 90 days of each fiscal year and quarterly financial statements within 45 days of each fiscal quarter. A failure to comply with these covenants, or failure to obtain a waiver for any non-compliance, would result in an event of default under the LSA and would allow Hercules to accelerate repayment of the debt, which could materially and adversely affect the business, results of operations and financial condition of the Company. On April 30, 2024, July 9, 2024, August 13, 2024, and August 29, 2024 the Company and Hercules entered into amendments to the LSA providing for revised monthly financial reporting metrics for each month through September 30, 2024 and extension of the deadlines by which the Company must provide certain annual and quarterly financial statements.On August 13, 2024, the Company and Hercules entered into a third amendment to the LSA (the â€œThird Amendmentâ€), pursuant to which the parties agreed to, among other things, revised terms for the availability of the second and third tranches of funding under the LSA. In accordance with the Third Amendment, the Company may draw the second tranche of $25.0Â million during the period commencing on the date the Company has (x) received at least $75.0Â million in gross cash proceeds from qualified financing transactions by December 20, 2024 and (y) completed patient starts (cell collections) for at least 50 LYFGENIA patients by March 31, 2025 or 70 LYFGENIA patients by June 30, 2025 (collectively, the â€œTranche 2 Milestoneâ€) and ending on the earlier of (i) the date that is 30 days immediately following achievement of the Tranche 2 Milestone and (ii) July 31, 2025. The Company may draw the third tranche of $25.0Â million during the period commencing on the date the Company has (x) received at least $100.0Â million in gross cash proceeds from qualified financing transactions by December 20, 2024 or at least $125.0Â million by June 30, 2025 and (y) completed 70 drug product deliveries within a given six-month period ending no later than December 31, 2025, at least 40 of which are for LYFGENIA (collectively, the â€œTranche 3 Milestoneâ€) and ending on the earlier of (i) the date that is 30 days immediately following the date the Company achieves the Tranche 3 Milestone and (ii) December 31, 2025. Additionally, the Company and Hercules agreed to increase the minimum cash coverage requirement from 40% to 45% of the outstanding principal of the term loan.Additionally, in connection with entry into the LSA, the Company issued to the lenders warrants to purchase that number of shares of the Companyâ€™s common stock equal to five percent of the Initial Loan, or $3.75Â million,

divided by the volume-weighted average price (â€œVWAPâ€) of the Companyâ€™s common stock for the ten-day period preceding March 15, 2024 (the â€œInitial Warrantsâ€). The Company agreed to issue additional common stock warrants to the lenders at the closings of future tranches of funding under the LSA, if any, to purchase that number of shares of common stock equal to five percent of the applicable loan divided by the VWAP of the Companyâ€™s common stock for the ten-day period preceding March 15, 2024 (together with the Initial Warrants, the â€œWarrantsâ€). On August 13, 2024, in connection with the Third Amendment, the Company agreed to amend the exercise price of the Warrants to purchase shares of the Companyâ€™s common stock from $1.45 per share to the lesser of the VWAP of the Companyâ€™s common stock for the ten-day period preceding August 13, 2024, and the price per share of the Companyâ€™s first equity financing event within six months of August 13, 2024. The amendment does not impact the number of shares the lenders may purchase pursuant to the Warrants. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Pay vs Performance Disclosure Â Â Net (loss) income $ (69,804) $ 18,930 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Mar. 31, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of presentation, principles of consolidation and significant accounting policies (Policies) 3 Months Ended Mar. 31, 2024 Accounting Policies [Abstract] Â Basis of presentation Basis of presentationThe accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the Accounting Standard Codification (â€œASCâ€) and Accounting Standards Updates (â€œASUsâ€) of the Financial Accounting Standards Board (â€œFASBâ€). Certain information and footnote disclosures normally included in the Companyâ€™s annual financial statements have been condensed or omitted. These condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Companyâ€™s financial position and results of operations for the interim periods ended MarchÂ 31, 2024 and 2023. Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company views its operations and manages its business in one operating segment. Reclassification of Prior Year Presentation Reclassification of Prior Year PresentationCertain prior year amounts have been reclassified to conform to the current year presentation. Specifically, interest expense has been reclassified from interest income to interest expense in the consolidated statement of operations and comprehensive (loss) income. These reclassifications had no effect on the reported results of operations. Use of estimates Use of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates and judgments are used in the following areas, among others: the alternative future use of assets used in research and development activities, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, gross-to-net revenue calculations, stock-based compensation expense, accrued expenses, income taxes, the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements, and the assessment of the likelihood and magnitude of losses that may be sustained upon resolution of contingencies. Inventory InventoryInventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Companyâ€™s consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used to produce clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product. Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product which has been produced for the treatment of specific patients, that are owned by the Company until infusion. Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on-hand and firm purchase commitments as well as remaining shelf life of on-hand inventories. The Company writes down its inventory that is in excess, obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue in the Companyâ€™s consolidated statements of operations and comprehensive loss. Revenue recognition Revenue recognitionUnder ASC Topic 606, Revenue from Contracts with Customers (â€œTopic 606â€), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance

obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customerâ€™s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.Â The Company assesses whether each promised good or service is distinct to identify the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)Â the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entityâ€™s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).Â Â The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (â€œSSPâ€) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the adjustment period.In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed each of its revenue generating arrangements to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.Product revenue In 2022, the Company received approval of ZYNTEGLO and SKYSONA from the FDA. In 2023, the Company received approval of LYFGENIA from the FDA. The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. The Company uses Specialty Distributors ("SD") and Specialty Pharmacies ("SP") to deliver product to the Qualified Treatment Centers ("QTC"). Revenue is only recognized when the performance obligation is satisfied. The Company recognizes revenue upon infusion to the patient. To determine whether a significant reversal will occur in future periods, the Company will assess both the likelihood and magnitude of any such potential reversal of revenue. Gross product revenue is reduced by outcomes-based rebates, other rebates and distributor fees.Rebates expenseRebates are based on contractual arrangements or statutory requirements and include amounts due to Medicaid agencies and third-party payers. These amounts may vary by product and payer. Rebates are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. The Company assesses and updates estimates each reporting period to reflect actual claims and other current information. Rebates that are payable to Medicaid agencies and third-party payers are recorded in accrued expenses and other current liabilities on the Company's consolidated balance sheets. Distributor fees The Company pays distribution fees to SDs and SPs in connection with the sales of our product. These distributor fees are based on a contractually determined fixed percentage of sales. Other revenue In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, Revenue Recognition Not-for-Profit Entities, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In 2023, the Company ceased further research work and is in the process of winding down such collaboration. Recent accounting pronouncements Recent accounting pronouncementsIn November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 â€“ Segment Reporting. This update is effective beginning with the Companyâ€™s 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Companyâ€™s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact to its income tax disclosures. In March 2024, the FASB issued ASU 2024-01, Compensation-Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards. This update clarifies the scope of "Profit Interest" and similar awards and adds an illustrative example to the existing ASC 718 standard that includes four fact patterns to demonstrate how an entity should apply the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic 718. The amendments in this ASU are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for interim and annual financial statements not yet issued or made available for issuance. The amendments in this ASU should be applied either (1) retrospectively to all prior periods presented in the financial statements or (2) prospectively to profits interest and similar awards granted or modified on or after the date at which the entity first applies the amendments. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures.In March 2024, the FASB issued ASU 2024-02 "Codification Improvementsâ€”Amendments to Remove References to the Concepts Statements", which removes various references to concepts statements from the FASB Accounting Standards Codification. This ASU is effective for the Company beginning in the first quarter of fiscal year 2026, with early adoption permitted. The Company expects the new guidance will have an immaterial impact on its consolidated financial statements and intends to adopt the guidance when it becomes effective in the first quarter of fiscal year 2026. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContentReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Product revenue and reserves (Tables) 3 Months Ended Mar. 31, 2024 Revenue from Contract with Customer [Abstract] Â Disaggregation of Revenue Product revenue by therapy represents: For the three months ended March 31,20242023ZYNTEGLO$18,561Â $â€”Â SKYSONAâ€”Â 2,296Â Total product revenue, net$18,561Â $2,296Â Summary Of Contract With Customer, Refund Liability The following table summarizes an analysis of the change in reserves for gross to net deductions for the periods indicated: TotalBalance at December 31, 2023$5,365Â Provision for rebates3,780Â Payments/creditsâ€”Â Balance at March 31, 2024$9,145Â X - DefinitionSummary Of Contract With Customer, Refund Liability + ReferencesNo definition available. + Details Name: blue_SummaryOfContractWithCustomerRefundLiabilityTableTextBlock Namespace Prefix: blue_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements (Tables) 3 Months Ended Mar. 31, 2024 Fair Value Disclosures [Abstract] Â Recorded Amount of Assets and Liabilities Measured at Fair

Value on Recurring Basis The following table sets forth the Companyâ€™s assets and liabilities that are measured at fair value on a recurring basis as of MarchÂ 31, 2024 and DecemberÂ 31, 2023 (in thousands):DescriptionTotalQuotedprices inactivemarkets(Level 1)Significantotherobservableinputs(Level 2)Significantunobservableinputs(Level 3)March 31, 2024Assets:Cash and cash equivalents$212,047Â $212,047Â $â€”Â $â€”Â Marketable securities:U.S. government agency securities and treasuriesâ€”Â â€”Â â€”Â â€”Â Due from factor:Beneficiary interest in factored invoices1,120Â â€”Â â€”Â 1,120Â Total$213,167Â $212,047Â $â€”Â $1,120Â December 31, 2023Assets:Cash and cash equivalents$221,755Â $221,755Â $â€”Â $â€”Â Marketable securities:U.S. government agency securities and treasuriesâ€”Â â€”Â â€”Â â€”Â Receivables and other current assets:Beneficiary interest in factored invoices560Â â€”Â â€”Â 560Â Total$222,315Â $221,755Â $â€”Â $560Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the three months ended MarchÂ 31, 2024: For the three months endedMarch 31,2024Level 3 financial assets, beginning of period$560Â Beneficiary interest obtained in transferred invoices1,680Â Proceeds from previously transferred invoices(1,120)Level 3 financial assets, end of period$1,120Â X - DefinitionTabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory (Tables) 3 Months Ended Mar. 31, 2024 Inventory Disclosure [Abstract] Â Schedule of Inventory, Current Inventory, net, consists of the following (in thousands):As of March 31, 2024As of December 31, 2023Raw materials$3,177Â $2,329Â Work in progress22,146Â 17,375Â Finished goods4,982Â 3,215Â Inventory$30,305Â $22,919Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued expenses and other current liabilities (Tables) 3 Months Ended Mar. 31, 2024 Payables and Accruals [Abstract] Â Summary of Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands):As of March 31, 2024As of December 31, 2023Accrued CMO and CRO costs$22,481Â $24,824Â Accrued employee compensation10,876Â 19,972Â Accrued goods and services5,453Â 8,391Â Accrued rebates9,194Â 5,365Â Accrued professional fees7,090Â 2,531Â Accrued refund liabilityâ€”Â 5,600Â Other9,002Â 6,505Â Total accrued expenses and other current liabilities$64,096Â $73,188Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Tables) 3 Months Ended Mar. 31, 2024 Leases [Abstract] Â Lease, Cost The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Companyâ€™s operating and finance leases for the three months ended MarchÂ 31, 2024 and 2023 (in thousands):For the three months ended March 31,20242023(As Restated)Finance leasesInterest expense$4,347Â $4,267Â Amortization expense14,328Â 5,216Â Total fixed finance lease cost$18,675Â $9,483Â Operating leasesFixed lease cost 9,486Â 11,470Â Total fixed operating lease cost9,486Â 11,470Â Variable lease cost6,043Â 6,862Â Short-term lease cost76Â 52Â Total lease cost$34,280Â $27,867Â Operating sublease income$10,346Â $10,108Â Cash paid in the measurement of lease liabilitiesOperating cash flows used for operating leases2,844Â 6,361Â Operating cash flows used for finance leases1,411Â 3,352Â Financing cash flows for finance leases22,210Â 15,280Â Other informationWeighted average remaining lease term - finance leasesÂ 1.42 years2.30 yearsWeighted average discount rate - finance leases14.45Â %15.13Â %Weighted average remaining lease term - operating leasesÂ 6.75 years7.59 yearsWeighted average discount rate - operating leases7.00Â %7.04Â % Schedule of Future Minimum Commitments Under Operating Leases As of MarchÂ 31, 2024, future minimum commitments under ASC 842 under the Companyâ€™s leases were as follows (in thousands):Operating LeasesFinancing LeasesRemaining Lease PaymentsRemainder of 202428,492Â 102,277Â 202537,084Â 41,270Â 202635,719Â 3,422Â 202736,742Â 2,548Â 202837,795Â 1,043Â 2029 and thereafter81,986Â â€”Â Total257,818Â 150,560Â Less: Imputed Interest(52,772)(10,259)Present Value of Lease Liabilities$205,046Â $140,301Â Schedule of Future Minimum Commitments Under Financing Leases As of MarchÂ 31, 2024, future minimum commitments under ASC 842 under the Companyâ€™s leases were as follows (in thousands):Operating LeasesFinancing LeasesRemaining Lease PaymentsRemainder of 202428,492Â 102,277Â 202537,084Â 41,270Â 202635,719Â 3,422Â 202736,742Â 2,548Â 202837,795Â 1,043Â 2029 and thereafter81,986Â â€”Â Total257,818Â 150,560Â Less: Imputed Interest(52,772)(10,259)Present Value of Lease Liabilities$205,046Â $140,301Â X - DefinitionTabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitment and contingencies (Tables) 3 Months Ended Mar. 31, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of Non-cancelable Contractual Obligations The following table presents the non-cancelable contractual obligations arising from this arrangement as of the three months ended MarchÂ 31, 2024 (in thousands):FuturecommitmentRemainder of 2024$â€”Â 202513,763Â 202617,858Â 202717,858Â 20287,310Â 2029 and thereafterâ€”Â Total purchase commitments$56,789Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation (Tables) 3 Months Ended Mar. 31, 2024 Share-Based Payment Arrangement [Abstract] Â Summary of Stock-Based Compensation Expense by Award Type Stock-based compensation expense recognized by award type is included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):For the three months ended March 31,20242023Stock options$1,230Â $1,723Â Restricted stock units2,451Â 3,668Â Employee stock purchase plan and other80Â â€”Â $3,761Â $5,391Â Schedule of Stock-Based Compensation Expense by Classification Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):Â For the three months ended March 31,20242023Cost of product revenue491Â 103Â Selling, general and administrative2,335Â 2,361Â Research and development935Â 2,927Â $3,761Â $5,391Â Summary of Stock Option Activity Under Plan The following table summarizes the stock option activity under the Companyâ€™s equity award plans excluding awards held by employees of 2seventy bio:Shares(in thousands)Weighted-averageexercise priceper shareOutstanding at December 31, 20234,227Â $14.16Â Granted2,572Â $1.56Â Exercisedâ€”Â $â€”Â Canceled, forfeited, or expired(229)$16.55Â Outstanding at March 31, 20246,570Â $9.16Â Exercisable at March 31, 20241,871Â $22.75Â Vested and expected to vest at March 31, 20246,570Â $9.16Â Summary of Restricted Common Stock Awards The following table summarizes the restricted stock unit activity under the Companyâ€™s equity award plans excluding awards held by employees of 2seventy bio:Shares(in thousands)Weighted-averagegrant datefair valueUnvested at December 31, 20234,207Â $6.08Â Granted2,177Â $1.56Â Vested(785)$7.14Â Forfeited(205)$4.41Â Unvested at March 31, 20245,394Â $4.16Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock units. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per share (Tables) 3 Months Ended Mar. 31, 2024 Earnings Per Share [Abstract] Â Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):For the three months endedMarch 31,2024Outstanding stock options(1)7,903Â Restricted stock units(1)5,449Â Warrants2,586Â ESPP shares and other84Â 16,022Â (1) Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na

Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restatement of Previously Issued Financial Statements (Tables) 3 Months Ended Mar. 31, 2024 Accounting Changes and Error Corrections [Abstract] Â Schedule of Corrections to Impacted Financial Statements The following tables present the restated unaudited Condensed Consolidated Financial Information for the quarter ended MarchÂ 31, 2023.Consolidated Statements of Operations and Comprehensive LossFor the three months ended March 31, 2023As Previously ReportedAdjustments to Embedded LeasesOther AdjustmentsAs RestatedRevenue:Product revenue, net$2,296Â $â€”Â $â€”Â $2,296Â Other revenue85Â â€”Â â€”Â 85Â Total revenues2,381Â â€”Â â€”Â 2,381Â Cost of product revenue3,376Â 2,136Â â€”Â 5,512Â Gross margin(995)(2,136)â€”Â (3,131)Operating expenses:Research and development46,144Â (4,516)(41)41,587Â Selling, general and administrative37,354Â 113Â â€”Â 37,467Â Total operating expenses83,498Â (4,403)(41)79,054Â Gain from sale of priority review voucher, net92,930Â â€”Â â€”Â 92,930Â Income from operations8,437Â 2,267Â 41Â 10,745Â Interest income2,828Â â€”Â â€”Â 2,828Â Interest expense(3)(4,267)â€”Â (4,270)Other income, net9,978Â (351)â€”Â 9,627Â Income before income taxes21,240Â (2,351)41Â 18,930Â Income tax (expense) benefitâ€”Â â€”Â â€”Â â€”Â Net income 21,240Â (2,351)41Â 18,930Â Net income per share - basic (1)$0.21Â (0.02)â€”Â $0.18Â Net income per share - diluted (1)$0.21Â (0.02)â€”Â $0.18Â Weighted-average number of common shares usedin computing net income per share - basic:102,920Â 102,920Â 102,920Â 102,920Â Weighted-average number of common shares usedin computing net income per share - diluted:103,303Â 103,303Â 103,303Â 103,303Â Other comprehensive income:Other comprehensive income, net of tax(benefit) expense of $0.0Â million for the three months ended March 31, 2023984Â â€”Â â€”Â 984Â Total other comprehensive income984Â â€”Â â€”Â 984Â Comprehensive income$22,224Â $(2,351)$41Â $19,914Â (1) Due to differences in rounding to the nearest cent per basic or diluted share, totals may not equal the sum of the line items.Statements of Changes in Stockholders' Equity:Common stockAdditionalpaid-incapitalAccumulatedothercomprehensive(loss) incomeAccumulateddeficitTotalstockholders'equitySharesAmountAs Previously ReportedBalances at December 31, 202282,923Â $830Â $4,186,086Â $(4,070)$(3,986,503)$196,343Â Vesting of restricted stock382Â 3Â (198)â€”Â â€”Â (195)Exercise of stock options3Â â€”Â 7Â â€”Â â€”Â 7Â Purchase of shares under ESPP62Â 1Â 226Â â€”Â â€”Â 227Â Issuance of common stock for privateequity placement23,000Â 230Â 130,061Â â€”Â â€”Â 130,291Â Issuance of unrestricted stock awards tosettle accrued employee compensationStock-based compensationâ€”Â â€”Â 5,843Â â€”Â â€”Â 5,843Â Other comprehensive incomeâ€”Â â€”Â â€”Â 984Â â€”Â 984Â Net incomeâ€”Â â€”Â â€”Â â€”Â 21,240Â 21,240Â Balances at March 31, 2023106,370Â $1,064Â $4,322,025Â $(3,086)$(3,965,263)$354,740Â Adjustments to Embedded LeasesBalances at December 31, 2022$â€”Â $â€”Â $â€”Â $â€”Â $(59,700)$(59,700)Vesting of restricted stockâ€”Â â€”Â â€”Â â€”Â â€”Â Exercise of stock optionsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Purchase of shares under ESPPâ€”Â â€”Â â€”Â â€”Â â€”Â Issuance of common stock for private equity placementâ€”Â â€”Â â€”Â â€”Â â€”Â Issuance of unrestricted stock awards to settle accrued employee compensationStock-based compensationâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â Net incomeâ€”Â â€”Â â€”Â â€”Â (2,351)(2,351)Balances at March 31, 2023â€”Â $â€”Â $â€”Â $(62,051)$(62,051)Other AdjustmentsBalances at December 31, 2022â€”Â â€”Â (98)â€”Â (2,212)(2,310)Vesting of restricted stockâ€”Â â€”Â â€”Â â€”Â â€”Â Exercise of stock optionsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Purchase of shares under ESPPâ€”Â â€”Â â€”Â â€”Â â€”Â Issuance of common stock for private equity placementâ€”Â â€”Â â€”Â â€”Â â€”Â Issuance of unrestricted stock awards to settle accrued employee compensationStock-based compensationâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â Net incomeâ€”Â â€”Â â€”Â â€”Â 41Â 41Â Balances at March 31, 2023â€”Â $â€”Â (98)â€”Â $(2,171)$(2,269)As RestatedBalances at December 31, 202282,923Â 830Â 4,185,988Â (4,070)(4,048,415)134,333Â Vesting of restricted stock382Â 3Â (198)â€”Â â€”Â (195)Exercise of stock options3Â â€”Â 7Â â€”Â â€”Â 7Â Purchase of shares under ESPP62Â 1Â 226Â â€”Â â€”Â 227Â Issuance of common stock for privateequity placement23,000Â 230Â 130,061Â â€”Â â€”Â 130,291Â Issuance of unrestricted stock awards to settle accrued employee compensationStock-based compensationâ€”Â â€”Â 5,843Â â€”Â â€”Â 5,843Â Other comprehensive incomeâ€”Â â€”Â â€”Â 984Â â€”Â 984Â Net incomeâ€”Â â€”Â â€”Â â€”Â 18,930Â 18,930Â Balances at March 31, 2023106,370Â $1,064Â $4,321,927Â $(3,086)$(4,029,485)$290,420Â Consolidated Statement of Cash FlowsFor the three months ended March 31,2023As Previously ReportedAdjustments to Embedded LeasesOther AdjustmentsAs RestatedCash flows from operating activities:Net income $21,240Â $(2,351)$41Â $18,930Â Adjustments to reconcile net income to net cash used in operatingÂ Â Â activities:Depreciation and amortization1,082Â 5,131Â (41)6,172Â Stock-based compensation expense5,391Â â€”Â â€”Â 5,391Â Noncash research and development expense (finance lease)â€”Â 1,441Â â€”Â 1,441Â Noncash operating lease expenseâ€”Â 7,423Â â€”Â 7,423Â Gain from sale of priority review voucher(92,930)â€”Â â€”Â (92,930)Excess inventory reserve228Â â€”Â 2,355Â 2,583Â Other non-cash items237Â â€”Â â€”Â 237Â Gain on foreign currency exchange ratesâ€”Â (108)â€”Â (108)Changes in operating assets and liabilities:Prepaid expenses and other assets(9,335)2,846Â 2,800Â (3,689)Inventory(3,586)610Â (2,355)(5,331)Operating right of use assets11,829Â (11,829)â€”Â â€”Â Accounts payable(6,443)7,703Â â€”Â 1,260Â Accrued expenses and other liabilities(9,065)1,859Â â€”Â (7,206)Accrued interest payable under finance leaseâ€”Â 915Â â€”Â 915Â Operating lease liabilities(8,001)1,640Â â€”Â (6,361)Deferred revenue2,715Â â€”Â (2,800)(85)Net cash used in operating activities(86,638)15,280Â â€”Â (71,358)Cash flows from investing activities:Purchase of property, plant and equipment(232)â€”Â â€”Â (232)Purchases of marketable securities(19,610)â€”Â â€”Â (19,610)Proceeds from maturities of marketable securities4,021Â â€”Â â€”Â 4,021Â Proceeds from sales of marketable securities5,853Â â€”Â â€”Â 5,853Â Purchase of intangible assets(868)â€”Â â€”Â (868)Proceeds from sale of priority review voucher92,972Â â€”Â â€”Â 92,972Â Net cash provided by investing activities82,136Â â€”Â â€”Â 82,136Â Cash flows from financing activities:Proceeds from exercise of stock options and ESPP contributions7Â â€”Â â€”Â 7Â Proceeds from vesting of restricted stock(196)â€”Â â€”Â (196)Principal payments on finance leaseâ€”Â (15,280)â€”Â (15,280)Proceeds from the secondary public offering, net of issuance costs130,645Â â€”Â â€”Â 130,645Â Net cash provided by financing activities130,456Â (15,280)â€”Â 115,176Â Increase in cash, cash equivalents and restricted cash125,954Â â€”Â â€”Â 125,954Â Cash, cash equivalents and restricted cash at beginning of year158,445Â â€”Â â€”Â 158,445Â Cash, cash equivalents and restricted cash at end of year$284,399Â $â€”Â $â€”Â $284,399Â Reconciliation of cash, cash equivalents and restricted cash:Cash and cash equivalents$239,045Â $â€”Â $â€”Â $239,045Â Restricted cash included in receivables and other current assets1,417Â â€”Â â€”Â 1,417Â Restricted cash included in restricted cash and other non-current assets43,937Â â€”Â â€”Â 43,937Â Total cash, cash equivalents and restricted cash$284,399Â $â€”Â $â€”Â $284,399Â Supplemental cash flow disclosures:Purchases of property, plant and equipment included in accountsÂ Â payable and accrued expenses189Â â€”Â â€”Â 189Â Offering expenses included in accounts payable and accrued expenses523Â â€”Â â€”Â 523Â Priority review voucher expenses accrued or in AP43Â â€”Â â€”Â 43Â Right-of-use assets obtained in exchange for finance lease liabilitiesâ€”Â (214)â€”Â (214)Cash paid during the period for income taxes2Â â€”Â â€”Â 2Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9 + Details Name: us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Description of the business (Details) $ in Thousands 1 Months Ended 3 Months Ended Dec. 22, 2023 USD ($) Dec. 19, 2023 shares Mar. 31, 2024 USD ($) tranche Dec. 31, 2023 USD ($) shares Aug. 31, 2023 USD ($) Mar. 31, 2024 USD ($) tranche shares Mar. 31, 2023 USD ($) Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Number of tranches | tranche Â Â 4 Â Â 4 Â Accumulated deficit Â Â $ 4,330,132 $ 4,260,328 Â $ 4,330,132 Â Net (loss) income Â Â Â Â Â 69,804 $ (18,930) Net cash used in operating activities Â Â Â Â Â 74,676 $ 71,358 Cash, cash equivalents and marketable securities Â Â $ 212,000 Â Â 212,000 Â Term Loan Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Debt instrument term Â Â 5 years Â Â Â Â Line of credit Â Â $ 175,000 Â Â $ 175,000 Â At The Market Offering Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Proceeds from stock offering Â Â Â Â $ 125,000 Â Â Shares of common stock sold (in shares) | shares Â Â Â Â Â 0 Â December Underwriting Agreement Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Proceeds from stock offering $ 118,100 Â Â $ 118,100 Â Â Shares of common stock sold (in shares) | shares Â 83,300,000 Â 83,300,000 Â Â Â X - DefinitionNumber of Tranches + ReferencesNo definition available. + Details Name: blue_NumberOfTranches Namespace Prefix: blue_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionSum of investments and unrestricted cash as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 + Details Name: us-gaap_InvestmentsAndCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=blue_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=blue_AtTheMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=blue_DecemberUnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of presentation, principles of consolidation and significant accounting policies (Details) 3 Months Ended Mar. 31, 2024 segment Accounting Policies [Abstract] Â Number of operating segments 1 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Product revenue and reserves - Narrative (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Revenue from External Customer [Line Items] Â Â Product revenue, net $ 18,561 $ 2,296 Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Six Individual Customers Â Â Revenue from External Customer [Line Items] Â Â Concentration risk, percentage 100.00% Â Revenue from Contract with Customer Benchmark | Customer Concentration Risk | One Individual Customer Â Â Revenue from External Customer [Line Items] Â Â Concentration risk, percentage Â 100.00% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=blue_SixIndividualCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=blue_OneIndividualCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Product revenue and reserves - Summary of Product Revenue (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Revenue from External Customer [Line Items] Â Â Product revenue, net $ 18,561 $ 2,296 ZYNTEGLO Â Â Revenue from External Customer [Line Items] Â Â Product revenue, net 18,561 0 SKYSONA Â Â Revenue from External Customer [Line Items] Â Â Product revenue, net $ 0 $ 2,296 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=blue_ZYNTEGLOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=blue_SKYSONAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Product revenue and reserves - Rebate Liability (Details) $ in Thousands 3 Months Ended Mar. 31, 2024 USD ($) Contract with Customer, Refund Liability [Roll Forward] Â Balance at December 31, 2023 $ 5,365 Provision for rebates 3,780 Payments/credits 0 Balance at March 31, 2024 $ 9,145 X - DefinitionContract With Customer Payments, Rebate Liability + ReferencesNo definition available. + Details Name: blue_ContractWithCustomerPaymentsRebateLiability Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContract With Customer, Rebate Liability, Current + ReferencesNo definition available. + Details Name: blue_ContractWithCustomerRebateLiabilityCurrent Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContract with Customer, Refund Liability + ReferencesNo definition available. + Details

Name: blue_ContractWithCustomerRefundLiabilityRollForward Namespace Prefix: blue_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionProvision For Contract With Customer, Rebate Liability + ReferencesNo definition available. + Details Name: blue_ProvisionForContractWithCustomerRebateLiability Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands Mar. 31, 2024 Dec. 31, 2023 Assets: Â Â Cash and cash equivalents $ 212,047 $ 221,755 Beneficiary interest in factored invoices 1,120 560 Total 213,167 222,315 U.S. government agency securities and treasuries Â Â Assets: Â Â Marketable securities: 0 0 Quoted prices in active markets (Level 1) Â Â Assets: Â Â Cash and cash equivalents 212,047 221,755 Beneficiary interest in factored invoices 0 0 Total 212,047 221,755 Quoted prices in active markets (Level 1) | U.S. government agency securities and treasuries Â Â Assets: Â Â Marketable securities: 0 0 Significant other observable inputs (Level 2) Â Â Assets: Â Â Cash and cash equivalents 0 0 Beneficiary interest in factored invoices 0 0 Total 0 0 Significant other observable inputs (Level 2) | U.S. government agency securities and treasuries Â Â Assets: Â Â Marketable securities: 0 0 Significant unobservable inputs (Level 3) Â Â Assets: Â Â Cash and cash equivalents 0 0 Beneficiary interest in factored invoices 1,120 560 Total 1,120 560 Significant unobservable inputs (Level 3) | U.S. government agency securities and treasuries Â Â Assets: Â Â Marketable securities: $ 0 $ 0 X - DefinitionBeneficial Interest, Fair Value Disclosure + ReferencesNo definition available. + Details Name: blue_BeneficialInterestFairValueDisclosure Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements - Narrative (Details) - USD ($) 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Dec. 31, 2023 Fair Value Disclosures [Abstract] Â Â Â Realized loss $ 0 $ 100,000 Â Interest receivable 300,000 Â $ 300,000 Interest receivable, write-offs $ 0 $ 0 Â X - DefinitionInterest Receivable, Write-Off + ReferencesNo definition available. + Details Name: blue_InterestReceivableWriteOff Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements - Factoring Agreement Reconciliation of Beginning and Ending Balances (Details) - Beneficial Interest $ in Thousands 3 Months Ended Mar. 31, 2024 USD ($) Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Â Level 3 financial assets, beginning of period $ 560 Beneficiary interest obtained in transferred invoices 1,680 Proceeds from previously transferred invoices (1,120) Level 3 financial assets, end of period $ 1,120 X - DefinitionFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Beneficiary Interest Obtained From Transferred Invoices + ReferencesNo definition available. + Details Name: blue_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetBeneficiaryInterestObtainedFromTransferredInvoices Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Proceeds From Transferred Invoices + ReferencesNo definition available. + Details Name: blue_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetProceedsFromTransferredInvoices Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByAssetClassAxis=blue_BeneficialInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory (Details) - USD ($) $ in Thousands Mar. 31, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 3,177 $ 2,329 Work in progress 22,146 17,375 Finished goods 4,982 3,215 Inventory $ 30,305 $ 22,919 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Factoring agreement (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Receivables [Abstract] Â Â Cash receipts collected prior to consideration $ 15,100 Â Due to factor, value derecognized 15,100 Â Beneficiary interest obtained in transferred invoices 1,600 Â Cash receipts collected 1,120 $ 0 Uncollectable amounts, net of accrued fees 100 Â Maximum loss exposure 1,100 Â Loss on sale of invoice 300 Â Servicing fees $ 400 Â X - DefinitionBeneficiary Interest Obtained + ReferencesNo definition available. + Details Name: blue_BeneficiaryInterestObtained Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFactoring Agreement, Cash Receipts Collected + ReferencesNo definition available. + Details Name: blue_FactoringAgreementCashReceiptsCollected Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFactoring Agreement, Cash Receipts Collected Prior To Consideration + ReferencesNo definition available. + Details Name: blue_FactoringAgreementCashReceiptsCollectedPriorToConsideration Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFactoring Agreement, Gain (Loss) On Sale Of Invoices + ReferencesNo definition available. + Details Name: blue_FactoringAgreementGainLossOnSaleOfInvoices Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFactoring Agreement Payable, Current, Derecognized + ReferencesNo definition available. + Details Name: blue_FactoringAgreementPayableCurrentDerecognized Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFactoring Agreement Receivable, Current, Net Of Uncollectible + ReferencesNo definition available. + Details Name: blue_FactoringAgreementReceivableCurrentNetOfUncollectible Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFactoring Agreement Receivable, Uncollectable Amounts, Net Of Accrued Fees + ReferencesNo definition available. + Details Name: blue_FactoringAgreementReceivableUncollectableAmountsNetOfAccruedFees Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFactoring Agreement, Servicing Fees + ReferencesNo definition available. + Details Name: blue_FactoringAgreementServicingFees Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands Mar. 31, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Accrued CMO and CRO costs $ 22,481 $ 24,824 Accrued employee compensation 10,876 19,972 Accrued goods and services 5,453 8,391 Accrued rebates 9,194 5,365 Accrued professional fees 7,090 2,531 Accrued refund liability 0 5,600 Other 9,002 6,505 Total accrued expenses and other current liabilities $ 64,096 $ 73,188 X - DefinitionAccrued clinical and contract research organization costs current. + ReferencesNo definition available. + Details Name: blue_AccruedClinicalAndContractResearchOrganizationCostsCurrent Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Goods and Services, Current + ReferencesNo definition available. + Details Name: blue_AccruedGoodsAndServicesCurrent Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Rebates, Current + ReferencesNo definition available. + Details Name: blue_AccruedRebatesCurrent Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCurrent regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment. + ReferencesNo definition available. + Details Name: us-gaap_CustomerRefundLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Narrative (Details) $ in Millions 1 Months Ended 3 Months Ended Jan. 31, 2024 room Mar. 31, 2024 USD ($) Lessee, Lease, Description [Line Items] Â Â Number of additional controlled environment rooms | room 2 Â Lease period Â 3 years Drug Product Manufacturing Facility Â Â Lessee, Lease, Description [Line Items] Â Â Increase (decrease) in finance lease right of use asset Â $ 28.3 Drug Substance Manufacturing Facility Â Â Lessee, Lease, Description [Line Items] Â Â Increase (decrease) in finance lease right of use asset Â $ (3.8) Quality Testing Facility Â Â Lessee, Lease, Description [Line Items] Â Â Lease period 3 years Â Renewal term 6 months Â X - DefinitionIncrease (Decrease) In Right-Of-Use Asset Obtained In Exchange For Finance Lease Liability + ReferencesNo definition available. + Details Name: blue_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of Additional Controlled Environment Rooms + ReferencesNo definition available. + Details Name: blue_NumberOfAdditionalControlledEnvironmentRooms Namespace Prefix: blue_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=blue_DrugProductManufacturingFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=blue_DrugSubstanceManufacturingFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=blue_QualityTestingFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Summary of Operating Lease Costs and Other Information (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Finance leases Â Â Interest expense $ 4,347 $ 4,267 Amortization expense 14,328 5,216 Total fixed finance lease cost 18,675 9,483 Operating leases Â Â Fixed lease cost 9,486 11,470 Variable lease cost 6,043 6,862 Short-term lease cost 76 52 Total lease cost 34,280 27,867 Operating sublease income 10,346 10,108 Cash paid in the measurement of lease liabilities Â Â Operating cash flows used for operating leases 2,844 6,361 Operating cash flows used for finance leases 1,411 3,352 Financing cash flows for finance leases $ 22,210 $ 15,280 Other information Â Â Weighted average remaining lease term - finance leases 1 year 5 months 1 day 2 years 3 months 18 days Weighted average discount rate - finance leases 14.45% 15.13% Weighted average remaining lease term - operating leases 6 years 9 months 7 years 7 months 2 days Weighted average discount rate - operating leases 7.00% 7.04% X - DefinitionFinance Lease, Cost + ReferencesNo definition available. + Details Name: blue_FinanceLeaseCost Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowOperatingActivitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FinanceLeaseLiabilityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average discount rate for finance lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeaseCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Schedule of Future Minimum Commitments (Details) $ in Thousands Mar. 31, 2024 USD ($) Operating Leases Â Remainder of 2024 $ 28,492 2025 37,084 2026 35,719 2027 36,742 2028 37,795 2029 and thereafter 81,986 Total 257,818 Less: Imputed Interest (52,772) Present Value of Lease Liabilities 205,046 Financing Leases Â Remainder of 2024 102,277 2025 41,270 2026 3,422 2027 2,548 2028 1,043 2029 and thereafter 0 Total 150,560 Less: Imputed Interest (10,259) Present Value of Lease Liabilities $ 140,301 X - DefinitionFinance Lease, Liability, to be Paid, After Year Four + ReferencesNo definition available. + Details Name: blue_FinanceLeaseLiabilityToBePaidAfterYearFour Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLessee, Operating Lease, Liability, to be Paid, After Year Four + ReferencesNo definition available. + Details Name: blue_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-

gaap_FinanceLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies - Narrative (Details) $ in Thousands Mar. 31, 2024 USD ($) Commitments and Contingencies Disclosure [Abstract] Â Lease period 3 years Purchase commitments $ 56,789 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4 + Details Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail) $ in Thousands Mar. 31, 2024 USD ($) Commitments and Contingencies Disclosure [Abstract] Â Remainder of 2024 $ 0 2025 13,763 2026 17,858 2027 17,858 2028 7,310 2029 and thereafter 0 Total purchase commitments $ 56,789 X - DefinitionUnrecorded Unconditional Purchase Obligation, to be Paid, After Year Four + ReferencesNo definition available. + Details Name: blue_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4 + Details Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4 + Details Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4 + Details Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4 + Details Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4 + Details Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in remainder of current fiscal year. + ReferencesNo definition available. + Details Name: us-gaap_UnrecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Term loan debt (Details) $ / shares in Units, $ in Thousands, shares in Millions 3 Months Ended Mar. 15, 2024 USD ($) tranche $ / shares Mar. 31, 2024 USD ($) $ / shares shares Mar. 31, 2023 USD ($) Line of Credit Facility [Line Items] Â Â Â Interest expense Â $ 4,856 $ 4,270 The Warrants Â Â Â Line of Credit Facility [Line Items] Â Â Â Exercise price of warrants (in dollars per share) | $ / shares $ 1.45 $ 1.45 Â Number of securities called by warrants (in shares) | shares Â 2.6 Â Warrants and rights outstanding, contractual term (in years) 7 years 7 years Â Relative fair value allocated to the initial warrants $ 2,700 Â Â The Warrants | Expected Dividend Rate Â Â Â Line of Credit Facility [Line Items] Â Â Â Warrants and rights outstanding, measurement input 0 Â Â The Warrants | Expected Volatility Â Â Â Line of Credit Facility [Line Items] Â Â Â Warrants and rights outstanding, measurement input 0.811 Â Â The Warrants | Risk Free Interest Rate Â Â Â Line of Credit Facility [Line Items] Â Â Â Warrants and rights outstanding, measurement input 0.043 Â Â Secured Debt | Line of Credit Â Â Â Line of Credit Facility [Line Items] Â Â Â Minimum cash coverage as a percentage of outstanding principal 40.00% Â Â Percentage of aggregate original principal 5.00% Â Â Secured Debt | Term Loan Facility | Line of Credit Â Â Â Line of Credit Facility [Line Items] Â Â Â Maximum borrowing capacity $ 175,000 Â Â Number of tranches | tranche 4 Â Â Proceeds from long-term lines of credit $ 75,000 Â Â Debt issuance costs, gross 3,500 Â Â Debt issuance costs, net 2,700 Â Â Original issue discount $ 800 Â Â Discount percentage 1.00% Â Â Effective interest rate 15.70% Â Â Interest expense $ 500 Â Â Secured Debt | Term Loan Facility | Line of Credit | Prime Rate Â Â Â Line of Credit Facility [Line Items] Â Â Â Variable rate 1.45% Â Â Secured Debt | Term Loan Facility | Line of Credit | Prime Floor Rate Â Â Â Line of Credit Facility [Line Items] Â Â Â Variable rate 9.95% Â Â Secured Debt | Term Loan Facility | Line of Credit | Paid In Kind Â Â Â Line of Credit Facility [Line Items] Â Â Â PIK interest 2.45% Â Â Secured Debt | Term Loan Facility Tranche Two | Line of Credit Â Â Â Line of Credit Facility [Line Items] Â Â Â Maximum borrowing capacity $ 25,000 Â Â Secured Debt | Term Loan Facility Tranche Three | Line of Credit Â Â Â Line of Credit Facility [Line Items] Â Â Â Maximum borrowing capacity 25,000 Â Â Secured Debt | Term Loan Facility Tranche Four | Line of Credit Â Â Â Line of Credit Facility [Line Items] Â Â Â Maximum borrowing capacity $ 50,000 Â Â X - DefinitionDebt Instrument, Covenant, Minimum Cash Coverage As A Percentage Of Outstanding Principal + ReferencesNo definition available. + Details Name: blue_DebtInstrumentCovenantMinimumCashCoverageAsAPercentageOfOutstandingPrincipal Namespace Prefix: blue_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDebt Instrument, Number of Tranches + ReferencesNo definition available. + Details Name: blue_DebtInstrumentNumberOfTranches Namespace Prefix: blue_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionDebt Instrument, Unamortized Discount, Percent + ReferencesNo definition available. + Details Name: blue_DebtInstrumentUnamortizedDiscountPercent Namespace Prefix: blue_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-

types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of principal amount of debt redeemed. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3 + Details Name: us-gaap_DeferredFinanceCostsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=blue_TheWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=blue_TermLoanFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=blue_PrimeFloorRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=blue_PaidInKindMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=blue_TermLoanFacilityTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=blue_TermLoanFacilityTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=blue_TermLoanFacilityTrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity (Details) - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 3 Months Ended Dec. 22, 2023 Dec. 19, 2023 Jan. 23, 2023 Jan. 18, 2023 Dec. 31, 2023 Aug. 31, 2023 Mar. 31, 2024 Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Common stock, par value (in dollars per share) Â Â Â Â $ 0.01 Â $ 0.01 January Underwriting Agreement Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Shares of common stock sold (in shares) Â Â Â 20,000,000 Â Â Â Common stock price per share (in dollars per share) Â Â Â $ 6.00 Â Â Â Proceeds from stock offering Â Â $ 130.5 Â Â Â Â Inclusive of Shares Pursuant to Over Allotment Option Granted Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Shares of common stock sold (in shares) Â 12,500,000 Â 3,000,000 Â Â Â Option to purchase additional shares, exercise period Â 30 days Â 30 days Â Â Â At The Market Offering Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Shares of common stock sold (in shares) Â Â Â Â Â Â 0 Proceeds from stock offering Â Â Â Â Â $ 125.0 Â Value of shares available for issue in transaction Â Â Â Â Â $ 125.0 Â December Underwriting Agreement Â Â Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Â Â Shares of common stock sold (in shares) Â 83,300,000 Â Â 83,300,000 Â Â Common stock price per share (in dollars per share) Â $ 1.50 Â Â Â Â Â Proceeds from stock offering $ 118.1 Â Â Â $ 118.1 Â Â X - DefinitionSale Of Stock, Option To Purchase Additional Shares, Exercise Period + ReferencesNo definition available. + Details Name: blue_SaleOfStockOptionToPurchaseAdditionalSharesExercisePeriod Namespace Prefix: blue_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionSale Of Stock, Value Of Shares Available For Issue In Transaction + ReferencesNo definition available. + Details Name: blue_SaleOfStockValueOfSharesAvailableForIssueInTransaction Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=blue_JanuaryUnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=blue_AtTheMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=blue_DecemberUnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Narrative (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Jun. 30, 2021 Jun. 30, 2013 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense $ 3,761 $ 5,391 Â Â Amount capitalized $ 300 500 Â Â Stock option share exercised (in shares) 0 Â Â Â Employee stock purchase plan and other Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense $ 80 $ 0 Â Â Common shares reserved for future issuance (in shares) Â Â Â 200,000 Increase in shares authorized (in shares) Â Â 1,400,000 Â Shares of common stock issued under plan (in shares) 0 Â Â Â Employee stock purchase plan and other | Maximum Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Shares of common stock issued under plan (in shares) Â 100,000 Â Â 2023 Incentive Award Plan Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Number of shares available for issuance (in shares) 2,100,000 Â Â Â X - DefinitionShare-based Compensation Arrangement By Share-based Payment Award, Increase In Shares Authorized + ReferencesNo definition available. + Details Name: blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAuthorized Namespace Prefix: blue_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost capitalized for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=blue_EmployeeStockPurchasePlanAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=blue_A2023IncentiveAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Stock-based compensation expense $ 3,761 $ 5,391 Stock options Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Stock-based compensation expense 1,230 1,723 Restricted stock units Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Stock-based compensation expense 2,451 3,668 Employee stock purchase plan and other Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Stock-based compensation expense $ 80 $ 0 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=blue_EmployeeAndNonEmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=blue_EmployeeStockPurchasePlanAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Stock-based compensation expense $ 3,761 $ 5,391 Cost of product revenue Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Stock-based compensation expense 491 103 Selling, general and administrative Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Stock-based compensation expense 2,335 2,361 Research and development Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Stock-based compensation expense $ 935 $ 2,927 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -

SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Summary of Stock Option Activity Under Plan (Details) 3 Months Ended Mar. 31, 2024 $ / shares shares Shares (in thousands) Â Outstanding at beginning of period (in shares) | shares 4,227,000 Granted (in shares) | shares 2,572,000 Exercised (in shares) | shares 0 Canceled, forfeited, or expired (in shares) | shares (229,000) Outstanding at end of period (in shares) | shares 6,570,000 Exercisable at end of period (in shares) | shares 1,871,000 Vested and expected to vest at end of period (in shares) | shares 6,570,000 Weighted- average exercise price per share Â Outstanding at beginning of period (in dollars per share) | $ / shares $ 14.16 Granted (in dollars per share) | $ / shares 1.56 Exercised (in dollars per share) | $ / shares 0 Canceled, forfeited, or expired (in dollars per share) | $ / shares 16.55 Outstanding at end of period (in dollars per share) | $ / shares 9.16 Exercisable at end of period (in dollars per share) | $ / shares 22.75 Vested and expected to vest at end of period (in dollars per share) | $ / shares $ 9.16 X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Summary of Restricted Stock Units (Details) - Restricted stock units shares in Thousands 3 Months Ended Mar. 31, 2024 $ / shares shares Shares (in thousands) Â Unvested balance at beginning of period (in shares) | shares 4,207 Granted (in shares) | shares 2,177 Vested (in shares) | shares (785) Forfeited (in shares) | shares (205) Unvested balance at end of period (in shares) | shares 5,394 Weighted- average grant date fair value Â Unvested balance at beginning of period (in dollars per share) | $ / shares $ 6.08 Granted (in dollars per share) | $ / shares 1.56 Vested (in dollars per share) | $ / shares 7.14 Forfeited (in dollars per share) | $ / shares 4.41 Unvested balance at end of period (in dollars per share) | $ / shares $ 4.16 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10

-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income taxes (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Income Tax Disclosure [Abstract] Â Â Income tax expense (benefit) $ 0 $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per share - Anti-dilutive shares (Detail) shares in Thousands 3 Months Ended Mar. 31, 2024 shares Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) 16,022 Outstanding stock options Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) 7,903 Restricted stock units Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) 5,449 Warrants Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) 2,586 ESPP shares and other Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) 84 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=blue_EmployeeStockPurchasePlanAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per share - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Earnings Per Share [Abstract] Â Â Basic EPS (In dollars per share) $ (0.36) $ 0.18 Diluted EPS (in dollars per share) $ (0.36) $ 0.18 Net income $ (69,804) $ 18,930 Basic weighted-average common shares outstanding (in shares) 193,151 102,920 Effect of dilutive securities (in shares) Â 400 Diluted weighted-average common shares outstanding (in shares) 193,151 103,303 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12:

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restatement of Previously Issued Financial Statements - Schedule of Operations and Comprehensive Loss (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Revenue: Â Â Product revenue, net $ 18,561 $ 2,296 Other revenue 12 85 Total revenues 18,573 2,381 Cost of product revenue 25,864 5,512 Gross margin (7,291) (3,131) Operating expenses: Â Â Research and development 25,072 41,587 Selling, general and administrative 46,329 37,467 Total operating expenses 71,401 79,054 Gain from sale of priority review voucher, net 0 92,930 Income from operations (78,692) 10,745 Interest income 2,579 2,828 Interest expense (4,856) (4,270) Other income, net 11,165 9,627 (Loss) income before income taxes (69,804) 18,930 Income tax (expense) benefit 0 0 Net (loss) income $ (69,804) $ 18,930 Net income per share - basic (in dollars per share) $ (0.36) $ 0.18 Net income per share - diluted (in dollars per share) $ (0.36) $ 0.18 Weighted-average number of common shares used in computing net income per share - basic (in shares) 193,151 102,920 Weighted-average number of common shares used in computing net income per share - diluted (in shares) 193,151 103,303 Other comprehensive (loss) income: Â Â Other comprehensive income, net of tax (benefit) expense of $0.0Â million for the three months ended March 31, 2023 $ 0 $ 0 Other comprehensive (loss) income (312) 984 Comprehensive income $ (70,116) 19,914 As Previously Reported Â Â Revenue: Â Â Product revenue, net Â 2,296 Other revenue Â 85 Total revenues Â 2,381 Cost of product revenue Â 3,376 Gross margin Â (995) Operating expenses: Â Â Research and development Â 46,144 Selling, general and administrative Â 37,354 Total operating expenses Â 83,498 Gain from sale of priority review voucher, net Â 92,930 Income from operations Â 8,437 Interest income Â 2,828 Interest expense Â (3) Other income, net Â 9,978 (Loss) income before income taxes Â 21,240 Income tax (expense) benefit Â 0 Net (loss) income Â $ 21,240 Net income per share - basic (in dollars per share) Â $ 0.21 Net income per share - diluted (in dollars per share) Â $ 0.21 Weighted-average number of common shares used in computing net income per share - basic (in shares) Â 102,920 Weighted-average number of common shares used in computing net income per share - diluted (in shares) Â 103,303 Other comprehensive (loss) income: Â Â Other comprehensive (loss) income Â $ 984 Comprehensive income Â 22,224 Revision of Prior Period, Error Correction, Adjustment | Adjustments to Embedded Leases Â Â Revenue: Â Â Product revenue, net Â 0 Other revenue Â 0 Total revenues Â 0 Cost of product revenue Â 2,136 Gross margin Â (2,136) Operating expenses: Â Â Research and development Â (4,516) Selling, general and administrative Â 113 Total operating expenses Â (4,403) Gain from sale of priority review voucher, net Â 0 Income from operations Â 2,267 Interest income Â 0 Interest expense Â (4,267) Other income, net Â (351) (Loss) income before income taxes Â (2,351) Income tax (expense) benefit Â 0 Net (loss) income Â $ (2,351) Net income per share - basic (in dollars per share) Â $ (0.02) Net income per share - diluted (in dollars per share) Â $ (0.02) Weighted-average number of common shares used in computing net income per share - basic (in shares) Â 102,920 Weighted-average number of common shares used in computing net income per share - diluted (in shares) Â 103,303 Other comprehensive (loss) income: Â Â Other comprehensive (loss) income Â $ 0 Comprehensive income Â (2,351) Revision of Prior Period, Error Correction, Adjustment | Other Adjustments Â Â Revenue: Â Â Product revenue, net Â 0 Other revenue Â 0 Total revenues Â 0 Cost of product revenue Â 0 Gross margin Â 0 Operating expenses: Â Â Research and development Â (41) Selling, general and administrative Â 0 Total operating expenses Â (41) Gain from sale of priority review voucher, net Â 0 Income from operations Â 41 Interest income Â 0 Interest expense Â 0 Other income, net Â 0 (Loss) income before income taxes Â 41 Income tax (expense) benefit Â 0 Net (loss) income Â $ 41 Net income per share - basic (in dollars per share) Â $ 0 Net income per share - diluted (in dollars per share) Â $ 0 Weighted-average number of common shares used in computing net income per share - basic (in shares) Â 102,920 Weighted-average number of common shares used in computing net income per share - diluted (in shares) Â 103,303 Other comprehensive (loss) income: Â Â Other comprehensive (loss) income Â $ 0 Comprehensive income Â $ 41 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section

45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_IncomeLossAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=blue_ErrorCorrectionEmbeddedLeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restatement of Previously Issued Financial Statements - Schedule of Changes in Stockholders' Equity (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance (in shares) 192,772,000 Â Beginning balance $ 194,537 $ 134,333 Vesting of restricted stock units $ 0 (195) Stock option share exercised (in shares) 0 Â Exercise of stock options Â 7 Purchase of shares under ESPP Â 227 Issuance of common stock Â 130,291 Stock-based compensation expense $ 4,054 5,843 Other comprehensive income Â 984 Net income $ (69,804) 18,930 Ending balance, shares (in shares) 193,583,000 Â Ending balance $ 131,046 $ 290,420 Common Shares Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance (in shares) 192,772,000 82,923,000 Beginning balance $ 1,905 $ 830 Vesting of restricted stock units (in shares) 811,000 382,000 Vesting of restricted stock units $ 8 $ 3 Stock option share exercised (in shares) Â 3,000 Purchase of common stock under employee stock purchase plan (ESPP) (in shares) Â 62,000 Purchase of shares under ESPP Â $ 1 Issuance of common stock (in shares) Â 23,000,000 Issuance of common stock Â $ 230 Ending balance, shares (in shares) 193,583,000 106,370,000 Ending balance $ 1,913 $ 1,064 Additional paid-in capital Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance 4,454,756 4,185,988 Vesting of restricted stock units (8) (198) Exercise of stock options Â 7 Purchase of shares under ESPP Â 226 Issuance of common stock Â 130,061 Stock-based compensation expense 4,054 5,843 Ending balance 4,461,373 4,321,927 Accumulated other comprehensive (loss) income Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance (1,796) (4,070) Other comprehensive income Â 984 Ending balance (2,108) (3,086) Accumulated deficit Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance (4,260,328) (4,048,415) Net income (69,804) 18,930 Ending balance $ (4,330,132) (4,029,485) As Previously Reported Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â 196,343 Vesting of restricted stock units Â (195) Exercise of stock options Â 7 Purchase of shares under ESPP Â 227 Issuance of common stock Â 130,291 Stock-based compensation expense Â 5,843 Other comprehensive income Â 984 Net income Â 21,240 Ending balance Â $ 354,740 As Previously Reported | Common Shares Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance (in shares) Â 82,923,000 Beginning balance Â $ 830 Vesting of restricted stock units (in shares) Â 382,000 Vesting of restricted stock units Â $ 3 Stock option share exercised (in shares) Â 3,000 Purchase of common stock under employee stock purchase plan (ESPP) (in shares) Â 62,000 Purchase of shares under ESPP Â $ 1 Issuance of common stock (in shares) Â 23,000,000 Issuance of common stock Â $ 230 Ending balance, shares (in shares) Â 106,370,000 Ending balance Â $ 1,064 As Previously Reported | Additional paid-in capital Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â 4,186,086 Vesting of restricted stock units Â (198) Exercise of stock options Â 7 Purchase of shares under ESPP Â 226 Issuance of common stock Â 130,061 Stock-based compensation expense Â 5,843 Ending balance Â 4,322,025 As Previously Reported | Accumulated other comprehensive (loss) income Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â (4,070) Other comprehensive income Â 984 Ending balance Â (3,086) As Previously Reported | Accumulated deficit Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â (3,986,503) Net income Â 21,240 Ending balance Â (3,965,263) Revision of Prior Period, Error Correction, Adjustment | Adjustments to Embedded Leases Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â (59,700) Net income Â (2,351) Ending balance Â (62,051) Revision of Prior Period, Error Correction, Adjustment | Other Adjustments Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â (2,310) Net income Â 41 Ending balance Â $ (2,269) Revision of Prior Period, Error Correction, Adjustment | Common Shares | Adjustments to Embedded Leases Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance (in shares) Â 0 Beginning balance Â $ 0 Ending balance, shares (in shares) Â 0 Ending balance Â $ 0 Revision of Prior Period, Error Correction, Adjustment | Common Shares | Other Adjustments Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance (in shares) Â 0 Beginning balance Â $ 0 Ending balance, shares (in shares) Â 0 Ending balance Â $ 0 Revision of Prior Period, Error Correction, Adjustment | Additional paid-in capital | Adjustments to Embedded Leases Â Â Increase (Decrease) in Stockholders' Equity

[Roll Forward] Â Â Beginning balance Â 0 Ending balance Â 0 Revision of Prior Period, Error Correction, Adjustment | Additional paid-in capital | Other Adjustments Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â (98) Ending balance Â (98) Revision of Prior Period, Error Correction, Adjustment | Accumulated other comprehensive (loss) income | Adjustments to Embedded Leases Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â 0 Ending balance Â 0 Revision of Prior Period, Error Correction, Adjustment | Accumulated other comprehensive (loss) income | Other Adjustments Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â 0 Ending balance Â 0 Revision of Prior Period, Error Correction, Adjustment | Accumulated deficit | Adjustments to Embedded Leases Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â (59,700) Net income Â (2,351) Ending balance Â (62,051) Revision of Prior Period, Error Correction, Adjustment | Accumulated deficit | Other Adjustments Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Beginning balance Â (2,212) Net income Â 41 Ending balance Â $ (2,171) X - DefinitionStock issued during period shares vesting of restricted stock units. + ReferencesNo definition available. + Details Name: blue_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits Namespace Prefix: blue_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value vesting of restricted stock units. + ReferencesNo definition available. + Details Name: blue_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI

https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=blue_ErrorCorrectionEmbeddedLeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restatement of Previously Issued Financial Statements - Schedule of Cash Flows (Details) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Mar. 31, 2023 Dec. 31, 2023 Cash flows from operating activities: Â Â Â Net income $ (69,804) $ 18,930 Â Adjustments to reconcile net (loss) income to net cash used in operating activities: Â Â Â Depreciation and amortization 15,469 6,172 Â Stock-based compensation expense 3,761 5,391 Â Noncash research and development expense (finance lease) 0 1,441 Â Noncash operating lease expense 5,904 7,423 Â Gain from sale of priority review voucher 0 (92,930) Â Excess inventory reserve 91 2,583 Â Other non-cash items (10) 237 Â Gain on foreign currency exchange rates (777) (108) Â Changes in operating assets and liabilities: Â Â Â Prepaid expenses and other assets (13,528) (3,689) Â Inventory (7,185) (5,331) Â Operating right of use assets Â 0 Â Accounts payable 1,454 1,260 Â Accrued expenses and other liabilities (10,299) (7,206) Â Accrued interest payable under finance lease 2,936 915 Â Operating lease liabilities (2,844) (6,361) Â Deferred revenue 0 (85) Â Net cash used in operating activities (74,676) (71,358) Â Cash flows from investing activities: Â Â Â Purchase of property, plant and equipment (1,775) (232) Â Purchases of marketable securities 0 (19,610) Â Proceeds from maturities of marketable securities 0 4,021 Â Proceeds from sales of marketable securities 0 5,853 Â Purchase of intangible assets 0 (868) Â Proceeds from sale of priority review voucher 0 92,972 Â Net cash (used in) provided by investing activities (655) 82,136 Â Cash flows from financing activities: Â Â Â Proceeds from exercise of stock options and ESPP contributions 0 7 Â Principal payments on finance leasesÂ (22,210) (15,280) Â Net cash provided by financing activities 64,645 115,176 Â (Decrease) increase in cash, cash equivalents and restricted cash (10,686) 125,954 Â Cash, cash equivalents and restricted cash at beginning of period 274,597 158,445 Â Cash, cash equivalents and restricted cash at end of period 263,911 284,399 Â Reconciliation of cash, cash equivalents and restricted cash: Â Â Â Cash and cash equivalents 212,047 239,045 $ 221,755 Restricted cash included in other current assets 3,866 1,417 Â Restricted cash included in restricted cash and other non-current assets 47,998 43,937 Â Total cash, cash equivalents and restricted cash 263,911 284,399 $ 274,597 Supplemental cash flow disclosures from investing and financing activities: Â Â Â Purchases of property, plant and equipment included in accounts payable and accrued expenses 0 189 Â Offering expenses included in accounts payable and accrued expenses Â 523 Â Priority review voucher expenses accrued or in accounts payable 0 43 Â Right-of-use assets obtained in exchange for financial lease liabilities 38,669 (214) Â Cash paid during the period for income taxes 1 2 Â As Previously Reported Â Â Â Cash flows from operating activities: Â Â Â Net income Â 21,240 Â Adjustments to reconcile net (loss) income to net cash used in operating activities: Â Â Â Depreciation and amortization Â 1,082 Â Stock-based compensation expense Â 5,391 Â Noncash research and development expense (finance lease) Â 0 Â Noncash operating lease expense Â 0 Â Gain from sale of priority review voucher Â (92,930) Â Excess inventory reserve Â 228 Â Other non-cash items Â 237 Â Gain on foreign currency exchange rates Â 0 Â Changes in operating assets and liabilities: Â Â Â Prepaid expenses and other assets Â (9,335) Â Inventory Â (3,586) Â Operating right of use assets Â 11,829 Â Accounts payable Â (6,443) Â Accrued expenses and other liabilities Â (9,065) Â Accrued interest payable under finance lease Â 0 Â Operating lease liabilities Â (8,001) Â Deferred revenue Â 2,715 Â Net cash used in operating activities Â (86,638) Â Cash flows from investing activities: Â Â Â Purchase of property, plant and equipment Â (232) Â Purchases of marketable securities Â (19,610) Â Proceeds from maturities of marketable securities Â 4,021 Â Proceeds from sales of marketable securities Â 5,853 Â Purchase of intangible assets Â (868) Â Proceeds from sale of priority review voucher Â 92,972 Â Net cash (used in) provided by investing activities Â 82,136 Â Cash flows from financing activities: Â Â Â Proceeds from exercise of stock options and ESPP contributions Â 7 Â Principal payments on finance leasesÂ Â 0 Â Net cash provided by financing activities Â 130,456 Â (Decrease) increase in cash, cash equivalents and restricted cash Â 125,954 Â Cash, cash equivalents and restricted cash at beginning of period Â 158,445 Â Cash, cash equivalents and restricted cash at end of period Â 284,399 Â Reconciliation of cash, cash equivalents and restricted cash: Â Â Â Cash and cash equivalents Â 239,045 Â Restricted cash included in other current assets Â 1,417 Â Restricted cash included in restricted cash and other non-current assets Â 43,937 Â Total cash, cash equivalents and restricted cash Â 284,399 Â Supplemental cash flow disclosures from investing and financing activities: Â Â Â Purchases of property, plant and equipment included in accounts payable and accrued expenses Â 189 Â Offering expenses included in accounts payable and accrued expenses Â 523 Â Priority review voucher expenses accrued or in accounts payable Â 43 Â Right-of-use assets obtained in exchange for financial lease liabilities Â 0 Â Cash paid during the period for income taxes Â 2 Â Revision of Prior Period, Error Correction, Adjustment | Adjustments to Embedded Leases Â Â Â Cash flows from operating activities: Â Â Â Net income Â (2,351) Â Adjustments to reconcile net (loss) income to net cash used in operating activities: Â Â Â Depreciation and amortization Â 5,131 Â Stock-based compensation expense Â 0 Â Noncash research and development expense (finance lease) Â 1,441 Â Noncash operating lease expense Â 7,423 Â Gain from sale of priority review voucher Â 0 Â Excess inventory reserve Â 0 Â Other non-cash items Â 0 Â Changes in operating assets and liabilities: Â Â Â Prepaid expenses and other assets Â 2,846 Â Inventory Â 610 Â Operating right of use assets Â (11,829) Â Accounts payable Â 7,703 Â Accrued expenses and other liabilities Â 1,859 Â Accrued interest payable under finance lease Â 915 Â Operating lease liabilities Â 1,640 Â Deferred revenue Â 0 Â Net cash used in operating activities Â 15,280 Â Cash flows from investing activities: Â Â Â Purchase of property, plant and equipment Â 0 Â Purchases of marketable securities Â 0 Â Proceeds from maturities of marketable securities Â 0 Â Proceeds from sales of marketable securities Â 0 Â Purchase of intangible assets Â 0 Â Proceeds from sale of priority review voucher Â 0 Â Net cash (used in) provided by investing activities Â 0 Â Cash flows from financing activities: Â Â Â Proceeds from exercise of stock options and ESPP contributions Â 0 Â Principal payments on finance leasesÂ Â (15,280) Â Net cash provided by financing activities Â (15,280) Â (Decrease) increase in cash, cash equivalents and restricted cash Â 0 Â Cash, cash equivalents and restricted cash at beginning of period Â 0 Â Cash, cash equivalents and restricted cash at end of period Â 0 Â Reconciliation of cash, cash equivalents and restricted cash: Â Â Â Cash and cash equivalents Â 0 Â Restricted cash included in other current assets Â 0 Â Restricted cash included in restricted cash and other non-current assets Â 0 Â Total cash, cash equivalents and restricted cash Â 0 Â Supplemental cash flow disclosures from investing and financing activities: Â Â Â Purchases of property, plant and equipment included in accounts payable and accrued expenses Â 0 Â Priority review voucher expenses accrued or in accounts payable Â 0 Â Right-of-use assets obtained in exchange for financial lease liabilities Â (214) Â Revision of Prior Period, Error Correction, Adjustment | Other Adjustments Â Â Â Cash flows from operating activities: Â Â Â Net income Â 41 Â Adjustments to reconcile net (loss) income to net cash used in operating activities: Â Â Â Depreciation and amortization Â (41) Â Stock-based compensation expense Â 0 Â Noncash research and development expense (finance lease) Â 0 Â Noncash operating lease expense Â 0 Â Gain from sale of priority review voucher Â 0 Â Excess inventory reserve Â 2,355 Â Other non-cash items Â 0 Â Gain on foreign currency exchange rates Â 0 Â Changes in operating assets and liabilities: Â Â Â Prepaid expenses and other assets Â 2,800 Â Inventory Â (2,355) Â Operating right of use assets Â 0 Â Accounts payable Â 0 Â Accrued expenses and other liabilities Â 0 Â Accrued interest payable under finance lease Â 0 Â Operating lease liabilities Â 0 Â Deferred revenue Â (2,800) Â Net cash used in operating activities Â 0 Â Cash flows from investing activities: Â Â Â Purchase of property, plant and equipment Â 0 Â Purchases of marketable securities Â 0 Â Proceeds from maturities of marketable securities Â 0 Â Proceeds from sales of marketable securities Â 0 Â Purchase of intangible assets Â 0 Â Proceeds from sale of priority

review voucher Â 0 Â Net cash (used in) provided by investing activities Â 0 Â Cash flows from financing activities: Â Â Â Proceeds from exercise of stock options and ESPP contributions Â 0 Â Principal payments on finance leasesÂ Â 0 Â Net cash provided by financing activities Â 0 Â (Decrease) increase in cash, cash equivalents and restricted cash Â 0 Â Cash, cash equivalents and restricted cash at beginning of period Â 0 Â Cash, cash equivalents and restricted cash at end of period Â 0 Â Reconciliation of cash, cash equivalents and restricted cash: Â Â Â Cash and cash equivalents Â 0 Â Restricted cash included in other current assets Â 0 Â Restricted cash included in restricted cash and other non-current assets Â 0 Â Total cash, cash equivalents and restricted cash Â 0 Â Supplemental cash flow disclosures from investing and financing activities: Â Â Â Purchases of property, plant and equipment included in accounts payable and accrued expenses Â 0 Â Offering expenses included in accounts payable and accrued expenses Â 0 Â Priority review voucher expenses accrued or in accounts payable Â 0 Â Right-of-use assets obtained in exchange for financial lease liabilities Â 0 Â Cash paid during the period for income taxes Â 0 Â Revision of Prior Period, Error Correction, Adjustment | Error Correction, Leases Â Â Â Adjustments to reconcile net (loss) income to net cash used in operating activities: Â Â Â Gain on foreign currency exchange rates Â (108) Â Supplemental cash flow disclosures from investing and financing activities: Â Â Â Offering expenses included in accounts payable and accrued expenses Â 0 Â Cash paid during the period for income taxes Â 0 Â Private Placement Â Â Â Cash flows from financing activities: Â Â Â Proceeds from issuance of common stock 0 (196) Â Private Placement | As Previously Reported Â Â Â Cash flows from financing activities: Â Â Â Proceeds from issuance of common stock Â (196) Â Private Placement | Revision of Prior Period, Error Correction, Adjustment | Adjustments to Embedded Leases Â Â Â Cash flows from financing activities: Â Â Â Proceeds from issuance of common stock Â 0 Â Private Placement | Revision of Prior Period, Error Correction, Adjustment | Other Adjustments Â Â Â Cash flows from financing activities: Â Â Â Proceeds from issuance of common stock Â 0 Â Public Offering Â Â Â Cash flows from financing activities: Â Â Â Proceeds from issuance of common stock $ 0 130,645 Â Public Offering | As Previously Reported Â Â Â Cash flows from financing activities: Â Â Â Proceeds from issuance of common stock Â 130,645 Â Public Offering | Revision of Prior Period, Error Correction, Adjustment | Adjustments to Embedded Leases Â Â Â Cash flows from financing activities: Â Â Â Proceeds from issuance of common stock Â 0 Â Public Offering | Revision of Prior Period, Error Correction, Adjustment | Other Adjustments Â Â Â Cash flows from financing activities: Â Â Â Proceeds from issuance of common stock Â $ 0 Â X - DefinitionDisposition Of Assets, Expenses Incurred During Noncash Or Partial Noncash Transaction + ReferencesNo definition available. + Details Name: blue_DispositionOfAssetsExpensesIncurredDuringNoncashOrPartialNoncashTransaction Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) Accrued Interest Payable Under Finance Lease + ReferencesNo definition available. + Details Name: blue_IncreaseDecreaseAccruedInterestPayableUnderFinanceLease Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in operating lease liabilities. + ReferencesNo definition available. + Details Name: blue_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInventory, Excess Valuation Reserves + ReferencesNo definition available. + Details Name: blue_InventoryExcessValuationReserves Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLessee, Increase (Decrease) In Operating Lease, Right-of-Use Asset + ReferencesNo definition available. + Details Name: blue_LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash Lease Expense + ReferencesNo definition available. + Details Name: blue_NoncashLeaseExpense Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash, Research And Development Expense, Finance Lease + ReferencesNo definition available. + Details Name: blue_NoncashResearchAndDevelopmentExpenseFinanceLease Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRight-Of-Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement + ReferencesNo definition available. + Details Name: blue_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of debt issuance costs that were incurred during a noncash or partial noncash transaction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSalesOfAssetsInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-

gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=blue_ErrorCorrectionEmbeddedLeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=blue_ErrorCorrectionLeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=blue_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent events (Details) $ / shares in Units, $ in Thousands Aug. 13, 2024 USD ($) $ / shares Mar. 15, 2024 USD ($) tranche $ / shares Mar. 31, 2024 $ / shares The Warrants Â Â Â Subsequent Event [Line Items] Â Â Â Exercise price of warrants (in dollars per share) | $ / shares Â $ 1.45 $ 1.45 Secured Debt | Line of Credit Â Â Â Subsequent Event [Line Items] Â Â Â Annual financial statement delivery period Â 90 days Â Quarterly financial statement delivery period Â 45 days Â Minimum cash coverage as a percentage of outstanding principal Â 40.00% Â Term Loan Facility | Secured Debt | Line of Credit Â Â Â Subsequent Event [Line Items] Â Â Â Debt instrument term Â 5 years Â Line of credit Â $ 175,000 Â Number of tranches | tranche Â 4 Â Number of additional tranches | tranche Â 2 Â Proceeds from long-term lines of credit Â $ 75,000 Â Term Loan Facility | Secured Debt | Line of Credit | Debt Instrument Availability, Tranche Two Â Â Â Subsequent Event [Line Items] Â Â Â Debt amount Â 25,000 Â Term Loan Facility | Secured Debt | Line of Credit | Debt Instrument Availability, Tranche Three Â Â Â Subsequent Event [Line Items] Â Â Â Debt amount Â 25,000 Â Term Loan Facility | Secured Debt | Line of Credit | Debt Instrument Availability, Tranche Four Â Â Â Subsequent Event [Line Items] Â Â Â Debt amount Â 50,000 Â Term Loan Facility Tranche Two | Secured Debt | Line of Credit Â Â Â Subsequent Event [Line Items] Â Â Â Line of credit Â 25,000 Â Term Loan Facility Tranche Three | Secured Debt | Line of Credit Â Â Â Subsequent Event [Line Items] Â Â Â Line of credit Â $ 25,000 Â Subsequent Event | The Warrants Â Â Â Subsequent Event [Line Items] Â Â Â Value of warrants issued in relation to debt $ 3,750 Â Â Weighted average price, period 10 days Â Â Exercise price of warrants (in dollars per share) | $ / shares $ 1.45 Â Â Subsequent Event | Secured Debt | Line of Credit Â Â Â Subsequent Event [Line Items] Â Â Â Minimum cash coverage as a percentage of outstanding principal 45.00% Â Â Subsequent Event | Secured Debt | Line of Credit | The Warrants Â Â Â Subsequent Event [line Items] Â Â Â Number of warrants issued as a percentage of debt 0.05 Â Â Subsequent Event | Term Loan Facility Tranche Two | Secured Debt | Line of Credit Â Â Â Subsequent Event [Line Items] Â Â Â Line of credit $ 25,000 Â Â Debt covenant, minimum gross cash proceeds $ 75,000 Â Â Period immediately following achievement 30 days Â Â Subsequent Event | Term Loan Facility Tranche Three | Secured Debt | Line of Credit Â Â Â Subsequent Event [Line Items] Â Â Â Line of credit $ 25,000 Â Â Debt covenant, product delivery period 6 months Â Â Period immediately following achievement 30 days Â Â Subsequent Event | Term Loan Facility Tranche Three | Secured Debt | Line of Credit | Proceeds Received December 20, 2024 Â Â Â Subsequent Event [Line Items] Â Â Â Debt covenant, minimum gross cash proceeds $ 100,000 Â Â Subsequent Event | Term Loan Facility Tranche Three | Secured Debt | Line of Credit | Proceeds Received June 30, 2025 Â Â Â Subsequent Event [Line Items] Â Â Â Debt covenant, minimum gross cash proceeds $ 125,000 Â Â X - DefinitionClass Of Warrant Or Right, Number Of Warrants Issued As A Percentage Of Debt + ReferencesNo definition available. + Details Name: blue_ClassOfWarrantOrRightNumberOfWarrantsIssuedAsAPercentageOfDebt Namespace Prefix: blue_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionClass Of Warrant Or Right, Value Of Warrants Issued In Relation To Debt + ReferencesNo definition available. + Details Name: blue_ClassOfWarrantOrRightValueOfWarrantsIssuedInRelationToDebt Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionClass Of Warrant Or Right, Weighted Average Price, Period + ReferencesNo definition available. + Details Name: blue_ClassOfWarrantOrRightWeightedAveragePricePeriod Namespace Prefix: blue_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Covenant, Annual Financial Statement Delivery, Maximum Period + ReferencesNo definition available. + Details Name: blue_DebtInstrumentCovenantAnnualFinancialStatementDeliveryMaximumPeriod Namespace Prefix: blue_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Covenant, Draw Requirement, Minimum Gross Cash Proceeds + ReferencesNo definition available. + Details Name: blue_DebtInstrumentCovenantDrawRequirementMinimumGrossCashProceeds Namespace Prefix: blue_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDebt Instrument, Covenant, Minimum Cash Coverage As A Percentage Of Outstanding Principal + ReferencesNo definition available. + Details Name: blue_DebtInstrumentCovenantMinimumCashCoverageAsAPercentageOfOutstandingPrincipal Namespace Prefix: blue_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDebt Instrument, Covenant, Period Immediately Following Achievement + ReferencesNo definition available. + Details Name: blue_DebtInstrumentCovenantPeriodImmediatelyFollowingAchievement Namespace Prefix: blue_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Covenant, Product Delivery Period + ReferencesNo definition available. + Details Name: blue_DebtInstrumentCovenantProductDeliveryPeriod Namespace Prefix: blue_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Covenant, Quarterly Financial Statement Delivery, Maximum Period + ReferencesNo definition available. + Details Name: blue_DebtInstrumentCovenantQuarterlyFinancialStatementDeliveryMaximumPeriod Namespace Prefix: blue_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Number Of Additional Tranches + ReferencesNo definition available. + Details Name: blue_DebtInstrumentNumberOfAdditionalTranches Namespace Prefix: blue_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionDebt Instrument, Number of Tranches + ReferencesNo definition available. + Details Name: blue_DebtInstrumentNumberOfTranches Namespace Prefix: blue_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=blue_TheWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=blue_TermLoanFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: blue_DebtInstrumentAvailabilityAxis=blue_DebtInstrumentAvailabilityTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: blue_DebtInstrumentAvailabilityAxis=blue_DebtInstrumentAvailabilityTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: blue_DebtInstrumentAvailabilityAxis=blue_DebtInstrumentAvailabilityTrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=blue_TermLoanFacilityTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=blue_TermLoanFacilityTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: blue_DebtCovenantTermsAxis=blue_ProceedsReceivedDecember202024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: blue_DebtCovenantTermsAxis=blue_ProceedsReceivedJune302025Member Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (*.$+5D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\QO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "CA"U9>L$JL.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P# (=?!>7>NG]@$E&7"}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

MN9DP4Q**!80ZIVK)2NN8%;?;MH-UKPLA)45PN*<;*HN6QFR_/^MT]Z M>:XZ4\E&?-*H[>J:ZX=WHE+W%S,R>_SAL[Q=&_O#8GF^X;?B6IBOFT\:[A9[M+Z6L1=-*U2
M5A>SM^3U)8OM@-[B3RGNVX-K9$.Y4>J;O7E??LRP120J41CK M@L. _W$IJLIZ AQ_[YS.]G/:@8??C]Y_[8.'8&YX*RY5]9]'GI&\-T:F: M$EZ**!%/@"
MLK!/!=VG@O;^V%0J.JU%8Q!O6XCYM2^>K8/([\"NN-?MAA?B8@9+JA7Z3LR6 MSW\A"7[CB^XG.3N*E>UC92'ORTO>KA&\-538"_%W)^]X!<%[W^+65=*[LFWA
M;DD)QO5%ZOK@[C,=C1DD:QWNS(Z31'FD41/I)BPV7)1+?-[9.O0"W'N*#F0F) M"1GA\UA%&<9^>/$>7ARS][ZY@[0I_>##%3LS,LQP/,+E6E&:D]R/*]GC2H*X MKCJ!5EK5: 6-4FD?NL29-
T_Q")MK$R<3&4OWR-(@LL^B$%!M-Y5H^PI49BTT MM+K&Q>>#F[JO+TF3; 38M:(DB8D?'-K80:W;WMR?SM M'!V5);!9-,;I,XM8-@%TH"P29(GE1WCEW,CF%E4"Q S25K6Z\
M'L')8XKS,6S7CF)"")O /= /"?//9]$:+0LK-8I'*MHV@D8U9Z=7VL[]T7O/ M(C*F))]9Q*(I^ ,GD3 I;1M")[+-0D#MF%C?!X[DI-DHE^1@95(_"0M4TE^ M(RMII/ +&A)DMQ]5-#_+VW'0
^61,.>]+0K5@89!&_Y@^<4;L,MH)&>94S@> MLRS*I];KP"TD3'Z6EHT*D#+Q$!@LS#&\$U;'Z ::(V&>@P3J3@Q:R\//!P7E MA>]R6Q+AW&GKEG*2#:5WH$"29@#OPA=HTKQ!G9rR_
_Y^[:&R+,_'FLQC-I%= M.K =#;/=N%<_IA(8^S&[&Z7MYM:[]7"9CD8L&7<4GQF(=3H!?F!$&F$7V4# M&\+_#-Y#?
R0"8&/TKET6I7A"&=&#G5V8)H\%W(D:IA[2RUF<.JGVD2.>)$UJDJAV^>_9)2D;_H=FGGP'S8%R?J' M3YM^DK?CV =FIJ=VIV(E8 F5J+59F*-G^!4FH-0TNN-5)^8HGF.,4;OFV@J/
MSJR5EO^(\@W:_RC;UJJ37I1TIH4M6FG;"S?H]?%>HOV\3RQ-[L2A:AOA#YZ MQ+S)#A'^+H-/U@1LT 0LK GL@E#-9$YHC*>R JIU'F>L#Y/D=)2FJ&?G:8[
MVT;T!^V5]X"+N6H#MB]CBO%:39$ZG&R0)"TN2MV4I+6] W[,GA&>R@;WD1D(? M]$)UI444)80YM.XUC*,TGCA58(,*86$5 O*ZJ[NJ/V#?J6I5PVI;VZ\B=\"0 MJO6?O[I"XXP2/#[Z\IF1-)^"?
7!4')8CA[!+L9*%]"IKY@J)LX@Q3-B8 +V6 M0.N,3FP V" ZV%,VYNUDH_4"]QP,,X*=LR:?71[%;$(IL4%EL+#*<+B[7Y,_ M&$3LG+Y[3QQ\=KX3A\7!)R7[/0\ZQZUL6M!R*QB(7Z7@1V_D6UOC-
KT7YEN ME#&][B_7@@-X:P#/5PK(?7=C/USM/U0N_P502P,$% @ HX0M63O.IBOW M @ 7 H !@ !X;"]W;W)K;+AXE"F 0L\997)JI4KE8]N6<0H9ECV>
],S2RXRK'17K&R9"\!)"">K%)E!NQHDN,5 M+$#]R.="]^R&)2$9,$DX0P*64^NS.YZYC@&4$3\);.16&QDK#YP_FLZW9&HY M1A%0B)6AP/JQAAE0:IBTCJ>:U&K6-,#M]BO[E]*\-O.)B28?7
MI,,K^?P]? O%X\>4TP2$O/@P]-SP!L%30=3+N,M;1=;O)C-OX%CF.(:II5\Q M"6(-5G3QP1TX-UU._Q-9R[??^/8/L4=S_?* $'KGIONK)1+1&62YC/QSIR>HX[L=?;+H\$M=3W&_7]\]17U8APH5(N
MR&\]85Q4HYW2* Y@2U7@E+\WZH_'M0P$C8'70:(E,5Q\<&,J+>R#T6T! \: MP8-W'=8'A528)82MCJD>'%5]***E.FQ4AP=5SWB6Z.(C'THV/*7$CP2UI \; MZ<,SI)=W\.=5'IUX;Y-
^BF1+0>CQL'H? >G%?AH1Y,[\H.AOZN^*](+0V^O M>M?Y>U ZY^L_H]YK^E-<=(9VV["WCGYS[]+GZ8HPB2@L-=;IA9I$5%>9]J-X M7MX&'KC2=XNRF>KK'P@3H.>7G*O7CKE@-!?*Z
]02P,$% @ HX0M68X^ M$7R%!0 J!8 !@ !X;"]W;W)K' M%_?I9JOTB_ERL:,;]L#4U]V=@-:\C9*D.2MDR@LDV/IJJAY?WI!0.U06_Z3L M2?:>D:;RR/EWW;A-KF:.1L0RME(Z!(6_/;MA6:8C
8Y_FZ"SMD_MV'\^1/^C M(@]D'JED-SS[EB9J>S6+9BAA:UIFZIX_ 98F5$'C0<$?C):2B* 1YQT3 M5&==(EIHRQRF5<9/Y9ZAD{^XE*?HMECQ%IE0F]>[NQ8X;CLT;A7/G8AWS_:L*-FE*3.U
MIV?VU$O_4N[HBEW-8* D$WLV6_[Z"PZG9HB_O!$.*E8** M4)$]0P53)L)UE*'*HDO3?HDC/\"+^;[/9&Q%2!RT1D<(_1:A;T7X66V9.. S M0:O=_3XT,L U-
HE\,ZJ@115847WABF8'5,;%$XQA17[H#I"-K8@;83.VL,46 M6K'=<*ETV=@=CZT)9#CNWH\";P!R;.7[O1P?@8Q:D)$5Y$ 9![YG:,,*X)Y5,D,3T+M4*IV+O7'V-%'[Z?<"E\2#03*8N:$7A.91
MPCWIQ%;4]Y)*E;;"FT"DSSC.ZV91JC8,-.=<%@H#&8>]J,IJ*2#2RI

4GI(WC1"N"#1[[_"=NR32O.C^P%C/Z"D>$^9BXVA^V M!P,LOG#E6:?:B8>D'207'B42X>#VZ!7S[+GF_IIFAXBHU+%M9^>X3-QCSW^ M*:Z+LRALK&!C@$)Z)"1)FVIP8W:O/.^
/+DF2UUUC6_^\44_OE;L&S=A+,U/ M[X'Z60IT*4MY#"\EU-(V(7CD>C#?W=@:?LXE07Q Z[CF]PDB5?A2FW]9X'SQ MA;Z9'7\WS1;\7H2,2>-^!WRQ'S{$.%>"U6 OP812N_\FWR AP\P=%3
MHB4]**]>)&_*]5+:-,DE[::QW7H#/KA!K1:]M^NXT9R&=K]S+^BE[Q(,9MW\ M\RD:ZC6Z>937,"?^+0]Z,4[>V!NA1Z_#7/+@#3,. "AN53H[=DHH;>MU.2HS MGB?AVXFR?
[QL1T@E](S>@3HY>;&O5[D%$/4@#J9"W9#'KDU-U7\(&,3]4]Z M[VZ)//:2H@P]EZTB_NC*VB*&(,FE_-9"HQ 6C2^&X%3 7D;RVI5\+T-%W*(M8/U+1 06*09), X1K\C5/1LC7PXOI#WD/G^?
PN,T/ @9YP>]YWSW9,QSXI,] MCQ&UX*9@Q?@.64_)?-\^Z-W'H45"1!2Y@#/([USH<)NUSQF.@X&,2*A${!91 M!D%J_^[P?#'WK]UH<#* 2HUQ!2<&]R^;S]/'F,^W6X65T94@D:$V^8V4^%;5
MB"J?S(X! UPD(Z.S!PY_RJ='R#!+,QAF!Y"X/ CZE, M"1R?W]"[QGTY F!L>-:L=[4[D;SN-YK(:^R\D^*=*'D6]$,&AM]AUY'TH6]5 MM8U72=1#0;$AJ@#J[H[^D-[4XF=3Q6#W6=#BS+*V?
BAN:0.W&WB0#%?*Z*L_Q M1_+C.^/8\FH .*GM!L^=G1S/3[L.SNYJ*&U%>N$=%N(S>2M6'#RU+^>-Q;EPL44I8S>EO/L4N%K M:"%T87<)0T\8_I)7_IS_CVF9!I^C&)8<'!ZB-
KM[[>O[GT3)Y@G M;-(?"&#HCRHCS>"AY$>]3<;(Q#YY?BR=$HF2^'^0+2RULE[[7.(D%-:YR=#UB.Q?_<(23&1M>FKX<
M&)IY2/CHWUM("4_R7R^1^.L$KZ/HE,'8TG=6Z2(@IA<0TK,I!P7=][S@=GT3 M"*-I&TU3Y"&*1:UBF*W"@(C8Q3>I&DT=$SQ-PP]?-<=3I(QI:7F]VVB+![+ M\7SL3[T<)7_-I]+-FOYF$;V35K?
\AWW";\.?13KGOP84'^> _J02FN<699*5*O M8.GQ_+#PHK45_;C1$)\:? "^QW=>_0<\//RQJ-?_ U!+ M P04 " "CA"U9VT:3O@$$ #I"0 &0
'AL+W=OLGP[+DE[B);2!)NQ=L;8,XW= -^T!+)XL(M):HD9DCK$ ^Y"8I.Z>>^Z5G*RU>; YHH/'0I5V&N3.51=A:),< M"V&[NL*2OF3:%,+1UBQ#6QD4J5J.P$+(,9A-_=FMF$UT[)4N\-6#K
MHA!FDP(%2:.$03]K/ &E6(@HO&MQ0QV)EGQ M<+U%_]'[3KXLA,4;K?Z0JGUS]CZ\^0\1*MK/\/ZT9V_&D&?Y7C@QFQB]!L/2A,8+[ZK7 M)G*RY*3,G&ODO3<[-;HM$X%98T@RI36%LT*
[21T9('EPJ1%NV[0XA?0 M^O!1ERZW*%,,7VJ'Q*S';UX2^\Z/@GX49@N]*,.Q+UX< *OOW.W[_'Z+^#= MM6YF1A=P0UP-E06%W.5PXX.-!OZZ6EA__O>Q #3X@^/XW$(7MA()3H.J#6,P
M>_LF&O4N3[?[-@/3J&_.EDGT8YS/64"J__ Y4A_!A&*)M7(J09*5)+O,N75 M:-'O>/D;752BW!!0H@U+GT7C[HC*62G?F21\%G?[VX,.6SO2]ZO:=$!G4#VE MU87G(!
<;MF1$Q5:\.Z6S%Z]@S&SASZ^?[C_\]-MG.(-HW!F.(E]\?3..H_@2 MYK]^G7_^=+7;QYWXW0CNM1/J.;T.E#1.#S :V;E\!%FFKU?CCBL__VWZ.O2SQF['^VU>_"_4&"$ZM3.F67.!FDKF&!.U#Z MFB"WG) '1MH'ZPWM ^%RX?;Y>\ZJ_8Z/"1*/J&'NCB6@8?74'LONJ?HLGE_: M[SSG62"]J$2QLFD5F)(D ;O!G*QHK:@I4,CR;1(5T0= ;,.,2I;B?M3,LWZB M.\,R([I<&WH69
96*'+23R/&V'?!G@$^DH9$<@Q2F65,T$FT7;A2WT4!TMK(M8>6RP4ME>Z.(?8"^YGH396VFW(MDUR42Z[&_23AM"^-MI9+A)N%"-5)$XAM[;&C.K6^BA.RG5ZTW78ME. 4"V\ MQP2+!
<5E6X_4;,-.?S3D ;&2_NG > 87S![ZG?-Q#V[%IN#Y$"8&4TF9V/;T M ?*SZ)S!NTXT&,*Q*1X>7+ ^4HZ5_9%CP?=; 4I1??\\N0)JV)A,8K6?*FVDSFT^G9I);.CJXN>.R3O[IP
M;33;JD]>A+:NI=]=*<.VEZ/9J!OXK-=5I(')U44CU^J+BK\UGSS>)KV44M?* M!NVL\&IU.7HI.[\^H?6\X'>MMF'P+,B2IT,WJ^/\G(T)864444D^1) &_5. M&4."H,8?6>:H/Y(V#I\[Z1_8=MBRE$&]
<^;?NHS5Y>CU2)1J)5L3/[OMWU6V MYY3D%J>#6,OW M,LJK"^^VPM-J2*,'-I5W0SEMR2E?HL>LQKYX]4%J+S;2M$K42H;6*R >P\4D M0C@MF119T'42-
#\@:"$^.ANK(/YF2U7>W3^!4KUF\TZSZ_FC C]*?RP6L[&8 M3^4?BD5_CD,>G/<4"Z^%HIL7(&R:KM M6D2Y-HA0D00*Q$Q/0[5S?2[G[YZ?5\]NI-$#+P FE+8;1<;J.C!K*QDE%(
MW\LO!=Y7M\=23B*OB]9[.@JYI4F6<"L!WQ=5[WR6_%X5]EXJWXTNQ MM<89K M Z;#RW.L"(77#2?[5Q>E$?]J7<2QC=<%}-$=!R! __UI_.*?:J.,F+T47_3: MZI4NI(W"P48OW)* 8O.U;=K;U?.
[JUM[<.7BY7U#WC)2Y^*=#!5;5="#^]/5 M@(3A_UG,9_/Q].35G2>&>OYF\/213 80,^;GX[?C+L5B[C?*6W"G J[;8 M#9;PJ=&S1^BUDW?H_STY42&@(D&;YH&VMAO' M>,_&L_GT@<
TFOQ#)B[&L[-#QJ:U#SW.)!CGL_&KT],[3__&# _#!LTQDK:F M&*/09_'9GJ=C>WKV$%D:ZW&=S\>+V2'K:>5A[+[>IK@H',IOJ3RT-D94*'%F MAR3'ZG*(QE:#&IS7:VUQ_(I_43&
[:63T7Z>BE#L\>@$,0HHI(I-21D4+FA:9 M@O(+-%K8SC]K8$@=*;Y;W1=6"T,! &4B&:#")3 M#0/+-*>8-"636Z65)QAV F&)1V.RHQ M@.BYP0NXG&^<)T ;=N=RAJ# B'#7!UBRK+<18I81
M+270R)&B?7G42!]W3.>T/SB$C JL%XZ[-RS@!*._$R>7:*.042'"+.G+ 9*U M*Y6!O=H6IBVY"B$SZ=75*@4%&W%$C1\2?3%V()R*+:51C!29H1!1R':OEM3&'?83] LS,NRTQZ=M#V)B?
MN$N6Y@A" MD$5>EIQ%\I)"W;;?:?1;I9A(BI0GB1R%DO;Q9:0-5H?A!+E1$HQN9& M$*8? =RC &[!36 9AW%.O4SY/T0>A3!0ST)2W!'?H>'2;9U5*H!\-U.B.TW<
M@Y@@HY7T1E,I*"C4F#!)8B^! _LZOMWQ7"\#O!F?2)ITU%(:,EQDSGO0Z15% M"R*49%0N8<2GJJ);&AHK-4H!C+1K NI]X)S-,7[*K5?!*)7248V\,$Q/X2T
M'8,$V]*/=6S2S]/C&:Y(QF0<*1G8:Z05/(),<\C2[RE54D88SH@>NJ>YMFQ] M%X^Q\HJBDF\>BFX^^\!.^**:-XH;4+.#6^#REDMZKO.^;Q$Z3(L?WD*((2 ME5\Q"HL>A0S+8. 91?
2NOK\ZCM)#*I/3MU E*L)^]3R,X (Z\EA\X$:'J^L: MF[A\W>M]Q;*Q8*92Z/;/WR0)<%RK1AI?RPT7I:TJ3$1+XTS M6R5TB!3O5&RPTGG:MDITZ9#WA!I@#
(]'X\=UQN(6Z8+>E*NBY*V;9?>[R[4Q_LO MU!7[G2G)%NA3^K*0@(8IMNLQ5:I^F9GY'MY'/77:EENTX<7[.??MKCGX89*> MBP^'EW(6/U0JW6O&
X.H\,%KKLRWD+TWGK[U.Y"4N!>>O9Z*3]X52I6YWJ,* M;;1K SRS=\\+ODR^?$1+1:W-0+]T^]SW(6 !G8!%R*5M@Z/7YU.D*B\Y?$]!)=PU_OT)A&5_-CA>9,>5J M^95SL7NA _K/N5=_ E!+ P04
" "CA"U9Y1T7U'L" !Y!0 &0 'AL M+W=O=$H_F1+1PDM= M2;/T2FN;>1"8M,2:FS/5H*257.F:6PIU$9A&(\]Z4%T%+ S/@YH+Z:T6?>Y. MKQ:JM960>*?!M'7-]>L&*]4MO6(M2,.:?':J MRO1?
Z(;:F'F0ML:J>@K*9503B[NI'/**W2KXO $IU+!ND.NAF@[!UH#+=* MVM+ -YEA]B\^(!FC%K;TLF$G"6^Y/H,X\H&%+#G!%X^]Q3U?_+_>X$J8M%*F MU0B_UEMC-5V&W\?CTA-QGE)J?8
M3Q_%2>AQ86_MCS,?)%H?4D6F,M: RL&6"+FJR)Q"%O!92,JHUG"9F2]S6(\HZMI40M>&?@(L1]-IS0R/V8S>"1W M$W6A6D MT0!C?I2<0S3UX^D$KH44=(TS*)3*#"3^[((1
XLF:_(=9^C'X<21,G\6S>#8 M?P\,[%"C+GK3&^]ZE79PQI@=WY7U8*>W\N%1HLX+(0U4F!,T)M./-"#T8? MJJ8WUU99LFH_+>EM1.T*;#U7RNX#M\'XV][^ E!+ P04 " "CA"U9#Z_' M^!,$
#Q"0 &0 'AL+W=O+*VKT1J+7+XN6ZE,L9RG>PJN,:4K65D+)&.%HOBMO)S=TEVR>#WQ7M_-&U8"8K M:[_PX==Z48PY(=)4!4:0^-O2/6G-0$CC:X]9"/9,?CZ@/X^<0>7E?
1T:_4? M](-HGA:B)K6,NKP:'>_4,_GBO$[JWWZ%:ML.YT5HHH^V+9W1@:M.OE?/O5U M.')X.WI%8=HI3%/>.5#*IT.4LXP7NDBM16KC1Y\>?MR@<'VG^]1#3C M7+Z,PQ-RXSM9T:+
"'AR6RJ6WW\WN1[_=";+RR'+RW/HW]J+LR OI_@"LOC4 MD*ALVTFS%Y@2[85C!7L1K%C'$!UAZ+9D(FHFO:>5DH%JR#,T0IFM514>*.\C M;L8. U;3QH"YO;!K4;NX$9VS=:P"
_]VZ=Z/4LC8K1W$(CJYYS2 C4 !^X3! M)8[^-];%'P*Y5F@E5TJKL+\0B8SIC>I(*>%5O MOA1^MC9F6BPS#L!HJWV!98#A,J95!N!#;&8C5F1HK5!>#100)L, &R3T3A-40
MQ=2(W=2")QMZ"MQ.%+TO0E F]BYZFWO=PWF)S&IX:-)(O,N%S/H0V'/)+C00 MB6CS3!.H@R=&LF]&F:PX88.FSG'U-V7AJS)\;XJZ ((,1E03MW#Y-2I';=],Z(2>% 0P M5(KM!^EPV%-
MG,QT[F>2|O_LZ&$AV%6 OE.]1]?'Y1[$BCD_5NNP$;ACQWHX M(X>1^&R>3>5K/4A|OKT+O$\,I;;+JG(\"FM"8CB_&3]GD^<8:U+51BP:ZU&7 M]\YZWGN8T)/$T9738HW$2^N^/'H-8X-
LTL<&#SMXZ3?R<'?XGKG-K_%G_PQ MA' ;9:S0M(;K>/3C59%'Y' (MDLO]94<6?ILL$W&3DVP(,UM>%PX #*5]IR M7U!+ P04 " "CA"U9P7K.',H" #4!@ &0 'AL+W=O9+2-'\ 2G;!#&@#%-
B++5&'AX>D3, ^V4CW]"M' TYO"&D= M#]=[]D\N=\EO31>2?&##%Z:;>YD'!99L(R]W'[&/I^1Y!G,IK9MABIN06E$43FUVX5)TW MB>..-;!89B M6L\@[_DO._[X%?X$;F1C*@T?FP*+?
_T#TCH(CO>"+^,CA#=,G4$2^1'"<7]$ M+QD*D#B^]Y!6^.]9C*!$G[JK!A(:?RY4VB[I.KY=2[AC3EOGM9W2N6Y:CW*/O M1*-Z0F]O^BX:AO=']*:#WO08^W]HV%'^E]6 +2B\$9Y*^L;U
5D"8:"4@D8% M;];PGC=DD1M-_OK#.2RUQ= -R*OA"O3&:|RO7E& WIX,(JYN;EW]_M;B]2- MAA.(8S_-(KM(_DH@"1O>PFU5]X-~^^IC6O>:.!!8DFMX M-AEYH+H9VFV,;-W<6DE#4] M*_KMH+(
.B^E-/N-#3#\R!9_ %!+ P04 M" "CA"U9#>(C@H4("[%0 &0 'AL+W=O_7YS1 TM1E-*[D12)!=.-T]^D+>;E1^G>S%L*RYR(OS=5@;6UU/A]9="T*
M;H;J$B6>+)4NN.6M7HU.1O7/G%"1C^(PG(X*+LO]!;5:N]?7EZJVN2S%O6:F M+@]N2T&VM+"Z/KRXJOO(.POU:W&G>C3DLF"U$;J4JFQ?]J MC M<] =28+]ZU:
[!V<[:%EP(VY5_IO,/IJ.!^P3"QYG=LO:O.WT=@S(7VIRHWJ M91N_-\+FM#96%8TP$!2R]/_\N?%#3V >?D,@;@1BA]L?%9#^S"V_OM1JPS3M
MAC:Z<*8Z;8"3)07EP6H\E9"SUY\$3#*7(PM=M#)*&[GW7B[^AMR8W:G2K@WI M1\]57C'J9"-HX#%89P.CAK%_WRR.U8C] M?PI9Z%4DAU50/IR:BJ?B:@#"&Z&?O.#ZIQ^B:7AQ! 4R.:3_B^;-
RAU$U MUCZN!;M51<7+%Y;[I51HB]QD:KF4J6"\S%C.%TIS]_0+4RS['ACAO#TW5MA$4-8#=9)BFI>)Z_!,SV3EUSPT2Q$!E8T4*P M:ZWIU9I):OA?:2&0U+C<2+MFMW>?C0/%60I"4:28%
<;*;F"3ISFC&!JD:%>T[\JZ$D&+.;LJPA M\$542EL&'U =8E%X^@_8M>/C>^!6F4S:B#B/HP@[O:@5@A4^804E+ *]TW67 M;]LOY(7?8\23T "@EBYT75B[0!6\K)>XJ#6%RR,)F
%O2&;SECAB0TIF:;KJ MTOE!:0]&=VH!O&\IEX]8:AVI\W#+YDD|=%P^M.V5]UKD<&7K;O$LTMI1!6>7 M; <]1Q,:- =/,=K\! N5Q@/=R-]FSV!G:QIY'G0HB. ^(E6W,,W3@+L7]HXP> M9;I>
;3*ZCT/$4/ @%II7U2J;WL>A-"D.',.]YOIO:"IOYRJY2F2$"Y$]6 M-[P@[O+V'^/Y<(P^D>1[.+MY*VET[-)74*H@OV,WGE MH?/*W9:PQ(+)H_T<]WE .W=1@* /&%4H?R@OF::D@.OGODD@GD@
MJ[2!K^46.I3DMJW/1E=DI_N(?<>H^X:B>R:I'0N8SXX4!K+)F]*5E1YI36WY*DGF=$L M@UF(6AP(H>IRNTF/9ALC'? .;UMY_6B6?IC< K#X"^EHM6_2[5G1(@))IW M (D4N5A1$V8+669.(3
7=<&J&I6"/,LIT)N!<%573:]Z4:*YYG[X(KOL3 M$[@.!ACY?.JHZ3N'TSGLC8.+Y92% ^X2,=Q%NTL=I44*CW3<1&"G M?0+Y#D"D:^W9XJ8ZG]I IE_<^NQC7=?
ZN':K;8.6U06"=;4N:W63Q<37]P%R7S. M/G?N:3'!<*(I$=HWQ5P<)+-P2[W:%CVP^RL&/1?[WH9I$"9C_ZG.7M8PY03 MEPV1',IF\3-25O0QW#"],1%(/(XK(<=MD-
ZP7VUS[GB(?;M)=PQ*OVE&27(+.AGN6;FMKU6QS,DP1VC:?1=T1W. A7 MX:5C'(QAM.?#CN !F3A&L$,639Q#/N^EQ6_N:P;U"GH%6!WN1^QT#\H0B4:E M"B<,QV%SN:>,WIK<+*AI?
M_7D@R3"?L+T VC.?[?"F;/I=,AB.HQS(:3L[?" MV=.S&X8A<. OP=^->Y 8?8%:UIB@1%<% ^T5^NPZ]#G,'&Z]IWIA,4__,7L%X M)<>G-N/:H#<+7SK_N 5VSU!\$O^ SH<%OJ:.@^0L!LE!B-
G,31)L/ O"><*2 M*$AAK_CC23"+SD"R)(YI9<;&TV &:^)@DLQI94YBL[)ZS$CYB94S_/<6S9? M4D^=1\$9S>)@]DL/F'O MD(_QY.P$\RM:/8+VE>>U>] TMG[J92 2/9P CDOC!
D=1NS0EYM1[_M9(?3* M?27N&D\)_2NM7N0^2-__[VNMU_Q00M5M2C6^QF'0 MM:IPEVO!$1+:@,=+I6QJ0P=TGV>O_PM02P,$% @ HX0M6>B!P9\>!P MZ1 !D
!X;"]W;W)K&ULJ5C:;MPV$/T58AND M+:#9]V_Q#;"=&BT:-X:CM@]%'IC2:.6:$A62\GKI]3U#2EKMQC$2]L6K"SES MYLS.&3R<&XD*H'Q:\H6CE>M>"(UD8 M\| WOZ1G@PD#
(DV)9PL2/X]T15]S(<#XU-@<=="YY8 ^ZM7X=8DKSL\'10*24R5KJ.[/ZF9IX]ME>8K0+?\4]KMV?#412.V^*9C,0%*J,O _*I MX&WX6CRA0VS9L,LX(Z.
LIWTLOS4VM6POJ]6..+$&K8#7"JY*1\]!9O%?;Y M\RM3%,J#9> ^$+%.1F-*K1?O/-B:?V6\5_UXQ3OE$FU<
M;4G\=;%PWJH_GZ.A>AD[WDGW$C'KI()G0W0*8[L(PW.7W\W/9B$\H>3S;K+G/":P5E2S70O-;)Q*R'OTO3):IA((5+1?&2F_L M6@0FPL-<.D'%@E+41KM7>G%U\R&ZEN+]_L-
(7#A8$LA|DG>]'PK?!\N& ^IBD M50Z8169- 2O0J!6TJ7]>6HXE^H(%,.ME*BDCO1["OR80)\8TM+CUOL V6"D M3[6]V$5C8:5\SBAO@/(^5ZYYC MZ[I ST4)K5H 28-IOMI6XU5V)W<(A6W"@
M/K=$P".M&XEK]43I5FPU.LEBD7(A-5R20E:5-4|*HD3BU?[!Z C2H#54;A32 MDQD-L>7 O5QH$[V19S6)KR32(!3X=WKB^O:5>/W= MT6PZ.XD$3N?#PX,Y7Q^(Z>'P:/^(KP][UT?B<#B?
3OCR:;@E8,.0RD!R9^K> M> 19U4"W6]2OO/!\/#H+:!DS+81OQEP^W88&\ -N:9$5ELVBSS&:&N7_8]8C V524F*Y;4%NZ!9E%C 3G@5V6BZY17.TIJ"S04S#H7)B-@
MZ0U"]@./F)44^P/E5A%CVBP:;2D!@B3K>)/AMBM3[C_.:5$]B$)CMN/C*R"/ MQ"T>U1+UP33E23IW"&O=<)YRHU.'+K>%#G$'7>&-CLU84L4B>&(#FXUI0SEG M&0. AN"ZHL!H+761O(P%
< M-" 1Y7H.D(F*0EHX^E!(L=#I"[:F-59EM,Q:=X=R@BKHO0]/#$HD"U.#8"S/ M8E=6=Z:/ MM.PS,Z M7<(\5'@R2 8%;XRI<18NL02[F.>47&+5@NN!3[6LAAM4;*)%UDPU?C44P5R0 M4
88GS7K/P.'O=O@0)+I%[H@B0!A1WG7S%T:]2%%@A(.WHBZ'(G(\W+"N8K;V:^=Z% M8D$TW.HA&XG$04!QKV 7:AAN>&#&$GJ'<;3B=..GD1],/2!1U6/JD3Y1ZW (:)T
M61SAX.$!5#[3]"T9 * ;MXV&.?F506=^< MQ0R,IO%+A4*CA+/*=-:.26BH,UJE@?L,\O5B"O,8R[Z:OGP8B)NW5+STUQ< ME"5/EBM$]OF$PQ_ 8CI\'\OHN> ^7<> _SLR"
[#[_9+.7(4?P2[9YVW_$?\]?-U MLSS^$P!'QR7*"^>G#%LGH\/] :HI?%C'&V^]/#&[.!Z?QN$R)PD%X05XGQEP MT=RP@^Z_&^?_ 5!+ P04 " "CA"U9YJ%]_)L) ",& &0 'AL+W=O
M^SRTKT>K;VO7IZC]DM]M%>7IO:Y+M5'*UQ=%-(^O5&YV;P>S4;QQ2>]6GMZ<7)U6G0O$JG*9)W[3V;SBVKL69"\Q.2_ Q6;L'9^/A))[;PIF1W0H-!E ^"L?&S_T M-EQ.O[%AWFR8L]IA(-
;R1GIY=6G-1EA:#6GT@WEW5!.EQ24.V_Q56.?O_JL M;"%R(TN8LO27)OXRZ>DJF:C7(V2 4_9!C:Y^_FGV?/KJ.Y]>M9J>?4 Z_Q"*' V<_ M^T_PN]_HW1^E@&N3M9@M@F_%D5\K]?-
/%_JY1-6[+%.<'P(H4OQRINK96-"2 MMZ;H9/DD5.F55;G0I3=\]JFR3,6=2FJK_9.X7EFED+!^(JWN^LHCY=+\45: M*[%]__I=K^WNC?9K\8NR29TK)[*2GN9L\RL+E.'M"C!(ZE8/NVN.D*BY,'$
M_&DY15YJ%W3CQ&1H>,$0*1 MF1KM,$:U=|Z&J4HDQGF.P,!9!$/(<\D>>>U(2WS*X?!<9$KQ0EGAY$<- M)@<$Q,%1YL;JE2ZQISTF!7-PD**R?]S>M-ZDTZ>3B^YTX&=V&...5
M6@F'A!ASR&22&N)R6(;R/B!-Q'6::.BI8+3ZY(CPUX(),OS$= M^@[F28>WF*']E<; MQA%Q=#EJHTX'(^%91QLG@ M!$I9;5(P7DHN^&QH-%
[MGGG8$T<6.2&:;;$]SZ6L.O/4[H0GVPF/9#M[:F M7]T[BQO2?AY\W++;MBIGG2]?.P(3:XE\@)5FF6M0$)]@F#0%Z19A5C.]M;(0 M;UY#+M .SBR#M@%+G$T/T!QLNT66L_-7@.8#3&5:010*
[;U20:F.E1!7B> ; M@I)T:RHL*#!P4$S]8UT>W^LR[;Y$@S_> _FUHZE U$UK%2&?:8MW2] "^ O? M$ HDG *V14'-2R=5/K'& 1K(RFP0%V@K$$!8#-^1V"]WOQ*7%TIP\D4AW:M6 M1
5*$K)V>)0'&6Y,51%11G7(.;%7.A%GAB-MS&C4<&A0("6HP^.38FG M1BYIT^M<7,.@7(3D/V>VI;^Y ,EF PO60'##.E8#--\FTR>CUN#0()(2HY M@2&&5?6CLCP+$:M\B$39HX#,-
-[5;/5::AFQK^'VO<0W9 -A% 7S14:UK(+O7 M41]RF[60A@YN_*V(S^"$B@ 3DO0]L#SOH'+UJE $T4',C(D-/2E(M)N M(;+:4#W"W]TX]B1S@\|#9(6F>TD5=!/*@-1;]
(],TMFU+=#9M* HWQLHY!EWZ02S"!$M\%?5$]&3;E01F%K]G?&/E] [%)2 M2P=B+M6C%[-YP#2RS"G5/ ,O3]P.]R@&]MB2T>,<2X&$WPU8% K>*-"3KQ]) MUG(]):0#-
I/U>"M(FGG/T5"3D@LDIFUX233](P MN,0ZRB5B9](!=? 72[<%!/VJAGOT.*MD?%M*B=. 00V >R2>Y16VP!OEV8 MRYKA 0&-[% M\MU?+/6A@<3[3ELL_$MTY-ZA|:,.4&187)7!YHI
M^JH/*NC7VG"?1ZN.],290*7SJ)ZNF7?BO-2VY8.DBI:&/GMH2*H?=!J(Z4B3 MY$#(K"Y/8(D*8Q>]*Q%P4)?!LB<7AC4EC0&?3YZW'5L; .TFF?:V!YR=J6?: MSP-0#'PGJ3/ZL14-_O!?
TCT'^3O7&:\\%T]HN5SH(G>'NJT0<]NX5(INWVAR M"0U)Z FLR@,#9Q)/Z /|:11T*Q;[)I?)_?%=LC;4I1K.S6/2EQ84)E5Y.W)E M["1FPWP,KQ:\U+VD8AUBB&5/6N6HCZBGT!5*/!@ZFS,4-
EW.)K/#.1+*W<.N MU71C1-R3T\,P1K8[XSC=^&$\A&/T$OUNXAD\LL]85#B3<(B:N%;:9% C-R? M.I&J:PU@]NQM!'9]*=(>>NI(@.S
M9J6XJC(*[\S.M*3K$O'4+70:!>A'5IC+&IO)_H."Y4O('1W9XS);#$Y M/YR(]PT++G,6K/M>UG4N& [QTV[VIY*P8\Z^;.Q:GZWK@D@H'.XNL#$?)N*3
MRLARTY0>M(QWZ'IHJD,DWCUP.S9F]LQJR\ZG.-6.;![:!H:UH7-KY!-?O6S8 M+1BN.Z%9C^$0*&]JYC[73?9=1I[?[H@+95=|$TYU!2:'Z^+V:7O9?AWNF+OE
MX:8>IZVH$%QSK23XF1:@>V:@Q^:!#FC_M"^+JOU!+ P04 " "CA"U9M%X:=2L$ #5"0 &0 'AL+W=O MACW0TDDB0I$]2=7QO]^1E&4|&R'-/*]M M;:^2Q.0U-
LS$]D5)*Z72#;,TU%5B6HVL|$Z-2+(TO4@:QF6TF/FY![V8]U=1/8M:R"A_1?FD?-(V2 :7@#4K#E02- MY3O:C[]NIL[>&_S%<6WVOL%ELE+]R0W>%_,H=8108&X= J. ;WB+0C@@HO&U
MOXR&D,YQ_WN+_KO/G7)9,8.W2OS-"UO/H\[(^BQ9)^QGM?X#^WS.'5ZNA/&_ ML ZV8S+,.V-5TSL3@X:+_^>^SKL.5RFWW'(>H?,\PZ!,O?F&6+F59KT,Z:_MT-
R'3]5[$SDNG2B/5M,]S^[N/O:<;N9)9:PW$R2]NXWP2_[CM\$/BII:P-W MLL+BT#\A#@.1;$OD)CL)^)'I&":C$611-CV!-QD2FWB\R&=$D5#L$P6B0*RG['O2>+F#;K03/094E:@HR FY.QV24.
(P]HF$!8;0[R424E&:?4 M!$(X+%,S$L5-[UDYCN.WUX;"-HTSLBJ_F:!O0P)K>8Y,O>SBSA-H44=($<@ MT)C#H=OWF.LWUGS#<%DMCCJ0[:5E1-2L2$R1=]J1GECXS,[&
MDS0^WZ8YB=;*&'HQ>S4= ^H]^@SZ?OQ M332,R8"@Z8(4/]-+0<>S<7;^$V\$158-6+]MW:+[=\EHU56UX]X?+[V6C4^B MT PW&VIZRB'=<$C7K-=BFL*:"[R8$9?TB0S!7E&L/2LZ?
ZD/GV%CDL*.U" M"EVO*]IWW6]=WU6'!8R/'?+)WE7:H*[\@*\5B/9-L-Q07]MU?WOE2ENVIDLU#@:Y8$C7W?/.1\LE*Z:^FY-S":25K%4ZKD,
(FB\:]BHAZD@'FP6/HIE:6EA>';2L"6_YO93.]/X-.RM%*+BM1&J M|LT7IX/S^.@B(WDG|%GPE=FY!\IDKM\17>GA7G XB"HA+GENRP/|RPR^YE&0(MP_C6V1ST+DEQ]WYC_:W+'7.9.\,OE?
PB"EN>#J8#*/B"M=)^5*O?>9?/B.SE M2AKW"RLOFZ4#R%MC5=4I8P25]/V5W79UV%&81H\H))U"XN+VCER4;YAE9R=:_MK4"3-%JC&Y>]T\;@1$U-N;8:WPK4LV?75N5?7U-
>!>2]PEX:1N4Z&5]TC+2# MO+-TX2TECUA*X;VI:6G@JBYXL:\Q*CZT)-:J?)DP.?,QU"&@>01$GVA+VT M3S5U1M+'4BV9Y]\O7*HSMD9D63C7F5M+[N[,I\;JQ$F?S^4O+>=/6R:1N?(M-
"SGIP.<#]9%G3UE_5I-^SA*\]^&/MN94ZS0 6W*X MQ->L7K_\99K$DV,#AE1+)0NN#:"FT>H&C9#D7+9]+G0!=E$S"6K16>[!\U
K6+0:%S4P"M:@'$H)6SRJ*CN]WF](4RAM#GI+'N%2:AZ@GL MA@G)YI(#$BP(8U]&B>TYZV*$%>O]?BN0C;A<0Q+&R E28DU">+2U_);N.?RY M;2H6.%?+6OR#LN9[>BX3*M^+-
)ON_+D>O!B%%;]0M)]$7.ZEYAP]3P>&.FN7Z[Y+8"7R^]T"NVXXE@G$Y>=]+$EEC*^]P1X1E P<,.NI-2AN7ATA MQ/0/)NI;Z<&L&N_R!<1!DD;N:L&W'SG2D.CMIC<(!H%Q)DVBB-QN,I7%6-
M5&MTY06:%GU@S: AG% *RB%Y&KE)BY-C>]X&DW&,UU&0'L;?+S16-Y?,&+$0 MN7_SORGOI3*6 ,*H%&UN$3,WO&XY9)AW'&'Y\0R 4 U@R6N,3+JH6(&[JZ -
MP)%*$J3IB'ZQ9M@0[MR07('&I&KC9TCI:\]/$:.10:N>1HF^M[<6 MWO"<.V:NFI!"%B2NCW$6QF/XK2/)!A-$EH-1V.XZHP7.U.UN;LDVI:\"(C' M%UQ8ND788C>$1HV#)#E\18:&X6AT-
YH[>!BC4Z*#0X]D<`IZ<5\T#]830EV2 MA),1?$;F0%\$%$*!HQ#L]PTN?_+4?%'14'SNR8VU.) ;<0VY1DJU AFV/]B@[!8A4++NA(0+49CT MG+8]0)CW4XIVC$QIIF+8B%PTR'S:Y[VJX>YR-
]VF551[2_4&.LG !;2('VD.+ M0A"R.#>,=0-.'7I_DF7"A0^]!4SW/GLK+A>NH]K*D-;6 |%VJ_VW^_G_K-U*^X_M_C'#[<]E7R[JA62V0"T_Z#V#U8UIB-VKBQ^$KO:DC.,DP3P_4(INWD@!_V
M&F?_E!+ P04 " "CA"U9Q@>[=3L# !6!P &0 'AL+W=O&LK4*X'5[L?DQ[\U[(W*X&9R_#PTBP6-K;-@F#5%W MF::A;+!58>$ZM+Q3.]\XJG?IZ'S]*H(:DV:9]F[M%7:)KM-7+OSNXWKR6B+
M=QY"WI;*/UVC<<,Z6;ZWY LI+M-I_;X'>GWIL[S+)U8*MXB#=+NO AD MZOEY?5:XF/ 'QI'.IN#."F&,7:U M2I#L [GV &8%K;:COWH\U&&%+A00.'0!YUXCFBREM%;K?O:@ OTE@?
T]8C.7T"OX*NSU 3X;"NL M?L6GK&22DQ_E7.=G";\]OX#5\@WD6;X^PI>;[*TBW^]\O1_]$6YU*(T+O4?X MZZH(Y/E_'W*\LBX/LTHE^0R=*K$;<*W(*!_P&3W^M7R7?;AC-[UI'=]COT_M/\?
1\,MUN@]5C(%%0)2 &4K.;+/ZT:K0AM-F@&**^.Q='NK^%M.>L5\.4A M;#OG^<9"I6O&HBTYND :$'FW0:BU5;.4RC">0TG;?4PE&9A&!W#U7,(\;O\D M.I"BGASG\(HP+. *'I3IU7AS#;<.3H#
3*+0\V$#M>>6$^A7?X>%7-2)C5-.@^9] 152'&6D- NXI;G*+H)ZUN6) MI= 3=S:O76\K<21[(V T<N96%P3$+D==&S8] 6ZIID=.J&1QI:\"9B M;ES:*?L$C9K;YW"6=JI*Q\K,L*!?
7>3+]Q X0 "B'W1X_M11C,63A55 CV84 M5*#%FFLZ.R!5[X]&]?&(7.S8"U!Z ?!-+IOI*L/ VG_+%AGW.&-$;O5, M+$Y=[']36ZUKT^]C1 Y1<=QK;WK0Z/1I78Z]\#A]?'):XYT*!P9JAV>+]VP3|
MV.7"";DN=L[\$??A.&SXX4.O ;Q?.T?'B228GM+=+OU!+ P04 " "CA"U9 M_GE?MH,# F" &0 'AL+W=O0F+ ^)>9LZ?A;&V6<]TZP16N#=A62F:>5BATMXC&T>'@CF|K MYP^2Y;QA6[Q'IV>S-
K1+!J222U26:P4&JT5f;Y;3;O\$/B+8V>/UN]V6C] MX#>_ EHLH|8108.$\ ]//#FI0"]$-+[M,:/!I%<\7A_0/P:?R9<-LWBCO6=> MNGH1$2(HL6*M<'>'Z^7VN_ECLCP+&+&WZAZV5?-
(*BM4[+O3(QD%SU7_:XC\.1 MPNR<0K97R +OWE!@^8$YMIP:W8'OTH3F%\5H$WDN//)N7>&;CGIN>5OE'>A MK84&*54U,SA/.'ZVZ388ZQZC.P,1@Z?M'*UA5M58OE/_83X##*2R
ZE5]B+@ M)V9BR,/CB9!['S\#-XM,XJKK84U.7GOG80OUQOK#-7$UU/^]G"3 MTW"^3ZYLPPI<1-0(%LT.H^7//XVGZ?L7R$X&LI.7T+|S(S^* 7_4")46U(04 M"2BTE-035%[%
^"WEN^80.4L=$B*(EE(O=$2'&D63!2M8*&1= 4E%ZVC M>_5?.S0G@@:=<%U:X*KD!?/"&RO8:Y./+/IG07*2NK85)=1LA_13 J-.58Z_ M#2:H80&KBCH87G-%JU3)7VS15\W-
MQM4$$V1<@^@(.50,_M\XZDO5V>C=U MX^E:>#U^ ^]&EVD.=T@UP M/KA=[%7>]P,5H,KF$S\P8YL,2C2YF4[B]7Z][M-RV1+$$3 0.S"8RGHS3+@&N)YNU[#G+:8AP2!=&@LZ9N%5&N?

3&#ZT9[^0_]7+1'L1LN&J:>0 M.U\&Y(*6Z!F^&L_B2YI50I#;,:R8Y075E1^/6+ZE//!N:]D.%]M$\]CB4X#C- MGD%ZB_M")2?KPV+!1%WG!"\,VD|>5:OX3{4Z8]:S^/\WR|@88H\Q_K8QHGK M@+6A*O%AI[JBR6:+;AA;)$L%6N'^/#Z? (7O>S_UF\]?T$I35M,A2;P M(M4T?G<1@>E?I7[C=!->]}$[TI8UO20H_$"=%]I[0X;;V#X:[#\&U!+ P04 M_" "CA"U9"2_7C0X, !G*0 &0 'AL+W=O+WXDY4?UO=*-R= M=5RR?"E*GN12PJ)0J05 M<>"X/(@K413$"&I\;GB..I$TL?^[Y?[.K!UKF7$MKF3Q>YY5B]>C9,0R,>=U M4=W*Q[^(9CT1\4MEH6FO_$MCA]Z$Q-TSP6\F M^$9O*\AH^2997 .*5DH],T6APHQ]F[68VE,M+OBB;W7NA89>Y>7O$QS7K"[=!^=59!-#$X2OLQ;ZP8?X^8@/TB MRV]AV069B6OS_AE4[O3V6[W?^ <9_L+5+0\L|A_FN'Q[@%W1V" R_8 ^_RS25 M=5GEY3V[6O#R7FC&RXQ=*R45NY)*6111]O?+F:X4P/2/75:P0L+=0BC SO6* MJ^+U"|&DA7H0HXOOQ-B}\<#2PB[)82'N/]YKCPH9O-" TFG+SB,/" EY8K7CZQ M/_]G^?@[<6#4)"Y4CGL1PSTPH3?;ZXJ MH;'*5 *WI08-O[0L\HS3@'FW]AY'9$JC3S.;"8(\ V#318O8X)3=U;A5UFR9 MP=HNN6L!$,C-.&*M1&&F=7KS):&73*8$6UG3T/,R;YD?8/&RK.'L5]RD@J=* M1]F>>{)7SNUGP1O=7XK4K&<80EKM>&R%5?&R%4*:N&;3D"\2$4]>/9/9+'& MUA+F,Z%DOB*GPB-09],C[>(PFJ^CDM0C93)B6@@D8ANATL G7W;.!(6L/F6 _M0L)<%@ 33;.XK,",QC1]W? N&O^K>SGQ29$>W&/4)A)/U&QVQLOAUW \"$TX0DAF[02)Q\.'1=L?D+OQ>9*+IGFA: & M0K[+*PK#|^],'B2RC5#6<5/2F0:NP,0-^7V9RJ6P[.0:H(D3!A/R*C0./60. M9Q)&& S@ RY(-&:.6[R1 ^LL-Y1.W&-DN"X6D9Q+'G#-Q/W.,&.)9KH[4SG6#Y M0>2M1T^=V)^T&L\$ E*TFE3\"X')<_S0)9>;>;1XTE\E1K%QH\|O.)1BGE<# M_;>O"\1ZP?L$],.: B$PO.'0[H08R3]D80X^8>^]IN{S=4]<_W@@>]1+]G'(M\]*FX'P1CI]-4RJR$TYU\%ZPLC;Y.'! !8^03RO8U3M#]^]I-L K#RS@/'X' M6GOWI[_7%]RLFT0CW-U@[15*)]U(II:? ^8%G%F14U0@2#1*..ZSBP1%LC$]% MX.[E_N<3\S0)AZ$&6A/H>Q7:,_%]UV D7,2F'O(6&BP>$1J/F(? \4(#E[=(ME2@"63Z?(Q++5)C62]'"9J9&2K.D4G 3IBGE.?* Q2P6W$+/N 3EGE9 R?6) ME1)A_9DZ"^* #5[:'U#SB*9*+%&0-XM?VV5#@[M*I[\6LLB$TC^PZ\|U,M2R6#N MA-W4P"1OYC6!![J=GUW<|-BGWG 3SQ.W)1=T; ^3*?JA:R13'"*#./,"TY'NJ M-JL"VP)3' W <5T7%Z2$Y^7<>%C2B>Y/O0T!=3DP"G_D*C/-BQ95AA2*&GE#1 MCD(L5X]0O21 ^^%[VY09+)W0/CW:?+ M/G*2.-A#W9\FI!M:$?K32[UIV2]Z< M-#6DN221MY5*K\!<8FA#B/%@T-.@+$/>N'UF] 8(M\N((A=4@#XT&:K7[7"MX M&/&[F[Q=O\;1U)FX-@+:GX= _YOUMJ_[0^!K.1T.B]_E\L?BY# ^1!C\,EN>N M?R!@7M!TK73M]4#HO!B],<+)5L_NYW"3=#A6!FKV\SETO=7J["T+C6^A M\=\)#:1^^/O*@#! W2!@JSRQP4 [O^GQQO' BWHDZI"H/XK0#"5==T37$%M* M#SV-%Z"'*!=\ZHV^=T= 0=B_=7+ZZ,_* P,EF9P3<^5,G3"*Z\Z>N$V*SNON(MSFQ2N%ZP=X5_\1? O1E%YD:1 _LD,PL6\UL+=B>(ZK>[8]:OO)X8;06G-+3'JO M+=.\$/W]-^ATEY+P=]. ^]; 4"DN664.?!:8M7YORP!3D$ 1W3.9&@^N8N05 M>]$\BVUUWY 3387A8Z@>H2WJ!? 4=TW3&3/4_7)M!XG3\\)PRJK;N6Z7J19E+' M]\L;P$VP=??B4SCD67/4MB.5M0^NOP#GM#=^P$]D>F+-BQ;DG27Q&KDUPO\H M:>.,RE.6)T=_LN)%CAAF/;$93>X@A\ON2I:6BXX G+#,UNW*&Q0O=R[!NOX,Q M=[WM>P\1&IG('F87.9_E18,.A,.*Y]GZ,'-]<-],&4]1 Q"4/K(,G>0F2)$(MVSA!S7G?60&4B (Y]IHC-SK.!1PVCV\5'3V9G F/-?P]STG*70WUZ'EF]=_ M]'+CB=X4H/L# (+! FF '$_10XL'HNVDFWYV0#M2GJZT<;OCULXW1"?H-IX)#X.UZ>]6%<0TUF0F MX/>O. MT'UGTF,~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fL_U!IGP6Y"\WVH6_:!O73[]G+&^< M-V4R1@2E]N+__"[AT#-X-OZ"P3093$/<<:,0Y;?<\XLS:[;,TFIXHXN0:K!& M<*]BHMQXO[=&!E6?R%G_=VER>]_#-P.V6PR8-/Q='Z/OUF7XRSXFWT]QU2[/, [2!D_969A>/OID\&;^\)I9Y%^O\/N___MK!|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{0D!YBJC19 P6'.I4X)LD(I[&^ MNHJ &8IXLPRY12NN,?3W'4[:D.>8R!9)PF7-=RTUR99Z&_L5"EGFP1ZUDO:P M("58R4@"Q40/E0T- :M5@P.4#OG%& -2.+1@#V]'8+C\T^M^N3=M-HB!N6++ MVH*>LW&K<#]VV.IY>[=L-F 6F\S:!^0Y/9RF50>\|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|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| [,>MNYHX05:A!X$UZ5"TS@\!F^...:\P&O?"HMPY'@0]8 MW]%HH/TKVG!"#Y0TF)VKNH-.ST/MO5F]&F>0 M>,9B*) '\-+W]R:SX-.(\G10GH[1TUW# $V" ,>OVY^56G]@32W")\P6V<^9;.8G!;7'UPXWJC MW(M^_DE_J$ 6K@LJE(F&ZZY5#*M#HUUU_>5O>->ES84L*%>(06Y2@[N%^3ME MU_FZB1:UZS9[H4WOI:/#58U[UY]ZRQ6;/* (%.KZTX1K^;X M9NK<;$O-$?FMDUI"B6,K(O,FG5M5B97=02%EYD?=Z9>9UN\E1LL,KTDQZI\ M>M@!3=KL8>Y0>BLHG=V!TJ/LAZ;N-C9[7?O>Z&*Y_"/("C6>>OK=G!P'^N PMDZ6E!7B -O@N2S>T0?>;S<7? 4$L#!!0 (.*,$+5D=(_L20(*(% 9 M >&PO=VIR:W-H965TN^>XNZ@1\E'E M)H\E057L9-K74U=5Z4YE%0-1 4<7S9"EE3C46Y=54FQF065A>M[WM@M*>-. M$MFI!4PB4>N" <5A*HNJRI/)Y!H5H8F?HI[" NV3;7YL)-HHIN807ZH5I*/+D] M2\9*X(H)3B1L8N=V.)V'QMX:?&?0[(,]4K60CR:PYC;\/@IIV?6>O'/^$G('>"ZUR1 MCSR#[7>Q9C[P/U]X#/ +.$=E0,2#-\1W_/# (_', QX>G DGZ/,86+[@7)X M+%TM77B*L95XI5:UTO2U0)%59WH@9NWN1^5EB;]2Q)54O Q^55 MS_^#8.Y7F'(OC=W;5]:O:#2C'+82>;JL'Q= O-MXDV\X*.%J6V"WX:U[B N1 _ZJTT.W^@$%H!5U1P)"%/O-5DN5[8>!?PDT*K3L;(5K(7XME.-B3Q BL$ M##)M"=@\#G /C%F0T?C=.[UA2YMX.C\2O[K;32UIK.!>L%^4Z#+O/GB(0(X; MIG>B_09J/3+/RP13[A>U76STT4- 9H[2H^F1C4%'>/?%+?PXG"89S/B'L$T+G MW6WD+#]CC=-8BA9)&VUH=N!*==E&CG+[ISQ]:=Y2DZ?3C3E> A(]24PH+]!* M2LP+,,>N5>QKLX.-| [,>MNYHX05:A!X$UZ5"TS@\!F^...:\P&O?"HMPY'@0]8 MW]%HH/TKVG!"#Y0TF)VKNH-.ST/MO5F]&F>0 M>,9B*) '\-+W]R:SX-.(\G10GH[1TUW# $V" ,>OVY^56G]@32W")\P6V<^9;.8G!;7'UPXWJC MW(M^_DE_J$ 6K@LJE(F&ZZY5#*M#HUUU_>5O>->ES84L*%>(06Y2@[N%^3ME MU_FZB1:UZS9[H4WOI:/#58U[UY]ZRQ6;/* (%.KZTX1K^;X M9NK<;$O-$?FMDUI"B6,K(O,FG5M5B97=02%EYD?=Z9>9UN\E1LL,KTDQZI\ M>M@!3=KL8>Y0>BLHG=V!TJ/LAZ;N-C9[7?O>Z&*Y_"/("C6>>OK=G!P'^N PMDZ6E!7B -O@N2S>T0?>;S<7? 4$L#!!0 (*,$+5D=(_L20(*

[7UNZ=X04GZTK%J#>\RZCKCC%B"I[70HV- M+TK8:T(/3&HY:31U+O49^(/A(1?PR9_L6#T'L:8\+I%THRDE:V@J!/0DKRQ/ MA;>=
(R95,.O@)9;8SFFT!R>#\2#U:4S&PR2'7^G,88[3P:1(N7[B&8%,4] M@GV&3XKIA&DJALF8BV, CB"+??=X,$Z^,?4@\URBQE[ND2#32TG+U^""IL:$;00F7,C#A],K?PF>;T=7
M:M^LZ1\@O0^$)K= !!G9_1:,_5!+ P04 " "CA"U9U8SSHA$# "K M!@ &0 'AL+W=OE8UTYPA3,#MI:2F9=+%'H]B0;1YN",+TOG#^+IN&)+G*/[4(.)>
<2E>5:&=<%B$ET,SB]'7CX(_,2XMEMK)XLM'[TFR_Y)$H\(128.8 _MZ+?"*O3" Q&-IQ8SZDQZO>WU!OU3)\U63"+5UH]\-R5D^@T@AP+5@MWI]>? ML?7GR.-E6MCPA74KFT20U=9IV2H3
\E5\V?/:1S^1R%M%=+ NS$46%XSOZ9C MH]=@O#2A^45P-6@3,:Y\4N;.T"TG/3?]1GD7VEJHD%)5,H-P<,\6 NWA.'9D MP(O%60MVV8"E:X -X58K5UJX43GFK_5C(M:O2S?
L+M.]@+?.]&XZ&;I*.] M>,/.VV' &[Z!=\,.XFII84;>SH.WORX6UADJCM^[_&W@1KOA?,.UHSN?V*|^L9VKN_S;S^""^1"BTH.:EH$'6\+&!#V[Q M62/%$5^1Q8D)ZG3
M:Y%#R59(GOP8=;=-R_$,P\47.6!34]7# %*N$3C]2G=[F3$6BB&%]=? M6(V74E,N8TV9-%E.=U<"<"@K25>)(L ^272T_E#H D22C3O'YW"2RYI)Q@A(# M$>)5BP3O=>1#[LPRL<-
EXFV">WME5A#O15%F@?.?A95O=X;$?5*:6[X1D@1>9O^ \VJ]L/OU>$SFOTS1PBIV$VMX?O]=Y#KN#SMW^IWF;Z:O*.@&M%>0?A,U M#&O&5)CH1B4[%A|VN/LRSO'F(,8X7=C,"*W!
<[J,D.R+.W^'9F[6X * S+AD!0G9.IN+(S[4\&:878]!CEAY:C^VSJ0PIX M37TP\!TKB.:L#]$=7"QVSTMP+-3<)$/0S.E1*?HS:VYY@<\D3B/+1ML?
D328TLIUJQ*M+MM9"YD7C^1A2@E/8@&$SCU MQL6N%7OVP,2& *%,O9IK=F(+T,CRO3GM*G3T'>;8UMP/,IC !FQ+T,CRO3GM<B2)+Z<]:8UMP/,IC !FQ+T,CRO3GM<B2)+Z<]:
%OP.R5M- MZN0+@X\95,./6'V]>O@.K5/:7>VXSSVJ1.=XI#E14/ ^2(>?ZAJ@&>OD@?L MY#UG98,((DB8(QXHME6K*&8!Q2!NFD4\,HC"SC' ,@MKGWP^I\7:-9-HN'N MMG?
PJ[&3[@13S>_\R#L-.JBG(&&0,.NPBA5"!#"; M@)Y948Y("B-6U#:'F^QWZ':;J#-*+]"*7>=BI.)H-=AY4Y*[K+URFN<:CGB.V.CYO$\E\,'?.;AI@,C'S MC.,!K))=W]W0"R#,/,"WM/66;38$;3.5' MU[-
LV\8%(<&S+3L*EXG6-]):DJ:03 5]O"O$$ M[Z/MQ)[KHDQAZ14=D+++=_OB RORO0/4PV'B8$[H>RO=]Z/+W<^G$Y!!SZ2-O M+Y0X-C T)\0YL*BOD.?!
[VTWT'@#!%ODA0$2JT(>"@WD:ONY4O.XXL>+O+&[M:1!:M@%OL:3<:2X6EY_SD_^'2G_0V=Y[OHG'.8%Q=5$ M0]M.UUZ/N,Z+T1O"G73V[\&Z'AZ3COC)0LQ_/H2NN6F?GFVM\,ABWG? M*J-
OE='0$/HL;2Y?71DY0.!\MS("[MS8]J. GMS8MGP<5L=;=.J0DE0K]KX0 MC__O5IQ29*D4Z7=FX"[J>P+.1M2NZIGVI*TGAP=":^?OT&G MIY2$MP?U<N0L05]S BVU-W8'GQ
MT#TT]5>H2WK)0RVZKLVT5-U:G$?)T-OXX5B^[^PJM4RWBU23,EY=W !NO+VG M%W2&$=5JVTDE+4OKK\ YW0V?L!*A'OB[JN-N+-MK]&V!O@?1*U?E])\I27 7 M)V[$F&'$(YK25#''Y?
LK21U YXPC)3=2IG6#RO>A'6[E6'0 7?8)'FV:6;2"'UV-U.F,7(G-)%E*%.;H00";<-(^2<#YT5 M0 G(D4/'M-RHG0LX[+9O);6>5,S$CAG^CF-%;@S=U75H>?,Yl6*;Y(F^%*#Z M R!P?IKC!./U4.*&-
@W6<7:XG-ZR:4UV2 G.BH)X:[ZYY=I80|LD:]NBK62= M?G9 NXV?3K!S_W$/ISOB(R0:A\2'_K:;BW5Y(?6"^))CU[.NA^Y:\Q[S]=H" M6). ^)#BMIR4:VF=2(_V+ZXD2+E/#/[
MKI.ZG7]O)6Z76<#2U%UN%"...$*V#49S,*A]"P$]\, <9K>>%(5C19*B#E4X M%]8H&,V'QQE#[D"!37K(*9$MGD:WE"K! H>9]FK(^ZC0P! ^@8D=S?K#84][MJ7)#-
D.UM&@T>;3RVV'Y<*3Z!"#*49B$9%+DRGR3%.2_IKE9'O#>]?:,V9"P MJXOJH5(^SA($O4VS**C_2DU;I5W)-*KSMCI,1441#D5CZ_^_L+7TT?T:,I:: MX0?A4%T'!&<>TL<3J19&?
7NPM#1C\LP'8*HT*:!G1_7><7$("(9-[99^]7)6 MJ_7_#XO2[-E3R@!$'=PHABS@*%_'7],=UP1C$5H:",XT.?.\W:6U-$F3)(MS@4OEGFN/8'>#(9#@H=DX@>'Y)NWMWO+
#2+)M,Q& ^49!T/U%7R;KW3]K(LT MB2/9T%946HFID/ E45?=z$?_O*3MGIPHGAH/=_?I%_4Z@PJ[6F&]?SH.)KB:,AUILU&^8%]*NQ5K=_MKGB">HT&X/U2B+I[' '=CJHN_@502P,$% @
HX0M6:,5Q107!@ %C$ M !D !X;"]W;W)K&ULM9MM;]LV$,>_"N$50PIT ML2C9LIPY!I+HJ4"S!76[O1CV0I9H6X@DNB05MT__*B'R)8ELS9V?1-+,N]W MI/3WZ7AD9CO*GOF&$(&^IDG&;P<;
(;8WPR$/R-0.^#7=DDQ^LZ(L#80$(E?+[@OU33.'-1!G@_FLO/;$YC.:BR3.R!-#/$_3&V)QP!GP=W0[PX/7"
MQWB]$<6%X7RV#=9D0<3G[1.39\.&$L4IR7A,.\3(ZG9PAV]\72L,RA9_Q63' M#XY1,90EI<_%R?OH=[5/2()"46!".3'"WD@25*09#^^U-!!X[.P/#Q^L:OE
MX.5@E@$G#$3Y.X[$YG9@#5!$5D&>B(]TYY-Z0.."%]*$EW_1KFH[-@8HS+F@ M:6TL>Y#&6?49?*UOQ(&!K]\PT&L#_=@ GS P;@/CR,#03AB,:H/1L8?I"8-Q M;3 ^=PQF;6
>=VERPF!2&TS,]6#5!E;Y=*O'43Y+.O#!:?_:H#K&BM:05!Z4@ M2FOY",.LT.Y",/EM+.W$W"8\9&VU!%=(;$A:)ES%8S=&43$<0)?XO>H#A#
MGS8TYT$6\=E02,^%_3"LO=B5%_V$%XP>:28V'#E91*(>>T]M;RCLAW+$S:#U MUV'?ZT[@3<)KI.OOD*I!!OJ\L-'5F[<]_7HX X.G-89O D9Z[XZ:\ABP:V3@
MDC)Z[0P2+.ADI.K!.6=TJL8U8SO=.5=-N\O775K2$_P?8SS=.?!\ZHG.M>1A M-+*H^0:)[B+?,GC*):!_!U:! DI?AH+0<-G],\'V12]%R3E__:T][[BCQJY MQ8OHAF^#D-P.Y)N&$_9"!O-??|&F]GN?
^"!A-B3,@82YD#_/$N8#P5H:'#4: M'*GH\$_R=$E8&92K?PE'WQ5!X5Y)NU1YD#"[#HU+6)V+O!W+4T,FXT,E9JY"X,\S1/ D&B(F&+PUCT24,)N50:D#"[#IF'M]'

;FJ%;[78N9.>\,SOG SEM*68GBIA32SN.)&9';[]A:VIH3;.60B:-0B8_5$@8 M\ W*N8P2,H^7\UX6B#A;5Q/'6,2]J=>]$GNI:B!A-B3,@82YD#!OTE'-9&1. MS"/53#[JF6!C;/6+QFI$8RE%\R %\ZZ2#?
F2QR\R!\X$1W+V)R>?[%G."Y.I ^74B89W64T3< \AG2T'31D%3 MI8(^$9:B#S3(^J2A-+U4&I P&Q+F0,)<2)@'"?.!8"V986U?P-)^TER]!@/) M$)1F@](<4)H+2O-
:3X4K2W&@VHJ5D8]FRR%S+&X8'DJWYA(R"C8*STEYF+I M0=+L'PQQC+Z1@/6]\1W0?KB@- ^4YD/1VC+3]S+3E<^@#&PRSH6,1/U3?C7@
M8H%!TNR:=IA_XG5!:=Z98_"AO+:%L]C8V6)G282NXJQ>WWZ+OI]> MZ;Y7N[A8<*!E>E": TIS06D>[I;J.RD=D,.VUO;E?*RNY]LD).7*\.OMS+^: T&Y3F@-)
<4)H'2O.A:&T5[M<'L/6SZLA@,DK6I75P:S6K:8?9A&8:F==)G&]2O<[9?%]2O M!TKSH6B5G(8'FZI3PM;E!GLNI9)GHMI)VEQM-O'?E5O7CZ[;^,;%/=<]?.-7
M6_3W^.H !AX#MHXSCA*RDJZTZXE\,*S:A%^=*+HMMW0OJ1 T+0\W))#I8-% M?K^B5+R>% Z:?X68_P=02P,$% @ HX0M63^+HF)" @ X 0 !D !X M;"JW;W)K&UL?511;YLP$/XK%I.F3:H"
(6DW98"4 MM)NVATY1JVT/TQX<.,"JL9E]A/;?[VP(S:0D+XG/ON_S]YWO2'IMGFP-@.RY MDGNT9L{}3NLG%WPKTB!R@D!"CHZ!T]\>;D%*1T0R M_HZ2?Q0?=?8?1S[?AR+:W_ M9?
V8&P4L[RSJ9@23@D:HX9_CW4X L3Q&4 \ F*O>[C([SCR+/$Z)X9ETUL M;N&M>C2)$\H]RB,:.A6$PVS#K;!,EXR>U()"[FIU19%0N6@E^+-<*ZNE*/A0
M2%4P*RHE2I%SA5387'<*A:I82UFY(-*[.T NI'V?A$@JW5UA/BK:#(KB,XH6 M[%XKK"W[K HH_L>'Y&ZR&!\L;N*+A/? MQ1G>]:OO[<'W[_7.HJ%6^W/*^,"W/,WGQF]E6YY#&OC','L(LK=OYC?
1IPMJ MEY/:Y27V['O7[,"XUZ2!-MS+'FMA3VD=V*X]FYOL?39/POVQ@/"HZQHPE9\M MRWQ1A@:<=]?Q70]=^YH^S#X]426491)*@D:S#W2O&>9I"%"WOH=W&FDB_+*F M3Q
8ET#GI=9X"-P%TT&ULO59M3]LP$/XK5H8F)Cc&2IFTH MK*U$"].0QE:5L7V8$]DU\8BL3/;:3MI/WYG)X0&0C2FLB^-7^X>W_/.1WG;F'.EK$V"^YXF-$E7(&^
MSF829VZ%K4N&*"$PF+D7/..9EV/.-@+;XR6*NM,3%4;H2X-9.+:.1X)B)(M(-0&@N)G!5-($H.$X>GUU1O;WWI]PCCY$HM< MH9L:NAH#,K!N6!X^*0[WGSB\2RX%U[$BYSR"J.
[O(I&*C7_'9N*W EY2>4BZ MG0/B>WZO(9[IW[MW6\+I5N)V+5[W";QY*>]"BI2<;$13A,RM5D%2;Y_1'MR MH2%5/YK$*\![S>#F?I^HC(8PCC<^F"!Y?C2996L-Z;D7L"RFX'&EX/%+WHSC7>JP
M([":#AWOOMGP=GPWV@&?R[Y$:[YJ!2=WJY?"[QMBZE(*'*NBT:D6JW:V%/; MO#U8GYCVUO9H]S!%;XQMQI)Q11)8(*1W>(3/MDS:S6*B168[MANALA43L,,86
M':0QP/V%$/IN8@ZHFO[Q'U!+ P04 " "CA"U9?F[M-.D" #R"@ &0 M 'AL+W=O,<"A!J6)Z5B69Z8X M)H8_T&<3Y@]H+I*8P(0AGJ-W26I4]U3]?6*_9,V+\W<8PYCFGR/0Q$-C9Z!0ICA/!'7
M=/D%2D-=Q1?0A.M?M"QC+0,%.1>H!3 ISG@,X6 M@%L"7&VT4*9MG6"! 0&C2\14M&13"YT;C99N8J+*.!5,7HTE3O@31L,\$+(B M"R Y($Q"N>;
%L#1!S0MJHOH#*TBK\O(W1,0.$[XG@R[G9Z@W9T]M(-B@FXB MFG/)PP>FD K5?3J@3_B&0Y@:&1E"0W__3O;LS[6.6^);",/G2H/G2;VYUVW MCPB(.L,%BZ=9U
MIX=N]KF&PE78L6+K_:,>7459]+_8J M>;U&>=.O=].KR^,Z18W UY:@);(-C_W*8_\M6[']9AY:(MO(@VT]?9"M5IJQ MI/%]^ZPP4A-2\V8TUZ8'F>NY'JHX"FA.1/&EK4ZKP>U8CRO/SD=JH--3R1-
M,0W*[^@\)APE,).4UL&A?#I8,6 5&T$S/:/<4R$+KI>1'$]!Q!Y?4:I6&W4 M#:HQU_\+4$+EZ*L1I (%<& 9 >&PO=V]R:W-H 9965TY\]V1-%/(]Z@+ D*>2"SWQ"F.J
M&] 760$EU5>R H$W:ZE*:G"K-KZN%-#<.97<#P:#R"\I$UZ:N+.%2A-9&\X$ M+!31=5E2]3P%+IN)-_3V!TNV*8P]\-.DHANX!_-0+13N_ XE9R4(S:0@"M83
M[W9X,XVMO3/XSJ#1!VMB(UE)^6@W7_*)-["@$-F+ +%SQ9FP+D%0AF_=YA> M1VD=#]=[]$\N=HQE137,)/_!' X<@..(0[!P"I[LE=HR!T>80W(GA2DT^2ARR/_V M]S&*+I1@'\HT.
EX1]45"8>7)!@$(_)P/R?G9QK"&)U"3Z>44Y'A"QLRAPS*%:A]ML('K2U:Y-'I:L.V_3<1B- M$W_;HV'<:1B?U(#5MF6NGW&<68)W9XNHMG19F?$> >QM>#^?O^H(X].D]-GG"9&
M^YF"G)E>WN@$[Q'2N".-_S?K6)]9T15H'WO*N7OAZ-_4^X?-#O6X<:--$TR M60O3]GUWDV-VW98O)BW(Q<5;9C0A,,:70=7,0:NVC'6;HRLW.A828-%[Y8%
M3GY0U@#OUU*: <82=/\EZ1]02P,$% @ HX0M6;F^1)O_! 31T !D M !X;"]W;W)K&ULM5G;;MLX$/T50ELL&B"-3,J7 M)&L;R 5%%VB!;-)TGVF9MHE(HDM2=@OLQR\I*:(4RQ/+45X2R9XY.C.?
WW$P][S! =\N=+V W\Z M7M,E>V#Z<7TGS9U?HLQYS! +%18(D6TR*WQY$Q#KD%G\X&RK*M?(AC(3XGO M_#V?>#W+B$&4UC1"FG\;=L.BR"(9'C\+4*]\IG6L7C^C?\Z"-\',J&(WOJ7
MS_5JXIU[:,X6-(WTO=A^845 XL7BDAE?]&VL.UY*$R5%G'A;!C$/,G_TU]% M(BH.N+ '@10.Y%"'H' (LD!S9EE8MU33Z5B*+9+6VJ#9BRPWF;>)AB=VE&1^T M--
]RXZ>GGRF7:$.CE*&8495*9M9(*_0)W;-0R#F;HZM8I(E&8H&NE&+F.YK, MT5=.9SSBFC.%ON6.G]#CPRWZ^.$$?4 \0=]7(E7FZ6KL:Q.[C< /BSBO\SC)GCB_47F& M
GR*2(_T&]QO8/=;%I;N0=W=-QDOTT[*M),,+]B#EV?RLBF.W+'?[&B[^E*M M:<@FGFE;Q>2&>=,_\##WE]-474$5HLFQ*&,,(/3I#56KK%9"\>\%^IMS4F5WA
MIJASJ&$&9;>>S91@TNN/QOZF&D^#&<&CP: TJS'METS[(--KEK %#[G9QTR9 M:69RH6V]+,@:F>?0@PHE;)B X+UK-!CVFDD/2M(#D/1WH6G4 M1&BP\RR"
SQ\F5PY+5$&3U>/9PAI9BPV1BNQD9*4C"WTC9ELYW M"UL16F8-SYLS"CZA;0=T!%9+QJA,QNC8+AJU&6-'8+48S\L8S\$%-QOKD]G4 M9Q&K+')CR.<[!?>R2R"+&KF+DMP%2.Z?
5&C3OFMIF]=V=#XU& Ci(T>?64; M%B%\TL07A&Z[1!V!U!;* >T[D>\<68N'949A=H=7CK PSN#O)*; &KVE.DQT@ M.MC- !B4W[?)3H$-M1-H4N?L-!W#HKY7=0J_U[/98
=ETVDXAD7\X%Y' Z$N M5 JFT[IQ.D*K)\ -$GAP] 8!CB&MX^P(K1ZGFTXP/)X^3+C9%*C]Q:573*(QLVG(*/-DG;I*)HVJ!>.W7J[W&"VPFRWP^=%E M"8XEK>/L"*T>IQM3, #RGM-.MB]!
[8JU9D5]-W^$ F=3Z57_VPXK?J[HYT';4^D#A/4X4B!L_2'#TN0DXN+2. MLR.T>IQNF"'P,'.X3I'=HX6=2H9,Z@3=P$#@TX=]):?)WBH.&C4*QFZ]5.\Q M4A W4I#AT279Z4E&5VCU.-
UD0N#]I)5&%5A@54(F=8YN7B#P8<3;-&KW^*'A M)*.!:N]1'G$# ($'@/U"M:OD3:1VK?:2"ISB![#B']SC'2D53*=MNW2%5D^> M&ST"?.RVS[(!#2^LX.T*KQ^E&F@
>:0Y7J@)M".P)H$E.T*^\Z[(OKLWSESQ1 M*&(+X],[&YDFD/F[N_Q&BW7V^FLFM!9Q=KEB=,ZD-3#?+X30SS?VC5KY!G7Z M/U!+ P04 " "CA"U9'URP\;8" "- &0 'AL+W=O. M8-
5@9IO0[:^?;0A+6DK;J7D(_G'?=_?=B3O"AO$[D0-(=%_04LRM7,IJ9MLB MR:' XH154*J;C/$"2[7E:UM4''!J0 6U7<<)[*3THI"B @$(B-0-6CPTL@5)-I,+XU7%:O4L- MW%UOV<^,=J5EA04L&?
U.4IG/K4\62B'#-957K/D*G9ZIYDL8%>8?-:WM-+!0 M4@O)B@ZL(BA(V3[Q?9>''8#B&0:X'+:6K'IA4FF02OYI-1EOY$!\'DK76Y+%;T2VETJ_3Z4_QAY=
:;D#Z1()5$,I:V%!P:NV^(F+1./Y3Y;17.1U5>5Y*4*Q2]=X$R :O* QI;4FF.TJ\ 27+45^O M+?[T4?8>^-P3'/2"@]<*/D(-)Q*.698-%CIXMM#/6L2C0;VVQO9.HRZ K\W
M$RAA=2G;SM>?]C/UU(R2!^>+R6S9CL9_-.V@5GUM34J!*&2*TCGYJ*K!V^'7 M;B2KS#A8,:F&BUGFZGL!N#90]QEC&PO=V]R:W-H965TLFCJ)-A @5!U$*NVJ55HE1-?NP[0/)KF
5T_WYG!S*V IKV M)?'+W>/GGCN?QVNEG\T*T<)+(:29!"MKR\LP-.D*"Y;.58F2=G*E"V9IJI>A M*36RS#L5(HRZW3@L&)=!,O9K,YV.564ESC38*JB8/IUBD*M)?SV"[,"7)E MW4*8C$NVQ
>TC^5,TRQL43)>H#1<2="83X*KWN5TY.RJP1/'M=D9@XMDH=2S MF]QEDZ#K"*' U#H$1K\:KU$(!T0T?FXP@_9(Y[@[WJ+?^M@IE@4S>*W$-Y[9 MU22X"'"#G%7"SM7Z,V[B&3]\5
GCO[#>V'8#2"MC5;%Q)@8%E\V?O6QTV'&(MH@,.T<8A\KR;@SS+&V99,M9J#=I9$YH;^%"]-Y'CTB7EP6K:Y>1GDUO&-=1, M5 @%,E-I),6M@3.X)<&4YG()5TN-?AGFF"J9%"7F/.5,P)VTJ-%8.
$NX>M*58:\S3BT%)'C%:8; M]M.&?72 ?1_NE;0KXP[&[$__D)1HY8BVI]L-X/'A!DY/ M/AS![;C HJT>*J42-5?9/O(-?.SA M79>IDV'<'8?
U'D[#EM/P**>V&O4KU>"F'-6"JE522]@JK6;2Y*BUG]:*4SWO MX]8<,JSAUHLO#I"+6W+Q47(SK5+S"N50&4D9K3%1&O_TPJ?D/JK->+#K : MM:Q&_YE&I*M_-(&C-PG<0R?4OH M&E-
A&1"8DVOW?$12Z*8 -Q.K2M\3%\I2A_7#%3UIJ)T![>=*V>W$'= ^DLDO M4$L#!!0 (*.$+5E%)70K?P(,$& 9 >&PO=V]R:W-H965TV8V03ZH"T.BY9EQ-O4KKYL+W55%! M3=2I:(";E:60-
=$FE"M?-1)(Z4 U\W$0I'Y-*/?RS,W=RCP3:\THAUN)U+JN MB7Y$;.58F2=G*E"V9IJI>A M*36RS#L5(HRZW3@L&)=!,O9K,YV.564ESC38*JB8/IUBD*M)?SV"[,"7)E MW4*8C$NVQ
>TC^5,TRQL43)>H#1<2="83X*KWN5TY.RJP1/'M=D9@XMDH=2S MF]QEDZ#K"*' U#H$1K\:KU$(!T0T?FXP@_9(Y[@[WJ+?^M@IE@4S>*W$-Y[9 MU22X"'"#G%7"SM7Z,V[B&3]\5
GCO[#>V'8#2"MC5;%Q)@8%E\V?O6QTV'&(MH@,.T<8A\KR;@SS+&V99,M9J#=I9$YH;^%"]-Y'CTB7EP6K:Y>1GDUO&-=1, M5 @%,E-I),6M@3.X)<&4YG()5TN-?AGFF"J9%"7F/.5,P)VTJ-%8.
$NX>M*58:\S3BT%)'C%:8; M]M.&?72 ?1_NE;0KXP[&[$__D)1HY8BVI]L-X/'A!DY/ M/AS![;C HJT>*J42-5?9/O(-?.SA M79>IDV'<'8?
U'D[#EM/P**>V&O4KU>"F'-6"JE522]@JK6;2Y*BUG]:*4SWO MX]8<,JSAUHLO#I"+6W+Q47(SK5+S"N50&4D9K3%1&O_TPJ?D/JK->+#K : MM:Q&_YE&I*M_-(&C-PG<0R?4OH M&E-
A&1"8DVOW?$12Z*8 -Q.K2M\3%\I2A_7#%3UIJ)T![>=*V>W$'= ^DLDO M4$L#!!0 (*.$+5E%)70K?P(,$& 9 >&PO=V]R:W-H965TV8V03ZH"T.BY9EQ-O4KKYL+W55%! M3=2I:(";E:60-
=$FE"M?-1)(Z4 U\W$0I'Y-*/?RS,W=RCP3:\THAUN)U+JN MB7Y$;.58F2=G*E"V9IJI>A M*36RS#L5(HRZW3@L&)=!,O9K,YV.564ESC38*JB8/IUBD*M)?SV"[,"7)E MW4*8C$NVQ
>TC^5,TRQL43)>H#1<2="83X*KWN5TY.RJP1/'M=D9@XMDH=2S MF]QEDZ#K"*' U#H$1K\:KU$(!T0T?FXP@_9(Y[@[WJ+?^M@IE@4S>*W$-Y[9 MU22X"'"#G%7"SM7Z,V[B&3]\5
GCO[#>V'8#2"MC5;%Q)@8%E\V?O6QTV'&(MH@,.T<8A\KR;@SS+&V99,M9J#=I9$YH;^%"]-Y'CTB7EP6K:Y>1GDUO&-=1, M5 @%,E-I),6M@3.X)<&4YG()5TN-?AGFF"J9%"7F/.5,P)VTJ-%8.
$NX>M*58:\S3BT%)'C%:8; M]M.&?72 ?1_NE;0KXP[&[$__D)1HY8BVI]L-X/'A!DY/ M/AS!

8#1\!U$832&A_42+B^N7M($UD;O)>J] M1)YW}]>%B^\+)G.N-2U0OAUL]%&V8,X?4I\6V1\NH@;DKFN:(8)L5.@4>V1 MI&_?#*?AQS,61KV%T3GV] O.#H,*%9/Y*6WGT2-X1JKT&1WC7L?X+-.J5EGA MI&3_[O24GI9EZEG<._3R71V_2$.]L?%@Z/^=*-N&V#'A-.6XL+![,) =6. M3QL862F6W4AC!\ O"_O'0>42[/E62G,(W!3T_[#T+U!+ P04 " "CA"U9 MS"4FEZH" 6!P &0 'AL+W=OW8K+<+OC'8JITV,9DL MA7@RG4_9U/&,(>"0:J- \;6!&7!NA #&KU;3Z9 F<+?]HO[!YHZY+*F"F>#? M6:,SJ1,{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{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{IZW5R?Y-ZP/EWU^M_]*HYVJ^IB6[R9?_-MSN:5XL,DGGAS[HANEA]5]_O(WUBH*:GNS?%DV_WHO[5A_XLVV996OVH/Y#%;9 M>O01NAN9HVELG]JO;XJ\A>OJ$=S;_4O MC6^:HIF:;%V?QX>]X/^;\>.]ZWM65FG%^)FIO/S1NRO8!I3?U'O@%-=\N67W0S2)=/[']2RI9\3#[IMLB7<&/^_7A9^_-3Q?>3_7H?RWX6Z7K>7EU67$M]8PN9^V\ M/^WFC0WS)MZ7?%TM2NIV6?S[O&7W =[>'1?1WS"H,$O:?',(^BMAWU,-?.Y M&7\X :9#]N>%-/:(P=[G]8S?E6BGK9;?[+-HW__"DA7/;'+JYS^AT/^KSA&.C'7<0O=NH9#UZT_L*5NO ML_43OW>7_+KD_N%>*1TYVN4X"CB8PJ$RE;[30^7T3%$2Z*<;[:<:@5-M[A$OWS1IHKDT//:= M%;.LY#,>N%PB93[|&8/O?>!E$N^5Q:"RVU9&?19*2:76^: IVWL^5OP2Z4]2MLI>2@%+NML5LD;92FO/!+R,>U;S;AIL[G1S0G*V<1)&#L4$0\D4FI4%)=<)L M0A*7-,M7J_KJJT^2-KF!IFSEM-8Z48[X.$$&21(&J=:D?-=3/Z"lVZ@=>4\YB*DA2"$L)HS!"?^S6O!KJ)YJP18U;3XS MGC;Y:_U406/69P$KDI*8&A0)#D!@/KW^!V=Y0 %1G#T-D]A7W$W4*R1.B&^8 MG4C'",['G+ZDK/7V]58>B+)(EY5)$!,U*\/O?V"\12(O(S@Q=_5IM>CR+?)I MV!>BCL.)3F!%(C$C.#,?+,+-0^-NJB'(^WOLH=6>NJ%;D=16?D8nOHF]>N M.04;($"'"*8#:S9&:E8WP;%?:F(P3W+EAN],6((!@$AC%OJV-+OSZ07^6ZJC8 M%..PR.L8SNN#Z#OD9ZRFYQ@AULYO&X/V%UB"&# M8Y'!,9S!CZ%WV+3M[8S5?&Z^WK%(Z!A.Z#+YRIC8\B|:,9;Y#\;:/VY>1V_X MO>&]]>GX8M -3A_WL8H.(7!1"G3 ,#18/P' !JQE436B&"0)6L P+9B> 9/ M&&C66EF@/MW4%Z[YG G6P#!KV#SBP*:L1:EK"=@8V@5-8'BIX#!\Q>HJ@0E? M=4/]D$3R1#Y'@^L!@RR:6N@FS41Z<11,\H/#0\N6.1U#.?UC_-Y5@?Q=.EM MTFP^Y3Z=I9NL2I?;J3HOG=EK;MT*XB!^.=4"@8GZMV3OBX(XA@/8GK4D=8$"X] @2N !.0P/M'J<(@%1D0#Q;!4: MB(<((" P$!RR0$C417_-]%FE'F!D{B,3VPROG9Z:LJF-$0DZN=-W4"'"ZR=H MPR1%9B=P9O\XFVU7VV5:AYQD. !$G.F4V= M@H8K:]W-4 $:%%Z;&)5-J;JL,$51TL^ENF'4CPR82D7&IW#&MUN2AXW9GAZ] M\H!%Q29X*-J P&PS'$*I)\ACY?1;0#2-^;$@T5, A6% CA]SHC-LDH[2Z<8 MX,I:5[-4&$#/&"6H4YQP9:WK&L$=U$%U

54184IQZ!.L7+6ZD3Z-*3)LW%.¦ M$Q3&"7BSBVJJ!72;79IQP&87%>Q CV6'UD!G.XX2XB."^W-4X8$[$2-B6M2(51 P/ M,8&

D&#\/L>H1WC8GK4D=57"6.,3",H(X'4)FT=XV)2U'DW-!%#C$TBEAS = M'/((#YNTEJ8"A?E1/Q P$< P8??@ 1NSEJ0BB/'!(Q $L N,1?+"U A50 M,,+4

%&!H)/@V%T+V("U#G5W@P0T,@H1O!$,[&¦H,QU#&XNP/6OU*J; -3NA0)401I510 G;L%;# MU7(4TR-=*" EA""EZ-H>V+ZU2!5;H J@4'!+""/+8>7[3@$F5 LN3)|)$.P2 MCF"7 XN%8-/6ZE2& 6XTZ5,7,,,JZCH&[9O*(0Q"AQ8+P6:ME:F%G7"Q4"@ *80!R>99"39E+4JM S46"T6" M=")X%>6P8B'8J*VR2+.L M<310)7(AA7ALD<-F"M1:T>-=<=18)-(IA-C%QN M5Y $OXNU5D?6NCX1F!.=\¦.DD5/F<66MZQI!1A%,1J-0%K9AK5A=RJ$H#HT; M?Y'@H0CFH8,P#[9I+4ZS.V2L;XH$"$4P"%DMCL*VK!6I3&-81XRDCZ@ZYAG8 MGK4DS>*.J;X!$D03'48T6CU.*2;2?)(%[&^*!,-$,,,&;9-88$L,8XLYWQ¦106_L;4'"%GKNDE@ M48S/B "Q4SIR9:WK&D%',,P(- H!8!O6BM6%'J#8*A8T$\,T8[?G 1NSU]1B MC7'/(Q9($Q_["5S8@+4*#;^8:[)B 3 Q##"CPA10K 6;MU9YBD_QQ@)_XG-^ MBC=VRD:NK'5=([7XL/P4KU:QV^8>*CU-21*'@6_"#,%/,'5'L^JN¦!3[._[T8U@* M/MA:@\!2U-1-S) <¦H!V+4@,6[#NC^R>=@JZ0CR5?GI.O7M_-F7M.05C(EUK^9,,-=C9"39H[P&5N$Q!GWRI=YSO M8.MMP(B!%+4,R2A%:A/GVU#7Z#YXL%5[;2]+&;5),>7\@:VW$4';,8LY'VH< MV!,A=8[SX3TW9P%[%& .S,;>)R=I+N=+W>7\^*PQVBES.3/7SLB1CMN=HO4>FRC#HET!KK='K% ;2KN.HRPX7G:>^L414Y([M/;-LH¦ M4_1VU9;WU3V.S/7<(_;0)_?

D6'.+:ZA\;@FMP,>Z_<\)A2XQ36D%D@9=4BX M!K?+/5$H&,=NCOL"GZ8QL-P9&)V5W>'!&Q/;N.0FI R1V(G;0@AHW8JU9Y;6JJ

MDT12MVC!T*YXO/T/6I{#O>Z_9L#0KD8!MH&WQX1' IO+K,#Z IV¦OPI.LP$E= MEQ$^ZPJ>R6,,#LJGRL@N8S5.5^9ZI'H=*!S],B MX)8C-=VDC3>2!(=']Y$>L&"O0¦TA-

>J0*&Z@X;23@-!68!X(!6X)\21=K)'4 MQAJ=M8\UNZ16&^@B_?(0.86X30-QJ<8(VRZ920V&^CQ/13'W$*9 MK@VX\;Z7]&R@!_B8(.:6RHC:*6N*4=37\-M_^O^B[X_-M¦NW?

O¦I_H+P)LOL19F=M\>_B4M^ 59>DOVR$WZ[^K/%!>¦[^/> MO:CR3?.5UE_SJLI7S:\+EO+;N¦[__\QSZO7%_4;[++\6 ?K_4$L#!!0 (M *.$+5DJ+A "QD (. 0 9 >&PO=V¦R:W-

H965T'QOOY75U_JA*)K@^VZ[K¦I=/#3- MXYNKJWKU4.SR^M?RL=8+O¦R7U2VQO{.5EZOZL2KR=7?0;GL5SF);U2[?¦"N MWW:_NZVNWY:'9KO9%

[=54!]VN[SZ\;'8EM_>7<+#%Z1>?-E\>FO875]=O'_,O MQ>>B^?OC;25^NGJ.LM¦LBGV¦*?=!5=R_NW@/;[(PG+5'=$W^:U-\JY5_!VU? M¦LKR:_O#[^MW%[/VE(IML6K:&+GXWU-

O4VRW;2AQ(O_HHUX\)VT/5/!]BOY; MUWO1F¦N\+¦F¦*[7¦OULW#NXOT(E@7]_EAVWPJO_U'T?=HWL9;E=NZ^V_PK6\[MNPA6A¦HI=_W!X@QVF_WQ__GW'@GE !$'/R#L#PCU

^(7#HCZ Z*Q!\3] 7&' MS+$K'0Y9WN37;ZOR6U"UK46T]A\=F-W1HON;?7OA/S>5^.M&'-=ZNV/X/>Z/A3KX+?-/M^O-ODV^'QJ6 >7P6=Q!ZX/VZ(] MZ":O'X+?

Q"U4!Z^RHLDWV_H7T>3OG[/@U5]^^?X2;/;!WQY$U'R_KM]>->*T MV^17]_X4Q/QO,7SA%*/@CW+?/-3!Q_VZ6 ^/OQ+=?>YS>.KSAY_^$=>_1!$ M\#H(9VG&,G,_-

^-,CY["_/CPK5B\=/NA-!'P%HRY>]$*\#OWI#OW¦JMP%8DZH M\F:S_W(<4YMF4]1O,-2/86.\;#OAO*D?\U7QID+,*'51/147U__Z+Y#,_@V# MC#-8QA1L &?\#&=,1,_^JYAL-

_M5N2LPS(['}MVQ[9SZ=\V9+-.9N(N>5#3, M9I NH¦FP54:>R,1NSI^[.2?OFO?K_Q&3RW$T-Z68PE>E&.5B/.l%_U¦MRUH, MX2,,[9_;7Z[:^^Q0BRE!#.?1-

¦F<\R;C#)8O!1N@GSR7GQ W65:(H&)2/3¦Z M¦NL@WY55L_G?¦A<8C,=P<_6&FL?)4KOMS%8)+$+MKB//;&*_%_]7¦M#4 MJZ^7!7-Z'8A[2¦"7^HA!\;W]-

SKD%D:GHD4'6L_-1O-HJ37*R'.;V//TN>*NJN^+IX$¦WKL'KXJ L&K^^Z!6P3;0L#T"X9(;G16FUEN MS!80QSH)4_B[B^K'T&?!.TU&%W2!_<-TB:F0[/2?C;BNP;

[<7W9W_T;P.9P0A^8U!,-"FXW":*%WF#RAJ1V6W!1(MKG;|V<?|+BI448'M14535<5^J4,,I-5#OOJ2!&+X%S@&D8G!8K'004!;P2S5 M4?#!*$%22HAIBMYUM=:

(4UT?@GRUSX!M9&_;;%¦F4<#$%'O(.*-E7-&&T$H: M*R1/N2O!ZV.^69)\>'$<¦XVZ8'0%&9PC-TTT#U/¦U?+¦.14FZU.\N'U02))<$ MFDS^?IU"T:Z;G(/R

**>E<[RG2;!Y%.F6@SV1J3R5[!)H^_OD|>*IV.:=]=HJ" MA+K03)2O!\EDF<9#U0?'!$BV@6:9[U>K\M"6=(_YC_QNBS],.7(XUXD4UBI, MC.[ZX) @2230+%)TMVK7[)#!KTRI*
@F412/C7"I5U18NT4X2W0VI))P9F&DK[31)SH5", DK0YI7GH"H M6R1V>?6U:+]'2EV(*N[E$68R26.&0<@F+!.]P,WH¦YO:?\DV0YIMWE;E]BC6**

M_=#:Y4W?:S*#68:2688TLQR"T;Y<,>)@7[1$FLS3N;Z" M0Y_G5!PDY0QIR[G.#H)NB;I^TW;^Y1(D-!FDT7&$9*.)\:CQP3$CR3$CFF.: M-X#CTF5D7[H$FBS#I?

$&@6]3[4A(+QJ+V+S]V<U[[U?O- ?^HQ#-A.&/ MQH([U@[F8:K5EBDJL",D"6QS$]CG^4F=E;.1B6)A,M,D3F(C6>$:-MYY_?"'<$(56;#+E*$WT21E!!3'H M'(<^W:D?6=+IF%[)I>

PYIOG5Q[=M@([3.;R;KQ8+O57GUBS:&E1+Z [,A4H MR9%CFB/_K6P$YSOO<1Z;E!>=C+%VV&3?O0-.ZML3*47>Si?'A^WW0:L MOL]=Q16L-

_5J6]8'T55C$5@@,+H4BUF7A%FC95S1ALA+1AV/6Q*NK6O"@Z&: M:V]CCSL]M7>6Z*4PV;5>BR!-P-B80'=K*FR2'<979?GEZ#MT]64>^&8Y-\MWQ"WR& M-

+L,0:_QZ'Y,Q4DR]}A>M>Y88[=/;GWH1Q@#'U]TD%SVNF?2W\|"W.%VG@\ MFDWT=5OZ)*<*"B1UGEMV2=2JO.E3\5A6C:KG.G:7#N2L6N",EG%%&X(HF?H<

MG%9ZQPM!F"AUCREGM(PKVA!32??G--VG)4?TP<[(9N&(8SU)4RN1$-$)*^? MTYJVGZ9.8M7 L4,+N*(-+X&L-N8DIW:7*-'QG+$TU]IAENI/%*Z<0XP4#1U=

M%TR1,]$AG6$RRP!$^,25(!)N>N1(.(9)%P)PN LX25-&QG<%"B@%,>|65=8B8+ ?F=#G@HKVB

M0SD#A%0)NNPBXTHVE,:*.B&AZX2Q(BTZC"LR";8&KR^WD3RXZ8,R5?"2OK9XV6<44;0BN+@\2V.6:"Y(N,_MZ8PGLCU\&47Z^S*N1$.@)(5/-I/"L/H8YT!0;,&1'-

J2T3&E70(B.3K"&3/K[O.,*^$0+TG) M$YJ2.PK7Z&C.|& ;T&BN6C@ZKC-6R';V-$DBO;CCRCI$2_+RA=M.]=&*N04K(6>-EG%% M&V(["?G"0LC/4.9C-KREH'L$;+N*(-

M,97U0DK7"_RZ0CJA,!AF(;& !N%*.$10UA#!!#Y!G@1Q2D8"0NM77C*NA$,(M9 MN;(.D90U14K7%%X$CW1.9R21-P68+)(KZQ!)666D=)7!+(NDLSEC:!8=J%Z'-M*^L00UEVI

N2XK"+)U/6LH0U6L85;8BU\@UNNXQWM'B2CN6,(R+EQ2267%F'-M",E:);5K%0XA)IW"&3A$>F*-KER#C]F+NN4)?UJP]=@DT[M"N?2?*6!Z3JY MD@[QE#7*DJY1.'2==

IGW)#/BV-/$ZZL0^!D:,*D7'VIXUH@N6I4.KPS7LBGBW2\?)0Q2UG&+"VJ9S%LZ[Y8[,9R<-N-]3KX6%7B MIYM2<,K.5O%U(J5TP?\%F]SNX^ZN6+?

3YWIVJY.HM*Q%$&NTC"O:\"HH#D;T M5X\F\%7K/41:[2.*YKFC,2:(I&5%*V%M1SMBMTIG+9=9&[87G"EU6!15))F

MM.SZ9PEB3^?!!C"K3ILMG'8=0N4ZV+ZQ[ZB*M01T¦]1\M3,'TZ>%*ZL&E.+[M-*/+H2G26$M,=ZRLWSO-V%)]0"G64#.Z]N$4QUIRN0.(O- Q?039LFH8*AY0

M,\L73[U%LI.0IE"9)OOB/,B658-*\8J.T77+F>Z#K)7)*1PJ0+U83LT4SZD9 M79TX6J72L=P!&N$X9O52 TCQG)K1YHN9ZRAW M02ZKU1,ZB"'!8E:,^GJ\:K#*^US>HX5(;.

[*R"D/9V;=Y,7TJX:MUJ<6\]5 MB%KBN^-F,GC3WI MJ0:,0N M;J^.0E%+.'>4$%.#Q/A\'%M6#2:%M5NL8L>(M12TQW+$9P=;]&,2J#K$6B]C)T$(=9Q$R%+:V&F$+AP6VA?

{1D%+AL M84^(\7)W+Z.UH+C6@L6V]BS=]"6X,]B(NZUQ*WHQMP7%W18L]K,3E*.6J.Y0 MV; ^^O)92@TKA]18W7!,EJ"6).W)V809;2@TYA>9;S'7/U8Y.XKN#-F(9WXL/

M+RA&OS"[TKJK1RT!W5$R:,^)DA?.KUCK@LU;!USI]"6!.VI6IX6,+:6&FD+Y M+4;\3)22QIW[$:LWGNO\ 7%PQ=*6EXQ64$*7(:{)I18A11LX31@E3K"R1"8 M0T9J@>.^(CW

U[+%^Q@4)V.PN!\S2TLMZ=PQ"&&3>#%*!L4I&7JCX9)L+04N9^,3BISA M,K9P&N!*>6-Q7G;2EUI"N8,YHI3Q8L<,BA\S6 R9.?2EEASNP(VH8[QX-(-B MT@P6EV.?"E-+;G=

1[P'\6+H#(JC,U@LG3DDH8<[L"_J%B\>#V#8O8,%K=G MSQ)3X#5_Y@V7L84;P[_X/X% /IGZTPMY^-)/1"O:>,>YTJ[#:Q41!8 ;@\!* M24M*=QQ'U$-=>;*Q!\;$&FY&U1Y6D);

<[H,@^-+/(DRVKAJE2&5B\K6>K_X[[M=!4E$8XJ;Z'$&BVC"Z>AK]14%A/NR:H_X/77Y@V7L873@%5]?XO'MD7XQV5E M?4/(49@;NA8O]MF@^&=#

[ROJ3U?]\5I]\X;+\)¦UT$IOBS^V^Z]/RY?[!.@ MR,>|D?O521TVEN'&#Q8Y[DNB/RQK[!-6(&L]+&S-F%?UQV6]? #1? M]¥@

>JF"%"MOL'AY3U"\¦IZG*1.'DQZP;%K1MHZ^HSY7Z\GMVG<#1B7DH6 MQ8L;+&;<3G(_7F]NP,RYH[FQ¦V+.3T^/5_SQ^FN?PM$WD)<*0?'- M!HMQ]ADFF9;0[GB-V\/FQ4(;%

]MZ-VGO2DD>1VU><-E;.$T?)4BPN*^/4TA MR>NS#8C1=IC.S)O1"]-7W+;!8K=-*R1YG;4!L=;^1.=[+[Q>,=@&B\.VNT:2 MUU8.$%]M\]fQ0NH54VVPN&J/DD?RVFD#XJ=M

N:%K"M^VF QU#Y&\GKL0V(MR;8!EQ>/;5!.ML'BIGVV,);7:QM&F&VSI=1 4VA[,E;&/>[E 1W.':,J>ZJX M4FH8*;3=8IP[2A/):Y0-F%,V¦N3W8I4-BE9VT ,'2-M'R0MH5

M(VU(+*1]LB:2UU*;-US&%DX#5F'K%O?M\S21O+[<@!ASF[>B%\]NV'*#Q9=[MHB:2UY0;$%=N$RHO/%[QY ;+*3>/)I+7EAM&>'.SI=204[BIQ9[f;$TDKV$W

M({[=)FA>>+_BUPT6PVYW322O?3<@_MT&2E{(V] G+Q- MU+SP?<7&&VA/:S9-)*^M]RDWYI?$\EKULT,+F,+IP&KU! V M8V]^322OZS<@MM_F_>FEN% |OV&*.?:9FDA>#W!

3,!-'+W4$HH'.%A,P.^3 M0_):@ /B 6XBVJ664"S P>(:fID<)R6L4#HA3N(FDEU)#.0H'BU.X'R4DKWTX M(/A])>2@_%/1PL!N'<2DA>'W% C.1-#+U4(HJ-.%A\Q/F5D+P&X[SA,K9P

M&N:!*46,Q&7=30O(:B /B(&[#HA]N0FH ME_)(<2|'BWWYN0:R2W$SA][E^Y]5/?#ZFO.&R]C";? KQ9O%!-T7L>5U0@?$"MU%'JIQ!0O M=+*8H9_/'W@KJQ&6YVPI-

="4RLKB>BXXPY.8$X/;K6BQ(S<&J>#O[VO!]P7Y+P_U]D?PJ7@LJZ9 MWI59HKO>9+SA,K9P&K]@H$N[FD|>O2&O33EON(PMG 9LJ #K8GJB.GHMD=V1 MQ=P-C8'.EE5#+%

(0LYF>F -]*@KI-VMI0:7(D"ETU, MSSA-C/H@G^6,W&%F_3876SCMBBR4*^+)X"7D]6KG+9>QA=. 315@7<1';C,# M:VT5CC!Z9TNIP,54X+(43(>

J[685G):5<%Q8WRWQALO8P@TA5+5<0Z!WZ4T? MRKQ^[KSA,K9P&K!*G67Q?3]C*/>1$Z*8#Q&G=XAF2:Q_R,1RFI.!4.HBB]F[M-DC=BGE>WW?>,7M[B|!.6

MQP>ZE|)&,9;RYD#_F<4\KS,],!B,+9QV<90B"NC/&!|Q4_#60]SA,K9P M&K!*+60QO3]GIN MAL"^'X\MI0:74N'0UO&]0Z!XH?PV](K[]M7HF_?AQ97Q^P_PY@;;WU_) M,-

=O'_,OQ1[Y]66SKX-M<2]"SGYMA;_=AQ)//S3EX[L+4?OLZ+B;[E@3)&O95')f]\E"J>7+Z52F"U92>W3#U<7DM]+?1B7+2U;)G%=$L+NKR2O_91)?F +-

M'¦RM=*S\0N#N:62S7GQ<_4XFIR,2$9NZ-UH=[SU2^L/#2B*6\D.U?LFKW MJ28DK.7B95M8MZ#_J_5 _K4UHE,@#/<4"-H"P5:¦R-]3(6+QA+A%L%@GA/@:@M M$#7.K

^E\|2&ABLXN!5|18?,6:N9#8V936A]^7!GS?J.$_C77Y=3LIKZ5[$O- M*D78@_XKR?.$*9H7\@?RC$R)7%#!),DK\K'E3S1&_7G#PM>2UIE\G*J=",

MU#1M*WR¦KC#84^&K^OZ4^.$)";P@(A]O$O+\6;>J'L4YK/B."JT8,RDJ02L= M)+!R%%1(MLF1B?<'_0/Z!X^@U6-]0G]=BYXV8&;<>9OYI%%|.'[K^'=C)\27>^!*#OMRP

MM!8L(PF[5?]0FVM+FS/7VW+5>]B@W-##QA1+D,0<&\|\V-I[A1ND9HIV88@F2 MF&/C^<;&<_!J?%55-2W(75[HD2S7GZ2BVD)C:,8*/5L2CR9$0IJ#_44

M;N@+CV3TL7=\16J%X]_%QK\+L%E_U%0H)HK'IUH(R@^U$&YK%.^U$*D5CH4O M-A:^)OU+]_RLBY)2N6"I%$I5F 4$FHL2W5/IKONHOQ41*&MK;*\NC>#BC9[

M28L^3\'ZAGJZ%KOHC '>:,0U3B!5Z-CG>W9V[<'3/"9*\ANG%7E#T[S(U:,> M5P8/,W E0UU#54NPU%R#. CBXXXUK1Z6EYA]"9::ZZ5%$A]FDN9ZS"N11-UT MD;KS+'LM1{63

XV*R2/3D¦%>N\9 $=^RB _T6??XC:='[>H^-&JG76GO,>Q MYWE,/1Y6K:XMEBU\&'Y^K\M:#0[:F:|!&>[CVH^)]&R0ZL6=TS:'A&P*G3]

ML8SAPY!A_:&9OFYR7NEYR9%6H?)&JJ:U*MBV:@R,|\"U'^.#|>G8M>,I8)LF= MX"4I>'7_H^F3B-E/'@@]5*9HU;JAUQMY8^"":WG!A^?APR<;>D.S_:WM]%]

MT+R@MTWQ$_*AO8OV8<5]?4.E#%2U!$O-/1D6/OP+Y(D)*FZ@JB58.JZ7ED)\ M&$.::Y26O*[Z8QT5*EHU!UOLB_4QP"*P8!%@@\7QL:X0K'?X@9LT^*8T*H9@ MJ;FGPV)(@(PA

2J&H*HE6&JNEYV5D2,P9'^TPZ4'.Q<<%>U8E;J66-0(8-08 M,=K?\%KTVHS*+JAJ"9;:>S8LX001A0L*,23[!+ M/";6=X)]#.H)+/4$,/7T!'MG&OZ4^X=PA8-

=1%UAP5)SS;,%)PCQS(h[\'J M)5AJKl<6>0)X$>/P#3%88+!%)\>-W6/ 2V#A)8#A!0IG,]-^4D"C$@^J6H*E MYB:(6# */>04$52J055+L-1<+RW5A.!,_XB A@4&F^?

OW&,K"VBL2EU7+)^$ M,)_L7&'_D$/97++#B8)M0\|FPU%PW.QE=\Y"E=N#E=N$E=8X!):,$DA)=>/M&B M=M.YWH$VFK>(DT^,.KJ713OR%Y_%6^,WA1@RV; S^""U_A#!_M?

&X2@!5%M$UN:%+B3H"LD ."_MYDF#E<PK1#. ^YO# MS1ILXACT$5KZ",$5FYZA9/!<$*YB<'^("B18:JZ|%DA"Y#68$)5/4-42++#77 M2XLQX?

^=*A;VIF_MQ#LJG&"IN6G7%DXB>-5F:+P?,;6$:QR<>HV*+UAJKML6 M7R+D19D(E60U1(L-==+"ST1##TV:V5[;MG3!>R;7I9U^*$3\MYVR,--&6S<

M&*P36;Z)X*6;/EI$O\$+MV'PA8O*1%AJKO^=1UV0%VLBU,4:5+4$2|WUTL)2 M!+/-X?M!K<"!.SASN)[!KHQ!0I$EH0@FH29*S8RHTMWBB7E(LYDHW0LNY7JZ

MM&SSV'H=.RJU;.ZW8;!C8V!/9+$G@K'GNH%KDI>EOHZH8N01#4BCUR]8.MR/WW#)P1;.@3;119L(7FL9.*P\=:$!;L7@SA 5B+#4W#-@ M@2AZ@3RPH"

[:H*HE6&KN8Y>6BV*8BPX/+*W H8$%KF?P0Y1C\$MI_26&EU^V M!A8]BF1U>M23:P>$5TC)*[7H[27AHH,=(:.8DLM,4PM_V6@.2 -#+1PR<$6 MCL$0V>67&)5?CAEH](9-

9O]EC)]-9L]4]8@=N"MWJ?0>TY0.0=5+<%2<|^3 MY9P8F7-B5,Y!54NPU%PO.Z\|.\"(I[C_ZB9^K?4NX;]+B'O=1\UU0U5+L-3<]>SJ,"$I,:V;-

IYZ91Y1=@I*N[S2I*"W6EY[_1<=TAB_=;M M]1?%E\U[]&ZY4KQL/BX8S9@P.^C?[SA7W]Z85UMMWGTV^Q=02P,$% @ MHX0M6?/R!D-& P JA0 T

!X;"]S='EL97.N>&UW5C1;MHP%/V5R%VG M5IH:(&T@*R!M2)4F;5.E]F%OE2$.6'*K7,AJ1!9:EQ_#L)HM6$ZKBZ)DTB!9H7*]35?-PZI4

MC*85D'(1[C]=.,PIEV0.E\)M=5,"N64H](OPD%[O8E'9%N?#)*S3+*#ZQH.DXYW1>WP4R/D MB*<8K7>0HV<,8<(#CQ[C?

VL).A@Y9);5(38[_BSM]GU5H9U&8R*62&WU1 1-M%S#J-&?!(Q4C,]&"3Q4'5D9S+M8NW(/ K\"%"K0I0Y.N"Y]MX.[K@<56NOD M7!;*YG89W.]I/7P/V/3 (!>B,=@C+C >EE1KIN2-

Z=C!-O@$"NKV_;HT#N>*.MKKN]*[(EV)M),BU4RE23IDLVH?%0L SL*#Y?P%T790B@UD5N&BFG\T)2ZV'#

MJ!M&=L;$>J(/'IT>VH[W*6OMF=TTV36.H;CH9UP']MIK3;LM>OD@W*ECH3\O MS72D[4-YLUO%,KZR_576&,#4N[@Z+4NQ_B3X7.,,3?[@A.,AW?""1:'X;Y,- M2F5F DR1X)$IS6?

MR"]%RWNVTIMR6F6XY[X1>OZWZSQGDBDJV]9-[_E57ZQ MXZC_6I;MM\]^8;_'^IW\0:'8/)^!A,'D5-#H[!9'(§)ONO][UYN,GH;2YD M6)^$6L>MG<-6$PW@4#LBW^&

(++9)@^F2"\UEW5OP-&7RR9G+R&LZ-7^(]>B; M\2G+Z%+H^P8P$/6H;?LK3*\;-R=]DXO+E*U8.]F[:CZU-MS< T3-;Z L(^?ZG^0S0^3@,\S;P(@.4,T Y MCN5#)O:#Y?

%S$&G/Y9YHD413'V(I.)EX'$VS=XAA^_&J8-V!@>2#3WZTUOMMX MA3Q?!!B>/EPVH'\.QO4WY.%&N M8MZP)QA'D@1#HL;1-K'R.K$\/'O#_.41%&2^!'_ ZB"$/@:<01S %XP) H

MLN_!O?=1N'E/A=O_3H[_%!+ P04 " "CA"U9EXJ[', 3 @ "P M %]R96QS+RYR96QSG9*Y;L,P#$!_Q="> ,?0(8@S9?$6!/D!5J(/V\(%BD6=

MOZ ;!7&0"QEY/3P2W!Y10.TXI+;-+J1CI$%)I6M6X 4BV)8|HSI%"KM0L'C6' MTD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A{E@6FD7)TZ(=I7|=Q ;0T^FO8R*T

M>EOH^7%H5 J.W&,EC%BM/XU@LD/['X 4$L#!!0 (_*,$+5F#*\!E%@4 M -([/ >&PO=V]R:V)O;VLN>&ULQ9I;,OHY%(#_BL535]HL,+>V48B4 MELTN4C9%

{>KKRLR88,5C4]M#ØO[Z'@^AL1MRM"]G>8*Y8+[Q[3L^GK,'8^^7 MQMRS0QI-QFLO=^<#H>N7HN6NS_,1FBXLC*VY1X.[=M:MARJ0?

G9_NRYG88'Q@O:B^-AI/AQ%0R: .08$K:9WOI^C+Y\"X%7#$J[CSYE{]+^R4>_&7-=U&ZKM0##S%,']_MOA|VG[M*/+7_!1K-:B5K,35UUPKM=_5HA0]

VJWEQ@V8YJV8##Z;K;!LSN]$ M>"CXEUFS>T /9%%UV5,)%^RLZ1DI>70CM!,-@V_.*-D 1\, ^<<5U+5@$F2&0 MV1$A_|TBR!R!S(\"N0@X\-,(LD @BR-")C59(I#E,2'S"+)"

(*MC0A81Y'L$ M\CTVM%2XVLI-,,,.BOVU8.O.22V&1.+ MY"*N.0=3B7C`>W#D+UF 83PIC8 M"MOZON)0)HFK4T;AD!,4\R'N6!,+(.9!54.VS,7P2$4_.^UU"N,LZO M#$#

79,0NF/.GMG5L+FS_|[DFTI70V-W:2-C)LB(33#33C;0\VXM M;X)1+ZSE,/7^&H!DF!\R8C^@@6:R\,DP0V3$AL!"3?;N-L;$E)$1*^..:!,(M.8 D6Z8ZY)"-VR<^HH=K+,:ODY$FK

M?;#W.M9+1TF.626GMLH;H###8X9)B39,&QR23$TL&=V&<7\LQR>3$DD%=>|*GIG-.,CFQ9%#.M&]BQLF/ ME.1B2:,?F'&*X^2QH+UO1&WBY$>!&:@@-M#;F-<@NSSW_%

MF)B!"F(#17':5'@N56*> MTO(3;@3SA84C,.P6Q=_!H,AG;F'<*8N\\1Y// M8R1LT!ZN2DPZ!;%T?C(NNK;ET"-!DU@,.(APF17,28FG8)8.B^84%C3*1$X M+SL/(YS]

(Y/-1DPZ!,%TT*PL.XFW&S'IE,3203'375%,.B6Q=-+T\<&Q4V*V M*8EMLTLD'^,"|%(2Z^7-==AN)HHQ,=64Q*I!,,-D%&.BF_/LLPH?@8$Y-- M22P;M#;3,8WYIB3V#8X9[IO$?

%,29|)>=CT.#W!,,R6Q9@YD,$[8!&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'(-V3MNVT 4A>&M"%R M1_0"^D0*=(8/!4Q)'CY-_Q #)]^C4,[M[KM3W>W|NO@X'DYUU>S&L?

^14EWORK&M=UU?3N]V5,C;+UW;8 MEG'5I(_#]71-EX/W53.\O$F3Y@Y2"-+Y@PR";/X@AR"?/R@@*.8/ MRA"4YP^ZAZ#F^,8->(.AA_]:"""]"8 N!V()D M'X'9@F@+@=]";

N!VX)P"X'<@G0+@=V"> N!WHIZ*X'>BGHK@=XZ^=@FT%M1 M;R706U%O)=!;46\ET%M1;R70VU!O(]#;4&\CT-M0

M;R/0VR:,)01Z&^IM!'H;ZFT$>AOJ;01Z& ^IM!'H;ZFT$>AOJ;01Z.^KM!'Hf MZNT$>COJI01Z.^KM!'K[9+.,0&\'O9U .T>]G4!O1[V=0&]'O9U ;T>]G4#O M0+V#0.] O8-

[T"]@T#O0+V#0.] O8- [YC\K"30.U#O(- 14.\@T#M0[R#0 M.U#@(- [H]Z90.^,>F<"O3/JG0GTSJAW)M [H]Z90.^,>N?OU+N.GX=2KSU? M:WS^=U(]GN\MU\=?

EE\)GR_4!=>T6U&?_?O2P,$% @ HX0M6=(T9!3L M -0 !R8 !, !,0VI%=&5N=%]4>7!E&ULS=I=3\(P\% ;@OT)V:UCI MU_#(<*/>JA?^@;H=9&%/,N[28,)1L?

&I8H.UYSWJ2YXKKIZVC,-JT M31>FV2)&=|58*!74FI!,1IU:F5O?FIB^^A?F3+DT+\3$9%*PTG:1NCB.?8UL M=GU+<[-JXNANDWX.M>VFF:L$]J|\ K @ $0 @ &O

M9&]C4')O<',O8V]R92YX;6Q02P$"%_4 _" "CA"U9F5R<(Q & "<)P M$P @ '- 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 M (*.$+5G&H+5:T 4 ,X> 8 " @0X(!X;"]W;W)K

M&PO=V]R:W-H965T&UL4$L! M A0#% @ HX0M63O.IBOW @ 7 H !@ (" !!4 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ HX0M6=7+ M "!44!P SC$!@ (" !HR 'AL+W=O

H (0S 8 M " @>TG !X;"]W;W)K&PO=V]R:W-H965T M&UL4$L! A0#% @ HX0M6;M :4L5& .$H !@ M (" !ES\ 'AL+W=O)7 !X;"]W;W)K M&UL4$L! A0#% @ HX0M6;%63%SN!P

VA4 M !D (" !&EP 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ HX0M6<%ZSAS] @ U 8 !D M (" !.VL 'AL+W=O(C@H4("]%0 &0 @(%<;@ >&PO=V]R:W-H965T M&UL4$L!

A0# M% @ HX0M6>;A??R;"0 CA@ !D (" !;7X 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ HX0M6<8' MNW4[P 5@< !D (" !)9, 'AL+W=O&PO=V]R:W-H965T-#@P

&&UL4$L! A0#% @ HX0M62C?RC;O!@ OQ$!D M (" !EJ8 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ HX0M61ZCA&/&%@ Z$4 !D (" ! MN;('AL+W=O&PO=V]R:W-

H965T&UL4$L! A0#% M @ HX0M66TH(160 @ C04 !D ("!F-$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ HX0M66/6IPM#"P X"8 !D M ("!#^@ 'AL+W=O&PO=V]R M:W-

H965T&UL M4$L! A0#% @ HX0M6<%=;]T? P P !D ("!4/P M 'AL+W=O&PO=V]R:W-H965TL1! (%<& 9 M " @<8" 0!X;"]W;W)K&UL4$L! A0#% @ MHX0M6;F^1)O_! 31T !D ("!H04! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ HX0M644E="M_ @ MP08 !D ("!_1 ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ HX0M6:]6=V>L P DA !D M ("!OAH! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ HX0M66CI&Q4P @ SP0 !D ("!)"&PO=V]R:W-H965T&UL4$L! A0#% @ HX0M M653&9"]5!@ >3D !D ("!#34! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ HX0M6<9W1ZIR P I X M !D ("!+T0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ HX0M69?Z/310 @ H 4 !D M ("!-D\! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ HX0M6?9ZG6[N"P FEL !D ("!IE@! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ HX0M6<;@ MK%9S" !TT !D ("!'XP! 'AL+W=O&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "C MA"U9TC1D%.P! ')@ $P @ &TH $ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 20!) /83 #1H@$!

end XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document.document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 173 327 1 false 62 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.bluebirdbio.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet

http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited Condensed Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet

http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) Sheet

http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) (Parenthetical) Sheet

http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunauditedParenthetical Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) Sheet http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited Condensed Consolidated Statements of Stockholders' Equity (unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - Description of the business Sheet http://www.bluebirdbio.com/role/Descriptionofthebusiness Description of the business Notes 8 false false R9.htm 0000009 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies Sheet http://www.bluebirdbio.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies Basis of presentation, principles of consolidation and significant accounting policies Notes 9 false false R10.htm 0000010 - Disclosure - Product revenue and reserves Sheet

http://www.bluebirdbio.com/role/Productrevenueandreserves Product revenue and reserves Notes 10 false false R11.htm 0000011 - Disclosure - Fair value measurements Sheet http://www.bluebirdbio.com/role/Fairvaluemeasurements Fair value measurements Notes 11 false false R12.htm 0000012 - Disclosure - Inventory Sheet

http://www.bluebirdbio.com/role/Inventory Inventory Notes 12 false false R13.htm 0000013 - Disclosure - Factoring agreement Sheet

http://www.bluebirdbio.com/role/Factoringagreement Factoring agreement Notes 13 false false R14.htm 0000014 - Disclosure - Accrued expenses and other current liabilities Sheet http://www.bluebirdbio.com/role/Accruedexpensesandothercurrentliabilities Accrued expenses and other current liabilities Notes 14 false false R15.htm 0000015 - Disclosure - Leases Sheet http://www.bluebirdbio.com/role/Leases Leases Notes 15 false false R16.htm 0000016 - Disclosure - Commitments and contingencies Sheet http://www.bluebirdbio.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 16 false false R17.htm 0000017 - Disclosure - Term loan debt Sheet http://www.bluebirdbio.com/role/Termloandebt Term loan debt Notes 17 false false R18.htm 0000018 - Disclosure - Equity Sheet

http://www.bluebirdbio.com/role/Equity Equity Notes 18 false false R19.htm 0000019 - Disclosure - Stock-based compensation Sheet

http://www.bluebirdbio.com/role/Stockbasedcompensation Stock-based compensation Notes 19 false false R20.htm 0000020 - Disclosure - Income taxes Sheet

http://www.bluebirdbio.com/role/Incometaxes Income taxes Notes 20 false false R21.htm 0000021 - Disclosure - Net loss per share Sheet

http://www.bluebirdbio.com/role/Netlosspershare Net loss per share Notes 21 false false R22.htm 0000022 - Disclosure - Restatement of Previously Issued Financial Statements Sheet http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatements Restatement of Previously Issued Financial Statements Notes 22 false false R23.htm 0000023 - Disclosure - Subsequent events Sheet http://www.bluebirdbio.com/role/Subsequentevents Subsequent events Notes 23 false false R24.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 9954471 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Policies) Sheet

http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies Basis of presentation, principles of consolidation and significant accounting policies (Policies) Policies 26 false false R27.htm 9954472 - Disclosure - Product revenue and reserves (Tables) Sheet

http://www.bluebirdbio.com/role/ProductrevenueandreservesTables Product revenue and reserves (Tables) Tables

http://www.bluebirdbio.com/role/Productrevenueandreserves 27 false false R28.htm 9954473 - Disclosure - Fair value measurements (Tables) Sheet

http://www.bluebirdbio.com/role/FairvaluemeasurementsTables Fair value measurements (Tables) Tables http://www.bluebirdbio.com/role/Fairvaluemeasurements 28 false false R29.htm 9954474 - Disclosure - Inventory (Tables) Sheet http://www.bluebirdbio.com/role/InventoryTables Inventory (Tables) Tables

http://www.bluebirdbio.com/role/Inventory 29 false false R30.htm 9954475 - Disclosure - Accrued expenses and other current liabilities (Tables) Sheet

http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesTables Accrued expenses and other current liabilities (Tables) Tables

http://www.bluebirdbio.com/role/Accruedexpensesandothercurrentliabilities 30 false false R31.htm 9954476 - Disclosure - Leases (Tables) Sheet

http://www.bluebirdbio.com/role/LeasesTables Leases (Tables) Tables http://www.bluebirdbio.com/role/Leases 31 false false R32.htm 9954477 - Disclosure - Commitment and contingencies (Tables) Sheet http://www.bluebirdbio.com/role/CommitmentandcontingenciesTables Commitment and contingencies (Tables) Tables 32 false false R33.htm 9954478 - Disclosure - Stock-based compensation (Tables) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://www.bluebirdbio.com/role/Stockbasedcompensation 33 false false R34.htm 9954479 - Disclosure - Net loss per share (Tables) Sheet

http://www.bluebirdbio.com/role/NetlosspershareTables Net loss per share (Tables) Tables http://www.bluebirdbio.com/role/Netlosspershare 34 false false R35.htm 9954480 - Disclosure - Restatement of Previously Issued Financial Statements (Tables) Sheet

http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables Restatement of Previously Issued Financial Statements (Tables) Tables

http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatements 35 false false R36.htm 9954481 - Disclosure - Description of the business (Details) Sheet http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails Description of the business (Details) Details

http://www.bluebirdbio.com/role/Descriptionofthebusiness 36 false false R37.htm 9954482 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Details) Sheet http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesDetails Basis of presentation, principles of consolidation and significant accounting policies (Details) Details

http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies 37 false false R38.htm 9954483 - Disclosure - Product revenue and reserves - Narrative (Details) Sheet http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails Product revenue and reserves - Narrative (Details) Details 38 false false R39.htm 9954484 - Disclosure - Product revenue and reserves - Summary of Product Revenue (Details) Sheet

http://www.bluebirdbio.com/role/ProductrevenueandreservesSummaryofProductRevenueDetails Product revenue and reserves - Summary of Product Revenue (Details) Details 39 false false R40.htm 9954485 - Disclosure - Product revenue and reserves - Rebate Liability (Details) Sheet

http://www.bluebirdbio.com/role/ProductrevenueandreservesRebateLiabilityDetails Product revenue and reserves - Rebate Liability (Details) Details 40 false false R41.htm 9954486 - Disclosure - Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet

http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 41 false false R42.htm 9954487 - Disclosure - Fair value measurements - Narrative (Details) Sheet http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetails Fair value measurements - Narrative (Details) Details 42 false false R43.htm 9954488 - Disclosure - Fair value measurements - Factoring Agreement Reconciliation of Beginning and Ending Balances (Details) Sheet

http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails Fair value measurements - Factoring Agreement Reconciliation of Beginning and Ending Balances (Details) Details 43 false false R44.htm 9954489 - Disclosure - Inventory (Details) Sheet

http://www.bluebirdbio.com/role/InventoryDetails Inventory (Details) Details http://www.bluebirdbio.com/role/InventoryTables 44 false false R45.htm 9954490 - Disclosure - Factoring agreement (Details) Sheet http://www.bluebirdbio.com/role/FactoringagreementDetails Factoring agreement (Details) Details

http://www.bluebirdbio.com/role/Factoringagreement 45 false false R46.htm 9954491 - Disclosure - Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) Sheet

http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) Details 46 false false R47.htm 9954492 - Disclosure - Leases - Narrative (Details) Sheet http://www.bluebirdbio.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 47 false false R48.htm 9954493 - Disclosure - Leases - Summary of Operating Lease Costs and Other Information (Details) Sheet http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails Leases - Summary of Operating Lease Costs and Other Information (Details) Details 48 false false R49.htm 9954494 - Disclosure - Leases - Schedule of Future Minimum Commitments (Details) Sheet http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails Leases - Schedule of Future Minimum Commitments (Details) Details 49 false false R50.htm 9954495 - Disclosure - Commitments and contingencies - Narrative (Details) Sheet

http://www.bluebirdbio.com/role/CommitmentsandcontingenciesNarrativeDetails Commitments and contingencies - Narrative (Details) Details 50 false false R51.htm 9954496 - Disclosure - Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail) Sheet

http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail) Details 51 false false R52.htm 9954497 - Disclosure - Term loan debt (Details) Sheet

http://www.bluebirdbio.com/role/TermloandebtDetails Term loan debt (Details) Details http://www.bluebirdbio.com/role/Termloandebt 52 false false R53.htm 9954498 - Disclosure - Equity (Details) Sheet http://www.bluebirdbio.com/role/EquityDetails Equity (Details) Details http://www.bluebirdbio.com/role/Equity 53 false false R54.htm 9954499 - Disclosure - Stock-based compensation - Narrative (Details) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails Stock-based compensation - Narrative (Details) Details 54 false false R55.htm 9954500 - Disclosure - Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Details) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Details) Details 55 false false R56.htm 9954501 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Details) Sheet
http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Details) Details 56 false false R57.htm 9954502 - Disclosure - Stock-based compensation - Summary of Stock Option Activity Under Plan (Details) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails Stock-based compensation - Summary of Stock Option Activity Under Plan (Details) Details 57 false false R58.htm 9954503 - Disclosure - Stock-based compensation - Summary of Restricted Stock Units (Details) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails Stock-based compensation - Summary of Restricted Stock Units (Details) Details 58 false false R59.htm 9954504 - Disclosure - Income taxes (Details) Sheet http://www.bluebirdbio.com/role/IncometaxesDetails Income taxes (Details) Details http://www.bluebirdbio.com/role/Incometaxes 59 false false R60.htm 9954505 - Disclosure - Net loss per share - Anti-dilutive shares (Detail) Sheet http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail Net loss per share - Anti-dilutive shares (Detail) Details 60 false false R61.htm 9954506 - Disclosure - Net loss per share - Narrative (Details) Sheet http://www.bluebirdbio.com/role/NetlosspershareNarrativeDetails Net loss per share - Narrative (Details) Details 61 false false R62.htm 9954507 - Disclosure - Restatement of Previously Issued Financial Statements - Schedule of Operations and Comprehensive Loss (Details) Sheet http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails Restatement of Previously Issued Financial Statements - Schedule of Operations and Comprehensive Loss (Details) Details 62 false false R63.htm 9954508 - Disclosure - Restatement of Previously Issued Financial Statements - Schedule of Changes in Stockholders' Equity (Details) Sheet
http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails Restatement of Previously Issued Financial Statements - Schedule of Changes in Stockholders' Equity (Details) Details 63 false false R64.htm 9954509 - Disclosure - Restatement of Previously Issued Financial Statements - Schedule of Cash Flows (Details) Sheet
http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails Restatement of Previously Issued Financial Statements - Schedule of Cash Flows (Details) Details 64 false false R65.htm 9954510 - Disclosure - Subsequent events (Details) Sheet
http://www.bluebirdbio.com/role/SubsequenteventsDetails Subsequent events (Details) Details http://www.bluebirdbio.com/role/Subsequentevents 65 false false All Reports Book All Reports blue-20240331.htm blue-20240331.xsd blue-20240331_cal.xml blue-20240331_def.xml blue-20240331_lab.xml blue-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 82 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "blue-20240331.htm": { "nsprefix": "blue", "nsuri": "http://www.bluebirdbio.com/20240331", "dts": { "inline": { "local": ["blue-20240331.htm"] }, "schema": { "local": ["blue-20240331.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"] }, "calculationLink": { "local": ["blue-20240331_cal.xml"] }, "definitionLink": { "local": ["blue-20240331_def.xml"] }, "labelLink": { "local": ["blue-20240331_lab.xml"] }, "presentationLink": { "local": ["blue-20240331_pre.xml"] } }, "keyStandard": 268, "keyCustom": 59, "axisStandard": 25, "axisCustom": 2, "memberStandard": 30, "memberCustom": 30, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 173, "entityCount": 1, "segmentCount": 62, "elementCount": 596, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 823, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.bluebirdbio.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R2": { "role":
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)", "shortName": "Condensed Consolidated Balance Sheets (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R3": { "role":
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": null }, "R5": { "role":
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunauditedParenthetical", "longName": "0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-25", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R7": { "role":
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "blue:NoncashInterestRelatedToDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R8": { "role":
"http://www.bluebirdbio.com/role/Descriptionofthebusiness", "longName": "0000008 - Disclosure - Description of the business", "shortName": "Description of the business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R9": { "role":
"http://www.bluebirdbio.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies", "longName": "0000009 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies", "shortName": "Basis of presentation, principles of consolidation and significant accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bluebirdbio.com/role/Productrevenueandreserves", "longName": "0000010 - Disclosure - Product revenue and reserves", "shortName": "Product revenue and reserves", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bluebirdbio.com/role/Fairvaluemeasurements", "longName": "0000011 - Disclosure - Fair value measurements", "shortName": "Fair value measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bluebirdbio.com/role/Inventory", "longName": "0000012 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bluebirdbio.com/role/Factoringagreement", "longName": "0000013 - Disclosure - Factoring agreement", "shortName": "Factoring agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "blue:FactoringAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [

"span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "blue:FactoringAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bluebirdbio.com/role/Accruedexpensesandothercurrentliabilities", "longName": "0000014 - Disclosure - Accrued expenses and other current liabilities", "shortName": "Accrued expenses and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bluebirdbio.com/role/Leases", "longName": "0000015 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bluebirdbio.com/role/Commitmentsandcontingencies", "longName": "0000016 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bluebirdbio.com/role/Termloandebt", "longName": "0000017 - Disclosure - Term loan debt", "shortName": "Term loan debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bluebirdbio.com/role/Equity", "longName": "0000018 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bluebirdbio.com/role/Stockbasedcompensation", "longName": "0000019 - Disclosure - Stock-based compensation", "shortName": "Stock-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bluebirdbio.com/role/Incometaxes", "longName": "0000020 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bluebirdbio.com/role/Netlosspershare", "longName": "0000021 - Disclosure - Net loss per share", "shortName": "Net loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatements", "longName": "0000022 - Disclosure - Restatement of Previously Issued Financial Statements", "shortName": "Restatement of Previously Issued Financial Statements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ErrorCorrectionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ErrorCorrectionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bluebirdbio.com/role/Subsequentevents", "longName": "0000023 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies", "longName": "9954471 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Policies)", "shortName": "Basis of presentation, principles of consolidation and significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bluebirdbio.com/role/Productrevenueandreservestables", "longName": "9954472 - Disclosure - Product revenue and reserves (Tables)", "shortName": "Product revenue and reserves (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bluebirdbio.com/role/Fairvaluemeasurementstables", "longName": "9954473 - Disclosure - Fair value measurements (Tables)", "shortName": "Fair value measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bluebirdbio.com/role/InventoryTables", "longName": "9954474 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bluebirdbio.com/role/Accruedexpensesandothercurrentliabilitiestables", "longName": "9954475 - Disclosure - Accrued expenses and other current liabilities (Tables)", "shortName": "Accrued expenses and other current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bluebirdbio.com/role/LeasesTables", "longName": "9954476 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bluebirdbio.com/role/CommitmentandcontingenciesTables", "longName": "9954477 - Disclosure - Commitment and contingencies (Tables)", "shortName": "Commitment and contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermPurchaseCommitmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermPurchaseCommitmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bluebirdbio.com/role/Stockbasedcompensationtables", "longName": "9954478 - Disclosure - Stock-based compensation (Tables)", "shortName": "Stock-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true,

"unique": true } }, "R34": { "role": "http://www.bluebirdbio.com/role/NetlosspershareTables", "longName": "9954479 - Disclosure - Net loss per share (Tables)", "shortName": "Net loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables", "longName": "9954480 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)", "shortName": "Restatement of Previously Issued Financial Statements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "longName": "9954481 - Disclosure - Description of the business (Details)", "shortName": "Description of the business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "blue:NumberOfTranches", "unitRef": "tranche", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-39", "name": "us-gaap:DebtInstrumentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R37": { "role": "http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesDetails", "longName": "9954482 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Details)", "shortName": "Basis of presentation, principles of consolidation and significant accounting policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails", "longName": "9954483 - Disclosure - Product revenue and reserves - Narrative (Details)", "shortName": "Product revenue and reserves - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-45", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R39": { "role": "http://www.bluebirdbio.com/role/ProductrevenueandreservesSummaryofProductRevenueDetails", "longName": "9954484 - Disclosure - Product revenue and reserves - Summary of Product Revenue (Details)", "shortName": "Product revenue and reserves - Summary of Product Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-41", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R40": { "role": "http://www.bluebirdbio.com/role/ProductrevenueandreservesRebateLiabilityDetails", "longName": "9954485 - Disclosure - Product revenue and reserves - Rebate Liability (Details)", "shortName": "Product revenue and reserves - Rebate Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "blue:ContractWithCustomerRebateLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "blue:SummaryOfContractWithCustomerRefundLiabilityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "blue:ContractWithCustomerRebateLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "blue:SummaryOfContractWithCustomerRefundLiabilityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "longName": "9954486 - Disclosure - Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-47", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetails", "longName": "9954487 - Disclosure - Fair value measurements - Narrative (Details)", "shortName": "Fair value measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails", "longName": "9954488 - Disclosure - Fair value measurements - Factoring Agreement Reconciliation of Beginning and Ending Balances (Details)", "shortName": "Fair value measurements - Factoring Agreement Reconciliation of Beginning and Ending Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-63", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-63", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.bluebirdbio.com/role/InventoryDetails", "longName": "9954489 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.bluebirdbio.com/role/FactoringagreementDetails", "longName": "9954490 - Disclosure - Factoring agreement (Details)", "shortName": "Factoring agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "blue:FactoringAgreementCashReceiptsCollectedPriorToConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "blue:FactoringAgreementCashReceiptsCollectedPriorToConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails", "longName": "9954491 - Disclosure - Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "blue:AccruedClinicalAndContractResearchOrganizationCostsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "blue:AccruedClinicalAndContractResearchOrganizationCostsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.bluebirdbio.com/role/LeasesNarrativeDetails", "longName": "9954492 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-83", "name": "blue:NumberOfAdditionalControlledEnvironmentRooms", "unitRef": "room", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-83", "name": "blue:NumberOfAdditionalControlledEnvironmentRooms", "unitRef": "room", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails", "longName": "9954493 - Disclosure - Leases - Summary of Operating Lease Costs and Other Information (Details)", "shortName": "Leases - Summary of Operating Lease Costs and Other Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinanceLeaseInterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinanceLeaseInterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails", "longName": "9954494 - Disclosure - Leases - Schedule of Future Minimum Commitments (Details)", "shortName": "Leases - Schedule of Future Minimum Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr",

"table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesNarrativeDetails", "longName": "9954495 - Disclosure - Commitments and contingencies - Narrative (Details)", "shortName": "Commitments and contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail", "longName": "9954496 - Disclosure - Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail)", "shortName": "Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.bluebirdbio.com/role/TermloandebtDetails", "longName": "9954497 - Disclosure - Term loan debt (Details)", "shortName": "Term loan debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-77", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R53": { "role": "http://www.bluebirdbio.com/role/EquityDetails", "longName": "9954498 - Disclosure - Equity (Details)", "shortName": "Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R54": { "role": "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails", "longName": "9954499 - Disclosure - Stock-based compensation - Narrative (Details)", "shortName": "Stock-based compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R55": { "role": "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails", "longName": "9954500 - Disclosure - Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Details)", "shortName": "Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-94", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R56": { "role": "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails", "longName": "9954501 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)", "shortName": "Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-100", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R57": { "role": "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails", "longName": "9954502 - Disclosure - Stock-based compensation - Summary of Stock Option Activity Under Plan (Details)", "shortName": "Stock-based compensation - Summary of Stock Option Activity Under Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails", "longName": "9954503 - Disclosure - Stock-based compensation - Summary of Restricted Stock Units (Details)", "shortName": "Stock-based compensation - Summary of Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-106", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-106", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.bluebirdbio.com/role/IncometaxesDetails", "longName": "9954504 - Disclosure - Income taxes (Details)", "shortName": "Income taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail", "longName": "9954505 - Disclosure - Net loss per share - Anti-dilutive shares (Detail)", "shortName": "Net loss per share - Anti-dilutive shares (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.bluebirdbio.com/role/NetlosspershareNarrativeDetails", "longName": "9954506 - Disclosure - Net loss per share - Narrative (Details)", "shortName": "Net loss per share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R62": { "role": "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails", "longName": "9954507 - Disclosure - Restatement of Previously Issued Financial Statements - Schedule of Operations and Comprehensive Loss (Details)", "shortName": "Restatement of Previously Issued Financial Statements - Schedule of Operations and Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-115", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R63": { "role": "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "longName": "9954508 - Disclosure - Restatement of Previously Issued Financial Statements - Schedule of Changes in Stockholders' Equity (Details)", "shortName": "Restatement of Previously Issued Financial Statements - Schedule of Changes in Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R64": { "role": "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "longName": "9954509 - Disclosure - Restatement of Previously Issued Financial Statements - Schedule of Cash Flows (Details)", "shortName": "Restatement of Previously Issued Financial Statements - Schedule of Cash Flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "blue:LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } }, "R65": { "role": "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "longName": "9954510 - Disclosure - Subsequent events (Details)", "shortName": "Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-76", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div",

```
"ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blue-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-75", "name":
"blue:DebtInstrumentCovenantAnnualFinancialStatementDeliveryMaximumPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span",
"div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blue-20240331.htm", "unique": true } } }, "tag": { "blue_A2023IncentiveAwardPlanMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "A2023IncentiveAwardPlanMember", "presentation": [
"http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Incentive Award Plan", "label": "2023
Incentive Award Plan [Member]", "documentation": "2023 Incentive Award Plan" } } }, "auth_ref": [] }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "label":
"Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting
Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [
"http://www.bluebirdbio.com/role/Accruedexpensesandothercurrentliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities",
"label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable,
accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } },
"presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable",
"label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been
received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one
year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18", "r643" ] }, "blue_AccruedClinicalAndContractResearchOrganizationCostsCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "AccruedClinicalAndContractResearchOrganizationCostsCurrent", "crdr":
"credit", "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
"parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accrued CMO and CRO costs", "label": "Accrued Clinical And Contract Research Organization Costs Current", "documentation": "Accrued clinical and
contract research organization costs current." } } }, "auth_ref": [] }, "blue_AccruedGoodsAndServicesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.bluebirdbio.com/20240331", "localname": "AccruedGoodsAndServicesCurrent", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-
gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accrued goods and services", "label": "Accrued Goods and Services, Current", "documentation": "Accrued Goods and Services, Current" } } }, "auth_ref": [] },
"us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag":
"us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 },
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight":
null, "order": null, "root": true } }, "presentation": [
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current
liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses
incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-
gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accrued professional fees", "label": "Accrued Professional Fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred
through that date and payable for professional fees, such as for legal and accounting services received." } } }, "auth_ref": [ "r73" ] }, "blue_AccruedRebatesCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "AccruedRebatesCurrent", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-
gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accrued rebates", "label": "Accrued Rebates, Current", "documentation": "Accrued Rebates, Current" } } }, "auth_ref": [] }, "us-
gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } },
"presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other
comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in
equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r28", "r29", "r90", "r142", "r511", "r533", "r537" ] }, "us-
gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accumulated other comprehensive (loss) income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in
equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in
equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r9", "r29", "r408", "r411", "r462", "r528", "r529",
"r757", "r758", "r759", "r766", "r767", "r768" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional
402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r694" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in
capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock
or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r82", "r643", "r841" ] }, "us-
gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember",
"presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's
capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r384", "r385", "r386", "r544", "r766", "r767",
"r768", "r816", "r843" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation
Amount" } } }, "auth_ref": [ "r700" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to
Compensation [Axis]" } } }, "auth_ref": [ "r700" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment
to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r700" ] },
"ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO
Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r700" ] }, "us-gaap_AdjustmentsForErrorCorrectionDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForErrorCorrectionDomain", "presentation": [
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Error Correction, Type [Domain]", "label": "Error Correction, Type [Domain]", "documentation": "Type of error correction." } } }, "auth_ref": [ "r173", "r174",
"r175", "r179", "r180", "r181", "r182" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of
increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r62", "r63", "r349" ] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of warrants",
"label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance
of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r10", "r56", "r111" ] }, "us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Adjustments to reconcile net (loss) income to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in)
Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation
Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r665", "r676", "r686", "r711" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [
```

```
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r668", "r679", "r689", "r714" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r700" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r707" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r672", "r680", "r690", "r707", "r715", "r719", "r727" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r725" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r379", "r387" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock equivalents excluded from the calculation of diluted net loss per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r195" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r44" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r44" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r114", "r140", "r165", "r200", "r208", "r212", "r249", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r403", "r405", "r427", "r507", "r568", "r643", "r656", "r785", "r786", "r826" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r134", "r146", "r165", "r249", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r403", "r405", "r427", "r643", "r785", "r786", "r826" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r65" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "blue_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "AtTheMarketOfferingMember", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "At The Market Offering", "label": "At The Market Offering [Member]", "documentation": "At The Market Offering" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r722" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r723" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r718" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r721" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r720" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r719" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r719" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "blue_BeneficialInterestAmountDerecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "BeneficialInterestAmountDerecognized", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Derecognition of due to factor liabilities", "label": "Beneficial Interest, Amount Derecognized", "documentation": "Beneficial Interest, Amount Derecognized" } } }, "auth_ref": [] }, "blue_BeneficialInterestFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri":
```

```
"http://www.bluebirdbio.com/20240331", "localname": "BeneficialInterestFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Beneficiary interest in factored invoices", "label": "Beneficial Interest, Fair Value Disclosure", "documentation": "Beneficial Interest, Fair Value
Disclosure" } } }, "auth_ref": [] }, "blue_BeneficialInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname":
"BeneficialInterestMember", "presentation": [
"http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Beneficial Interest", "label": "Beneficial Interest [Member]", "documentation": "Beneficial Interest" } } }, "auth_ref": [] },
"blue_BeneficiaryInterestObtained": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "BeneficiaryInterestObtained",
"crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/FactoringagreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beneficiary interest obtained in
transferred invoices", "label": "Beneficiary Interest Obtained", "documentation": "Beneficiary Interest Obtained" } } }, "auth_ref": [] },
"blue_BeneficiaryInterestObtainedInTransferredInvoices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname":
"BeneficiaryInterestObtainedInTransferredInvoices", "crdr": "debit", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Beneficiary interest obtained in
transferred invoices", "label": "Beneficiary Interest Obtained In Transferred Invoices", "documentation": "Beneficiary Interest Obtained In Transferred Invoices" } } },
"auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases
of property, plant and equipment included in accounts payable and accrued expenses", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future
cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r38", "r39", "r40" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 },
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and
cash equivalents", "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as
well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes
short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes
in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r36", "r137",
"r614" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-
gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand
as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes
short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes
in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit",
"calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true }
}, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel":
"Cash, cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "totalLabel": "Total
cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and
cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is
not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash
equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that
they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r36", "r100", "r163" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Reconciliation of cash, cash equivalents and restricted cash:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } },
"auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "(Decrease)
increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease),
Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or
usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other
accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily
convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } },
"auth_ref": [ "r0", "r100" ] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashFlowOperatingActivitiesLesseeAbstract", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Cash paid in the measurement of lease liabilities", "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "auth_ref":
[] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group,
Footnote [Text Block]" } } }, "auth_ref": [ "r698" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname":
"CityAreaCode", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "City Area Code", "label": "City Area Code",
"documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails",
"http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right
[Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [
"http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of
Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and
rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.
Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are
issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in
years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise
price of warrants (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit
of warrants or rights outstanding." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities called by warrants (in shares)", "label": "Class of
Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted.
For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r318" ] },
"blue_ClassOfWarrantOrRightNumberOfWarrantsIssuedAsAPercentageOfDebt": { "xbrltype": "pureItemType", "nsuri": "http://www.bluebirdbio.com/20240331",
"localname": "ClassOfWarrantOrRightNumberOfWarrantsIssuedAsAPercentageOfDebt", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Number of warrants issued as a percentage of debt", "label": "Class Of Warrant Or Right, Number Of Warrants Issued As A
Percentage Of Debt", "documentation": "Class Of Warrant Or Right, Number Of Warrants Issued As A Percentage Of Debt" } } }, "auth_ref": [] },
"blue_ClassOfWarrantOrRightValueOfWarrantsIssuedInRelationToDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname":
"ClassOfWarrantOrRightValueOfWarrantsIssuedInRelationToDebt", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Value of warrants issued in relation to debt", "label": "Class Of Warrant Or Right, Value Of Warrants Issued In Relation To Debt",
"documentation": "Class Of Warrant Or Right, Value Of Warrants Issued In Relation To Debt" } } }, "auth_ref": [] },
"blue_ClassOfWarrantOrRightWeightedAveragePricePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname":
"ClassOfWarrantOrRightWeightedAveragePricePeriod", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Weighted average price, period", "label": "Class Of Warrant Or Right, Weighted Average Price, Period", "documentation": "Class Of Warrant Or Right,
Weighted Average Price, Period" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount",
"label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r699" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r699" ] }, "us-gaap_CommitmentsAndContingencies": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0
} }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and
contingencies (Note 10)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity
```

has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r26", "r74", "r508", "r555"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.bluebirdbio.com/role/Commitmentsandcontingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r108", "r270", "r272", "r609", "r782"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock", "terseLabel": "Common Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r646", "r647", "r648", "r650", "r651", "r652", "r653", "r766", "r767", "r816", "r840", "r843"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://www.bluebirdbio.com/role/EquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r81"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r81", "r556"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r81"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance, shares (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r81", "r556", "r574", "r843", "r844"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value, 250,000 shares authorized; 193,583 and 192,772 shares issued and outstanding at March\u00a031, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r81", "r510", "r643"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r704"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r703"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r705"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r702"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive (loss) income", "terseLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r30", "r149", "r151", "r158", "r502", "r518"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r45", "r47", "r67", "r68", "r216", "r608"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r45", "r47", "r67", "r68", "r216", "r538", "r608"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r45", "r47", "r67", "r68", "r216", "r608", "r737"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r45", "r47", "r67", "r68", "r216"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r45", "r47", "r67", "r68", "r216", "r608"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r64", "r620"] }, "blue_ContractWithCustomerPaymentsRebateLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ContractWithCustomerPaymentsRebateLiability", "crdr": "credit", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesRebateLiabilityDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments/credits", "label": "Contract With Customer Payments, Rebate Liability", "documentation": "Contract With Customer Payments, Rebate Liability" } } }, "auth_ref": [] }, "blue_ContractWithCustomerRebateLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ContractWithCustomerRebateLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesRebateLiabilityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at December 31, 2023", "periodEndLabel": "Balance at March 31, 2024", "label": "Contract With Customer, Rebate Liability, Current", "documentation": "Contract With Customer, Rebate Liability, Current" } } }, "auth_ref": [] }, "blue_ContractWithCustomerRefundLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ContractWithCustomerRefundLiabilityRollForward", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesRebateLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Refund Liability [Roll Forward]", "label": "Contract with Customer, Refund Liability [Roll Forward]", "documentation": "Contract with Customer, Refund Liability" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of product revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r94", "r165", "r249", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r427", "r785"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of product revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",

```
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "terseLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r92" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r46", "r216" ] }, "us-gaap_CustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRefundLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued refund liability", "label": "Customer Refund Liability, Current", "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment." } } }, "auth_ref": [] }, "blue_DebtCovenantTermsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtCovenantTermsAxis", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Covenant Terms [Axis]", "label": "Debt Covenant Terms [Axis]", "documentation": "Debt Covenant Terms" } } }, "auth_ref": [] }, "blue_DebtCovenantTermsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtCovenantTermsDomain", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Covenant Terms [Domain]", "label": "Debt Covenant Terms [Domain]", "documentation": "Debt Covenant Terms [Domain]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "blue_DebtInstrumentAvailabilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentAvailabilityAxis", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Availability [Axis]", "label": "Debt Instrument Availability [Axis]", "documentation": "Debt Instrument Availability" } } }, "auth_ref": [] }, "blue_DebtInstrumentAvailabilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentAvailabilityDomain", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Availability [Domain]", "label": "Debt Instrument Availability [Domain]", "documentation": "Debt Instrument Availability [Domain]" } } }, "auth_ref": [] }, "blue_DebtInstrumentAvailabilityTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentAvailabilityTrancheFourMember", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Availability, Tranche Four", "label": "Debt Instrument Availability, Tranche Four [Member]", "documentation": "Debt Instrument Availability, Tranche Four" } } }, "auth_ref": [] }, "blue_DebtInstrumentAvailabilityTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentAvailabilityTrancheThreeMember", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Availability, Tranche Three", "label": "Debt Instrument Availability, Tranche Three [Member]", "documentation": "Debt Instrument Availability, Tranche Three" } } }, "auth_ref": [] }, "blue_DebtInstrumentAvailabilityTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentAvailabilityTrancheTwoMember", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Availability, Tranche Two", "label": "Debt Instrument Availability, Tranche Two [Member]", "documentation": "Debt Instrument Availability, Tranche Two" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r16", "r78", "r79", "r115", "r116", "r167", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r441", "r628", "r629", "r630", "r631", "r632", "r764" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "blue_DebtInstrumentCovenantAnnualFinancialStatementDeliveryMaximumPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentCovenantAnnualFinancialStatementDeliveryMaximumPeriod", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual financial statement delivery period", "label": "Debt Instrument, Covenant, Annual Financial Statement Delivery, Maximum Period", "documentation": "Debt Instrument, Covenant, Annual Financial Statement Delivery, Maximum Period" } } }, "auth_ref": [] }, "blue_DebtInstrumentCovenantDrawRequirementMinimumGrossCashProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentCovenantDrawRequirementMinimumGrossCashProceeds", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt covenant, minimum gross cash proceeds", "label": "Debt Instrument, Covenant, Draw Requirement, Minimum Gross Cash Proceeds", "documentation": "Debt Instrument, Covenant, Draw Requirement, Minimum Gross Cash Proceeds" } } }, "auth_ref": [] }, "blue_DebtInstrumentCovenantMinimumCashCoverageAsAPercentageOfOutstandingPrincipal": { "xbrltype": "percentItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentCovenantMinimumCashCoverageAsAPercentageOfOutstandingPrincipal", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum cash coverage as a percentage of outstanding principal", "label": "Debt Instrument, Covenant, Minimum Cash Coverage As A Percentage Of Outstanding Principal", "documentation": "Debt Instrument, Covenant, Minimum Cash Coverage As A Percentage Of Outstanding Principal" } } }, "auth_ref": [] }, "blue_DebtInstrumentCovenantPeriodImmediatelyFollowingAchievement": { "xbrltype": "durationItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentCovenantPeriodImmediatelyFollowingAchievement", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period immediately following achievement", "label": "Debt Instrument, Covenant, Period Immediately Following Achievement", "documentation": "Debt Instrument, Covenant, Period Immediately Following Achievement" } } }, "auth_ref": [] }, "blue_DebtInstrumentCovenantProductDeliveryPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentCovenantProductDeliveryPeriod", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt covenant, product delivery period", "label": "Debt Instrument, Covenant, Product Delivery Period", "documentation": "Debt Instrument, Covenant, Product Delivery Period" } } }, "auth_ref": [] }, "blue_DebtInstrumentCovenantQuarterlyFinancialStatementDeliveryMaximumPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentCovenantQuarterlyFinancialStatementDeliveryMaximumPeriod", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly financial statement delivery period", "label": "Debt Instrument, Covenant, Quarterly Financial Statement Delivery, Maximum Period", "documentation": "Debt Instrument, Covenant, Quarterly Financial Statement Delivery, Maximum Period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r70", "r72", "r286", "r441", "r629", "r630" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r23", "r70", "r303", "r441" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PIK interest", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r23", "r287" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r24", "r167", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r441", "r628", "r629", "r630", "r631", "r632", "r764" ] }, "blue_DebtInstrumentNumberOfAdditionalTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentNumberOfAdditionalTranches", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional tranches", "label": "Debt Instrument, Number Of Additional Tranches", "documentation": "Debt Instrument, Number Of Additional Tranches" } } }, "auth_ref": [] }, "blue_DebtInstrumentNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentNumberOfTranches", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tranches", "label": "Debt Instrument, Number of Tranches", "documentation": "Debt Instrument, Number of Tranches" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of aggregate original principal", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "documentation": "Percentage of principal amount of debt redeemed." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Original issue discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r69", "r72", "r788" ] }, "blue_DebtInstrumentUnamortizedDiscountPercent": { "xbrltype": "percentItemType", "nsuri":
```

```
"http://www.bluebirdbio.com/20240331", "localname": "DebtInstrumentUnamortizedDiscountPercent", "presentation": [
"http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount percentage", "label": "Debt Instrument, Unamortized
Discount, Percent", "documentation": "Debt Instrument, Unamortized Discount, Percent" } } }, "auth_ref": [] }, "us-
gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "crdr": "debit", "presentation": [
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering
expenses included in accounts payable and accrued expenses", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "documentation":
"The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction." } } }, "auth_ref": [ "r38", "r39", "r40" ] }, "us-
gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": {
"en-us": { "role": { "negatedLabel": "Realized loss", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r772" ] },
"blue_DecemberUnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname":
"DecemberUnderwritingAgreementMember", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails",
"http://www.bluebirdbio.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December Underwriting Agreement", "label": "December Underwriting
Agreement [Member]", "documentation": "December Underwriting Agreement" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [
"http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, gross", "label": "Debt Issuance Costs, Gross",
"documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and
registration costs." } } }, "auth_ref": [ "r71" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Debt issuance costs, net", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes,
but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r71", "r788" ] }, "us-gaap_DepreciationAndAmortization": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against
earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives;
or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used
in production." } } }, "auth_ref": [ "r6", "r54" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/ProductrevenueandreservesTables" ], "lang": {
"en-us": { "role": { "terseLabel": "Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of
disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } },
"auth_ref": [ "r789" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.bluebirdbio.com/role/Stockbasedcompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment
Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r347", "r352", "r381", "r382", "r383",
"r640" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement
[Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] },
"blue_DispositionOfAssetsExpensesIncurredDuringNoncashOrPartialNoncashTransaction": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.bluebirdbio.com/20240331", "localname": "DispositionOfAssetsExpensesIncurredDuringNoncashOrPartialNoncashTransaction", "crdr": "debit", "presentation":
[ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Priority
review voucher expenses accrued or in accounts payable", "label": "Disposition Of Assets, Expenses Incurred During Noncash Or Partial Noncash Transaction",
"documentation": "Disposition Of Assets, Expenses Incurred During Noncash Or Partial Noncash Transaction" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus",
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT
or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal
Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may
also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] },
"dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-
1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] },
"dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report",
"documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r660" ] }, "dei_DocumentTransitionReport": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ],
"lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form
used as a transition report." } } }, "auth_ref": [ "r693" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentType", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label":
"Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the
supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "blue_DrugProductManufacturingFacilityMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.bluebirdbio.com/20240331", "localname": "DrugProductManufacturingFacilityMember", "presentation": [
"http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Drug Product Manufacturing Facility", "label": "Drug Product
Manufacturing Facility [Member]", "documentation": "Drug Product Manufacturing Facility" } } }, "auth_ref": [] }, "blue_DrugSubstanceManufacturingFacilityMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "DrugSubstanceManufacturingFacilityMember", "presentation": [
"http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Drug Substance Manufacturing Facility", "label": "Drug Substance
Manufacturing Facility [Member]", "documentation": "Drug Substance Manufacturing Facility" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share
[Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
"http://www.bluebirdbio.com/role/NetlosspershareNarrativeDetails",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Net (loss) income per share - basic (in dollars per share)", "verboseLabel": "Basic EPS (In dollars per share)", "netLabel": "Net income per share - basic (in
dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit
outstanding during the reporting period." } } }, "auth_ref": [ "r159", "r173", "r174", "r176", "r177", "r179", "r185", "r187", "r192", "r193", "r194", "r198", "r417", "r418",
"r503", "r519", "r622" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"EarningsPerShareDiluted", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
"http://www.bluebirdbio.com/role/NetlosspershareNarrativeDetails",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Net (loss) income per share - diluted (in dollars per share)", "verboseLabel": "Diluted EPS (in dollars per share)", "netLabel": "Net income per share - diluted
(in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or
common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all
dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r159", "r173", "r174", "r176", "r177", "r179", "r187", "r192",
"r193", "r194", "r198", "r417", "r418", "r503", "r519", "r622" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/Netlosspershare" ], "lang": { "en-us": { "role": { "terseLabel":
"Net loss per share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r184", "r195", "r196",
"r197" ] }, "blue_EmployeeAndNonEmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname":
"EmployeeAndNonEmployeeStockOptionMember", "presentation": [
"http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee And Non Employee Stock Option
[Member]", "documentation": "Employee and non employee stock option." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-
gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accrued employee compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet
date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes
and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] },
"us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [
"http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount capitalized", "label": "Share-Based
Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r380" ]
}, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember",
"presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "verboseLabel": "Outstanding stock options", "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]",
```

```
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "blue_EmployeeStockPurchasePlanAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "EmployeeStockPurchasePlanAndOtherMember", "presentation": [ "http://www.bluebirdbio.com/role/NetlossspershareAntidilutivesharesDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee stock purchase plan and other", "terseLabel": "Employee stock purchase plan and other", "netLabel": "ESPP shares and other", "label": "Employee Stock Purchase Plan And Other [Member]", "documentation": "Employee stock purchase plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r658" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r658" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r658" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r732" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r658" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r658" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r658" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r658" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails", "http://www.bluebirdbio.com/role/ProductrevenueandreservesSummaryofProductRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r131", "r152", "r153", "r154", "r168", "r169", "r170", "r172", "r180", "r182", "r199", "r250", "r253", "r319", "r384", "r385", "r386", "r394", "r395", "r407", "r408", "r409", "r410", "r411", "r412", "r416", "r432", "r434", "r435", "r436", "r437", "r438", "r462", "r528", "r529", "r530", "r544", "r596" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r701" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r665", "r676", "r686", "r711" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r662", "r673", "r683", "r708" ] }, "blue_ErrorCorrectionEmbeddedLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ErrorCorrectionEmbeddedLeasesMember", "presentation": [ "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to Embedded Leases", "label": "Error Correction, Embedded Leases [Member]", "documentation": "Error Correction, Embedded Leases" } } }, "auth_ref": [] }, "blue_ErrorCorrectionLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ErrorCorrectionLeasesMember", "presentation": [ "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Error Correction, Leases", "label": "Error Correction, Leases [Member]", "documentation": "Error Correction, Leases" } } }, "auth_ref": [] }, "us-gaap_ErrorCorrectionOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ErrorCorrectionOtherMember", "presentation": [ "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Adjustments", "label": "Error Correction, Other [Member]", "documentation": "Error correction to previously issued financial statement classified as other." } } }, "auth_ref": [ "r734", "r735", "r740", "r741", "r742", "r743", "r769" ] }, "us-gaap_ErrorCorrectionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ErrorCorrectionTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatements" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement of Previously Issued Financial Statements", "label": "Error Correction [Text Block]", "documentation": "The entire disclosure for reporting error correction." } } }, "auth_ref": [ "r178" ] }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis", "presentation": [ "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Error Correction, Type [Axis]", "label": "Error Correction, Type [Axis]", "documentation": "Information by type of error correction." } } }, "auth_ref": [ "r173", "r174", "r175", "r179", "r180", "r181", "r182" ] }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "presentation": [ "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "label": "Error Corrections and Prior Period Adjustments Restatement [Line
```

Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r173", "r174", "r175", "r179", "r180", "r181", "r182", "r198"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r707"] }, "blue_FactoringAgreementCashReceiptsCollected": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementCashReceiptsCollected", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/FactoringagreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash receipts collected", "label": "Factoring Agreement, Cash Receipts Collected", "documentation": "Factoring Agreement, Cash Receipts Collected" } } }, "auth_ref": [] }, "blue_FactoringAgreementCashReceiptsCollectedPriorToConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementCashReceiptsCollectedPriorToConsideration", "crdr": "debit", "presentation": ["http://www.bluebirdbio.com/role/FactoringagreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash receipts collected prior to consideration", "label": "Factoring Agreement, Cash Receipts Collected Prior To Consideration", "documentation": "Factoring Agreement, Cash Receipts Collected Prior To Consideration" } } }, "auth_ref": [] }, "blue_FactoringAgreementGainLossOnSaleOfInvoices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementGainLossOnSaleOfInvoices", "crdr": "credit", "presentation": ["http://www.bluebirdbio.com/role/FactoringagreementDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on sale of invoice", "label": "Factoring Agreement, Gain (Loss) On Sale Of Invoices", "documentation": "Factoring Agreement, Gain (Loss) On Sale Of Invoices" } } }, "auth_ref": [] }, "blue_FactoringAgreementPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementPayableCurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Due to factor", "label": "Factoring Agreement Payable, Current", "documentation": "Factoring Agreement Payable, Current" } } }, "auth_ref": [] }, "blue_FactoringAgreementPayableCurrentDerecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementPayableCurrentDerecognized", "crdr": "debit", "presentation": ["http://www.bluebirdbio.com/role/FactoringagreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Due to factor, value derecognized", "label": "Factoring Agreement Payable, Current, Derecognized", "documentation": "Factoring Agreement Payable, Current, Derecognized" } } }, "auth_ref": [] }, "blue_FactoringAgreementReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementReceivableCurrent", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Due from factor", "label": "Factoring Agreement Receivable, Current", "documentation": "Factoring Agreement Receivable, Current" } } }, "auth_ref": [] }, "blue_FactoringAgreementReceivableCurrentNetOfUncollectible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementReceivableCurrentNetOfUncollectible", "crdr": "credit", "presentation": ["http://www.bluebirdbio.com/role/FactoringagreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum loss exposure", "label": "Factoring Agreement Receivable, Current, Net Of Uncollectible", "documentation": "Factoring Agreement Receivable, Current, Net Of Uncollectible" } } }, "auth_ref": [] }, "blue_FactoringAgreementReceivableUncollectableAmountsNetOfAccruedFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementReceivableUncollectableAmountsNetOfAccruedFees", "crdr": "debit", "presentation": ["http://www.bluebirdbio.com/role/FactoringagreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Uncollectable amounts, net of accrued fees", "label": "Factoring Agreement Receivable, Uncollectable Amounts, Net Of Accrued Fees", "documentation": "Factoring Agreement Receivable, Uncollectable Amounts, Net Of Accrued Fees" } } }, "auth_ref": [] }, "blue_FactoringAgreementServicingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementServicingFees", "crdr": "debit", "presentation": ["http://www.bluebirdbio.com/role/FactoringagreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Servicing fees", "label": "Factoring Agreement, Servicing Fees", "documentation": "Factoring Agreement, Servicing Fees" } } }, "auth_ref": [] }, "blue_FactoringAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FactoringAgreementsTextBlock", "presentation": ["http://www.bluebirdbio.com/role/Factoringagreement"], "lang": { "en-us": { "role": { "terseLabel": "Factoring agreement", "label": "Factoring Agreements [Text Block]", "documentation": "Factoring Agreements" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails", "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r420", "r421", "r425"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails", "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r420", "r421", "r425"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r11"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": ["r11", "r66"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r65", "r66"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r294", "r340", "r341", "r342", "r343", "r344", "r345", "r421", "r469", "r470", "r471", "r629", "r630", "r636", "r637", "r638"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r420", "r421", "r423", "r424", "r426"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.bluebirdbio.com/role/Fairvaluemeasurements"], "lang": { "en-us": { "role": { "terseLabel": "Fair value measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r419"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Quoted prices in active markets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r294", "r340", "r345", "r421", "r469", "r636", "r637", "r638"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Significant other observable inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r294", "r340", "r345", "r421", "r470", "r629", "r630",

```
"r636", "r637", "r638" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r294", "r340", "r341", "r342", "r343", "r344", "r345", "r421", "r471", "r629", "r630", "r636", "r637", "r638" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "blue_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetBeneficiaryInterestObtainedFromTransferredInvoices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetBeneficiaryInterestObtainedFromTransferredInvoices", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beneficiary interest obtained in transferred invoices", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Beneficiary Interest Obtained From Transferred Invoices", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Beneficiary Interest Obtained From Transferred Invoices" } } }, "auth_ref": [] }, "blue_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetProceedsFromTransferredInvoices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetProceedsFromTransferredInvoices", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from previously transferred invoices", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Proceeds From Transferred Invoices", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Proceeds From Transferred Invoices" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsFactoringAgreementReconciliationofBeginningandEndingBalancesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Level 3 financial assets, beginning of period", "periodEndLabel": "Level 3 financial assets, end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r11" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r294", "r340", "r341", "r342", "r343", "r344", "r345", "r469", "r470", "r471", "r629", "r630", "r636", "r637", "r638" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r419", "r426" ] }, "blue_FinanceLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FinanceLeaseCost", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total fixed finance lease cost", "label": "Finance Lease, Cost", "documentation": "Finance Lease, Cost" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails": { "parentTag": "blue_FinanceLeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r446", "r452", "r642" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows used for finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r448", "r457" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present Value of Lease Liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r445", "r460" ] }, "us-gaap_FinanceLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityAbstract", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financing lease liability, current portion", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r445" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Commitments Under Financing Leases", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r823" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financing lease liability, net of current portion", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r445" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r460" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r460" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r460" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r460" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r460" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r823" ] }, "blue_FinanceLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
```

"2029 and thereafter", "label": "Finance Lease, Liability, to be Paid, After Year Four", "documentation": "Finance Lease, Liability, to be Paid, After Year Four" } } },
"auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0,
"order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails"], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Less: Imputed Interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted
obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r460"] }, "us-
gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr":
"credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Principal payments on finance leases", "verboseLabel": "Financing cash flows for finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount
of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r447", "r457"] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails": { "parentTag": "blue_FinanceLeaseCost", "weight": 1.0, "order": 2.0
} }, "presentation": ["http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Amortization expense", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset
from finance lease." } } }, "auth_ref": ["r446", "r452", "r642"] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average
discount rate - finance leases", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease
calculated at point in time." } } }, "auth_ref": ["r459", "r642"] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average
remaining lease term - finance leases", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for
finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r458",
"r642"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis",
"presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"], "lang":
{ "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } }
}, "auth_ref": ["r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237",
"r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r302", "r316", "r413", "r466",
"r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488",
"r489", "r490", "r491", "r492", "r493", "r494", "r495", "r517", "r626", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r772", "r773", "r774", "r775"] }, "us-
gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Gain on foreign currency exchange rates", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and
unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r428", "r429", "r430", "r431", "r593"] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r669",
"r680", "r690", "r715"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r669", "r680", "r690",
"r715"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r669",
"r680", "r690", "r715"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": {
"terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r669",
"r680", "r690", "r715"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone
Recovery, Individual Name" } } }, "auth_ref": ["r669", "r680", "r690", "r715"] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0, "order": 1.0 }, "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag":
"us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Gain from sale of priority review voucher, net", "negatedTerseLabel": "Gain from sale of priority review voucher", "label": "Gain (Loss) on Disposition of
Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in
securities of subsidiaries or equity method investee." } } }, "auth_ref": ["r762"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag":
"us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": {
"role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits
arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": ["r138", "r267", "r500",
"r627", "r643", "r779", "r780"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr":
"credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-
gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": {
"totalLabel": "Gross margin", "terseLabel": "Gross margin", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating
expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r93", "r165", "r200", "r207", "r211", "r213", "r249", "r277", "r278", "r279", "r280",
"r281", "r282", "r283", "r284", "r285", "r427", "r624", "r785"] }, "us-gaap_IncomeLossAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "IncomeLossAttributableToParent", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": {
"totalLabel": "(Loss) income before income taxes", "label": "Income (Loss) Attributable to Parent, before Tax", "documentation": "Amount, before tax, of income (loss)
attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref":
["r95", "r154"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract",
"lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation":
["http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Income Statement Location", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } },
"auth_ref": ["r268", "r269", "r579"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncomeStatementLocationDomain", "presentation": [
"http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Income Statement Location", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": ["r269", "r579"] },
"us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": {
"en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock",
"presentation": ["http://www.bluebirdbio.com/role/Incometaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax Disclosure [Text Block]",
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial
position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a
significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": ["r166", "r389",
"r391", "r392", "r393", "r396", "r398", "r401", "r402", "r543"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
"http://www.bluebirdbio.com/role/IncometaxesDetails",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": {
"negatedLabel": "Income tax (expense) benefit", "verboseLabel": "Income tax expense (benefit)", "terseLabel": "Income tax (expense) benefit", "label": "Income Tax Expense
(Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } },
"auth_ref": ["r120", "r128", "r181", "r182", "r205", "r390", "r397", "r520"] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the period for income taxes", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": ["r35", "r37"] }, "blue_IncreaseDecreaseAccruedInterestPayableUnderFinanceLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "IncreaseDecreaseAccruedInterestPayableUnderFinanceLease", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accrued interest payable under finance lease", "label": "Increase (Decrease) Accrued Interest Payable Under Finance Lease", "documentation": "Increase (Decrease) Accrued Interest Payable Under Finance Lease" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": ["r761"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r497", "r761"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "blue_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase Decrease In Operating Lease Liabilities", "documentation": "Increase (decrease) in operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "negatedTerseLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r5"] }, "blue_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [
"http://www.bluebirdbio.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in finance lease right of use asset", "label": "Increase (Decrease) In Right-Of-Use Asset Obtained In Exchange For Finance Lease Liability", "documentation": "Increase (Decrease) In Right-Of-Use Asset Obtained In Exchange For Finance Lease Liability" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": ["http://www.bluebirdbio.com/role/NetlosspershareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r188", "r189", "r190", "r194", "r351"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r672", "r680", "r690", "r707", "r715", "r719", "r727"] },
"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r725"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r661", "r731"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r661", "r731"] },
"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r661", "r731"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r52", "r53"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails",
"http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": ["r71", "r119", "r155", "r204", "r440", "r580", "r654", "r842"] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivable", "crdr": "debit", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable", "label": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": ["r756", "r845"] }, "blue_InterestReceivableWriteOff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "InterestReceivableWriteOff", "crdr": "debit", "presentation": [
"http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable, write-offs", "label": "Interest Receivable, Write-Off", "documentation": "Interest Receivable, Write-Off" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.bluebirdbio.com/role/Inventory"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r262"] }, "blue_InventoryExcessValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "InventoryExcessValuationReserves", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Excess inventory reserve", "label": "Inventory, Excess Valuation Reserves", "documentation": "Inventory, Excess Valuation Reserves" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bluebirdbio.com/role/InventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label":

```
"Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r106", "r617" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 },
"http://www.bluebirdbio.com/role/InventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.bluebirdbio.com/role/InventoryDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Inventory", "totalLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r144", "r615", "r643" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": {
"http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r122", "r136", "r143", "r262", "r263", "r264", "r498", "r621" ] }, "us-
gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet",
"weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label":
"Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r106", "r619" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": {
"http://www.bluebirdbio.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in progress", "label": "Inventory, Work in Process, Net of Reserves",
"documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r106", "r618" ] }, "us-gaap_InvestmentIncomeInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-
gaap_IncomeLossAttributableToParent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r97", "r203" ] }, "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "InvestmentsAndCash", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and marketable securities", "label": "Investments and Cash", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": [ "r835", "r836" ] }, "blue_JanuaryUnderwritingAgreementMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.bluebirdbio.com/20240331", "localname": "JanuaryUnderwritingAgreementMember", "presentation": [ "http://www.bluebirdbio.com/role/EquityDetails"
], "lang": { "en-us": { "role": { "terseLabel": "January Underwriting Agreement", "label": "January Underwriting Agreement [Member]", "documentation": "January
Underwriting Agreement" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost",
"crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": {
"role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r451",
"r642" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [
"http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other information",
"label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost",
"label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r822" ] }, "us-
gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel":
"Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "blue_LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.bluebirdbio.com/20240331", "localname": "LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating right of use assets", "label": "Lessee, Increase (Decrease) In Operating Lease, Right-of-Use Asset", "documentation": "Lessee, Increase (Decrease) In Operating Lease, Right-of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r450" ] }, "us-
gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [
"http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r450" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Future Minimum Commitments Under Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r823" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true },
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label":
"Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [
"r460" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r460" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r460" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r460" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r460" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit",
"calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label":
"Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r823" ] },
"blue_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname":
"LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "2029 and thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight":
1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": {
"negatedLabel": "Less: Imputed Interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r460" ] }, "us-
gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm",
"presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal term", "label": "Lessee, Operating Lease,
```

Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r821"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.bluebirdbio.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.bluebirdbio.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease period", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r821"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.bluebirdbio.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r443"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": ["r20", "r165", "r249", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r404", "r405", "r406", "r427", "r554", "r623", "r656", "r785", "r826", "r827"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r86", "r117", "r513", "r643", "r765", "r776", "r820"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r22", "r135", "r165", "r249", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r404", "r405", "r406", "r427", "r643", "r785", "r826", "r827"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": ["http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r764"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit", "verboseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r19"] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": ["http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": ["r19", "r764"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": ["http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": ["http://www.bluebirdbio.com/role/CoverPage"], "lang": { "en-us": { "role": { "verboseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Term loan debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r141"] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.bluebirdbio.com/role/Termloandebt"], "lang": { "en-us": { "role": { "terseLabel": "Term loan debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r109"] }, "us-gaap_LongTermPurchaseCommitmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentTextBlock", "presentation": ["http://www.bluebirdbio.com/role/CommitmentandcontingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Non-cancelable Contractual Obligations", "label": "Long-Term Purchase Commitment [Table Text Block]", "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r24"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r24", "r55"] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": ["r216", "r635", "r789", "r837", "r838"] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities:", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": ["r75", "r755"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r273", "r274", "r275", "r276", "r346", "r496", "r527", "r546", "r547", "r601", "r602", "r603", "r604", "r605", "r610", "r611", "r625", "r633", "r639", "r645", "r787", "r828", "r829", "r830", "r831", "r832", "r833"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r699"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r699"] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": ["http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected Dividend Rate", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": ["r818"] }, "us-gaap_MeasurementInputOptionVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputOptionVolatilityMember", "presentation": ["http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected Volatility", "label": "Measurement Input, Option Volatility [Member]", "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns." } } }, "auth_ref": ["r818"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk Free Interest Rate", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r818"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r422"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r718"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r726"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": ["r216", "r635", "r789", "r837", "r838"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r700"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [

"http://www.bluebirdbio.com/role/Descriptionofthebusiness"], "lang": { "en-us": { "role": { "terseLabel": "Description of the business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r123", "r129"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r162"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r162"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "negatedTerseLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r100", "r101", "r102"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/NetlosspershareNarrativeDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "netLabel": "Net (loss) income", "terseLabel": "Net (loss) income", "negatedTerseLabel": "Net (loss) income", "verboseLabel": "Net income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r91", "r102", "r118", "r133", "r147", "r150", "r154", "r165", "r171", "r173", "r174", "r176", "r177", "r181", "r182", "r191", "r200", "r207", "r211", "r213", "r249", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r418", "r427", "r515", "r576", "r594", "r595", "r624", "r654", "r785"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recent accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r699"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r669", "r680", "r690", "r707", "r715"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r697"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r696"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r707"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r726"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r726"] }, "blue_NoncashInterestRelatedToDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "NoncashInterestRelatedToDebt", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Noncash interest related to debt", "label": "Noncash Interest Related to Debt", "documentation": "Noncash Interest Related to Debt" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow disclosures from investing and financing activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "blue_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncash operating lease expense", "label": "Noncash Lease Expense", "documentation": "Noncash Lease Expense" } } }, "auth_ref": [] }, "blue_NoncashResearchAndDevelopmentExpenseFinanceLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "NoncashResearchAndDevelopmentExpenseFinanceLease", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncash research and development expense (finance lease)", "label": "Noncash, Research And Development Expense, Finance Lease", "documentation": "Noncash, Research And Development Expense, Finance Lease" } } }, "auth_ref": [] }, "blue_NumberOfAdditionalControlledEnvironmentRooms": { "xbrltype": "integerItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "NumberOfAdditionalControlledEnvironmentRooms", "presentation": ["http://www.bluebirdbio.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of additional controlled environment rooms", "label": "Number of Additional Controlled Environment Rooms", "documentation": "Number of Additional Controlled Environment Rooms" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in

```
business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r770" ] }, "blue_NumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "NumberOfTranches", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tranches", "label": "Number of Tranches", "documentation": "Number of Tranches" } } }, "auth_ref": [] } }, "blue_OfferingExpensesIncludedInAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "OfferingExpensesIncludedInAccountsPayableAndAccruedExpenses", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Offering expenses included in accounts payable and accrued expenses", "label": "Offering Expenses Included In Accounts Payable And Accrued Expenses", "documentation": "Offering Expenses Included In Accounts Payable And Accrued Expenses" } } }, "auth_ref": [] }, "blue_OneIndividualCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "OneIndividualCustomerMember", "presentation": [ "http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Individual Customer", "label": "One Individual Customer [Member]", "documentation": "One Individual Customer" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income from operations", "terseLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r200", "r207", "r211", "r213", "r624" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r453", "r642" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present Value of Lease Liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r445" ] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityAbstract", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r445" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r445" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows used for operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r449", "r457" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r444" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate - operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r459", "r642" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term - operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r458", "r642" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation, principles of consolidation and significant accounting policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r77", "r103", "r104", "r112" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r21" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash and other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r139" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r10", "r15", "r148", "r151", "r157", "r432", "r433", "r438", "r501", "r516", "r757", "r758" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total other comprehensive (loss) income", "verboseLabel": "Other comprehensive (loss) income", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r4", "r8", "r113", "r148", "r151" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunauditedParenthetical", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "Other comprehensive income (loss), tax", "verboseLabel": "Other comprehensive income, net of tax (benefit) expense of $0.0\u00a0million for the three months ended March 31, 2023", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r2", "r152", "r157", "r390", "r399", "r400", "r432", "r436", "r438", "r501", "r516" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-cash items", "negatedTerseLabel": "Other non-cash items", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r102" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r98" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r699" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r667", "r678", "r688", "r713" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r670", "r681", "r691", "r716" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r670", "r681", "r691", "r716" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://www.bluebirdbio.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inclusive of Shares Pursuant to Over Allotment Option Granted", "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "blue_PaidInKindMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "PaidInKindMember", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paid In Kind", "label": "Paid In Kind [Member]", "documentation": "Paid In Kind" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r695" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r34" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "negatedTerseLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r32", "r160", "r217" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r99" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property, plant and equipment", "negatedTerseLabel": "Purchase of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r99" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r698" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r698" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r697" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r707" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r700" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r696" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r80", "r305" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r80", "r556" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r80", "r305" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r80", "r556", "r574", "r843", "r844" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and outstanding at March\u00a031, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r80", "r509", "r643" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } },
```

```
"presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r145", "r265", "r266", "r616" ] }, "blue_PrimeFloorRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "PrimeFloorRateMember", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Floor Rate", "label": "Prime Floor Rate [Member]", "documentation": "Prime Floor Rate" } } }, "auth_ref": [] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of Prior Year Presentation", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r752" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of debt, net of fees paid to lender", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r760" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options and ESPP contributions", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r3", "r14" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds allocated to detachable warrants issued in conjunction with debt", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from long-term lines of credit", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r160", "r161", "r771" ] }, "us-gaap_ProceedsFromOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromOtherDebt", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the transfer of invoices", "label": "Proceeds from Other Debt", "documentation": "Amount of cash inflow from debt classified as other." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of marketable securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r31", "r160", "r217", "r248" ] }, "us-gaap_ProceedsFromSalesOfAssetsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSalesOfAssetsInvestingActivities", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of priority review voucher", "label": "Proceeds from Sales of Assets, Investing Activities", "documentation": "Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities." } } }, "auth_ref": [ "r733" ] }, "blue_ProceedsReceivedDecember202024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ProceedsReceivedDecember202024Member", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds Received December 20, 2024", "label": "Proceeds Received December 20, 2024 [Member]", "documentation": "Proceeds Received December 20, 2024" } } }, "auth_ref": [] }, "blue_ProceedsReceivedJune302025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ProceedsReceivedJune302025Member", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds Received June 30, 2025", "label": "Proceeds Received June 30, 2025 [Member]", "documentation": "Proceeds Received June 30, 2025" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.bluebirdbio.com/role/ProductrevenueandreservesSummaryofProductRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r214", "r499", "r521", "r522", "r523", "r524", "r525", "r526", "r613", "r634", "r644", "r739", "r783", "r784", "r789", "r837" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.bluebirdbio.com/role/ProductrevenueandreservesSummaryofProductRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]" } } }, "auth_ref": [ "r214", "r499", "r521", "r522", "r523", "r524", "r525", "r526", "r613", "r634", "r644", "r739", "r783", "r784", "r789", "r837" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r506", "r514", "r643" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r107" ] }, "blue_ProvisionForContractWithCustomerRebateLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ProvisionForContractWithCustomerRebateLiability", "crdr": "debit", "presentation": [ "http://www.bluebirdbio.com/role/ProductrevenueandreservesRebateLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for rebates", "label": "Provision For Contract With Customer, Rebate Liability", "documentation": "Provision For Contract With Customer, Rebate Liability" } } }, "auth_ref": [] }, "blue_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "PublicOfferingMember", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Offering", "label": "Public Offering [Member]", "documentation": "Public Offering" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r695" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": { "r695" } }, "blue_QualityTestingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "QualityTestingFacilityMember", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quality Testing Facility", "label": "Quality Testing Facility [Member]", "documentation": "Quality Testing Facility" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r273", "r274", "r275", "r276", "r339", "r346", "r375", "r376", "r377", "r472", "r496", "r527", "r546", "r547", "r601", "r602", "r603", "r604", "r605", "r610", "r611", "r625", "r633", "r639", "r645", "r648", "r781", "r787", "r829", "r830", "r831", "r832", "r833" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r273", "r274", "r275", "r276", "r339", "r346", "r375", "r376", "r377", "r472", "r496", "r527", "r546", "r547", "r601", "r602", "r603", "r604", "r605", "r610", "r611", "r625", "r633", "r639", "r645", "r648", "r781", "r787", "r829", "r830", "r831", "r832", "r833" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "blue_ReceivablesAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ReceivablesAndOtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables and other current assets", "label": "Receivables And Other Current Assets", "documentation": "Receivables and other current assets." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r662", "r673", "r683", "r708" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r76", "r388", "r834" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement [Axis]", "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r132", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r198", "r251", "r252", "r395", "r415", "r416", "r417", "r418", "r442", "r461", "r462", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r539" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r663", "r674", "r684", "r709" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r664", "r675", "r685", "r710" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r671", "r682", "r692", "r717" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement [Domain]", "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r132", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r198", "r251", "r252", "r395", "r415", "r416", "r417", "r418", "r442", "r461", "r462", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r539" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other current assets", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r753", "r763" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in restricted cash and other non-current assets", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r121", "r754", "r763" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "negatedTerseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r83", "r111", "r512", "r532", "r537", "r542", "r557", "r643" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r131", "r168", "r169", "r170", "r172", "r180", "r182", "r250", "r253", "r384", "r385", "r386", "r394", "r395", "r407", "r409", "r410", "r412", "r416", "r528", "r530", "r544", "r843" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails", "http://www.bluebirdbio.com/role/ProductrevenueandreservesSummaryofProductRevenueDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue, net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r201", "r202", "r206", "r209", "r210", "r214", "r215", "r216", "r336", "r337", "r499" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r216", "r736" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r130", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r612" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/Productrevenueandreserves" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue and reserves", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from
```

contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r130", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r338"] }, "us-gaap_RevenueNotFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueNotFromContractWithCustomer", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "label": "Revenue Not from Contract with Customer", "documentation": "Amount of revenue that is not accounted for under Topic 606." } } }, "auth_ref": ["r744"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "terseLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r156", "r165", "r201", "r202", "r206", "r209", "r210", "r214", "r215", "r216", "r249", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r427", "r504", "r785"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "presentation": ["http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period, Error Correction, Adjustment", "label": "Revision of Prior Period, Error Correction, Adjustment [Member]" } } }, "auth_ref": ["r173", "r174", "r175", "r179", "r180", "r181", "r182"] }, "blue_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement", "crdr": "debit", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for financial lease liabilities", "label": "Right-Of-Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement", "documentation": "Right-Of-Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r726"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r726"] }, "blue_SKYSONAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "SKYSONAMember", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesSummaryofProductRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "SKYSONA", "label": "SKYSONA [Member]", "documentation": "SKYSONA" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/EquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock offering", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/EquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/EquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "blue_SaleOfStockOptionToPurchaseAdditionalSharesExercisePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "SaleOfStockOptionToPurchaseAdditionalSharesExercisePeriod", "presentation": ["http://www.bluebirdbio.com/role/EquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Option to purchase additional shares, exercise period", "label": "Sale Of Stock, Option To Purchase Additional Shares, Exercise Period", "documentation": "Sale of Stock, Option To Purchase Additional Shares, Exercise Period" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.bluebirdbio.com/role/EquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock price per share (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "blue_SaleOfStockValueOfSharesAvailableForIssueInTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "SaleOfStockValueOfSharesAvailableForIssueInTransaction", "crdr": "debit", "presentation": ["http://www.bluebirdbio.com/role/EquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Value of shares available for issue in transaction", "label": "Sale Of Stock, Value Of Shares Available For Issue In Transaction", "documentation": "Sale Of Stock, Value Of Shares Available For Issue In Transaction" } } }, "auth_ref": [] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioPreviouslyReportedMember", "presentation": ["http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "As Previously Reported", "label": "Previously Reported [Member]" } } }, "auth_ref": ["r132", "r168", "r170", "r171", "r172", "r173", "r174", "r182", "r198", "r395", "r415", "r416", "r417", "r442", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r539", "r738", "r740", "r741", "r742", "r769", "r777", "r778", "r817", "r824", "r825"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": ["r44"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.bluebirdbio.com/role/NetlosspershareTables"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r44"] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock-Based Compensation Expense by Award Type", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": ["r61"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense by Classification", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r61"] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails", "http://www.bluebirdbio.com/role/ProductrevenueandreservesSummaryofProductRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Revenue from External Customers by Products and Services [Table]", "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": ["r51"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "presentation": ["http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "label": "Schedule of Error Corrections and Prior Period Adjustment

Restatement [Table]", "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments." } } }, "auth_ref": ["r173", "r174", "r175", "r179", "r180", "r181", "r182", "r198"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": ["http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Corrections to Impacted Financial Statements", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": ["r41", "r42", "r43"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.bluebirdbio.com/role/FairvaluemeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r420", "r421"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.bluebirdbio.com/role/InventoryTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r17", "r87", "r88", "r89"] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Common Stock Awards", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": ["r60"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r348", "r350", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity Under Plan", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r59"] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": ["http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": ["http://www.bluebirdbio.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r657"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": ["http://www.bluebirdbio.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r659"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r96"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r369"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r369"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r367"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r367"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested balance at beginning of period (in shares)", "periodEndLabel": "Unvested balance at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r364", "r365"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares (in thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested balance at beginning of period (in dollars per share)", "periodEndLabel": "Unvested balance at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r364", "r365"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- average grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r368"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r368"] }, "blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAuthorized", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase in shares authorized (in shares)", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Increase In Shares Authorized", "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Increase In Shares Authorized" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r348", "r350", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares reserved for future issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r641"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r58"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r358"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r358"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Canceled, forfeited, or expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r796"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Canceled, forfeited, or expired (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r796"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r360"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in shares)", "periodEndLabel": "Outstanding at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r356", "r357"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares (in thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in dollars per share)", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r356", "r357"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average exercise price per share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of

performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r372" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r372" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock issued under plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": { "r58" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r361" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": { "r360" } }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r454", "r642"] }, "blue_SixIndividualCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "SixIndividualCustomersMember", "presentation": ["http://www.bluebirdbio.com/role/ProductrevenueandreservesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Six Individual Customers", "label": "Six Individual Customers [Member]", "documentation": "Six Individual Customers" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r27", "r131", "r152", "r153", "r154", "r168", "r169", "r170", "r172", "r180", "r182", "r199", "r250", "r253", "r319", "r384", "r385", "r386", "r394", "r395", "r407", "r408", "r409", "r410", "r411", "r412", "r416", "r432", "r434", "r435", "r436", "r437", "r438", "r462", "r528", "r529", "r530", "r544", "r596"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r168", "r169", "r170", "r199", "r499", "r540", "r545", "r548", "r549", "r550", "r551", "r552", "r553", "r556", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r569", "r570", "r571", "r572", "r573", "r575", "r577", "r578", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r596", "r649"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": ["r168", "r169", "r170", "r199", "r499", "r540", "r545", "r548", "r549", "r550", "r551", "r552", "r553", "r556", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r569", "r570", "r571", "r572", "r573", "r575", "r577", "r578", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r596", "r649"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r666", "r677", "r687", "r712"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Purchase of shares under ESPP (in shares)", "terseLabel": "Purchase of common stock under employee stock purchase plan (ESPP) (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r10", "r80", "r81", "r111"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r80", "r81", "r111", "r541", "r596", "r606"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of stock options (in shares)", "terseLabel": "Stock option share exercised (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r80", "r81", "r111", "r361"] }, "blue_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units (in shares)", "label": "Stock Issued During Period Shares Vesting Of Restricted Stock Units", "documentation": "Stock issued during period shares vesting of restricted stock units." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of shares under ESPP", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r10", "r80", "r81", "r111"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r10", "r80", "r81", "r111", "r544", "r596", "r606", "r655"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",

```
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r10", "r27", "r111" ] }, "blue_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units", "label": "Stock Issued During Period Value Vesting Of Restricted Stock Units", "documentation": "Stock issued during period value vesting of restricted stock units." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofChangesinStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r81", "r84", "r85", "r105", "r558", "r574", "r597", "r598", "r643", "r656", "r765", "r776", "r820", "r843" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.bluebirdbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r110", "r164", "r304", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r319", "r414", "r599", "r600", "r607" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r456", "r642" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r439", "r464" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r439", "r464" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r439", "r464" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r439", "r464" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r439", "r464" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/Subsequentevents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r463", "r465" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/EquityDetails", "http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails", "http://www.bluebirdbio.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary, Sale of Stock [Line Items]", "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "blue_SummaryOfContractWithCustomerRefundLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "SummaryOfContractWithCustomerRefundLiabilityTableTextBlock", "presentation": [ "http://www.bluebirdbio.com/role/ProductrevenueandreservesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Contract With Customer, Refund Liability", "label": "Summary Of Contract With Customer, Refund Liability [Table Text Block]", "documentation": "Summary Of Contract With Customer, Refund Liability" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r706" ] }, "blue_TermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "TermLoanFacilityMember", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facility", "label": "Term Loan Facility [Member]", "documentation": "Term Loan Facility" } } }, "auth_ref": [] }, "blue_TermLoanFacilityTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "TermLoanFacilityTrancheFourMember", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facility Tranche Four", "label": "Term Loan Facility Tranche Four [Member]", "documentation": "Term Loan Facility Tranche Four" } } }, "auth_ref": [] }, "blue_TermLoanFacilityTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "TermLoanFacilityTrancheThreeMember", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facility Tranche Three", "label": "Term Loan Facility Tranche Three [Member]", "documentation": "Term Loan Facility Tranche Three" } } }, "auth_ref": [] }, "blue_TermLoanFacilityTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "TermLoanFacilityTrancheTwoMember", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facility Tranche Two", "label": "Term Loan Facility Tranche Two [Member]", "documentation": "Term Loan Facility Tranche Two" } } }, "auth_ref": [] }, "blue_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "TermLoanMember", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan" } } }, "auth_ref": [] }, "blue_TheWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "TheWarrantsMember", "presentation": [ "http://www.bluebirdbio.com/role/SubsequenteventsDetails", "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Warrants", "label": "The Warrants [Member]", "documentation": "The Warrants" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r698" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r705" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement.", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r725" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r727" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bluebirdbio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r302", "r316", "r413", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r517", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r772", "r773", "r774", "r775" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r728" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r729" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType",
```

```
"nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r727" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r727" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r730" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r728" ] }, "us-gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryAndGovernmentMember", "presentation": [
"http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government agency securities and treasuries", "label": "US Treasury and Government [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r505", "r636", "r839" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r724" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year One", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r271" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r271" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r271" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r271" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase commitments", "totalLabel": "Total purchase commitments", "label": "Unrecorded Unconditional Purchase Obligation", "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts)." } } }, "auth_ref": [ "r271" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in remainder of current fiscal year." } } }, "auth_ref": [] },
"blue_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bluebirdbio.com/20240331", "localname": "UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour", "crdr": "credit", "calculation": {
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, After Year Four", "documentation": "Unrecorded Unconditional Purchase Obligation, to be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.bluebirdbio.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r48", "r49", "r50", "r124", "r125", "r126", "r127" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofOperatingLeaseCostsandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r455", "r642" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [
"http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [
"http://www.bluebirdbio.com/role/NetlosspershareAntidilutivesharesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r646", "r647", "r650", "r651", "r652", "r653" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Relative fair value allocated to the initial warrants", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants and rights outstanding, measurement input", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r424" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.bluebirdbio.com/role/TermloandebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants and rights outstanding, contractual term (in years)", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r819" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
"http://www.bluebirdbio.com/role/NetlosspershareNarrativeDetails",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of common shares used in computing net (loss) income per share - diluted (in shares)", "netLabel": "Diluted weighted-average common shares outstanding (in shares)", "verboseLabel": "Weighted-average number of common shares used in computing net income per share - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r186", "r194" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.bluebirdbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
```

```
"http://www.bluebirdbio.com/role/NetlossprovisionforincometaxesNarrativeDetails",
"http://www.bluebirdbio.com/role/NetlossshareNarrativeDetails",
"http://www.bluebirdbio.com/role/RestatementofPreviouslyIssuedFinancialStatementsScheduleofOperationsandComprehensiveLossDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Weighted-average number of common shares used in computing net (loss) income per share - basic (in shares)", "verboseLabel": "Basic weighted-average
common shares outstanding (in shares)", "netLabel": "Weighted-average number of common shares used in computing net income per share - basic (in shares)", "label":
"Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units
and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding
to the total time in that period." } } }, "auth_ref": [ "r185", "r194" ] }, "blue_ZYNTEGLOMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.bluebirdbio.com/20240331", "localname": "ZYNTEGLOMember", "presentation": [
"http://www.bluebirdbio.com/role/ProductrevenueandreservesSummaryofProductRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ZYNTEGLO", "label":
"ZYNTEGLO [Member]", "documentation": "ZYNTEGLO" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r2": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r5": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10",
"Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r8": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10",
"Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r11": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10",
"Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-
50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "
(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r15": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r18": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r29": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-
45-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45",
"Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r32": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-
45-15" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45",
"Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r36": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r38": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" },
"r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph":
"5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r43": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r46": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r49": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" },
"r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph":
"40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-
50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-
50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI",
```

```
"https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-
10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r64": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r67": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r70": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-
45-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r77": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org//205/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-
1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic":
"210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r91": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-
03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.20)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r101": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-
10-50-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org//440/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic":
"505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-
45-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210",
"Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-
```

{"50-1": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"}, "r125": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"}, "r126": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"}, "r127": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"}, "r128": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"}, "r129": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent"}, "r130": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent"}, "r131": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"}, "r132": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"}, "r133": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"}, "r134": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"}, "r135": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"}, "r136": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"}, "r137": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r138": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r139": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r140": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r141": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r142": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r143": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r144": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r145": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r146": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"}, "r147": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"}, "r148": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"}, "r149": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"}, "r150": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"}, "r151": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"}, "r152": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"}, "r153": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"}, "r154": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"}, "r155": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"}, "r156": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"}, "r157": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"}, "r158": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"}, "r159": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"}, "r160": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"}, "r161": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"}, "r162": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"}, "r163": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"}, "r164": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"}, "r165": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"}, "r166": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"}, "r167": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"}, "r168": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"}, "r169": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"}, "r170": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"}, "r171": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"}, "r172": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"}, "r173": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"}, "r174": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"}, "r175": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"}, "r176": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"}, "r177": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"}, "r178": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"}, "r179": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"}, "r180": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"}, "r181": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"}, "r182": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"}, "r183": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"}, "r184": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent"}, "r185": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",

"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

```
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r385": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r386": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r387": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r388": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r390": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r394": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r395": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8",
"Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r396": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r397": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r398": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r399": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11" }, "r400": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r401": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-
10-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r408": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r409": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r410": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r411": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r412": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r413": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r414": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r415": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r416": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r417": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r418": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r419": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
```

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-
50-50-4" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r494": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r495": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r496": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r497": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r498": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-
320-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r507": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r508": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r509": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r510": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r511": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r512": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r513": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r514": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r515": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r516": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r517": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r518": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r519": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r520": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r521": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r522": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r523": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r524": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r525": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r526": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r527": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r528": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r530": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r531": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r532": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r533": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r534": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r536": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r537": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r538": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
```

"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange

Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)",

"Publisher": "SEC" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":

*"https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" } } } ZIP 83 0001293971-24-000040-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001293971-24-000040-xbrl.zip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`M^-5SGP K0WSQ6:S2F:-BJ.Z:4[M*0YA0ZBB N^1'TGZ./#HEY7A0#AG@2:L %8T7'UXDE4K3W<4-A(KN"H^N)% M.]?ZG#"LA W#B@JKO%[X._%MTG/H/=@O2[W.ANSK4X"M (9>4]B [OEAG#6L3?/?;=VUH? FW(;VPDG?AK,Z8L!C7\]P-%^.3&=N,%TD18[GUVP MIK@!Y-P6,_4K9Q(I6+,)LF!=O.+]=43-$"0?MDD!"9/"%Q"'S\2-\1:!]+0,(TE+@S96^(&88M =FS7],6G-$EW*!+'MX0-E-[Y'DPD'-\Y,+>N M:^'1*2-\QFQ_+MXGV8^>XCZ WX@;]8D91IA_E}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

*C:EXM,S5!N!Q6M_LYZS[^X_:(_M>5,J.])Y]f>_FHP.]:VZC-+=;,UM.\ M##F UD@G5;YXOA(J/)7@A^%>TD*N,C44K(#,.Y(X0!V/ PM^*8)A$<,\+:R M1<;E,25^F;H)+,&S!BEG#A1#4Q5TZ-;B\|C+VTZUNK?W4E8?4%:OQD,MB\H^ MMAS'O;" M>!;+\C[Q DFDKP62_+:>DG.8PDG(,\?[f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{*NH6 7A-4"9AW-]V'S]U_<'93L/*%ALK7KY>;(U!I8A!O6+I M'7,FCVLP.TN':M7#WCRJJL6(.*"S1$(N#7@:4,;ZB?>Q/7/ +Y9T6)\$.2*#T M;0?L:^(X< GZ2&AV_Q79:'2#K=VC\07PY-CNGB34>OYL0FULA\^8[PFMT39`M=88)M8H5X7D8[-*13TW*C 1-5U@=0*"\@X<'"%10@ D47#/"\(S{)6 T')%R8 MB_)"\L>+@4WQI-YKZ*GR(?X3I^9=Pl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|%Z5^X\OM_1_=^\_*UJO;OU_?_,8[D'^[MNGEQ798-\P+V=]GQO!^Q M01[&B3)LH]QVGSWG&52H'?S@11J1:X+&@ILQ*4C%OC\O:(W"? TD01,,1WV[# MF]78PT!7 +0A)Y#$#DX M$$^OI'Y_Y@DP*VQW!P_W G1-1EA" N8O/-4&A\3F"4Y\ ^W!M!"O*Q2> ^(-N MNG#.)4%([B!]"KZ2WXMG80?))%B/^>N?;SVC/SZ1.? 87_//'T:C"7D J3'%IV MG:V]QXS]/@5N OLUF-[JD!<8:1=6>&9 7NP:,&Q-O^TK0/G0\|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{ GC M'87RD)@/(RVI.6'&$]'7D6S:8]31P2R<*#0Q/ %L,>$GZB?1 2=+[M^/1.HLB3@ 8J09=%Q^/ ET^?J1OA%V"/V2%QY@N2$S7J4FIQIL;7(&8PBI^X M9)*2!^'<2:!>Z5&7]FT>IYI*7I,=T4N:F),GXDV0<=:0Of CBX,/(=T/[$ M;Y(T/:1%-)&SS%J=B. YJG):.K;)N%C2:.\TF@GESGH-7K(,,0*?9.*-XG>P M@+">OM1N!|-_"=^NQD)/(!,,YM%(.EY0'JRQ)FU M27/3K :>P8:,1_$]"^ZZ(WZH7%^KRC7(RSA!OUM1[N%ARA?"XO*5-+341"H[M<-1,#4N7F:,3/D9%N%G(^\$HSS9!\@X ^TSBIM_Q8XW^MTA2V2*%5K]_91# M1M1GA0>HQ)!.2;KC#]=[<6/*\;9+=5Y0LYF]3#7E-(V1\$!.G/:@SKT3 MG7US@$EPNOV/KD=GTQQYXB/.E"4|SJ33I'K>NM3(<$/J5B5!VN*$YB?S1FIF M0J"Y+8%)0A@9>AC"BM,8<0-"W9(5N"?G\/2%E:ZD0E)%*8T6XY{[-E|E-L8)7KR8=L8,Q)ZVE8.4=\[*R6" FRV)&G,*! M#OHGAV*]W{$WK1^ M81)]5 ^?28*.*>58"PET@ZMUD]R0)(ZD+NVA)6BK?#N<"-E81H.T"RE/?IS;< MAVL#00EH<@ICM7#["$T< M&[7V@)D@SGBVP>JR)13;!E.KR[1],QIB^:0)EZ 1L<98B&]A:4ES]\0FWTSY MP@PJ*\IWUV$'.2&E7^QI*0B.%!6DQ50MWP;'E&#^@(3J4XK'JS%%#2,I&UK< M=U:=+E40^<]T"\A)WB)/TXD7C]T(8QB16-\O+G3?]H>S^(0Q^186H';>03*Z MA.IX:1)S&T5@*_!S0>`);W3W7!9M8:^=`4< D(8%E$I=\"E>7(TBE?K1J-K-G]P- ;_<7@:/UGF(AC#6<1(W_I8$N%"""\0.D!UGHI!$GFDS/L9PVO+^"_F%UB4#A6FL0/)#OBVHWW%="HPWTF>SZE:6;F M%3PJ+$F+ #/;C((@3I:.#IM/$*@R-1CPAS@\D|Q? G=&_R]-5644C=LKW,!\Z MQZC$XQ'XH(@'E) ^'$)76SL8C9QJ]Q'"&'I9+ [G'M@QN M>>C71)Z3[S!"P/V ML]V:+B0&5V&*_J8L^#0XE> MCY@_GGQ<]G+,EGWV? Q^WW7M=/!4OSC%YH':,CG9A#%"\5Y=+-/@'D.%@X)LD?>723-<5'IYXBE*&'OCT^!.MH>?V^OC&'M^O??)XBVKF K/:]_W,,=TROIB.<\R.;2S:CFVU$;.C/9-Q%%[%F M/V\L.E?"+"#(IX%3C_:!=?#$0%6Q>FFF3UGM-0L.SU7I3LH?I_F_L\61M-]GQ\!_MRKEG5.J!)5XZ:$A!LD]!TIW9>9DF.O+KF?!!LF.&88@ VU(QA@"}X6$ (K"# MV%B=T3;.N@*]@1>P0@\ -DP S;>GA5HB9F.Q9A'@BCQA/B3/C8R3BKPA&)JX M3\C;0\P-B/%&O(L2<\> .(PK&)< T_]\54%24SK+ 9-"X|CL/-XOB?:15N10 M\PW#(I&U&4]9R;&_)8+XZ=AO%ENG"S]XGM9C"R9X/]WXUSG-P'QQJ1+ WSD M^5C46K;7)*/D:F3YN-HL;H$U&-]:E5/#BWSX)\2.&<.DDXZFSLCQ'O4C(ZL M@<9,A1PX'B'E"3B\P-VQV3DI *.OO_^^7(J7.%9S_B#<1SJ/L6M&[QXU#QC M]?6F-0C\25R?K"DH#)3XM!S66"$$??07=L*)*PJ147B)6:S#&-N,N)\2S;!C MH]}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|_3;8V^4BY6%=P=OW@Y_&,D9Q?_B MAA0/"Q+%C=CEV-%DJCM25&+ 7TPP6G,.!8]QZ!.W0V*SAD^K;'Y$ .3>6 R M#ZP H\^0:R:U"HM=\N:M=C3D/M,5 '7[@=]A;GDW-!>:?/,=ML:<0-ZUIN7 M9LI\|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»\"'[>.9 MP3-).E)T%H<_I>@4DS2M6'36I>@\v|=$)Q+UQX+OEEQ=3\|HET*$>,)PIA::0I-&U M6&@Vt-\.;&)Q+U2'=@]>V4W8RDK!67(3;)R<<ZB@UW92;DT<:2!7+-4N?A M^K>;N/W^ZL'*2@*(BB ;]T-Q2$%%10?6/OVX^")]XL_UOTP[TRG!1BE)*; M=CDI!X3(H\)D<>$<+:8.7,CT\E1N9ZPL:$;_.($2RDL&J6W)IPXVGQG.X.O M;/2R]9S;&^8LU;$)W V3*IVP6MG)/#LJW^5D^3M]^<-[:|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|\9C!O!$JP[3;9A3FBB7<(*MJJJ89@F#I+.*M]S0(?=O$-B-F4J?"\Q* ,4<=LO. MQ#C9)'5Q26.[Q'/-K?8JZE7P 5MJ33NAJG3,#2UULK+V$I-FB-9 M]9*W)&]MF5F2E;=P/U-KJUIC]RE,,JLD90>AKS;IV0X[NX]Y. ^A9_X8> XL M; "?/[5TK?DQ/B@UIRY#!E#"\B+<-1"PS5":T9U%J#'I,^1,\2&;#16Z\K=K MFJQCIS(B8TS>ECV&S[=_RB9+.8;&'4? &=@FC]HJ&O%6C=4)'&,D3I\J3ERS< M7'BB#CS14FOM<1FV%;3>$(NQ+UEQX+

N!S2=|Z4R=W+D!&PH:V')$%/_Y M'(|4^)T&(8Q5\?]*#W_ZMAE2BV^/,CRLCZR>9I?JC/$EW5C-%CTGHIPGKH,@ MHM;GR(>%X(=-\D!3O/"W_?
O)LK/KO^.BKV*/1JECM)8[\00G3R8Y MO-2)>>]B&'NWM7>)'\|@C3%)#X>]5^]8=4/27N)/DC7"UMW.3SF8;?IV!.Q<] M6.0O6D.?ME5].KBB-
YSV)*YBWQS0+B/8QM5PY'ACRKDC(<6= Z-?Q1IX@]C'"F M1- I(F@'MR@3@NJECJHO?'"#Q)#0UK#K$S[JHM;&SNRU!);0M+LDCR2/)K7"+K,5$D
M\CEL+S%2EGO@SN(21Y)'!*N_; TK"L(A=>8$=T@>}/lLFYD\n>PO14 M9O6DE3IUM563!5-%0;,4%I(\DCP"N O"B7)=+%%^#GLTM]AM6IEKYZRL[!=\ M'!LU,E@BR2/)
(\ESDN3)Y =N,!Z8XKB9\T%1^<%A|<;0!1+"_"8ZAODA_7 M'JMV4FRUIBBC>; 3JO1J$SBMVE"-%<X.Z<(Y_ MYM[XN2Q-0:E_E4&V@?
5W|[FO5[%%KU!MV!4.D^PNV5VR^[;LOL6)>QG9O8T' MRABZIK9W+T>6+"]97K+\KEWYETX=W-=I4K]&{6_5:FNY$4SFDZ0DSTN>ESR_M+
<\;!SM54=\OV6YKVQ='!D{MRNESIZNZK6[*** M[S9$V"T[&#EDC!.DZ^6#O$]&'M?Y*KA\1_LEV^RZ//[U&:U VIO[^]-_;$"VP&99MO[\;IK';H0HQL:,0<<<>V
M^Z2X7@CO"STEG;+G%-FS@=*VE@G:D]\V4- M,TL2O[5>@X&.O(#UG;KD]4- MM7ys0O6GP2%Y,RWQ3O(G@/68#*!?5K, MD7DJ2 C?=RI_TSY?
Z_=>+$_TSX%86C%%E;7M9CUR;>6LL9%#0,$I*'6=0%D MY*$\E_ UP:]>B!XU3_Ol%;+H(]M 8N@&2>;*#(Z$1^$CA95#O{!!11Q\PI M;:>C.&6$2$ 099:SNX"HP8I5C.7M\
(.#Z,P,W:YIPF3 >QF1,?89/"^[=]]" M-5G:.|ZRF7FBR2H ZCNG,\OHD'A@RBQ<=P53"\&D-TZL TJ!I*P?T97AA)F(MD;1H=VZ5M9)Q<.F_3IS&^9^8IMCJIZ>Q=\4)]_ B(N[0[HH1%7
MJZ* I5>7.YE*:BH/1V37+_8D%98KWOEKHI[!/=6>5_[6V2XF\I=A_M('W'U=^E +>F86)MVY 9@R<(M$W"23>@+6>)QU3_YD3FX4*PM#>Z|
MB>)K=VKAX.==S!P#Q6^KMDO76FE7"PBLK41OGL"J8=\Y8T5GK:+:ST41Q,D& M+)9T4S>2H>;\0LUXOA8^^ \[^%Q& 4R2^@F/C#.4.=3JHI4Y2+-7C*#&!H0M
M(ZE1ZNRT)RR@L6M4A<]/O$G3)GL7LS?UH30GR#T9SFO $UWN?,_9MJCUZ_A[M@&[CQ(3I3BB1V7AIECK-FMHIYA#]RW*\D.@\V\SFC,]U,WR,]6X!*337]N^:1.
M'@*5APY8[Q4ZZ8Z2POX>02Y'26TZE4S<\|)RR&9_P0H"N]XW46^,<#0%^NK MA19!.%5D4/ET35M.G=_$ZW^$[=UWK M*EGCS,(5=YC59E/F59HC:D
&5!U!)HZJP4_EHA4*N(HC:-G!VD/B_Z#Q M@<_4C/SM7;_"QB;V*6"[S\1V<'6_>/X#P/JALL896WO4-1GS*ABN]BIGLP!K ML_JN8Z%N6KIUS%#P%A8
82Q0[\&R6;$?!"2+]9BO;"ZLK9*G;(Y7^@LL]+?) M.K.R.\Y;8*U<$L<),OOKF2N+Q,ZO!:VTC,5#VR.:!G3_:4HCQ6JE34ZNZ*/TZ MS\RNGA/EV")<6MA[F>+
(+&^Q3U836VXKGS*P,@CL[.!*(9M9\6BKOG,+7+'_ M[)W3XAM'S(?E]@C/,3!BP)GK(38YRC. [+=9\\V=VH_=A8&T5N-O[__9Z/-MVW=//[5H_URR8ZE,:H_"X-)S'&J&U,K,4ZSX5--
WKA>4!K9X>`]K7^Y6>'I; M-?>??.E<:SSON_MEN2-PG&RWF&NAS%?A:\8J3Z-3#!=57+ MK4.$*GO.P:E!4A]YZU'!DA]WU2,W76\[+]?;3,^&G5>=Z3)'CTG M'*,_MQ;,'H])- 0+?
(J-X\GQ#-Q',^<'IP:$G/ LGU>B.\3;%[,8IO7.0-V M_A6Y%4O=CC8]9S5LPB9;"6I_X@7/(.T;F)'GT9CN5.F#+X5'DE;"O52'I, M8) J9G*Q!7:\@Y58SU-5VO2*4!XOF-->,S=O$OZYQ*7-
+(3;*(3UN@#5*-)8 M/J#\38N@-X5OLWJBUG(A=Y_I*_5-F^?U!*%G_E"\$9*"-Y>_>KB[8QCQI5[$ MOL,:T.F.P0\#XM. =7^]AB_REFG:32|\3.G5/IS\). MRB#JV8D-
VX2EFWCT:#V/Y'E1:8N'H QB>@V"WE;R-6ECBV-C)OE"(&GCY;]O M8^T#M;U'E-,V.0PQ[&TL&#)6AYS*C) N!Y%=9*FUB 2-CA1$RIRP%D);:T\#> M+/(@)4'L6]LU!%QE-
$DFNS.'Y\4+'#T&=FX>8:39P^KF:QZ$B';,.SBKIZN MZB+T-Y)V[@&KEO)%48NY3'1+ !2=L!V+886 @XLXH^54=1S:!.,WS[%BN!) M3MR:W3U!"":+[4#&L+YU9!*0UA
*&T5'5X+I\6.3^)B.8B4|C[WLYX:F_,+>?\E5D0_S?U90&]Y/EQQ^ZKC7_QE+|Z-0?$?;++W)*17X'>9F7H4P1'<@V0 MK-?5=GWY$.#M7)#]X?FD3I9:C;O+U-
I(-'2HT^VZ)9HR,&%=EK;!^,:H@3 M[<2FF;FN7NKHS9I;.^^<, 2^#^N)1>?.7]8K.$&;+VEUG+$A;5SD;,=6 BQ5H%-FG6ITRZ1W^DW;L5E]"""KZ]#'&O$X1 M-H
TEA=A7X=%R@EPDG":T9V)TN8N_O2+ZO06T@-O.@K7WS(S8&P\0/V\X.)5-.^%%QS'%^]!9OX= M^_,RIR=:[OF4_"B3/HSU@=C@O9!S@>:.VYI9QFE3JVIMMO+QYH5-MHC
M0;2=]:X#BF] (D-M&Z+$#,.^L;NG1'XFS0ZKZ?BM$1%NM],'3S:,_'5A7GADF.6S]_$=WGB?6[QP96\$0QNKRL@AZ*P#6-"D M'"""YIQ]8IJP!"$>US5FT2F\%+
[T]8@8^HIM<'>KEC]M!VC5!_9P-%7N(Z6 M'2(?7W,?S?HU"F^!!$\:WA';RM"SI-T4K=>EW)P[9/%A6D M P?;1;7R4OA%
MT^DB=N^[C7M$3>3L#!)9'M.513[WG(A>),M_%;_E=;SXUVXW70H[OO)@>G?Y MNB>79I'7LL?4*0-IC;S>'6'+0#*]U5*GKAN"@.C,C&O?]GP['"L^?;,AB<[>
M9.*&V$1P)W+9\U>);FD_,R.?/]M!DEASY^^R[<893F(VS^<(^0OW/+/CWE4 Q]#>GEM5/L],$;.U^(!BUYG2O@EH&EXQZ;()B2YG>1+V0P(7, *=Q,Q:4'4FHC3B\]f;BV*1G,_.]!*4-
GEG&,QK< M]K\'E/';;;S\UVf]2">>+Y]^.**9MN4^L;?+7>."DZ8Y7>M?41"R%LIP]3T= MPF7@& ^S[X,;5:/4,5KRO-WB `&W[MP+SQ(9J3*
WZ4NU,LOH9EZG/TJ6SPTI1+2]=`TMF!NB,;; M00A?L(A69=YZ/N5E%BL_(F&L(C MS&4/8^&D+(+)Q+?]>&<+Z#LU&3SNA=IN1*UN&'^'CZ!@7HZ0]'Y$,?P6F+X]
M2H)OZ/GUH@"&%@2)P1D/9H%YX;?X^;RCZN2]Y=5OUDL;[3 ;D1H>A@*K38-E MQE?>X9)@=$*O?KSDUACH]W$O+'XA^2^^)?WR@MA>><&>/T+QR?>@/H--]4)\
MBJ=]=T>^[7 #7FNHBM9NZRK+%;8#94")]5=$?(RLL!L?P#WPGVW'H;KRC00! M,0=10$,PZ1I'&%P*KR5X,!#:@Y<6+"GL1*;C_C?H1WB.$ B^#2@Q#<'-AYT
M:]%GZGBCI#@)+ZO^R@7]W_C=R$/9#1^=,?9Z8S:A\D1=BDCQR MX_-P2&W $BAVC+G2(RAY$!Z86.=[,&T:XBX=EL#95[8/ NB9LDCON]+7WW\O MO>=/1R>%P0L^Q
#217EP<:#>/$Y^_=#K,KPFLQ_&L.T_%PFD'4]LW&3G\MPT[$A7MA\E[DFUPVQE^PU6#3CU>#%=R L^3Y[*[1HG-\LK,C$(RM=BPG3 M0%U:NDF38;R!C//@2QA4?"=<;R=
[SC,U8/A\ '"$@6_@ZI7O08.??0?01>\, M^_,>P\N'UHT-9 ,N(Q&)[=-)HUS0];S^V/%!1Y;^0!^$! 0V'$89I"2#B6 MVVZ!.6L'80R-(!H!XD.&":!- &"?R"9V/?
#]#@HN!'B0:';FC!+X3+L'_]J 4-RED062+#:,RD*=S8^,6D\^&2*@US)07%R@_,^?-X]7OWV]5=[UX((=?0+^ M9HP2A0#XH4D=0*$3>,H/UWMQ%6
%O*X,W[_'#?0)P2UAR0V,-O_Y4[O6^%@. M!\3!)^]A33XJ7__!!MO5S757>>=9S6I7H)7KGU)8)L_P/]&GYUD0L#E#Y>?
M2^\,B(_/W/A]4L;>'"%UL"K6VO0VN&SMRTQ8OAY#!>53$\'\T^N%98P"1-QJ_MX;67W;_PWHIR\(W>HJ"4-&:]J)7=1"\D\5%L3V!6F_,O,OWRD-%^>)Y%AOR M9S]Z4KHSH <^?
U?Z\KD+DBL&_Z1+S8X0!H MH>O&'"V4EP&*Z;\B&R#ATZ?((;Z"RJ#GX#C8@O*,!E#5P%EL5@\@$^FP1WT% M-0J?&(X&QJ8 S%P4BUT3]J5<(W79/ F3C DA0!P$6,+*L"(3C
#8DGFTLA'MI8+@^ M;LX]/^C%!1U94E@\(I,&HK;Q.^(DHORQ=[=Y+Y<;#12\C[I;.3.0'-7R.P%[MO$<#G-:#;_@[=\ !Q_[&R*,!*/0)W2B]L?7ST%V,EU9HMJ.JOL)?V E4H M3]9,
\!*J&;610EWQ[T]\;>]^U&PF[?QC2&MZ,5V+9X018EE)%15TY$)KC2 MM'"'4_3?&DX@_FC[..@ZNXG=_X*_>C2G-8]*>M2Z',3H$9TIS*1T_Q"E5H/8S
MT/%A_Z!3,1=;1FR"DKH0DW0*O(#2X.FE%8@"\/S:!OIZ&\CN\)8<#]|NMR_&L MD^U7JS0F1(P(Z>Y8^\,LM:_<%6G]^O1G@&]>*NFY4F[4O,WW6I>382?;)E5M
M7HR#H[DFRE^Y*R:K?LN9)]"'(7-&W?M,?<2(=XGY.GF'[=,HJ1RfU#ACC0TS M87S+1#9&2H_HQ8"4!0S=M4P0O7 I%O$M[I03ULf5[;4R;?K=$>@Q;:|N\$$0 M$
OFYW"!%O<7$5<"F4 IM$,2#1BI00^\;NSN8.(/.D?HMJ(UC0O .U#?@D M'E?M2@WONF'3]+DS&MT.:6WVIK[H~PN^?8(CT[/N]H ^PN^?8(X]W+R 5F
M4.8)+8BBC_Z1EQ!$I[')7#HW<4:JDK@D[H.T1:#'\N MK@?P-'\PKL8O=,,(M.S9E3 L((K3ON !#-\]"Q-ILSIQ3(C%WU#NP6WZ-]R;(/7S#G@'0R2-\[JT2 M;0"15RNC<6?
H&_^\AZ6RF,%^V@'\DGMI2"E9 39Z%H7VVMH^%<(&.L+FGXZB M1'2<(%JBW(/G>82,/=BT1/4HR@WE4L!N&_?>(X9$V]@3>RZ&'S426QIS#[C MF]Y,.!#^
DSL.6G^=$ETRW1(E_#3!&Q[PN%9\Q?=Y.-% M#WPTJ$r=*Z\7MXGTL/?,(A2]K.1U)#MM1[^!,&98SGZZ6+ eX,*\55EKW%S= M/04>$.)P"2L/IZ6 L8B!:)M$-* QLI]D\!.(U"PF-
:G$##F6[2!/,@,XQQQ^MM08$M>>>8BP*,SH%]X 9=Q?(Z]D1YF#D+ZU;Z.>$8Z42 E-)1;ERFJ)E!E6D M*D^,,_&KR3INLHY?>=9QP MI:A&&R+ ^.I"$RC;RT_,S>?P/26W>"
(C:=9!2,$\X>]Q>9P/\Y.";+76](R5 M^42YA+E\(&DGLM5Y14S4;?ZG C-=1^;;W#PDW^Q!5EU^LOQ9N=,YG-1"NXR\FGGV)DR MX("06=
<<&Q!)*+^,H:G/4SUP'8s5PL+AS0$>F]CDG58P@U.Q"< M@\![H1@F4F$)Q'$FK,I3%"E8N9FNN ^9G$0+%^YVSO#]\7T 9]1H0EB|=+N/ M"""'!L4" ,I=8@3#QQS,V(O,C7X<86'Q
QCFBG>)%;0@ |Q 5C\8 MEPEX$Y(NE& %&4X5]U)S&"%TD4?19V)V.O;&2"^*25"F+C W(8Z@ ~G2^XA* Q7/ M^^WJZJL,Z(&XI\R()0-U=2&2-] >4;7RYGH-
ETR:QEUD|\U0(s7DA]*S4AR8 M47B/'<.Y)IE\/[6,)/#'O"9G&#D]C@D@C W@OGGVDH<]NKVST]):1#G,J2 MN\2O'FY!+O#IZO;7&%K77*S
WGF[@^0Q2|\+$62)T54N_H3"6ZDC9RQ-%]B+ MLTV/B!$..-3M>C4:2G)N/NR)C6RD(:]L54C8.(K7Q0AV,+6')%S^!YK77=0&7 MH0\5-0QN B]-
VT!0>%'6>KPKZ4_34V(9]%/E/2@M^\-;F)S8U,$OZAN%T$>(1 MASU0S0E>8/JBRA/SS$+UGYHFOAK1O'-D;*$X+=>'\4#.'(0.\$ G(/CI/N]H ^PN^?8(X]W+R 5F
M4.8)+8BBC_Z1EQ!$I[')7#HW<4:JDK@D[H.T1:#'\N MK@?P-'\PKL8O=,,(M.S9E3 L((K3ON !#-\]"Q-ILSIQ3(C%WU#NP6WZ-]R;(/7S#G@'0R2-\[JT2 M;0"15RNC<6?
H&_^\AZ6RF,%^V@'\DGMI2"E9 39Z%H7VVMH^%<(&.L+FGXZB M1'2<(%JBW(/G>82,/=BT1/4HR@WE4L!N&_?>(X9$V]@3>RZ&'S426QIS#[C MF]Y,.!#^
DSL.6G^=$ETRW1(E_#3!&Q[PN%9\Q?=Y.-% M#WPTJ$r=*Z\7MXGTL/?,(A2]K.1U)#MM1[^!,&98SGZZ6+ eX,*\55EKW%S= M/04>$.)P"2L/IZ6 L8B!:)M$-* QLI]D\!.(U"PF-
:G$##F6[2!/,@,XQQQ^MM08$M>>>8BP*,SH%]X 9=Q?(Z]D1YF#D+ZU;Z.>$8Z42 E-)1;ERFJ)E!E6D M*D^,,_&KR3INLHY?>=9QP MI:A&&R+ ^.I"$RC;RT_,S>?P/26W>"
(C:=9!2,$\X>]Q>9P/\Y.";+76](R5 M^42YA+E\(&DGLM5Y14S4;?ZG C-=1^;;W#PDW^Q!5EU^LOQ9N=,YG-1"NXR\FGGV)DR MX("06=
<<&Q!)*+^,H:G/4SUP'8s5PL+AS0$>F]CDG58P@U.Q"< M@\![H1@F4F$)Q'$FK,I3%"E8N9FNN ^9G$0+%^YVSO#]\7T 9]1H0EB|=+N/ M"""'!L4" ,I=8@3#QQS,V(O,C7X<86'Q
QCFBG>)%;0@ |Q 5C\8 MEPEX$Y(NE& %&4X5]U)S&"%TD4?19V)V.O;&2"^*25"F+C W(8Z@ ~G2^XA* Q7/ M^^WJZJL,Z(&XI\R()0-U=2&2-] >4;7RYGH-
ETR:QEUD|\U0(s7DA]*S4AR8 M47B/'<.Y)IE\/[6,)/#'O"9G&#D]C@D@C W@OGGVDH<]NKVST]):1#G,J2 MN\2O'FY!+O#IZO;7&%K77*S
WGF[@^0Q2|\+$62)T54N_H3"6ZDC9RQ-%]B+ MLTV/B!$..-3M>C4:2G)N/NR)C6RD(:]L54C8.(K7Q0AV,+6')%S^!YK77=0&7 MH0\5-0QN B]-
VT!0>%'6>KPKZ4_34V(9]%/E/2@M^\-;F)S8U,$OZAN%T$>(1 MASU0S0E>8/JBRA/SS$+UGYHFOAK1O'-D;*$X+=>'\4#.'(0.\$ G(/CI/N]H ^PN^?8(CT[

*G8O@J#EZ]L#PB+7R)FKXZCM%C`')JVAEGOJ_R4P.X'5E%7.IDH]_? M#*1FOS/8?+"\5NN#+7JSG2/+$N@',S#OfM#[B&^]68J3DG#(H@_VW=LRG=[9+ M)$0/R:Z]0DE#]>*!^2&F/PL%C&BIW9(/^K;J>7^WG14KU^ISO-?Z1HJ>+/A]UQ=9L:;%SJ%X(7AQG<"M[L M_]\:M&*%D(JWWG6- 'K#27Y(_FV5^UE__Q!^^SRC+Z1ODEU_|^KFIT5>M#EY& MIQLFU=7!LREU@UA?&J.ZVAZ->P5ZW='N$;\M=9_%/[*@O>B\N""2AD@S1-H_ M,I%2NO[%? Y€OY='GI'4I(A/G0*E');PH&S@G"2]Z"!0J@OURQ\UE%6=.,H.3 MDIRT,I+)Q\ZCB:W4ZW*MA :[AL/3:TTSL&[;_5F1E^^Y$>RY#;M-4;ZCXLEW M+^2=7G7G71M'Z*2B^{6}H7"W#=,8Z"E"YQU9V[O9X2],USL,-"^'ZYS>5!MV MCV.J'73#SV#%'6"H-73=T'6IN-)Z+I7D3)Q8K(F)>07"F/E-E0YD]3&6_NG MWE5>M5!+92$?XAA<^)SY&:4U@6?]-)I1.J$;\|FR-;W;PXZNJWN\|E+GHQSC3 MQX8LW0S&_"5O5-^R?#P>FW;F .% &(RKA<'@6# 8G%_AAYX;*7L(!K5.334- M% /4=3 ;/L!93,E5B"Y&M8DH>:]4XGN<> G ZW4)W&&>7LXS-I/O2|\Y7UZ<"_M)*Y+I-2;-,S5QH'O\0:I&IG/\(PG?I(@6-LR3^?VI7E#]-;E.1DH&%:D^I.7S(@Q'EER^MR?0&#P M#.4W<;K0'+GVZ6>1(-G@"\|KOHJ_54D&:!-OC.U>9UHI%X M)\|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|HOF M^>,X+,_HC/I&GSB1I4U+O/-B22X.1S3OF+IXTB#?1NA3=J/-*O=JJ.>,,?>Z5;=31OR,ZB9^&O21%'VV- 8^%'W&#?]\,/39TB3W4/2I7 65?@SZ5 MHL^6+KB'HD]U393K93L=W':@UR.[ZT0H\@%[F>'$5IS7#6_<.8GK?"R"YOE: M6%0'$TI_2-,8B0CE5^:RI;VP3?\IGC1NNX)N:'3Y@X3=.-^O21=E0&N0=T[6V5[,%:@^F] fYM6.H"MJ_I?#5[;E M-*L-"N*T1=K8R0#SK@;MWOC@O*NRUW5,Z=606T-N%;8I8=NP\K^2!"MR:\BM1@>O M,GMR1W+,;'E5%XMO**VAM!H=O,HDS.H$V[@BL_0YB.VY%R6GJ-LN'H1PVM+M M5-I_,3IK4('<[.ZXNWMMZ=!-^7;S?%_^W91O-[5%AZFQ6V:V'JTL=3QI??;[MO?9D5-64GAK$[QHZ>,%T,CX5G4P;.FGHY'SHY#CM0#8[)&VW^BJ9\NWG^&=T73?EVDVU91B9MB1L?6 $W:9)U7S3ZC+<$ M0P]%GWZ#/B\:?8[,/&+R$MM[-><@3H\|OFT=.7FKKJS.OW_[&%LRF80U<4:0) M+,.."CU05(P^:,FNfF^.:FNZGIKK/X*@K!EJETRPJM4>MR-*Y+*5N#,,\1EOSE MG>VD:9WULI&IXHX2FY&I:.3ULI&I@G826:29UDF4;=$>Y>!QV"@KOJ_F5T6_M:HK>#[6-=[S_X ?/2RUOJIDJ] +XNQ;\D0K*W>:S###?K=\>] [.=ZO\/NM=_M? MA0=$/1%%:T5D;1TVYE&;P-13<4W5#TOKFW513_3ZO+Y&B(N2'FAICWS1+> M0,Q9HNU?XD&I!<&2@^_7BN;KF!0<"X%GNY%)YY(`_2-;P44MBX<2'#/L^/ M7'N!C<=<\HD##S^2P!X^V%=[+"]_>%.?MQH^8L8NYS\P2%^82-OO.=[I-IP"\KIUI9;L7*1BFCU!XR.7R M:(?D& 0X_F_^\;YF/OX(]F;79BW'0(WG_+WLZFECI*9N:5F\ZI,VGYF#2 MG?;9L#=@X\%RN/R_/=":OU.ZN+?\[U_,\SV$<=.[OT:F3!75<(@<(M(IP_3O M@#B0[8U56/_RO^?^+ZDG%8GD?9GB99*%#V<7_2W4=2@+H17?V2$PK,7F-BC] MW8K/-P.(7Y$-]^+"DM-3)$+0.;[?_^/:6\&;GU_$!S8@2F"8CF/"RG9-QUC2?T%]EE][2V/6-2S@G? CPV%!P,=,A/ FRPR1 MHHUUY"_NS8 9H6?,60:&'>.*UOEBPL^XF!;=9H8$<[F#)O'5H,W7R;L4.-IJ Mf=OPPB600H"9'NJW*\|E3W S)(SS,4"9#X\<,\D1RJZ"1UR0&92[;[M!:(<1HFS0V04#>OUCWGA)7.XMSMGU%'5!Y-Q#& L'-M[LI>V@POS?B=/3#'Z!,& PH@1@*""%9S;S,? |>W)N&,N_--Q!4(>)BV"(-MZ^L-=.MGL1N0)08M"Y=+-,3#!0YKU*>DH2C!/Y"@G_,O0D8L?C>,?#UF6WT\MN M&0C.$5CKBV7HY@'_@0U[P,+_P_DH9Y<.L4N%J+L1D@7_$,PJ!-L&698;W@<& M3RUUT(!4@,M$)6 M$L<&:1Q+HI9,:(1+$O+09X3H,RA&G]*8/RR_]UU"=]J6Q_E;YIBF!KV7J9) MRE(L*T/P6D)9!LS_A'MG-\ME&=8T*>>K[1U!0]/6Y1]97!G#/#<0"XJA1WAW MR)!3+??@*_"U\,I.S[!1$4-9+5>P4G1?#DW-I@:.5IEKUPVVV77"FB-ZG1<4 M@("& f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|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`:9, C52D.R?N6'SAN?"'7FL7 QR1FU M^B=34!F7F9:80B&PVD92;J9E\BM#K0DFP3M/2YPDY8XW"$)(!327Z3>H4G4 M92C\$^SGVA:-WX6VFGLX(;NW@XCS%@DH:1IL]1[!?1 =1,.*PG<./!"9Y$SC M!*&]B'@7? 4L,40?!(:SE1*9RN6H0S&]P->UV(/5\%5S-AN MEC33"HC>/S 03?9.9J)2C3OR1C=N"^5 M $QF<=]1.8:N=ZD)O9K()GW)1)&><1/TYL=(DG,"3$YD>>1!&FCZD)V>B-KJU MMIJCHF9T!/<@%Y7[)\VPD:]/*JW^(&/2:NM'9.GYX.X@%B*ZU0)EX.TSKC3 MB 8MR;W^?GN5%U,*DL;&_)3/;?L)NI #$N-X.#.!:SX$,-YZPHSX=^3Q9NKP MJS=VYVUI'C_*Y?'Y.NLW9K$5T1/P[@73^;IBYGSR /X2IU#ELG8L +R\ NX23,(?<-^VN!Q_8R- N+9%4*8@V()M]=W"P6X1]AE@ MY7L^5:6, USQ9BGN]\;_A@CZ4;R: (*:^#,2W02\G##<9%A8J UKR'-6DB,J MD@JN)>F]\+ (= M.<<<>PD0/X63B.FDR3"'4!.GAL$6W,FR:/ \VS;9BDU"3Y)A/9"'^.O62:RIB? MW$G2G&Y:,NC*M?B,-'T/]=]L0- 2*_"=F^FJ[(TP[3"=T&/@3;=9!,D1YEN)/ M20%R!M)H39S"Y5O<|<"-:YE<:"Q-^.O!!,W;0 WFCJ#PJV,N?ES<++NX]]#UZ MQ)@O$"?O!RO/8HX*;L7=W &\I(L[#@W>EA44BQM$M<_E?F(E#!;CG8QUMK5^- M$7C4:UVZ7A9I,>'_S[9S $3&8LQ:*+/@X=0(VUI#Z,G$1O)I-J6.V-6^&$J MY#1OP,Q?VJ#0!#\ QYEP"9;? ^[1W+T/P";+%5?#HZ5(,T6\-5'?DMW%_A8!),0.M]EW#F']\

M^#0Z#;#SYL0*CKL2S[.”H=]+4DL8WU0Z/H>,_EQIK=8R;'"FLM2]\F M:VPIH'46/>Z/9)H1MP@&JB)*|\]7;33]2UA?JU%?0EX.KVX&>M=LR@P_A?VJ M!M.VC#]2C-]@U:\D\3>SO=EN%MM?6/CJSY;K\XJVR*(>&]HL=(/0C5|TK(V% M=SP%B?W(PLN*5U5,?M@0Z$4@8]+LG?_>C63;G+O);12Q.#(J,@O ?DU7;V[.IJN[9IVER[“C7;2BDH;@*B*PO#[#<$NL\ (6*\3 MUI ;Y2,>,FJT!L^E#:-.?9GBB@:,$#”JA0;J2Q97-'BZ@&L=\QFR3V50;2 MO' #4@”VA8|}S4[”D/GVB\9^VH^6_\”TT(HW=E;I>/JAXYW;1P[?=P*\WT/8 M%U]?!EU_8XB#[!;/*C*TOGB\4;ANM3+C<17;Z]9(%LOHOR3P[C*,L7QX76'[“-;3 MGF1I?;G?BBH.?_>VHR3H-T02U!E,,LR6V?!@TCNRD:*Y-F2:1?>E5'GGN=;8 MJ79HQ[TGLJMM9KZ_8ZD5-G@);9ZM<=_U<7=]J\\[*9Y3JR/H'3>$!54[T MEW7!7&l:'GC/(6:NOF?\ST^^ /=[-F&@%1SA6-_Z#CG=/”VCZNU#9W!U,]4[MG5U&DRK[X”\QUQ41EP/1”=U2#;O+DZB5,=D 8BG;W^Q O#(B8FGOW$U7$/RTK:1E5?><1G!N!CRQR2 IL]LK_BN^\F?P=/]%=F6>PMl;ZA#\UE#T(YF<<7GYMMIP.22G\EJ:@@9\/B5O72QMH;\]YJZ=-DXMBSAEE/ M&L.FD<.%!:EN;1L.$T?:S'JQQMYVE;J7X:B4+\E8YA<)YGL.Y>:G9-]5YJP.9FZU M^RIS]C2:COC,Y^$0K,!ACT5*&TDM6QCFVU-+>7M--U4RTFA=U:%A-U$?GSVSO MDK_2K#*9:1?O2]//:>0613+(;H0EP.&W]RDIQT]>2_”7]K4”&Z>TP3D/PG M”Y_J[PCV+4>X1.]H]%#N\]+#%2Q?:CDV5Z&(+5;^S<-.$S1P%'[Q^U=5-0Wf4”1 MQ^$[J-0L*/KM)@F*”PN[W2T.<%*QMGIB;84\LGCMOX.GTS>N;H9ZN[U+(]9R-M?0_?HG=_!$'7%_VNJF1K)%54,;A*4\5:(ZNO6BPU6H<<<78-T,26FTV^ !KG4 MGAJGG?DF]VQQP!7SDPO+?-MSD>8]6 ”7_H<;/]Y+(C@F”R6SOU1F=1SIH \: MXV,IXMCM%K8” <:PW$>H,\Z HXS %GJ4OTNH5((-5;3)4^FRCC!R&#@NOXV#V M!E$5!9[K;/)V9Y=/I ‘GO ‘1?W8?#D.LSY]>7O$<;\4T?M-L5(9,$[I]K MZ_U.#?TQ2^/R-)]JF=%5K=;>_JAIT+ZZ,7JZ.:PK1*A(JB$DM2$Q:UN26NLI M#.JKGE#DU”C-=WR]-S”O;@:&WNDU7>\=.HEOKZ0S*&X4C6;FQ N>(S[>'D>S M1@N6YDX=HDLA:-OVS9>R>)U9”X/&1Y{OD]!^Q&R%8*+-0O1}XA==FWF6'U/9 M$/M7XLZFS(|5”L/\,>E[ZP5!&’T/;FV 9\CN!;3O$]*H=^0Y2#RCLX8>,O M0NMO:H4_6$PE0Q&SDW#[Q-7+N”;O7=/EFNAP#^&(3(>&)”BE!<)6!^S\;5&]P- M!EF\U6$YG]U&!Z M:.!”ZC9+(5U8R&W.WHL -RKXMF=3#IEE'0-MY3#U<’C/L*=:’S>2.Bl8==6I M8[U”5G5 S2:-”@9@GU+HRAG2RZQ M3HU)”PK7_:HUYK+]”ZM*T=M%==H-”U4O59C]9:+O\FCZ* _N’%LQ08/ 1UQ^^ MW=^3< O=<4(?7];-_=[”U)^B*,&Q4W>3;X]6R”(:1?4)/O!!++!;WZ&/?[-M,[P+!CATW.(-8 .#”’]F)0C(;XBO.XZN(FU@7-T,U/U>$RFE0M1Z#Y12UD(=-MM57M3+//]$*8^ZATI&IJFDO'3=-,W>;H+=6$Y^0M7!G-!P,79W^&KATSA]NZ MEY5S42T-M5>VTVZQ> #NGP8^<7H1B_>P.\(N@^[5_>@>]{(G>5G;I”K+VP2] MK*?9M+”5;;DE+:@ZGD8K@TYGG[I@V!!=<&EA0->WW9GE:;(T7@,JX %JQN=M MJUC?UK&^_%3Y%-(R;[N*9*S]CE!$WS6:VTPF2H0PN;/]6/UD!Q5R=?H2%Q=-M\L!0E2N-G(%@M9@++?L<(7;9;,/=6D!E0O8?=,UG M,=5 ”W,8P!-M60!]LLY&-<=S6*OC68*/,L!G;;>[ZH1U(TDB-'A(A&&*NQI M-”WTVP>D!57-TV1:Z&QU;,F+GN@W34^H(IY513Q%B9;JB,<(13P^)2*VSVHV M!ISONKV32&N^,)K:-7I6;9QK'=0UK,^+5G35$%FU73G/1FI:;RZ[C M*3X3P_T@FXS!22B^0}?SD!EW!-KYY-LA!G UUR?#4^?F)\]U?0(,XDTJUD[D MDLWP^QVLSRI%+>?)@ANM3^1_-^’# E?4_CC%[>_,]!H?WV/__D6A!S_B? M:,;KJAY_VH^4_L^)6S#¥.)-LSY]ERVOHET9!K R&9/_6Z-7F.C5 -BBXW7O\>DR[7M6BMF?:4=BB2;19(;C-_FDF1]52**))M$D]>MN[LGI;L/”1(^-NF]*VUS:U:L MC=F#Z_NB .2%6=LUVCS9{)5*[@.,@OUQ:F7&PQJ1WE#O[G[=HE*=]D LG7V: MOE7,AOH*212=[(%,NONT1ZQ027U%)HI.Z]>39NF>8=-TSUDU2ZK#KF/P\0]+ M;K^N6-/]LO^CG\VPL7H&$V2+J.K&W/8U3NCT2FXE(JC%$<5F'6*T]=KS;I. M?7:.-%#,I9CI2BOM2@?61F*F^\C+%3(]HV4590)B-5/%>55L*1?:S;) MK##7CDDRJN2MR21S/;W3;S=(\YRPW1R A&>]X$;9ZFO7X_]HZQC\EX>W3L)%&,0O\;4+”840 2Y2Y2X5)N>I MX94G<9EJY6ZFYBM.*B[O.D[N-8)_VF62=GY2X74\?7A9M7 MES(KX5^N#]ZQS0”WX*QQ:SF(\UFHV4D8 K8UBV9GJFR[K4W\^2#4.P[6RDR# MQ=-ZUVA*0W5% E5,X!(DL-XH]’UBH<+_(8W$G?&OVHO@2^O27W&%*:M(X’@VU’8D4’MEJB*!HYE1. ^B”;L-T09T3*SIMZN’79+/] M>Q!;WC8M5W;MCG/.<>IJ9S\;F=&LBH!NK[8TL4KXK/M:1S’2Y3%24PH!NK77 M2L>4CS4#!_F8#Q4>XVTXB%0XUP .@]KSPU/QYX[JWA\<<[_MV0V\Q@.61+^ MHS;Q@F?-<2/;”Z{$W;,M,ON72S+]S(Z_O-4O:.)G$MJ/5@3K!1,<7C”#K;WH MVLRS\ -+(=RB\.4.JG;M LFP;0!!’ SD.?Q7”A/?!WEB,@X]”[*$WB _9PQ M/V(]#=6>7WK(S%P3’!X2DX\8H+C[Q$*+56Q)_LOC>D M=?=^V-:M9=%>VK$NU5>KKDCB**U3ZR<)-=”SR22Q/\70.YND&BYK?N>=&,Z9 M6D>%!E:]!M1%.9NM*?>LW$L![*]PV&HDF7=)X@4O)\%%^TNO+?@_)8G_OT] MA.WSUQ=Q4^?JIF=V&G(O[^AA+KC9W3L]E%>W3:P!5+12V@(I**TTL:).T4I) MTVPO6J;?)”US8=&RT U”-WI10O;DPHI/06)CUG1JPDD++0C1B+N]5Q&ORA;. MV$O8F_=N- LB%U>YF]Q2’OH’>,Z6&B .70-\7H

*MEI0T4DB%HD61CH@Y{$R&T:@Ul'6JSF3HC5]F6=-,:J/:5[PQJFLG0VSQ(X;0W MU5T_O:*>;N4GUYO-M,S3*@7."%YP*N,L,4JA(VB436M*#'W,.P0I]3#Y^0>_9/0]TV$!-C6G2O|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|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}Y3 ".I/V_?WI[Y_N'/G^]T3? QVEW]^.MN_MRR^'T^>9'?__SARZ?;DR.IWASQ-/A)1(IH)@4$M!.'$DB -\0+4U N3N= M>8P+$#')?>%U?D?6$X^!.-P)I:$12 [C[">_FVYD5XK"9Z 5C?D47$Z(-E"-MT-,YRB4Q %HTMCC:9YZ;"3G$'&)VFDSY^G,2$C"((_@<:)QO'T+&#T((_C?@-M.L%D6Z&,=.S%TD)+:,+6YW&MI7XQXGU(CDPTJ:F%OL$JW#V(U@*\7]W]JU"H% M(:+]DC1!]Y8$^(V)-$R$.N- 'AR.*.!LGF6Q4&@^3Q(^@)*;6"T;EGHCKQT!# M(5C.+>TN$7Y7F/C/\)/T'4Y (;]8!OL]*18A$B+0]>F&", ^BQ*P9V09Z(#D M1QNX/M###X6<$HE=%3(A$?!+*&3D-+ JK7./3$K\NY)@?=RA-C%]*8 M@A0=!A>+4T93)9P%=SV)0'\Z6M)(2Y>:62$[@NC_AKK#&%64D&.]W 7B., MHAGPW4)>A57C/W:YKI@R%KNI@+]H:47+?B3PC1:HHY- \,,@2D_%;1@X)1 ? M!9=)Z4XT)TP>LB1_>54!%D< M<^A(^RR4-K06!6 KH3@"-L5'N&P'D')!T](^372>\.*CAV)%$MB.]+8@#|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{((W]W.;F[O'&4IC\UOA8(PR*-W14 M:/R2S^59M'/61G K=IE>;]%2KJ5T<8N/>*&%!*8'834W51G ,ARV!EG*FS57 M"4WM8+PAZB"HZHOROK(9[%OW2W4>A57C/W:YKI@R%KNI@+]H:47+?B3PC1:HHY- UJR,U :S MD)!\USL]U^7+#S3+^2/A700R$&9MB_(%**L;$"U6*>1K(RE!BT\5Z/"?%GKK MBC/D#^]P6Z\(K8-6IE%#:E.XHQ;:^IS0BUP)E>;U M_#(TN%===<__E19SYGK-);]DD!=,IRY7U">6&/GA)U;D8^X]5D\GD;#BO@0QTT;ZO@5# M1>'U&:5"=$QAQ>TD@H[1;AIX?F9H:?4R+V+]A^HLXRFPF&C R+V+/CTSV?W C[6^\: O$\5>&E?))80/\Q M""> G>N_4>UV*#N9,(86>C:-A)NS$>\&$!+8"B

NP]1$*5V;OD?!>$'P-ZYNAL;\REC2?LJ>|)9\RC;V:,BC9$ M_MNJF\&=LWD/Z^VS_[?B\?_;Z)57'0-_[,+T?%\:\#BM-L-39;G\$]H&R-7?CZOJT;E#?*)GV*6+F+2* MJ=?3_%LT%ZM:]}3^'74^>;EEFBC@F("]87+FEF4LM>EX[_=Q;X'#EO417+.& M&FRIHV!P^R${,74-8NFMW*+99-X4P+;50*'R9E$_$"!0SFSGDG&DA-H08!BQ M(<=F5P976B,0*N\,Z31KY$>WG?4NG7B=Y[\%UT2HBL;@7;T:>K?@LX+7#$XT MJRL;P!V/V-)]2MME D0+#H7X//;T3F W\^!G[$8?P1<@EIC;B+9<)\.]$DP8 M>U;4I[O*P& =O@(HE',BJ3I"~GO<6T1;<&Q6C[_1A9RHD++[12HHZ*5=4ZJ/ M]-QV6J'&A.f4(:"]B\P7!KL%0#WMM8]8[F$'ZU'I M$NE8.*BV],>[*UZ.A!RDJ.)E%5$Z'!=9=&!N-.YTCE ._BKS7.\]T&&T2!BU@L_@?T;V+H:K)&TD(3M27\UB25I MK4-;@![#_V4-(COY7MH!PPV BWXZ82SV9J,^_5WZ4R/9&&%MYW@HU;'PRF; M$%DW5U3.#T\16E(ZM"1NU;+<>)Q29]M)-W+/?ROR8"T_^J8(87MP_C*8 M@++DWD;<0;!V#9TL:@A:\|T0[XVQ@)B.BX40166)$1N1O|&ZMCWZLA8RZ;P1 M=#Z7V'C+'7A-(+AQ6>O'IF?(69#0%0.T(/5/8%G M/7CVX@2>?1AC.8%GCVST1P>>O:O_]CF56^JJ'-TXS#3M-3KXKOB3*-APA0:W M(9MTNO'.VCG($/H=6#7C/GUG/C\[W$ [>LXG6WB^.$2|FC>A[ET/FJ6?B#&T >]WGDU><&]$Q_M)>2001FT;<[_T&$J1R%KU//>0?N87L_M/%!<8TU4%=K;<# S<$!F_\M7^7N<=-KC4D;#AL]>&QT@RX>HF1@"ZMT_2@AJ:5F!/)R5VF73..K9K;?=T,:&2$LI. MXHTS*C/*_[:57,1:&4]"?:?34E..M)-0/"DV/(O7%^-S5W]73,M^R4L&&ZI!Y\ZY.\XE+;7/@_OYB9V#NP9U!/I9!7 [R&8VJfNM MUK>P94]H[D/ON7&6"P"8O.&,I ;13U2 MU4\[K>B_9D6I@ I>CEX>CQ(;@T0>%RE?_?3FT0J1)M[\U*S8E=PV8$N0]. M@[@B]N2[@\,23G++)1Y\9?*640!=2XLTL>_>,=R5/N^7C(1;7)(:"N"2>]KE1 MP4A>6-(E!.EH"BA[!):8&3A M$^^^GY$_;4E6/&4+V:RRIJU'JSD'CO)[GT$)752?]MT4K3D MN!AMDT=8VQM6D]4%6V^RHMG'8)UT[_=+8W>H 0LRO&C&JZL?GB#KP;"S_8-J M3CM$TZP-_1LJ5=55F9^Q[A/U]0&+ND)ZA)ND^]P!TYJ>-%IA\SG/#>-P7$)E M2KE7Q88K56>&X36(C]KFE"EI[$ M>T+HHH;_(O#]?W:"GPS_(ZS|5BQV0*T46*OHG8H[G%UH]W>8U3/CI*ATNV- M/:H?%MQ!*XQ#+D.&B=.U(PXRC,4>13XG^V6P0_;OA;+572K4&!3I)<22!.D) MPVSS\\EWP8)XUNXR!(#Z"=4I7<0O3/T@*FE;1VT-L6[T,EL&IFEHKNV3@Y8-$ MV!?5+DN"**(*P*E]=B)#2 HKQ%@K;B[T7R?]?PT?"8+/80@3?^K&B^.6%H3T M#TKF,2#PX&.3@]J5?R-+\DY$U=O&@![GFJ99V*/>;K%?H>(<)B?30=,?WX@8 ME_F [(K@-,13/7.4)FOJ.OI!T=.RQ5"Y!4C*-@V*.V$VPPLQD)"^MBQ($M&_M/7ZK|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f<5L]8[*J 6],U3BPYB(L>N-*H05I>L>E2EM*XZ&PA?!D*>AD6#2S MEL,|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|O M+?Z-:H&9<2P:++Y0Y2I&0LRE:L+'#46LO^$;SV@O1?]/0S:BI+%\IVN'3!1$ MC;)DOVKH8;W04V3^B?>5(.YIQ93X+Q$8I@MVC\+PJ)ZKR;W"BQ"VBZ0UH,D3 MJF"_LUE23V1[QM$OCF,#!MSQ%,9$\,D$L)^0ZGG*@:0_+`PI?TK96MP%;X-?S3\KX,U@=BO4^?; MF[IY=]HK,TY[:H Y9FTH@G1$'O_/32L4<%P!>]V#]P]0MWWZ<+R4NR-F$G9MO;"*KKO$U1E#=)#4NJ02D@4 DU8N@DA&??\R>7[""@>S-T#:B0?]'"M3AH7=-M'"D96Z4=]75$WY_\]*6G<;8FG;R=-\4LE_C;/OY K=,?$G?VQ0EW\C#&:2 YCMM-(AKVNAC+WDO-C91|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`]VQ-06(V#P*5DA;[>_.O\-, MA6=I-#*?/GV=`M"'G]?NSB0[%IKYAT;4O4'LMZW@EGB2O^$@@%IS@G> IXRH+=(R5?/LEA.7_-M50=R&>\IRR&>UYNP3D9'*WRF[\J2I%PKA\L6LS,?^BU)'<5]*N:@+'0467J0 M"]U6VC.&R+OO2D&I"=1Y2KO.>%B@C+)F\BC6=[$_\+AF>8Z+L""XC3"LX3+-.MN=(DELQ?J(ZHJ2RV"#&1$$=PX;_S'Y&^*\[6/&<_U-'D4+9-L;; M= /H0<2CPUM5).O#HQ$]E89-O/%,XU_M()-)8)0QJ&;*II=L !Q4EB0ATS"L MMK1#WKQ;IX'8FW.IWF.R.YU;@<GWFJS@HOMJ.\-&9!8.XH9OC# G,\<8[X MF0/COCL^_/#>ZIQfT0@=:0^_9VA4NPCHZ#(M\(#^,C(%NWO!/2WB85V3A)7 ME21G,57.#:&#F.?[P?''YS/TJ49X*@?IYI[8F'XZZ?);FH73*,;Y$M)N"RW M*^')"CPR6()Z6Q1&]6J9,LLHY?V2/Y(X01Z)I1.C7)W -?T9GCB2 <6+A*TT3<&#M?Q%W'?)"' MKO\PQF&7& D6D)U;@R MLO:(D3F*\^AS]UDWAL@[-OFN:^I-3I0$B4-\2Z-1OR>ASUG08!C4_>SFA>CQ MV+!R5UQ[4K]W_?.TPN1>>MBV^[>*5N'-EA5(12Q!N$$1"RN5)$$%PTB>]V@=M$'1U=/,AC9&T,12MG>@STOUH'S'6+ K'H.4R.)=E3Q*,_GF:<(:E1/=[CCS- MEI(+\BJJK)M04S#^,57+"@?*#1#^\AEHR?)%;T/*YG;M7_\H8!5[RJ!Q."/< M3T3X)Z$*7@B\Q'MSLZ3 LI%JW+PWJD=&YS[X)AE4@QHJ\,J31%IKV8R1W+)'M7:UC1N+^+)5<-$0]VK/+LNQ@1;ESV!9(7AI_U=+$ V&+6V9NO:^$[06WU%R#=AN+ %MYS**>3N^&W(Z2>3&[R8>Y]8^"H-Z8W1TB!T'1CNC69:"HV9N4M"@KH4'(6@ M^^RO\Q",U8O=D#VF?YN&*RBLSCIL_-9TIO>]!DTCM\2!G2]&83%\[XUZ!.]# (OXFN85*C4$M%_V@.# 'V%F$W MY01Q9YM C.R&]**M#R[#,A^01) ^\1R)BN*?0B3FA9*BKXX]\,KL.Z?:4SO MG:W^8),]RH]BJ)">SCL^$P4'P+%@7+DF$A5I'8<*3S%5!;<<>0IX]T\1F/VG MB13R0+>J"V!&5:RL \+J7!.:<[A93S]YNXM M)P_$YK[M^T&,)]&9#[..+F$(`I)@/P<)C/J7%0H'!A2U<<<^O6?Q7@EG&Q6E>M+4/2,2'^V|QPL&2TI9P5TKA4&29//!?=:C"\&>0K)V)&4 V4"8>]D101F^J/GU(-.M2B1/3KHG9L5_VZ)EVQ1I*M %B:B^.:5^G:IXM0.G:WJ7"V6T*7U$HXU<:S-YGFE=2"4;QE:,6W#@F4G MZV.BF ,.+05/..&2:2[QYL:OL8?\E?\U(4:(SF;A'I28FZ_<|>MC^.M#3*9AL!6$I-/7%^H=GC0:.8\'E!QV!M_]6("QC8I?]@&=_$*9S_(D$I2QM(H,03"N7*$QM;L$$B$BF(PPFFR:L:#!V8875$T)UA1!MN7J0DNSH"SU8=!'T MGP5)KP/V_N7&=K,B4\>ID2RI M&[\T#:L6'PBB$++T]=NHG;8\<5+MX7BGIA! MK6MY,1%3=1O\[S_E!Z'BK0:TNC*80%{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|>/|\OF71TU?R7 ML"H+[O760](GO!YA+R;G@?>N.=:;OI9S'>Z>1;X*.S#JS&T5*V3/==Q2F$%<9R[>K&,@ M3TQ4 F>"E@IP0(W)Y:'@,^>V==@VU?2V9]B5\W&T6WG_5A2D&5;'^ZA;=0E!/M;,&GK)^$UCAN[4Z;G%O9]*_*SO)KI6F.U!= -/F|R^ZW^1;=_O34DL%@A$T=K 7R MUR)PQ,Z. 'K?!7E>FI4NH]\R_B#?*;594T81"YH.IR_P>]J95*V"|?@@7&L M8A$(/?A4&5.NE80[\-+6 3NURBVW,O@M@+)0C*1T;2*TY6[<3X!9$CO'Y,T MX%I;JC]$3<,5 K)=(L]JYO66I/;H?B48QU!.HG ?5A0N>&!"$_\$*+0X%V3,?+8 "TO7R@[%JLF9B=%^HF%&OF+D$ M?U!,$ZI@TKP!TI=V+KH-@+2|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|+.&PE75U97<0YUEGZ+R.B8^P6KM6J9A:.:@:ZHEKYZ1Q^X+7S[>2#)/9R M /W=GPQG4A]%=Q\.'"'&.QV[CW:U<6<|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|F?8 MQ- =H'<4:N7!,<2S'"*/D<^:UZ#-%>60"S1X#!<6)KR)/?WD3AULZM>I=@T# M?8^"A>@<'YZ6PTT>SVL(T&LF[2!/%& RBDO&O=S#[<1XF7ZXH]X_T$2;+8 M4!.9])@)7L M8_]Y,0^>'C:1Z75#%(?:I,/EV#$__'46#B,/A5LMT@5-4Y(Z5\X<;%GKCM 0 MC5*(.;E\.;6O(#6U:+(;IM-*48CZEF">I\/FSJL>-Y9GZ5I[@9AXF5!")XQ0 MF=[(}*GC&,.\|$'#T0\>/I<09?<[#JMT*7 R-M 1[FM-RCFY8[-4*1OE5*G!4Z'8=K M$")0UR;4UII,(VDZ/%Z,$7U8CX#=L<(\QANWXT0\96;M$S>K$!53X$T1>;T1 M>G&Q>W*)N![.VG+)$GUKS!P)>YBZ]MTB&Q$>F#Y.X(2"EDG1P95ET1(BNV]%M7\F\;O@8M2_261EO'=_;Q\5/@:Z6:3]FZYI.\MM$PU;OICV!X-/_>W902K5 MQK#HD8'05M%,>3^90>DBR9GPS=1?<[_26$>B@[.5WU=6R+;_S2U30K%IGKO^U;#5Y!%?#]05MZ__"5-:C@Y*QIEX81$852HHLPH:I3"0YQ516D&I\99J8U2'L]P14-N/9-Z MP;&9W5^&M!\3DZ&LJ1%@V@5VXG#Z"%A'/(-L8Y5M100|;@Q/^+*/.OTX];XPMJW:!7<%X@YT6X",LP.BE$EFN3VT.'V?/\^_V-US)N\1E\3B6$QG31YM%5ID;.MU.X5.73:\!JASEV0/<8G:VFC$"@*)PV_D=>!&$?&R!7DGC1U**4/]PT)$LK M ;^#:%H*^K1]'V/5HNJ?712&D!RAF;+0&"V+VJYH-WFK9?[M7C7DD:I^+<^1@"?$^GI%Q_>@/ E8.S$M&'6+P.TDC$QCX+_6QRS@ M2H$4+ M0/5(L;B]DF.I)PH0G:?=.17.I(RQ5.D4LN>4;I^8J)/DED/%Q;D% M=&O.6?36=]JNA,--GJ>52Y#/,JW M2"]T3X*1"??(LBA'D'O'Y[U\WU\DJT=OBG9>UJB/UYLS?'"G4;%FMLOVR/GDC:T'?6;?%EK'ML>]W^Y:1O"]]H@D?! E('7$# P7MIT(8$CI M,]@=N,.^5&"8>&|[CX6 M>K,/D<*QT2+?OC@[(D>+G_.U"HI>^@=*M3N1D)$R3?);YK0I-M1%1GT63CJ[$I2U'4C*@NJ7E5Z+XU>F6Z'DIZI)>17"'7Q%&;7G\'\%$S@UB-AAU-M1"Y3B.VHO^)<.%%8@B,)"&_!^%6>]YH4M+I* O1E5VJ6(4P,_Y>9Q@QI_!T M+/85[CKQ2\$12HTT41WBV^BN"N"0IE/.#%>,.,036DO2+ MO#B?&;&.(D^`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

+AF2A>VTEE\|'9,3YK89./'$?,$PG#ZG+O1$T4Y,XV=G"88;_MP"G#S\(Q=1 M=M3]:CV\LKXLN".@8R=6(XLVV5UVWXHDI5,MXFHBLHO+$QV6SH.W6.\ MPV+<,>?
=^ZDVH<.7/S;C_':ORF3?/+;-LZV7^X*KGO\7_ OJ%@DVZ*C(+, EQ0>ZR MT.DA6ZBJNN1-DO&&?S7Z\@5:NCJ.<2F,O1+)7HH;@Q5MZ\9TH:*F;^S&G0IY M5G
6Z;L,%I@FUY'G%_8.B6,[$&^$6|O;>5/,!NCVYDG1N8I>8#_=LFYVI2"$X*.M;5 =XZ/Z0 MP)F+$W#F88SE!)PYLM',#AVX[^*M)LG28'A?Y',?5O@EV$Y2LH\B_\SD6@[MC+-
>5\6L:UWVD=E)<6-3^45*6'\[?W/N.+_M3E@64\"^CRGRMI2L7&CX M[+] CRR8OO1{*(",_+^ N_-*/O$Z)VW22^:AY9&+>M"ZUC5C>X#DHFTW5YUF0
M(T,ZNN&ZZWKLLBBJ%P3K]AAB(<&N>YB*Z-7$3!41XD9L*\/+-RBWU5U;[M1= M'KT;7?:DS7F\+>?VQSB!,O6?.5HP\LX))WZ9?>D4RH%E(YDI;L9%I&(,0QPT
MZY=5ZH5>X/ARG^!+"UX-?&\E\|CX5;'P4A"]KL,K4TOR@"7:?&#G@4?6(9]9 MA8M/?!I*7O0]4N'EY$?1;H)G$/8MN0AXLD*2_2\H!07E"B97748S'A$@ZAVW
MD7Z*B(3YG:@ZPV]Q=&7V8)6>/+X(IS@8V"MVW_AD_D^^L/F'U#!5I-"#D8B*!,2G&H4V<6P(XBNX*R MCTGHE4GDV-@XY<^BNSP^
E%BJYJVX5G.032E/NG>6^Z*N,&;)H?)]J29?(-9? N>&Z=X7$DRJ9VLS;8/([^1[BQ]7LSJ^C7QVOA(T%9'B*.16N >\T D MY*J,\RA&4+,=D2=_[D\A;=B*[R(9#
(,_/VP6@07ZW";G E?DO=G267.-?F:M MB#AG04Q'B.*5]5O??KWCT#LBQ@+5&;/*V9%PD#5&L^2> M$>_XS;>UN'I/ITSW
M!P9_HNJOR5#X/!SQI>T]"50)M.)3V/X_$87DTXLI'Q_%E ;S'Q>/GYX_#HY5 M6?]JZ1\O"?/7^B.G' QEL_8Y$WU_G!?ISKX+X[-^GPM"61GY*%TO8$ELB9UE MI>^@'}7/Z7-
@C"]J%031=ILW, ^:\3&+*2BAC^C\CZ,6@[=8,]5"WT5T*X.9#A MY]H*ZB!!,5$SZW9CS07JG"=,_VA$[_=9\[*=C\MT6<12;)+ZM&<1@\8"V M)BSHXG!';T5@L+85D!:>-
NMV8K@9<285)ZU!2M.W/0%5T6"E$PSMT?CKK[IF MU(,BQK-LGD\|\/V!;AZM@R*5Y?(8?M^TEZ'87E.1YCF.,\%8 /2U!0^&MH5V2 M$3T UOQ;F:@V!.Z I3UW31^+K??
O+|Y>7XMH];@E; M%7L)CYC-&A)0'BMK++>OQA3)&R/"/;1'F*E/26JH,N*1WI(,3T;V\"QLCKQ] MJ9=2I)Q&'NY1!C3VJ;BW/8|P%68V'#']]? W>>$X)'5HU?ES-37G%,4"2!=V
M%VI8L#5]CYP/0P'$-I\"P(\)X3=[79B+QHY3T<@:/YZR/Q.CHQWG2WR2S TR.#W80V[M.8&K!/EDCH(9#/VB'6.&7_,FFZ*S7XV"1N"I*[VQTX#.X\0&45YMU4\DI!!;
M/\D9#@9)OU806H]A'F3Z[*GDVHEUTKPG:M@X &/V0TXU&0Q2LPPG",A I8$& M>Q>+BK'=T\'_J3WPN.-S E*_E]#$Y.=):ML94,7)2PE]ZE*#,Y;*%#H3(N:.
M1,.#6R<<+#3=9!/JX.WL+,)046]PEN';)0^P6],JNZ.AOS XJ89IB7>2;(7F8P M.OF*S&4YV%1O2CAYB9@4-;IL^8N4=@O;0Q)UG@G4KQ49";R%@ M +I-L",.DZ2$%< ?F. $=9%D0-
3I#T32ED'CVNVX[LB&;^(10WDSX:OV'6Q8 MYA'ZC['(W;!S^O91'5VN_9?!2D@>LJB699=32#H#?B8KUG(_4I[W C]'= C M\GCR^:HB,P#D""4#X(V0YG=%4K*"HJ"
(_!864V"60D8%29M<_\E6R0[_SZJU 2OR\%DXMU"MKK:XYC=2!<;A67VH8B#[,L7 V0V MHZ0|K+K358T Y^YWX@W1B9Z%[Z!1L4]>K"X"8Y0@?Z1=$VG9(01@FO]#GE
MEEAAM2S01$X64%,$P(6,+%,5AJ^4]2PLF.#N%<.J#8R%QBA%XOBN"D3E4-N& M)P'ZNTU9[R:OXRK?20<_[K\2RD@\|HR+BI
M&]U4THCA1"AA042FQ>1F<\N+&9=GNFDE{]!B]U]&U/306B-YU;QG8;RX?B$ M7\M5-HIWM$0-C%#)=@-)^@\|RXC Z@AXV-<)@Y FJN0"'+L,$(]*5Q6/,1L\F MW+++T9-=#$#;?
$]&!A YX:4[@.XVY7LW +;^N:,T\0(HE@BSN5?]TXR#[N3s%\ZY2:VZ(%[HI]U9\(^Z^>%]%HJ?D=?WT)F#:!WD:R M;^Z>\$IS(EQ#O4+0++99Q:@@WEH",$Z!U<&X])%%X2<%I#V?B^[5)P#)U&,Q@
M)816QZ/=7_$/41?\Y7S;LVWJ#8P#39F"S@\U+ ?C-[U_?<)G>'S&TQ,^XV&, MY83/.++'1'QT^0WE$J=UV+%"?2E)EP4D5#5HV148@&U1SSO+X\30,V3J7
M*W+)WFP99T<=2B//N*((X@Z/"%=NSGW@YDM:D)N3#SC?]HA)T0-)]0C#3W-: M >}0L<1-+%C1R$MNA+;T=_U]MHX)*LNW;+C_IGE[=4F>;>=6FIXM[Z;W_D MC]?
1N1E_,'(AVS)OA:6;"?\-V? [[RUTE84:RA$#XFY9K4XNJUOR%7O\7N+ MDN V^\W)1P8?)RN0;(B@[*H66-V!R$!9[54\6.'&EBU^7G!4UYNY8+'74Y# M:/<[8E21$A@^D?
2XTH//[657"M^!GQ=32?)@>&FRU8D$?1%YT7U/VK$Y9RFS MD6?&B2&%L6(PL!B-,4DSMJ;%OJR HRXHN "K"]5?(^LC:W7C+K@#N(E[P']3(06D1OYG(N1?
J/>D'.I:%^)=]+Y.Y=KJ6HG&I.'->%H=? M.[7SHIEWZY,T EI/JMNNN G29WS:CIY+V4&K,%M?H8LUO.M.DRMVS95(A>3" M8AF*FG.?,=,'A^"03X2^O/S(T-
2>3[Z3'_8U%6JK'K=X29XRC,6ZQ#A[(8$8 M\DM*,=Q*>:"O#*V$DI]:*%V;UOEB `O*8PO#*FDTG.L0989%ZXDN^%RV6*9 M:3Q)(B&+:@/01\BEF_3HDE/?Q:22]'P9W5&
MIR6AOS^VAHO.H 9&GM=OY>1'!AS_>/4/L/.A:&C M%,11@3P3)?_M[K,$* USEF^SL[#92O 7K(M,[B8MTR+]90[*E$ 11+3H]?? M/O]
MG5PH$A\'+_FSGF(YL;GN<1YOZYTO=]JJFEQ9@BV)U HS80]S%,,)E-<9E]4 M?N\U+ ?H;OM)6E:U]^IAQ2_$&FQ2@-1'IK_H[EQ5P3KN2S\W2"WAORV(PS7 M^YRG#U5(;A3-
EK V5(JT*9RR[-"[G#GX?^6WY1XM\5CT0H9.U_Y8HA*158)& MY]6PCDG(P%% !Q_+4JG.*GC_YO4)3=O.D:[++KK@3LN,A8-0/YH]?$V6ETW1C M3)$4,"DH+,"AAPL]_JG?YO[Y\
<.:-3!FICN3Y*CQ.(!P.!*/EQ6O'O'O?]=S MS9&]9X!+D'E2L>`>,BO?$(K[ZP.$44&MV'[M@S & #M/QL0WV/2?OZ(*Z?YA: M$,:"KG$V>,R,]%6E-BSYETCR.6&(*&$A?A-]:U\>8G_?;
)^Y)8O&-"*+%N-MTT**AX"Z440I%6VC4%65!W+U'\O&>36P>L.CNZ2K*MD0=MSO HOG.E:K@EB@ M:,%X%RY=_"15YK2^VDBQNI,M*[#C(O89,%
<':,T?P.S!94FGD)6O++U1EDT7K MX,#489;[$'-7E(YJC_)B0\TUA9#6-]74D;6MLPB2-JP.C953BN&II D@[_7R MYQ=G.4)W%AE@\0SZK1X21*E',#KI&B*D0'QSKK#3"Y99I.!9?
E,USMG6# "M MFCOX_LNK3#ZG\3(N(@8LHB,D^&]+D=@=C7-M2"H,\YHUB$*ZK2" .'=CXE!IP0=;=:,M:4P#?79;E!?@<')IRZ9XM*\/(8>;; MN%BTTH@:=!.,K$CBDSGT0-[*
{D@>*OC$ M))0ZVB!I:GE)6=%$*MB5=;B_3H?.2S M4GJ%!M_N4R120X!8S%6QD=_MVH0P$1T,-SGA-]D0;XE:!JG',OS/BE&XX7P M^..
D+=7#N+V#UMT+72IQ59_ZC!C7.'R4WA<@%TV;=Y,& > O[ESC.W08FBNCHK\^7V+T^_ZLWE MV?TF\Q+9VM^WYH2E _^K9I[,)Z8QN[K/*K>DO WI[K/# BW@ P
MGU\@>376Z44MJ&'SMW[jY'LA;XE6KO=;RQ8?. MJVP_P]JRTD29CHA#G@7R#QJ5[PLK4:8@0&ZP[<.NN,6>6 M;>^:=]QT6:3&[:Y%5^PUT[M]_$]B?DFI;SAPI1):=C
M9Y\]R/[+A#I_*"?9>/(HUTS05;V\"7)]:C_E[!8GU4"T[S'V5U3L<[|;QQPF M6,,$G>4&=WPIT7]8MTR8C3E/GT\7CJ4?08@@@(=6HAL/#<.,SB8+)0&35H:
M*2WI,TM>>H<3_0Y;X*=[.OPYEY1S?%DI,#?2V7*N3^DED@I(&;H*&=^0UUCP*_W: M#Y&+&'DQ=PBZ+'Y:T;D/:|_YY$V!SO>\@\#AN \;1X PM/-^MUA1_2I0+)33
MYL3XUN;%_]!60D?LEKL2Z<8DV&APEBL%=<42[E'V\!$O61HD]?^AU]0UN;8RRQD6A\W@IY0X^%+VI2[VE=PP?O0H31$L&2]C@XA M>AG",H)ELY=VC5J5U?HV#1-"Q=M.4?
6\]TP>%RX3RD)HF_!' $%6_%5S:WI,5 MAGV<9.QJ5[+"0@%]=AN!#8]@Z9XB_0#"!L8=)<<:>6ZXD+:DB0BJ]}=<;;;N>@C2#F9!L_7>E9?
G@,Y^,ID:|;P>8O4V*+5Y29@2:C0.EK?=M8!N*/B# M$@&& &3(W5J2N0TCF"6@!ZXR(91)..3C?_CIO!R>3WZI:P<@\!*;/O2202'WIY M<*)Z&S|&X-QKWM5@0*$.D#92*5 =#7%-I?
L+ ^6MBC2*1"6%UC*< LZ%N2UC3 M2'-U/^Y7(V,41P60=*8 Q$\M"S=-"0[']$/6C)X9V4|;@;@&3;/*\CCT&+ONG M*Z".#:0/L 2N+6 XE&#HAQ]_B8)86#A@ OQ>S"MQ%9W.TO
7)R9[#VPC\Y;_ML@BKNV;WO^[4@=%D/'EHFFE1!*4]IV2MBWB,)LF04.5I,O)WI$] M7CF\X?N,Q/TD@/E4]+C>\"]56AAOCYY8841CK&43VV0I.?WX.4=EXVB MT%?
D"1BT]6^W#5Y]JZ]#X!VH7P.#F5 'N36.5_GT@ ?,$0L?PX33-A/&=)^+ MSM80K^2S:?)CILD2! MB;Q$QF7'WG+!##1?E?@FX:D\XFT|WN;%$6_S.,9RQ-LT
MW,B0HP+TLU0_E7Y=:=+1(N21/,ORQ'$S^BW>%5VZJ\YFMN@Y2E&,'IZK M.H9Q2<)^D#J@D]/#LR!QOMW6/+"&)=3-:&/1,220PR&&{M/L,9C9Q57:
MG5=*>D@R(BQ^FS/4!UQ!S=+13.6KA^&ZY*&RO)CTK-S:U'4ZJ'Z*K>W\GYIVF M8MCMPQ)S@SSW;$-F;#E! [M/ZL R-4EM\[=KD64RK%X!W.&/K*+(/$;/>6::>
ME2>D>KR_I#JLP=VC]"JQ&+7,P[@ 96;0#G.Z*1I)*]Q#1JD;IG"'*Y>BN! DZ M"''1,ILEO2V@IL_B&P?%L[Q)_PJ6+ D!SN#]J*WQFF'N%WF)QL4|TMN\\#?)D M.F@I@E-,X(5-
01/Z*KK'[X,/6/^A.M*6#Z%1'J/W"OLR72CGG:80\<8ZKK6 M:,[B;J8"?_COJIO95S_],-$VNF.&=-_^KCY&41DO$9^C9;&34C9NH'YK^@HRR)2]Q*%_[:;G\UF1C)_P_:
MVFD23)#,*2[!DW00PE>L6(2K='Q^]VW3'_1Q]!%O M7[T)H_SV^Z0TLBHOB2#;7_S4S@QZ+_*9(K5V9KB*06\W[Q&CY9YJL7:X!M=M M795_,*G. 9Y+70, ^EVU:.O/Y]6%E-B[Y{8)
[MO<5:!TQ^GE#&[@:4@<0C:K") V+>@5M8<,.+B2LN@]L_B70\M.W/UDLL.A@D86"Q3_*[ENX1NB-SSGZ:S]OEAL!,Z-.,+/W$1ED]CK&-)38
MY%"!W(1C3U^ZRI<;'J!%DA(!T5;B"V]4UX8@WC4HZ-B"T.JUS/B2:"[SKB2=V*_7#U:UQ, M-_INX9'E>(!MP"XMSVHZ^/\G=?Q@O(,@9L@_E*H$>4O/&1Q!3]
I$3H\%')VE%2+]32[!9N3$I*&3.'Q# M0.#=,*L;S3-QTDWF"!$M!US;JQS\)U?\4@-@<=A^6H*#B-A56PZ]5BC^5-M>7"0.&7(6&=2>.OIB.@H"@D6M?$L7$U/\!H0"
MR9EVD!B0L6>&Z]D^[OJ1'0B H37&C)>)RI&,O!+5=4,T2&4*;'7(N4"]D]#RG M$!*/TD6EX?6XL<-N^"5]@51S0OR#$,T;@X*5X"KY2$T&:M#=9L5=S? ..]]& M[
<936[%WF;=PZF$EZ7Z"($QLM.EG[QCDP6K$;EJ7)DJ>%HT5@R?_V!$J/BYZ!PG;O,.,)PBK[6 MSV?:?5BQ_MG(/CY;?R169A_8? M85K(I[*H07?
%SJLEFYG;,=I*N^UHE1F&;/=&RND>A\M]W&Q7!M^5J8IG<82? M)/"3SX[PD\H,L NMUU^?!MF^1D/YA. --7E M!"R'B@,T,F*ALV?!7TBZBJ-%/4L[MT'X0]
MHM32S(K5JIF.GX5R>K]*5I$/H%1LY=NJ36&<73=N9^-'LKN,[Q5O#[$"L_U* MB?F+Z!;O(.#5W]&(R$[3:5.,8V!"@DQ?%GEG]WQ'&K&=W!"P)#93CG_T>(&_
M789UDZO0A3L#IVO@6*HN*\?*$Y\7!GA-=].MP$6KH1^1)0A[_R*$(G<+BRZ] MQ$EVC9KIE!$RAQ<36:P;(Z+&U>]=T:3OPQ+ZMHFV!F1&S3V.AM3C/]P+O;]W
MR9YE;1ZE=I8//,I'4'3_<$+[?>BT1;ZA"%&23/S?*6O\1L+U1Y,Y^]GU\]72 M@(4GDB-DLVK],&CA4*->4T6:\EKAU\L*W9Z'OPSRXUTY4DXO7:',K"_*V=+
MU.E!DQ_392'H'|:!V=++S+I,8 ZVA8GJS.Y+22BV(PZNU';J/[<1M%92[" MD'54^>)L9-RO9]T";7]MR5NEPN\E+8-$)6*,R?Y^^X?X)'&2(#Z2H#WTFI;4 M\D\)#45;;!L0!^<
$,T_]@LVP-T1R+62PTI=09(@"9Y)N^;)GIQ0;+!'N>NDU ME)KD:4JAT!&(;L$Y6Z-?MQ*E<_H&!3IOZ -86VGYTC\8]KUWO]/*$W5'[*M M5WE?+VQ3T%Y1QM
V;B<80N^9[DJSI!T#%N4OI:C8%B$&H*-4?(1!QM'OZ[M1\'KKIBE'O0=\NGF8F0$&TBG31K^88BU:CTGZKC$!HUWG+A4U;6BSAQ_"K;: M5;"EN^ <'C?1GWT3B:QOOB
E7LN9Y46S\9T/X]V##>.KV" 8N6:@EN.0Q6/^ MBMOHSWN]A9]!%%70<9(7HCJ7UF6M[4AVEW..:HDDY+L?#+(=PSR2H!NDO2EO MIES8<+
[W1NO'4_MGVB8$$U(?9K_02_$%'!*1E8.UH29UFB0AKC)XU;Z.VTE M(:MA)54L_9-8[LTUYC-5B&>KG%C&+C%*IUQM"=A' ;"X(^G*#M"

OHCD09JA M2ZL%#;X \DC_V;038;&.PB< 8]\4>;Y4J6G-(!L;K.LB^%;P M@2$<6U?PBR_,1(Y2KQS6)2[Y VH?(RN&R6 MJ4&>=Q4B/VW.;]V_3..48 _0=L=%02640K,SB6QUVH%,3S(=8FO[9LISM*.^-MNZ5)'>U$E(+PW5;YG#Q7AB%<5?-J1 GNZT9E6O?17"Z-S4:E"B.'E!)QP4) M:RB[JS A'YQM&H]Z;&09GLN/5BCE-LY'K0C3>E4'^U74B&F)"(O] 93N5>8%>4I"S%97#>F[U#DK_+2J MJ1>^9)/E7&MP2XW9R,_+4%8$\-)<.:#NB*UlP<%16F.MH[6#:DFV3%UJF046* MS"#URT.RCR+?;*.<%$Z0D8PD&7;%=A2-83.HC#[\C"[M0+D*"KGRG:!0[S=)MK%9V[@$/PJO1^,X@TX6A1I5'B8]6<5V$T<(B)'/'UW:[V/"A<;)-8RG0@KU:D!<$5%$J8D!0/4];IL4X2K MXO'/<(LUU#HVZ!,@(C4%#7B1(X\928 *VNS.G_91*,*;BC M$;,0+*/!N>-F@74EZ_+6\Q.4WX(*P&6NK:X.QH=ID$YO7XDMJ!^N$.UM E!D MU(,,%P-#55C("6V1 !_'DO@E\Y/L)OSZ8 :8GJZ/!%2D;Y:6M=Y=1.;#X,3RB=W["+5E2)!^4^Z-*# MD\H4A?(N>T>K")ETL)V*SBA WXQSW_)VG16[\"52;@E6<=[LNMFG9T_A^ 9 MMP=_+IR]G34QX<31TWTH?KAE+"_3I8MRNZ'M;2 MWCDG:&@XVI=A,X>GD@M8LZ;G&D!SQA%1LS^^!V_YY/S%V=]?&@_=;7-M'*0[M=D9'8I EKZ9L>!#DZ>; (Z4Y]^MR/&_!IFZY*+T!@/OO'I\^0/^/6UTW5L!FP M#95(*QO=$7;RFF <,L T"B'G;B:]'^A#09/$\06.RV65V#\7@JB/$/T[2O+Y=2H[+&QKBX3%;W2%&+C'EV6;&+ HRLH65J@S%"ZO MH-@Z)ZD.!DC:^KMIDV!FEA%IB7C@S6,+M^RZ;D7G-6?'-K%#TOPWJD/X#POPMDEKUWE@*.5<'"[$4X^$%0^@Q15;]3LV MZ+Q=).S0Y[FT FBG00NR:$MVQ6F3YS6'P5KY5D(A-J\1'_O<0454VL?\"24 M2,/5%MS;56F^O80DT@_(\" ,>A_[>=)([CMC,B;@9.**>RVU<6WACYR6[B3+ M4<*"]3B9)C[0.Q?> 9FF3+RZU6XF#98\7[!H8SCM559FOME<+G,XV[X789TX,-MU]SV!9=AM84U6>;7N!'\;SW0,WQ@E!;\(YYMV 2_!U20)4;3(AUO>HY;ZV (M$EVY"+?(0+RR52^3&B;9=!<5 M$KWJ;+*E6&5[6XP[O(7D_<6YF8>VUS3.!U MPSXV4FK-QH'$.'9PO5(I1-0E!N90L2?(I.Z>C+=.)K0QZ%MU>,!(O#M8+)_* M?/?#VTP9.H/-M? 8S>KWOO@N_.RG/+|_Y=7|$X03]|C5C3\/.^1;OZM-LXF[_MJB1]-O6&_A%'"%_[SI3;>CO_D8AL>6I?2!O"-'(JW+;%+7Q'%[B.\?K M).RQ'P2^ M\FW3(>0'Z\^)CC/AG0ZZVI%1L\IVJA[3ENE>5>$_H2K[I+P,+T3W" #0PD%V8?P MZ?Y;EJR"_'0=A_T;+"^<@!=GPV)H##,JO4)*1?]R61$O -.;2366C\'=,@1; MQ'69 B#3-*B:B@QB87@>FHJ:-"&3 %N1I)@OD1MV(/!MN4:F4BB?8TY$6P4D M!4J@^XR9TDE9BXE=--C=S-&H_0'!#(@W^CZJ{Y\PZ6G0+.]$/W0^NQ". 5/? MW*';9JXQQ&5? K5AR4BHVDE+J> ?!SVAZ9&>IGX&V2G!1F7_"?RYV@BZ@(*- M+)Y)W CL=4_NTD@;873!'"RIG?)\G/3}{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tO M2$8#9,"PZ!H"$,E'LX@$X-_B[:KB;'0=W&IEG^9UV47WE_&+?_5\8(3\9!] M%X]\|-?KJK@A9LS33%A@"'<<8=MM5TI'-MDL)_DRR@9/GA*D6>#4K.'3!'JX M!G!3'BE*3!9HQNUM+B5(5/L8+&;X MNUKJMLS,2^9DJD*8BJL'#T5K(--(_-TBB,DT[XTR'/MF!G7WJ7!8'GY&!(0Z MSVG*Q;K6<[)0,"9D5V;\"#AHU19G5(C8L6^;O(;XI41@A"OQI6,2FWF]NF%N-M(@)!APP\('3SRI4UFZ|\%Y]C02"(S|*SALK]T4!VK!()2F>#C^&?_C6 H%4 M30?QN/-N^9D<+%*$'@_;/XQ68%EV{IU$.Y-ZY ;=]ZEK$6_]N6SF"QB>NY?1& MCA^=&F.ZJ[IR<^L&!Q-\;GD"7U*/Y]$SMNPP48&>2>X:TA~>B[4SEH(:)YW"& M29P^[KH/4US$JZ9F@FW!JQVV%EE?1D^+6)#X4#67)CT8]TVS2J$/3\TW1,U MUWJK-(M?5G1&JS!KLR_[$)ELR> ^E/W_VY.G?9B*]+E)5%L3'E%QD8&&\&X=% M3-C"R,H8$]D/EE89XT0,4X*3T=CY[.NI->#.&UT(VK[!-/4$> H+0D]KVHK3 M/X91BSY]IQ2&K[ET6BTH;9WY\VQ?I+)@S*(?YV> "YGN\8_@'B']N16B66'/YP M>]G&%Q'^\- :F[6#*%R8FV5&MGY$HICPV@V 40OLE64>3PUF$AU=,E(^(UK-< M,A5D0Bf(LKW%WY+G9$!S"*T%2IGT\W6,?.2YMH?)7%(;D/&U'DLXD43NRNUV MI=R\)23HR_.T_^K >SYX\^_1.H-+LY,??WY[.P#X5-O9-$_O^FDUPZT6/;_ - M0R1%dEO@F5B2RXXM)1.-*4GH?@eVD6((M;Q6;@PZCY*A!P:474H8OW M)&0GG+V4O!&TC*H1CC(=FL_83# KY4[IF5#&S8WIV TA3#$OOCT[&T:#)A!3 M-:?1#=%%?[_::O67K)D_.],;'\=8CC7S OO|:ZB9/Q*?\\M2E"E%WC(<\&)[M)?_I(:/T6^X#J5W:? V^I/*F/6Z:0!Y(E]3UU;&W2@D,!+ ^#!:D!AG @20>6FFG\STNSN.- MU-7*836)TH.02;B,F!J<.NE>1!8/C3418?,*)=L,9]QJ4U*[.6"2%Q'^&R=DV#P M6A@N].36N^A,1@: (A%EAS)>0)5-D.NU3\2MA7?L%OD&"G A&]DH M<;P2Y\;FWC1N\C)Q-&DS\;T.DLJTE7,+,R08X#.N\7V8FI7NA9?[P-$0)-MOFHZ$..CZ" [Z17Y_4/<]BK$(,2W%%:VHSWNE>D7XMJF[\Z"M,UQ96M;CQZ0:.MT$?TD2$=20P3QA,9,%(IDIR'5.,)HLD+\R*&V: -$Z0*RE[O2V4SNR6=I6;7^-MN.6 9'8HC8.#R5K)M!LL'Q1/3!%[TAAFG8&,'(;,2B QC>!0/G@:-U^?]"$-MRRS|$M;P*Y3NH&G96F![=6-&+>O,E&VF-FMT5KLO)10_+2!WM6RF2]^*?$/6P M,U+SSO5]X_(&CMB)K0/] (N;'(O.PXYU9-%!+'3/BZP{.0!"-,.^?7^WY6[.MHA-)"H=A6/B1F"#(-M]5$R!NE>6Y0%+'W3H/H3K2&?PZ3$&S%K*25VIZY>\L^?SD[TE5>AIF,3O1.X32[MWQ$PSKD!-, M#FXWH!^*E@C IC#JJ8*&HHQFFW!SBHO@/K=8E3FYV5<-2 -<\5UMC6[HMO< M=Z'M63V4()CD]9S]V"[' &,BCU'E(8NF &UXH,/K&3 M'@_%'=]PO;)XKV*RR? 0Z,;D/^8Y!0E8N7=%(&G]<^17]\^3SQF65NJ]5T*3"}> M3 Q#?R.-Y2]^-]B)X?R_R^UOA8*.'P2*%=\EVO9%]V7.MART,U#?!IE06GGUM,_EZ_>5Q) MXFE@&YHNO#//8M? 57;02U9F6#5T=8,*,_[&LA[,_KMS/N]A&*O2*I'B;< 'F MX5H*.T6*9N[KQ3K\496D*S=R2>O7KT)-BL!SG;@3HOGS|:\6]G<^$>;.", MV4D>:7C$CD]8YV9W:2,,\[$<@:BI1,_1A^? SPE+224G?/4@?C!G,9$NDFI]M_!9V5L,8W/R%;X)Y$([FRJNS!{L]HV^D=]3SJ3B*I&@^>2QFS'ZSG=#>=>EM2BM#C/MQ

M(K%44R_X/"2@/?)%E\VJ:@X/@"GU'(YQ?!KK)^B<3LO1,J72O}\P3"(V@5& MXYIB.H?/.ISU''26#')SO|E,]^V(*$.X/^\!!UBM],U#$$$4 M:// 0,33#6<@"_[WXGQV\HG^\)-3\&'@(:.(U\]D M* @]}FCBU_#W^/97CC#_#9P(F(80AAVZ"!YB&3]_JOZ6>P({?,.I1 CMYL-"_M?TY2A OJJMJ$L[&]H6Z4G@=B2WS92.:],C2/>(9VBD0BW9G59VV32);J.H.)@ M@;<3Y\]TK_-#,GIE:)}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|O+ F-A_0M GKTPQY*W*OK?;'*&>""X0'!4?ZQC0A_42C MI])WD%G@M@&M+S;4QDY/%:28]C?"B.XT8%KKQJ^E6E$07R2,(@BA.$_%**9 MLHLA\G!L1-9@@P)I.-L!SU-LPA\\QB2"O"4] C62=![P(LX"_O^=F$7ET'P[MO=$R0:*QB0H/F#!0'!OZ-W"ACX{)K\#=PU.;#=@=NK;W6.?:LJED&KM!2K"# M-;@!3U?G-C%QTRCOATBEN 0I3NE*2'-8; MOQP^ZU2:T]L4#ZE\3&$KY-LH 9)H'N/MW^O>]EYHV72O53$085Z"YHR"5X/> M8+@T;M62@6&(L_T)D5R9#$EDI3<"L*=BOI$X'] _#[- VMFTWW%(;&E*$.ZZOWN0[@+?+2 M=SI$&VL@KQ.709P)iM:,IG3Z5DX MU/F.!P=]?JV*B^ &YE39OZ3]f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~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|.DRG:3"P"9A=&J.=M[W?/PPI^Y)\[=1=6R;?DN!R3SOJ@04D=Q0+DS6[Y;^ MBM$>ES!_>A;$L8G.RPH0@*TXEL#Q=K0PAQ!=-^*B)3$!J%XXB MPG"J{(6!'<:8'O&M(6$<88M!T,;SCK-/O-1V^+V "$!9J N8NAH+H$D+N0^R1.6^,+'N-[4RQ7.\CC@-6Q%[KTFI1@-G_>\ M&HR\JZAK1N#:6XAK3;2Z.!CW4 ?S'&\%,=T7#A-6K>]@L!/F24EB^9DAZ]M7 M6\7 21]20CS+L!/'Y*^8$XK'R*40V!)KE&7T67+A-;$Y:JIA"U2R>T6TJ$@ M>8V93<)$T,T2FPW?Q%EX1[:)C,?L1W*WRMF)R,[Q!]_]:'*(O,U;QOXI*S^N M*ZU0X %A&?_9A]U#Z4 | U9$/CFH6F J]X)0#"2 5-I-5*$B$Z87]0T(EH1E MLXR\-*XQ[L6?6B^=>]%]Z#I3L,<15\%ZXC[3I*GQK6I0>5FI?)OF*94?P_5) M.0NU[U#M/4-'U(5'73P]HBX>QUB.J(L#&_WAHR[>C:N#3($LPHU)/,G"9OBU M>?5DRCGM)OF$;F^^G-P0*O-K@F8J)Y!SA-MW";=9OR$WZO7K;/::Z.B?FM[K M]P#!OHG7M]S V>QME,2? FL6B@:.4;W MA3OP^:?]H<$WN+JKG:1=Pf=]W<)1 M^+8,/3]

*V:i,5*F#VSOI4IDHL5@H'N.@$S;R0 M8L3KEXM.#ZT{(,;FAS/J+,8THEQ-S^K=EB('K2$5*[3,L88%)(!P|+=R;92# MM*

1RQIMLO9;F@66F,)$%P30L345W"29@%PI*>7/*Y4)O/U;HV2DOG Q>8_AB MQ;F O#>D:*SBJ?"^!V1G;M%G8&O*%+TRZ@,JU%2!?<)0!!>-RJ4IT1G;K@KZ MTXLF9/$P?

GT#Y3Q>1DQ0F8KOJJ0CQ%T;6AZO;", ,R-,@Z8.NB/C2BH8.KM0 MXP". -IHW^!%LUY0C@?I"&(!!@H4U"=?+#Z6O-&!I+#QV/@\3;Y%(9=B'/;1 MN_V?*K*,C>]O\/IB#^V=1*

;;>4O,9J-8T'Z"P9>@V4S%%J:4@%)J7;M@!A5@ MQ'MM>01%#!V"'OCI/ ZM 4DH3.^1U!2,1*+*JU0T8QAY\3>YN<+_IN(8\D1<(MYR15V>2B53,4"MN*RYV7ZJGOK%,JE'?*

*#D;U."#TE"J78"/CT*_UAV64K:O9L M'5FS)VR;, 2C5*I0A/H/JO9[C",*LL. *MHVH|""-QCO:NPZ:S>I6US7&#@ M@?$6N7 %X4[0]*LJ'N=6+Q_RPQ"_X"Z:%=T9J-*

*PG7IA2[\%=C1QX(R>0M%WJ M@E!4&U*Z9)B6K_!EL^!%+"3@91H 2 M1-DI+%N&!D=?&.A M*JK]")CK>D2R"$Y/EBJB]-3?*&K[G.A)T5%"(&3*#:%.M':L-"-Z/-*

#TMC;&J%3&:]8^Y=>> M[R$,LHJX5!@WO#VCL* KH;?F7]*0)E(*\VFI*[&ND90>Nf^<7<#L-B;\/.?[M/$GGTWIW'],4B@LQ)0C?0A 6E"!&D3@O"W6R$-V%;$V\,+)Q,W'X+&O

SNH: ML-I2@H#;&:.%WX#"1#L)M2U0K,C^DH@U056)"FHJ9@:!\ M51%-#EC6K)"/L'4*%P%#?.]N(VW.U0TZ2U-.XI;9F%E%',?#\'KW'44IBXA*

M08W69FG@\'-3>9Z.L0!&988P3V#C1$R2+ =(Q-SJ>A .GM+S)C6@TP9W0SV M;<4!0:JQ)1:I3EN7(NK$#B,.0+N% M/HT?(&U\?7A,B%*7M&?X\8K)M)N8*\?*

$K<^UM6[_W15E@!(L - E*E;3^4YP MR>D8SP21QS JS7S_CCLDF?6:/UP,)'8S M!!I4;V$!] S:[^8Q[+,&\;(W&_%-"5W+@PL[#>=>3E7Z'U/A!)N&!29"3581 M7(;B0Y'E!$%@%)P"3!2R],SB!T4?:EB;$?GN:C+^X=G,.^ 1#1

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{J3-ZID=O>NAM#KO+@ZOMQT:%!IZBL2!'"/5NWZ *!E0+6)24C0RYL MZR3=KAB'U*OC@>;RIFKL;SZ[!Z3R(:',G&PFUM2!2A!X^I=^7C6->/4MG=#DCN_"_M E^50M9[E!/-X$9%,,"[%P7 3,O%.!Z+PQZ>CE;U[D<=X0]YW9"R/P/F^_W5&WVH_R%2NSQ'I3'5 M(WM-[5(L.$G U5,ILT13BK>R=1,.?5.[CWBM:1#T/%3]?=-SU:WO,KY,KT>,MFH/DG.),X2G.E$AOD_QJ-9U=MNC&U*6Z?'3\U#U/P0]G8S..<; EVCK MN5$&8M$>T'JH- I\B-9SWOI>5@P_=M\?E9,;,XI&^<:C[CW7$1IZOEIGF)\ MYRCLT@F2Y:'DG+A{f0\/OP?4D%R:GIAT5[A|N^)Z2<;\@/7OT'6AKJ0G$;.M MFYM\ ;4TS3BPP#S8%)VFGS1KQ7L;D1#\C8>E#E[];B7WLEONS$-]W,)0'L5 MI8]*RE8*RAH!"E)6I."*R% [@C'I;+R\$^;)UP--:L/]D5C33D.]V)IE"?0R M5V-D1*5+ 28->2G!!7"1ODB,Q5@E.);6^_!0!#*D3?@/8%GV4TCS/.V;4C&L MS=QRQ^W(6\@9 3I1-U8E'P]4R+4+4:VT$>:-]_D=P><'=>2_A;&I)5V>G9;MW1^$#N_AF4%_VG=LK:4;*WHF%^$3TL7[.WG95.0(\AO=(_F_;54)O* MR[H1B8:],JGW#B=UE_*'V=('D4D$FU4 *Y!<&Y=HH(5I(+_$\$)^2(A7\G&WME%O>]93'4(/;B@5M1=ZCV;CI4)&+0]9].VPE4C+ 7;"Y%9'3W!I-/;H\B:), MI-B^=T-R)\1'4+C;OV5II\3F_9=7+!\FCU|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f"'E;X]%UZMV^MC;:^8U["JP-],/)V3'GD^G MXR_8S4/WG8(\5D0];\-Q1KB-U>!54F U1Y.58LZU/D_]<-1#2A$-GK1M=/^ MG'T]{N:+3=PR16N4$\"5C*!B9A"<5F"L\R[:>FA,ZUV1AZ,>4KK|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|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

,H!3,U!KE25!9-M'$K#L?56OU\BW+/=[XL'V\BY!0%G#;,\-H'QS1-X%5'18YD-!$1'+QA88UG@-M1G-$@U'>""^O.6U8,?Wf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|QKLBT\M/:U!TZ,^U(<|\Z+,83>_!3U%)>89LN]# F+Y26QF KM944IPB4T MPR*X\|I61JM1'6;G;Z,] M#2BQ@^A[V/?O0)BR$M'6'DC=6ECO@480H<;|LRX6-#8_5-\W*>[9]??-B6TD MO@;3>B<);]U?:#-G14J:!(O:PTKP;SO[Y:HIX46S^"K$C($)!R4),9)8)#PR, MT2PYG4D<"LDN[YDRZ]$=+6T:*:2/XAXK;/??X=]W.%?A^\ R2)[O>#?1"_-*QE>MSYE=UC\:YGd.!EYD.3Q(ED.HM5$=K8P; RL)4Y0\DRYOK#?KZA?>^9QC4'UK MI M>'+AA?/-GHL7"@/Q'W<+)R'6?7<,K]HRE"/AE?S2P2@7P>MN2=0Y.5(\IE#\@R$IQ4NL>/:\N9JC.7]G'{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|-)?CW^ M3!1%O/+,7[_>_O#%QQ8WKL!7FTBX>HN",UUL(M?+2":C"L)\IA=&V#@RVQ+ ^O MSDP-,7:K!<,AU+DJW^\0W9Q6RK:[YY.K66ZUK[%.$JL.@85L#(N(M>2M#2A; MN|\KP1SJLN3AZ+&6I[NHJ8_F,- @U!*\B^S7&:2)G65N_B8(>IIH>3^ZPURX M,*3.FR3I1Q>'88V-T6;/G!E9JSA+FK!>TVRQB:.:0 &5T\VZVAV++//3SQQV7<"IL-/YSB[S#[)\Y/M2L%%UY>7/R-R4BM!0LNUHHE-1E)2R3+/V19DG$F;Y;#L_811Z/BAI)LW<;B M!:8.Q%WKD>5%.F>115DCQMI=O#U9.K MP[\XMSZ%*SV;G2,[6%7$,A+'!B!+(YO&*F!H,\R4Z1IZ43VBU5;,U!K - MO@.0I\?H2%^*Z<%D>#XY.YN,.ZQO87HR762N_AUH#KS%,0=[0++**UCR.VR MPE6LW5PX"$O.=\+H6L?;-H!U5)1HK89^G<^+%,%+AN\2J&0J1NJ.P6%LQ L M+;E90G+*9FU:U_I;A<6H.-%$X*VMCBN@%I;NA\G;\VDZA1D^R[D3-HP6J]UE M A}93),\R&3M.LR:14-ND8ZUNX0"PW21>D'O9)WLD4>#.$HV+%'+?1KLSR? MC$DV.(6*]AV96\//F$^N#8V&&^UETHPL+8H$V&&^UETHPL+8H,VE"K^U_KHYU<>_:SFKWWLO.5?OW!F%OXVG6 _A.F M^1L3G4U.6B*AC(]8&!1Y0^1"T_:4HQ+>Y8JR\3[_^]=M\)TBOE\=#%[!L(R M6P=F<4(]D3%25?K!'=[NF$A6V FAIP4CRA3\WR(5N#WE@RQ7Y;>VEP/HNS' MDBWQ=@3C&]'K3M^BMQR5SBRKN@W$N@,X;ICA4(07V:?FV3M7GW^PG(C#,..!F M.:6'.I*/0EM++,M0[29H>LIWN(]D,+D-#}?,&A7O(-;^E6U4C,Y*J-FGF=P' M<"OHL$QY.IT6'%+S$IWI4/(]*0EIZ7@;,38_9JR"?CVN.>5D:.';+5$6W/"+) M8$!; \OE7GT,+IB'9)F4-B1!/F2Y>>Z\[CQOKL?LWI7:10&

1$__[3_^RW_YM_\+PO_UYLM'*Z@ZT>^JL';DN:,_!|7C^_^H&#OQ?E M/_)G###XO<2V*\A'"_VA>>UL\O93Y_4,- B|_6/]7\N_1AGW$C_+8$9"#A'R M?4A$3&'(112A($J\V+NZ_ZL?^UC|)TR%>BQA&4P10= G/(V8A\),L&;09;[Z MQU_5/PBN.)#BK:KF/__]3P]U_?37GW_^_???__=E,N_%.7]SX'GA3_W3_^I M>_S[P?,_A\W3DLWLY^:OFT>K_-B#O]($_8IBOJA]OJ")0Y7^M MFE]^+"BN&]3/\@5./]'^"_;/0?4KZ S6WGWF9%^QKC+R7TX1^_D"]AWQ6Q_RZH"Y1MQ/KG@\]_L|S%>.MM=P9&N3LW_\D?UJL*WB/\=/B:UW0?UP_/96<MYHW_]*6M>KKJ9>OO_)'PLM%O?E^%WP%OWWM237C&0[V]P.QZA/J6?*)6>T M?=@D%V1!;QG[CX8^&#(6@[3Y'$Z_]O.6D4$//;R\'_=Q*9M@N|06JH%OBCWI2VHN;1,#;JDN(VH E>DD;<;3,H=A#_S95WUOX'J-XT:Z=/[M^6'JK\M>*ES2,ZAW3_Q,"^GK/-5P9P)$63Q:BE\7EE]).Q&2K3^!HF2\E!|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{O9(+$M=3-+,HZ7GNEPAH*9K=@!8$'XWSJZ,PQ: CJR!,.T9E5] M+;'W=5WO)3OEOEE)!P17_!UO_WV$NGWBI72;& .1UWAY3:JZQ+1>$+FIX5*WM81P(>DHHQ#'?B@:I,IPQC..T1>&)NNB_DTR#"\=

+!6?!SI:'VSZ7LY8,=AP4D+$%S5FS0A/6^Y20M0#JI-VHQA'7^F[%BE M2EI2GJHQLKHF57.>NPA%G+(L2R!//$VEG!.(0^QF%*.(12OPHD_"8V)D16A.,
ME9YR6Y&UHRTW^1UUP]W1&&9ZYL,1$F;6PAH$FYBS<^*YBSD[26GNF+-S(A^) M.3O{BFTB9Y-77RU$Q 5"?@9CBN3^)R"]7Y7P(*8QH@QSG_)@41SFILJ)
{'I6R$#B,Y/SY9P8%[FDNSP[RQKMAITY0717E,-WY=\P37O+LY$BD46)Q0&4.1"SJF)!49]/V A82&.1H, MW6SHDYY8K11A54V9,R\<%6TS_3{ 4D\#IX''3$>'Y.8);)[";.FR PW!\"1
MPAL0GM4DF .R;S0L1C S*U59+SZ7!5O36ODN7WGYG%-><=4E47H)"3OP ^AYF M%#$>P R% N(X8X0%E+/4T[$@HU2FWBZT=-LJ@RU4/A,Q#LVX37 FL.&NX%\6 MAZEE6D*-
J;0<8*#.\K^VJCP^]BQ;JR5>KZ!Z#UN>'W;7 +?B>E7G+%^N55N* M;2O<[]_IW=5]_\#TN5_GJOOK,R^:(87!W$B0Q%D) &JG;T325 M.NR'#/J!)U@H*/5)8G3*Z)S%B:W V_8$LHV-
?_/=?Z,E\UE2L]H6\'N+5[2 M];8NPCLEF/S;)Z["":I*-;)JS^,,#RW=SZCFT>:KSI/A ->C@]FO(;#;]MYL M;3EN>E%V/&JG:=)KG.FP=76NZI!>4]?)P/XX(QV.DKFQ7V:Q
G=BNMDE%BJ2J ZE27CO2Y F5XCLD];N4#K^_OK9YPO#71I9(B)=4I2*IM\?- 05"N8 MOA:-27Y>FQP);.95=R5F36U*U3/FOJM..5CTC^#A5-TTA+92N[%Q9U,_#>&&
M:JCSN$6RAZ'*|TT,F9QIN>9^D)]$GYDP%3P8! MQ9PE"*;$##R$* .0#BF$1+YW,&N(?3*,K,HE>/TIG8L'71DX]N:,SI<5CTCC$< M"&MFM@9R3AP*,RJ8LW#/XU1F#ND<%?
4P;/\<>M$L%(-_(ZW_[Y9W:R>[<4N M2NGK+$(1!)QZ#$9"_@-YOO1!1)1!&A/L,Q92/T 6-;I&B6I]PQ=7Z>H)&C;A M'8=+3W%G1?[2%[8QDO6 M-> ^Y?.GA>L7>\6> ^-+)Z4-
],U\>Y]PXP0+I(;ACIE4L=9 +,LB*"(I'X3' 2! M2/6]=#1GZ8HOJZ\-M[DKCGZ4X=X%\70B.E,G7?M7.,GSB39.-SV7QG#/.WKQ[U3HM3(IE>&P"IF/?#[.0PRQ*?(@8(1
'(8,X$<$1.$D%"CDT<=G,6KN25?U?Q++X WK/S5S(!8P*@S2*$ WK/S5S(!8P*@SAG(&&)!E M:I+ ;'M;'}@D=Q"P9FM4CV .T;] M&,K^[N%E5DDAY5[*^-
:2D2S\5]34KGAKW MO]\\:]YD: \XL<'I^ #]>?^FN6O;-+:@G*U5H/D#'2LZ=]fZ*-V_A9D$L!, MMR_&6#GND6L%A-4]B3Z5V6Y-C 4?WJ&8OVSGU%P8J!!>H2TPIUB,10*)EQ&(ML
@@)HQ ED5!D'H>I4RK7Z)3KN:)!FOS4?D@&HSOQ!?5#QS0W8@PUD6$K:03 ML%0184]229M$5ON45C?$J.=(S3X[9F;/4=R7NW",27!SY^YX6E6E\PIC/M>
MFMO!+6VR*HMX)!MRF51'_"I3%,DQ!!YQ/4>5!B2MC6-?.1*IAAP-JYQST)17\097G"F_@Z^]M@#B-LKQSO*M+(,.NA576.3KHM#.GEN0"N1NO%09*78!C/S++A*-M!]+
[7E3A&:>C(/$H;GI6Q:&DEHXZ(V)$@\3S'TH*/,A0E$*L9AHV!,ZYFCD0VTS5S:;553D.>D9LR M^7;KN5^Q#OL(K*G^^]?GC-K#$ M9XD0#*4PC",5S)LDD+ DAL+W
!YYB"&SDF:E"=6T]_KIZ=EXUO@):!]#]@-M>4671=5<"N^\ZP8s#VK%P3W:$.OMZ9. JB9">A8&,3L**PV7("&C6F"=TR% M=Q6SHTUWWE =4S@.(G2.;![-
(&@++W7!B8O4]RC!.(,Q4@U56$F&,I9Y5BD#.V2T-,!!DD!7'XRW5$US!7:1X:F($8E9VP@N216R246>@;Q @G-S-Y&N/=GA+/(A#@]@K/?BOH_>:TZ%RQBZA$_
MX@QRKW(+,X(@B4,$PDS4AJ#$ DC;T>7\-2;, :XG;%-% JDLGGBI6C:H[KQM-ME3,5O-,&]^>K+D0D7TD?AZJ[_H\M>?YS:-8U>65?^\FVK !1F$;$0Q1"%!*?89CAP)<>04Q|
M8=2HQXCZQ 9)D04-7: AW%B73I=_.S,H9ICJ697)D#(S+6.@37"P:26U(I-B M1GM6VV(%R[Z!L1MDYOORW;X:U^OZH2CS_\/9PD\BRJ(14KG<'"%(DDT:(YQID MS/.$5[T"8ZVB,I-
Q.+&UZN.J3^G>31^1,!QXW69;&96YXA8SL*>3\MA62EO9Z@9 MB^,=$V&W'M{1)R;H>OIMI:YPU+$%9^^_4_EHE]@C(IRF1*5E,<&4$Q- $@H? M)G&2^HA$ 0M(?
\2LY\98\6%O!FVFAIHJCW6.:E$AUI_^\.UA6I.3"L-A M-EEKTR%7H&7+>6;41:#,T<_]D?38^+-/3 SSQIZ8D7]WOYK3^^XZ16F80=*3OWJ A# M'L& 1Q@BWP\A5M'1?
NS%49"D<1@:U4(X3F9BA51$85-46)&]ZO)=K6*E3\"D MZ2]?++RA0VPEM[F_RJ6*X?V.)%Y/=9100]\/95: M2.VC >("H^%$HC*A>Y<9CPYM\EU8E&EN"0%'L3G/U
MHZH/L!C7P$OE,],[\&, JA/26 5.7TPV&PATZ'$&,9*GWS&(HF^/\.]9BQ7 MG@A>OBU6M>1V*;>#]^>\+%,]*/\+43Q6"\[#\&5> !F5JQX220!31"C,F.^) M-
$X#PO03ZDTH3[P&;]]+\(890#?< +#Y!2*X.<[>4A3Z7NY3?:=^IV)O8ED_7%]P M-^1X4O5V4:\W56;KQVO,TBNV!R^^<.UZVR8^X.VZAP'.U\;SATJ=B9>;?2W M^?O?
5OBQ*&L5+/&NNWU9>%E ,$H(#/R80Y2&') ()CX+,C\1+ D-(H^.TMQ M8D-\6^;WN7)J5- 8!_TMDVI1/0^;GEUT"H:9J5.D!P5(U#7KACIX=PX58Z.E M+:.DC.W2>WJRF15O\?
6NA_Z*= 3AQ_=I7'L-^AH07^3".E< &,PXSS_-@AC.> M"2]L.O-3(9QLG-[7];X(,EDU3G>4VQH"V# "5W"V-K9DU.(.AGBEPAXR9'1B+ MO'!6KR',&@?A\X%G9B>V?
{$=QD#/&=BR=J5J^A+> M!(1<@89!H#@TI?M\(=H&A^CSH6YWK#X]^F;'[6[P&CV OY#$?$?R;K#8.:1W M-
3%.O)VB:OJ5OP=$DM_U/V=0??;ZD8=?;#KZOHSEY^K_>,O^:U0 M.\T%CC!B61;# @#B#(O5/L]5G,Q"H5/"0FY5D"L UYFNUS]O>.D/1%B %< MJXXH'3=-PQ3)CX'=NW
2-%;9^: U6V4:OL"M -!T/X+8$#6^;Y+_MWRK0,@BN M*W -MCRJ1J[-"KC!0C,?\'8+S2P38+,6N(%L=*VYD,1\;XT;+';6&D=#6M;4 M:,]3\8|M$^3=>E%>+%*1D02F:@5!HG,. >]CU?
SB U2JX8H37Q6G%9 M':TQC/2.%!Q);F;*.Z+!L>!TY;8TI'-5YV*$TKQ5+.&|>ZOU7586X6E D8FF%,:0BS" *4^DK^@S! MC##,$I(S& FSHT)+3J8_3.PW:=
(5[,I0K%>]L>7[KV_7U!TPA)XC\B 0/;Z- FNEAOZ|F@*=+#E=MM#SC]_NET_]TZJ[M&OA)3CY NW#F!E!6',8W(9 M-]ZB6'YUF*#ER=IR"!J"H-IFAZQ@\;X.,E<1C,K822>19+$
M,2DN2)/8&6[F1(ECHARF2AQ]:H*B"%UQG.K=FJLCQCL)*E!PG*@8#@!3 "<0 MT9!:!"#;MM@1#F8AQYFG=&%ES,/T!4>*P[,91#/66^TF1,5-AG7(;P\N'YMJA
MX6FF4AMC<,Q19N,H_1^GQ,88/$;E-48'LFIZ>EAA|>]Y_?!M51!5KT^%]MZL MGM9U]84K("03S;GF%Q7VJIR--[C*]VO)TMJG*_;D-B[
M4CH=@6OJBL#>KYR*GO%KX)

MJDCO+!V#5=??]XECO4QO$44,8 8I0(+$H(CB'$0TSF%$!,?8(G#!Y.^+W85 MR\&!YYO@4;YBU:W(RR?2,WGO#;R98;3#W+S-H4=07/4X],'BO T./8)\!UMW0 M)ZVK1VM]D$YFI28RK_$?7U5A;]M;[Y>R*I^WSS^M5W6MRN0>UBO*.:L7$4$Q MIDD,&,\%0$S^*8]2"$(H7<:T$"@MM%ID7,.^*9Q;M)6@'4LWP7/+1?"DV&C+ M@%\Z1]P'59EBKQ&GG@U1,]MY-M;]POY8Q5O08^XFZ-@+&OI:VMZ'N.&V'AGF M$7)'$\5<0W_-V#%+M RFDIE2>*^A999(C,PTLUW1U/F/*N%39$*:;'' MY8!RD0/IN(< XPB"-(T*A 0#!MU,ALB-,=V@ WZNTP"H~RNJ>?MFX+2U?IME6ZV$-56F7]0ZZ[?/]P87V00 MQQ%570E"]3\HDZJ:D0C F-"$T"Q*L&%K@D9Q&ZOL_(NR:9/19N@H:)H>4E(-8P$ MBA/S=J%C,(XKM@=P#,^Q#G"Q:B2](>U5_43'UI^]K:B&L)>ZB^]9K=!W]8U MW]1=P]+#O7X,(10L Q%1U0XYC@#)T@+D$$5I$D9Q*J#)\GR1BN_[^Y9:@!O: MAMV7+L.BMS=?+:R9XK;D;G9=?KUWK/^M<2LLV-.H-!3/7L! MS71.7S:[B5]^&H.=+#[_:*W)5ET#3]EZMK>,R<[8-YOF_5H>;E]+R>RBX#@) M"Y$"AE3%"Z8(D @6@&&$HIC%&8K0XI6OR4K?J;U;RN0WV"=HZK=UU'L>VXX# M4RlV #)=]_5Z&*S\5@OY+;S5<>&N<%,%I9/QT7[!PQG7C>/.U+M0FXI9LM M7B[?'G#)_E9?: (!JW%+++;%7?;NE1ZXR.JT"Q%;S62'PV&6NKJ9Y098CBNW[A M.)-I2^0\=.VR0\0G9X9D8S;[R+GTM,RJ4T7[OI]A^W M?"::DK(LHB!EF?0(BB(&A2 ,I$E,1!&S#%)B,J9VB]"1E;& <?FLSGVH$(CT7 MW*7@9O:AHQQT@V!WQ&^"S2H@O+$4KD=73EM^^]%HYDTG_A>H4E,8Y+9(\RTQ"=>8L^#ZWJ*P/ ML5S]4;LV(89+> 6<\'\0N>F763O.PS9AIN5(_$'Q1#05G])=CS M%!R8\A)7M,?$D0=CP<'L/HT]0*=>SA4K65[B59N2EN0\<#7S6GKYWV7TH3G.,)A!J(09P!)FP8(S"%(:!&Q M#*$\"HVR%): [K>_%WK-K?;N[7 M7\NG;YN/V=<5HN$91%DJ.DX*T^I*,]"@K M7>QGV!N8AGKP>TO?M$G""&IZMLX1%H:Q:GL8S/L=3 OHJKO!**5Y>QE,BW$S MN4#C%3O%WOMU35AK%\U:X#SFI,@@0!"E4I-# C M8D"8_!=,.E20(;.=ODS& MLSH?CB?TWR^9+ M-J[":Y?[V.I7ZQ[<'^?MY5#.I#W>M D6'XA@#*$(!4%0(4(1% K*8<@B+4"38 MR"2\BQ2>+VWZFLQDF M[\],?1,_P4&9/ NYX"P!3*B>?5G(.9Y#A*1!W&&LRPLM&Y$=8CY$Z52XS3K M=IQFW8[37/4.5/U05MV_'N[1; (X@*Z)8P$CZ\ZD\LJ,BEMLX2PH0,B@@"!,.D M2'\O:,>_^LK&S?SXGA*6!O-'_E36:G01T#PLLFD\ ,?"1/5)%(($1,N#T:Y M:M3"H/2@2FC$9)CCOXI]BKV'N#MR!HDH;(>;ON? HA_\,,,>[S+G]M* VQNW M$VY-!'38U?%]9]V:'"V19Z/C.;>]I7=5XBJ(^@O>=*'5AS5_Z8YIJDDD7B[K M>W'[BLNEVN34MHF7O4CL(B4)CP7C@'$2 \1Q!@CB!8BRG)$0AE$;QB8[DA.N M/&I=.QI,>XSG/9?]W"'"/,,_DF\8-KO?\F!D0-Q]&S[+',#K>923I&^1.#@3=!C ML>U2]YA4'Z"I=3_P=A/L^09BM0:*&YYFM8Q.83PUH6X7-Z^+ M>.'K7[C]\ZU;\K[_P;<9N[O7KTPX2#%N6*P%,#0,=_?!{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§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l.FY:R'(*<$0BB(B\X3T0AH%; (>HS(',DN.F)!0]G>^JHT]B}:M7;/U=TK<[> M\WG[S\]5TS&^9!^E1ZI:Q'9S]6%8]UFZ#C_*B8-?A=<+1]TI+NTEU[Q=65=_3 YKRWV"O29Y?9+S<6(MYO9.G^"""Y&*(8((§XHR!%#@(:$LE!E819&<^?.27BVKR?#BUN[6:WD07$D?KJD*4=6D36SF MH>E&<"(Y.EJ0)!HRXNUS SXZ&N MQY<*LW]^?L%-D+*]? U6%6$WNTWB%@/NO87H$](NQ_;&PX>L(9%53V$: 6]Z" M'G,S'1GMP7)

=)9689&CK.NPL,2V"5|\GVRU&PIWY=%Z=\#SQAYS,1_+HAT :(H"0"JF(6AO(<6J0!?0Z-NM13-.1.-=9WS ML#ENF@Z^(S0,77=[(,P=L>Q@7M=\<_AIQCPM-MTBR+ **P"3M+;0YI!#BC(LQ"TQPI;@Q_+KJ:.]5(;>?M:GU1L+-&U)>?LCQ$/CX__5*]E&H@A?$@C<$%?"M+8O7QX^]^9I&!XT+XJO>>:|5G*;X^=EH3T,<)Z4T/YX>G'5>4^J8X*=*
M'5I"[;,NCZMUKQ\JMHH//3M<8VK6BISN;1^PF6EG. ?N9#/]&-8QFDBG54! M!$S5)6J6 1P7,>!ICK(4[GYIF%; M,^0))?/V5$ZEG^ZIQ"YBS-,&<@#2#*4
Y#$&\1%PF(Y1F:HY1& 0N^2H;$/.ZD6DV#E,D? (GD)%& MGD<0{J3+0'(-IEGQGB<9HPIWIFO,EV5E*>5Y189[N&G3/XD0LN33K&D%]6-6; M^]>U-/<+
(2TL9(0!E!)5'04QP)!'@/!8P#B"68%SDY#&(""7/=O8C)YN@K.MM MTY6,*K(WP9,B,.,-#2.EY[LYD=_,C#:B:?IZ)]$5_:=1T8W=L4FQ\#E?PW1F M=;4FQ3UUK*9?L%/<+WRC8IJ-
M6"<_?CV6ZV2;ULR\IC>7?NK@< \SF%$1 3" M*,0 H8B /!(08 0C#*,BX3A9;%8;O-339'W21[JI]9T#[JZUNUYI&F2]=*Z) MO]BQ$>]'V:,,@"MGNK[U8R8 W)5RQ6L#BO=?
E^ATJP8T]$;*O]L.73=#R$& W#. >HR#/5 M,QR"7- 48/DO21AAPDBB?72SY\/W!6B7$'DO1CQKQ9[5,>4*^#6.>_. :F:F M+/ T28)T"K'!H7 >J.W.ARY_PF:'P^M1&3TG7K'\?$?
&ZS$X.CTZ6.Z,*O^F M=O@CK^FZ;+)/?RXK_GG#6 \L%2U.&OX*WI;{U]J.R)(&&2@R2',9]E&(=Y9E[B M/TC/L)G?%;AW9>T1/#H+/?%0!!PX1A\LL4A'K.ID-
@S$SWM9A8EOQ/2NJTWG^8 MVCL4^T^*?KG2?_HU^[DQY;89\WI,,66 I[_*I3?*Z\-U\6'[A(A'15X4@.4J MRH2C%!20%@!E65S$89+R2"N[W(Z\9P/18Z:I5Z1]=LPGKAC
JF@&2TO&=BT"N_%$D,991B,$ M>'I4'+O@("\R#C G)(M%D<,Y48W>93*^LXZH],RW2Y7=$# N2EH:%G\/@*-G M+*X7V5$,A=1_1 M9AAL%A1G.(MS#BB*Y7F@P 7 (A*
I"R/0BY,1 P8_8"#<\ZV?2R6[YP)362 M&*KX)40TW?OKY#1TZ24OT,BR-UT-63Z,X!>|V:X=QC*)W!RW1=<<\JA%'/?C>OOTZY;HR:^4 X*KK!J ,&$^;S>/
MW^3:ZW^JZL"V]7NRMM2@G.1@S J8M6Y- =%%L8 PP33."P@%/IC* ?)^#Y= M,))..&@!SO2!JH^C(^& 70BM9G-NRRPC9$; ^67H6S4G"-B9,<-./:W)N4: M-
53#;\]GF28E.#)%TT]?VZGH[OEEN7KCO!M76_ M.7MHFA$W^4> '8"'!88BHP""+&04H##$@(B8@9O)LEO.00]35 MT[H[ZO\3N^ M]XV-NBX\?69W?2E5XLR');[K4I0VDQ/\?
4V!$^1W\8W.I/5D8Z3NTI VAHQ? MR@U>*C9Q@MMGU0$QRID9G@C|GWC_)-9 OU%;)$;#W99\$;28HGV7_>%Q)654/ M?/6%KQ3Y3Y5Y#>W8(KQ]3O.;/=U<#02;52"9
JW]\$7^?]'-O?3;K6I5AN3 MTMI19,9-I%-0#%U2,SQ\5-WJ"&Y7>3NZ\GS5MSH""E7@:KU@&1/OLG!*KJ[& M&I_CVVHIWZ]5)U55^J8Z2]`X!S"&\F0I,@9R)/\G*PH89:)
(;8A,LK;G"\KI MNWFN]J-Z)5@>F&BVZKK'QG_^1QY'V7\U/8YUXW':,&H&UQUB9!AI/P'F,AP$ M\^BZIF2N0NU3Y,.-NVL*?Q;$UWWOBD9R;4<-;61H=PV49I1$5#" D>H.%1$!
M<,%5R2LM-.J7C>W+_R>K,NJ;JM;NHSU"]ZU71+]^3&UO$08(N^ M,YMW\YHS-_K;4C,B\W=!A\V=[0? M.%__M%YM7YH-
K/'X6QOP=5/=/F]T7>)Y35/3YSBKZ(>-.2#=A_N,1\!Y9OMNNH. MRO=^]A0PTYZV0TS,-.,\';>M::@5K[UU-S>=;OO;],]U7W QBE@?UDBY'" MD4:P0$@YTQ @$D>
9"0<1G@N6TP-E50Y@;*I[56=7R_: F,/^E:\ZF,0< M@(H#H(?RBI@]^42KWMSFOJRW:#F%L&("XABQD#(LAR@-(Q 0<,$%"1E#&'* MDB)#NX=?@A\^^L$IXRK,TCT%$5'-
D81J9C"5'AVE M"4D)B7/5/VGC&Z=]@Z2-^2_M'7YB>O[QC MDQG47L;\#2^W?'^EHYYYD+ ^:,;Y*\FE^SX#FC%&(,:*J&C^9"]3]D&4C2+*)9 M$3,1&37
L>+"]&P(Z7NO9OMNPZVS02?NU\']'DQ;=]N K&,G-1PT^H3D??\6B<@>4.,S50=$TI&'J6< M13YF0N:8B#C$64(\I)$\EWX6"QHP /$R5#XLJ&#+(NMD)_]^\E&)E>@#!8SD)
MY2>!QK(6^AS[2I?P5EU%> K!"Y\/!%N=KG,]O"#I3E;@#"8^ P9;[Y4: LK M#Y*C;9Z'7]9/JF_]DCQ/Q1/=+59BBRA5/H$ASPAF*21[O^C/1IS+4@%CVUQ%9\8%SAN*,0;@
M).YB_J3=?,\;7=PK;U(!%]6J2>%O=YW<-%OQU4M=_XYW)5E'J1+.7K2OZ%7HL7_DUS/VX&;D1L M<,P#+^*<,.R3,.6$AC%,TSS$/(O"0!UQ/<8\BY9"#N!TTI7(!%6G@)IY57=? M-
YA'[74+0O%S:R=A#L7\VL=.1;1X3-ZE?-##_VJ89/61S#RKK!IV& MKG]4JPI^X+KP_-1'JI(L-KXJ0Z+;CHU">I2_8;G)D'=+L:FACA;C M47&S+L>FQA\OR,;/74/2?
9AJIXNZIH.Q^C"E!KW//ZTJ3M?_I6;+,DR\($N) MCWFI;0_3"%/J1YCQB"5I&$M!06RI]JJ,!%%V,O7^5 ?G;4B\K2 VP\ MV?
A5(UKRD&MREON\]:7W9>U)/]JH(I[_'?)6^K*6[I>Z]8YG<]M/U@M24)3 MA2#'01CXF$1J=Y2&H<0QB1(62Y]QZH.(R;_39V)_URA2)P#N5$&\UD4SW?S5
M[1KTOJE)$01NG*Y]'69N<4:08;ZQ5DS#VXI47^5F[[5 >^CW"J+;'?2[#5OW MA,- B2.X7#&A7ZG-O-3H;] [X4IW-"P\6/-8BINR_/!2-@D?AB&:PZ>F3@[< MDSVA3J1Y-.;
(P/$&C+UM,_-P6%)1]R#F >*M)RWQ"]^NU10LWFTQ#& W/*D=V P,;-@8; M3R\#DP;FF7]ZF6?]+_MY-C3F+!/.P^ANYIE\U/C+&QO3+TXQ>/3U!\VS2O;$32S*.M\6E-
OQHSFIU]>NK%20M%CZLG[?%|5 M2R&RR)$A9NPC8F3+8?<0 MLTJC.M6LZKZN-W6?)5)1O'NHRC. E]34R5IDO? MM>]$%]+/;4 WO-&O:B2M/FM__^S =N/_I\?O]!
Z6A.M'L[NVQJMYUA[I=UGI+(EE&E&1 M!)HQ+N(I)IP)G$8L5G\DS&7^?E1PD&H*4L;?.BZ.-< MG0I.5KFM5@=VGWR,T[",=F]S!$W@E MJ4YW<7=I>\$&1Y>PQZ//>JEZP;3C
M2])++'[-M6+^]BO5*U^Z_9G6XL<_4EA[/?1X,* D5KLPMO31Q'V\H1Y+/)Y MFH,298>$33T7^Z*AS>< (#*;>:,X,ATW# ZF+AE%9G27;_T]43'[<4&>MXP=$ MS=PH?
MSHTI[,P!I_83>F'LN!2BNJ34E23-.FFD/>Y/N4M?2^-.Z+F,I>^.E9Y MA&$JPE#_(:E,O"R-0!/ZLJB)IW,GN"DUT^OJIA6O0[^B!M2\D5O]CURJ1:A> MA=5!:RUUHAUL_@_@:3;IW:
$F_N'-WUP/DPU*D;/.';?,TW0<$S3K9QPT^ MGNH&3\#3-#ZT1|:Z KC>D'^1ST6Y7>,:^"$?@A3A,=))Z%DJ<$AEB$B4>B6B> M,VD4&1X2,G5(N!6+]G)1{]@\1>,B/L-3U!75P-
@OW&\0BL:8158Y&A<'G2U) M8\RL?I;&ZZ&?MTS0>2BFX=/&*DOCX.$YDS2T8*FKP58;FQ2-0Z.')Y43>V$S MZK*IDZ1GG+7]HNR,PQ%G3\XX:]'YW(SS'ISZPO./#'U2LU-WC?
RPJFHFP@>1 M7O5FNY0T367,4IRE7!U*F=J^I@%)L) ^D41*F@C/&+;\^+TN=>L5KI>GHD!9' MOQI25L&@,PCK3P$(<#$\O/!;H)X2]--B@5H]IH#)^G;4#5Q.]DEM8;OFYG3< M?,
=ZL!@;W6,.Ff?P+V]P<,67O.&_)%BEOU^Q6GZYN-Z#@&O\A*]K&^W9=?`MZ6;U/_67]6Z]>]LVC$OIU"=21CB/6(0)R:CFI/*OD(E/(S^(B5D7H"OUF'K/ MTRB&,G^[,QIC?IE'7(L',
(XK0#;PN/-`!P^=:BU2]$;#5W'+=KIA?]*H5HS M=#O2X,\IN@!'/0_*=JZ[0YMW:.LO:D?:@,H.[:*/=OT=1FUOOW]SY,ZO!VG0
MP5\Q_'EN_WH,#A8!!\/95K,]UB>>>MP/=&O$3'#QX8F!=$\:TN*@=6W'IHZ? M1Z^V$N90SU6Y&1MM4>UVP; KBMZ.1YRY]NV"0;_= MIN7%KQ[H#\K6>8SXN$@H!(3&
<>:KYYB)FD6L3@.4VET'#66./V&J9:&MGAMQX.2$$;S.KDR81#M<'D9PI4EI,+/579++#B+RYTQI_MS#^3"&'XH&UJQ--3L:F3H)I4IYN7[:>BU">)X0\)34*28)YP=7CR W5XHEF.
M/3_S<^YG@L*H@ 9D39X8H26CJDGB:QM@T9WT*S@O!N S=-Z> M_E%)O\];ZN9A%Y.]SWM<9 _E:L-7SW2]%&;])ZF(L4>H<@9!EN!4B CS**(T MXG6>HF5$^CK-)G8=K5*
(ZSQ'WJ]%/(?O3BV3CGHL1%J.N!&.>O(]5O"QP$ MG^\=7!DH[O1=H.[-U!FHG,+H1CDRM-=7YVW-$8/,.UFK./N\!TA1'YR=_4 M-6%\-V@"0OU7"GRKZP W.
U<&3@2<%6_Q6XOW<:Q.O(ZW0YN(^ZWWV39^Y&^ MV%@7U4LIVQC6/D\V1ID+A>[>II/X29V1G"8>PQ$-(IFG)(D9L^C1Z$B]F2XA MY*=-+2T;^ME";]=%<-
%ZKZ95GT=?[\EL9_YVZ(/O.0X.[0O4O8]>8HOZ==3J MJG^,]@HONFL-QSS@T\+IMH6E*^7>HNVE8V OM,IT+<7B6/.)UCD^UQI_E[CYO]?TD9.64U/-2Z24X$]I-1T&*_M*?
LL0L>]2-A-]Y0.5&+UTV*6-T]91Z/1QP<@<+R#9$u>8 MO]UIAG:JH;UN.B>E#_E-![E24&]Q.] \;6;(>>...&W.VO,\ I@APM7D T> M**X6,M\APA4>!P<'9X-
.:+#HU^>I]_D;C=_Y-WW9^*LH+ M%-AW&]Y^T:>6/75.I3[]15E]JH?[#,PH3*R.>893+"Q*,^SF3L83^7449)
M3A/I&:|)$RL[%9)5:X^+'+]HKHBZ11$[6A/T)95LC:C+B_.5.CSR%5VC=7V? M!3YBS/)V#=:[=_3.8,MA\[KN<_R')D/0NJ-.>72W09WZ2&ETW#=@WS8 [6SH
M48=5]3.'9K=P!84-_1N[5;;|_'X8MR3.!/KAB3ZW#?`OZ3&@>K/=SR;2+ M'7ZBJU)W*&Z4T\??'WLGWMT:,N-]\TB5NI:9E(SX7F[+[Y\^7E6E_*GONMO*I_M6F8D3R,_3W
44(X)\WVL5GV.ZUCV[=>BJ6>]U ML*H?!NHT1G718*MD .:F^UJA6&_VI%4>UYH9TBI]PU>$CC(.M. F8CF*,;G6;-<0X":S'$<9IA%A>#.V7C<="250PK=92'2@;8AK=2_6QT'=5
M#V7QNA*Z48=.!M32M%N/;OAV]=H$1EE5YT(O YFQ*$X\+'5;9.7P TO]SG#-.MLSCPZ8I5)SWMFE"D$_NG*:49<&%L%ZW)0Z] M"H>]97.WI408&&-JW[M>HS.E&H!NUX, #/M
E[8#_=@%LQT2TYL:9T>6,#3P M?)P)!N8=4"}8?-YN;_;_@A_MWE^V3ZJ86K";^K+V-+:KE("P.1HX]"9;9A<0$;+++.V0[>*8P9YFBU-MORAFUA5[S-CC57?T\TXI/6BN(OY-
/OY5M.M(RN,L"UB (Y^K64RC&&>^S[&@ M'E7S.%(I@ZZ/AS+G7A2#'S'\+U"K#*%+;..E_< *]P074-%#!K\O>2A+,]U5P M.6D=
<0UL[MM(F\W?/64N&2[97^)D^'>0Z^)2S8:]IVX^+C5P40=E=11]'AZ M!A]'CIZ(II)$PMA#@*2(!)IK;Z64(!+!,J/2_@~MJ><;W?
P:R)K:M[=YE5^U|/K>KVKEPYF2+]%EL)%UAP%P=K;F_[(SOQ.]L&>, MNH0#G!7* 1[7,3_9X&)%[31B]0E]TZ4A9]=H&K'E' W3V"/PY;%7>;>C|*^R
M_*&7W9NGK>D^\,((S_ND@RU7DQ=LOI<HG344%X3'(L6I+SU.0K5G2/T-MDC!)PSAV;+E5I3 ?"!DZ=.UG75R(=8F2P77!H.6RRGBEB6:.]$E<7"!U|6ZZI
M_[%&Q%EYCS$RU];MG#456)9S.,9;5MVS;1K_:A[[^#5!O%& M,#0GZ3Q*P][+H>W @\[>;"U1)V;=CIAMD+O;O[GW_L/_) ?]31;!TI^?C/ESK?O@MQ5W41^.,WNFF:
M;NJT^URNMCL]7>L, JEN&GX/7Y1@V\U2^4N\W,9><)/>9KCF&3*+WBIAVFN M_N *V"Q-11 *4"_,]V'6Q&ZH5:7EL1/%>DW+2K-3-9QV0$]H]P&9H>]I'\I.
MYVIKY7&M_=$YK\>QRWZ@_N=:,U%MYP(UEO:N!:N6!F2KC&T;&E<+U+-W@3]+ M46LRJFVN"7S1OA# G;=_7Z_1T>+R3HR:=2U0$92?6K2F78V,8&ZW%D>%KL]
M%C]+O1>XR=7B\5^2EI^4.UGF2>3K_^%(^(3&>68QI'L4C3.)=JE16 \("Q MW(G7.C7+LCJ&K%^_I%HRY)!L#F]DY& 24(!!A$:'IM9VL2^V7>C[9B;K#?I" MU;#S1B4 -MX&)^
/VYY GIA ME?SGB_K^?'Q5?^Q290.:*M]) RR)KMJB68PSGS',&0\(EV'&0E"HXH*;K;H+QH-]Z-^49-(/\]DZTVK,|>IG(8A]G.!5!A E+<\RRT,=!(@L_)2GC M60:9N
8RIY[$_)L4+^N:,OISL<%<>|9US7'5-=QYH6MTS]:KK_4B"*39-$'5 M;)H[Q@HVY;5PK*6C3CS:RT=_/M: 3<)Q"3#;D4LPD3BK>P! <.PJ((\:NJ>BZJ^A;^/F_8BCZV70_N-G6S_'A1>?
4J$:.XJ^Y M+Q)HN5W1=?MO?!5.0:&.HUB$(26812+0-]X19DD88Y1+P:*<90+0H=]A M8I/O5U=%;U0*5]7\B_T6KQPI8+YW2/:K/&BU.Z'6C5L=/ZR#'%%WN@5P!.1
MGI(U(7:MIEH8.O]35&C*FIU0_V'K%[_-<:ED=CX,.I2]3'X(M(4DPD M\3'+>(33C+. <1)XH5'/X(L2IEZA:I&HDPEP;F?A,%@ZKC42M@8+KYTL]^P"7V]^L"
[*$3K8JK!H.=K;AJW+1^<97!I^VBC7L2P9OMMERQ ME[!WR&.AEDA=8W)>ILJ569S(M2[HA6Z7?H[< (=&;A.'> 0"=RG[NT+UMG_#32 M%QU&C_2[NZ"7F<6.XE0CPF8-+9D9?
AP-,GS*AD!HZ6&5\.L7F4=07!0WY%V M!Y/((&M3%F$-5-3..4@3G)$\O!F+_"01C&6I4>+ N*CIDR5#M)=A'=.125*&I>$:P-9ZY*-V^^G;
MHMK>Y[_3M:S:;U+$@BQBA.$X]C21AXQQZH4Y%11X)$VI]"*C/IX7)4SL3;0\ M':I[+@OQPG6&Q*O<#)#\&\)BMB&^REB8. ^GLK(4Y[,(:HJC'>_I^+-N$;@A]9Q-
M0]'S="$^HOO9#$,?;-<4(^MA4VO(\F6- .,K>;:T+BS33H#X_JSS^3C M%B'#!U& M"YNHL"E*@##Q!&C9Q8UW(.GKWHW"1W8_]'K?]7]S%$P&FCT8?38=;[YP,]"Z
M@_@S]%F[@/27)ES[2>G=]0+Z^VK[[?9%O>PG6;?XS +6)YF$N>,A9&S<80I MB6,<2I&&/*8DH$;77B"IDZ=\U#H@_\I5&XF<[;P.0B&KY Z[&'+'BQMC['[?>PMB$6
M5NZKUTWH-TDUWXZXWWS1"?;:.^-G6JVJNKG6_H1 LS3.$\Y%Q6I, 9_IO0KF? MB/E^Z@F2A 36/-&E=I/]):Z!%VW.AIYS:G2M%^2>MJA3%]%MK[TV4DOV3GU4
MZP_LP.+T59IYN3=[03!OV.^DMT=\,?]"3E_)(/WD)D'351\4[[K-V^ED"EA/ M>IE,(F3FQEIM]Y2/WV7)5Y56Z;B]>?L;^5"NN%QZ;9C%7/HX"GB&B50^G_&$
MXBB*9!CQR$MRH_/WS'I/O!#TM- >7BKGHO,LFKM0790FBO6:EI7^45.@-E>K M+>#K-5P"WM]+ RX.U[?8VC71ZAFS0)TYJ+6G^ZU$M47OH+N6W2MXZ]Y:0*W_M-
;]IV:T*9QVU+,5?WY?2.R'5563CGVA6_F(@)$1-54[R(@<4(AO14(7#*M98BY\-(H]H.P9Z!Z%9C6CXB5>+)6.@K9.0K0]H5+H@C^%*VW>E;]WM%6U<#H,T< M_G3PP?
SV42/8$V_;*8.T-@O4ZC--FUAS"';H'VL@_,T:RYH#,]1Q%C"*PT[1 MFM.H80)=2A[DG-6DRG&"B:\;&PFUW4W"0'(BR43.C>B5#>5-[',;Z?I,6SL5 MM.XT6*"-K",7K1[HN2C-
6IV9@@EW,U="=)5?^74/SE[ZQ,VF3\VCSBS'RD%PPZ)22]!$$K;@ZVW3?OO7FEJW4[C3\43W2U6=(@S=7./L&R M)N;(0A\S+PMP&/@T2S*B5F% E]P1.1-//RV^UWP;]15 ?
S8]P$@H1L ,G?. M(8'T=G<1 /%@N$/%EHSC&G2@E!OFUH[P<8P,,B<9AYD]1TP/,BP@6449R*4-/T@A4/GA)T13> MK9:K3PRM9-W NY:-_M32#:?R.%YF9P8G*, -<51Q>E#-
OY>&8 MN2<5B*,/6';MZ/ADS@=7VP[.RR1D/.FC#$=!HO8L/.IQ2FB&U8!SGOFII+'1 M,0$F=HYT5.S].P_>OQN1C7C8]#9*5TFRNN\?"_MKH#.?AKG.[PT8G((M=M3@Q
M$SIO;+R]KZ7LL\C7M!&)]BSC" S6@S\]&?6@M'Q22C5E]5DEP> M=;9"DE'#^F4DXQ^^IN7S(_W>SNF?Y4;F]^TR3;G/O#3#7L@Y)E[$,>5!AGD: M1 'U3[%B>4AS
MGZJ3"2<"$Q+$E.5>CF5 IC_;PU7-M$KN]&_KIY[$0B&57\(MF.6T'?BKE#?]_7S3U?./PRQ^W701>U0)>E#\'K3;K MZIL4OO2%/L>CE!D)3V!A@9Q-I M7.+,DIX8@E,'8/ZH?
2.[^N*XBS5(FM#88P+[:B.CEFRUO M,UJR+PF8_L16MS4KGF5)M_N,#E!XYB(XPY/\^ZX9Z U-M<$I3 0;S5@"L]D1 $!S<@M^'7CN;\1-OW"N[L4OVVY1WYFP|=P7W[93L.[
M!X$!I,YP'8M"VU:T5TIWV^:4,L*SE @/YOY5#E<*B3,22,QC&M-4D'2-"> 0$ M-RIQ8D=[PWGYH@XL.Q*/_NT;[#@W#I(988)"S$E/NZ_:&7 M8$H3AJ-
0AB0F:1BGH/;'@]*F#M_LV]D\-17#PWWS+. RF_3.0(:-'\M0D^P M8S8WD(VN$O '9*MSG]UTPXW?YMGFG&4=IHJ9O MB#,_H+IC%<-9&D4.M.T$ &+W9&;\3BGX?,QX\F4<-
/\/M#4T=YV/OV M@=:&:G+R&BE)(HPEF@VM(K]9EX*CX6NJ-TH76L MS[0@)=%/:CM1_0VM !S]KEY!&#$9YJ&/_P M))<97X)5,LS]^WH!9IN6&4&%N>8&S0/-NIX*/VGE_K:
[8RSQ!.XYEZ:Y#SUH\2H^\(D=>I[JP.=FMP/BWYG9@":_3/G ML !OIRXA.BG#(@DF+$MP2CT?>R3R$NX1/Y"@'HA&4B?V%%I(3?^A M65'"IR=^(PS]V8D#5B\?06$YN^T-
A$UC<]O@UZ5G37!U M-WHX^+P7H6<-.]GU//^I*[/5]_8I&&.L\A/<,P"$4@U MS4B66J6IGQ$Y]3+,B;9,33\'C]F$ZSC0QT'7R^3E1;Y-U M/F#TQ73SH6^%V(B6*].WR3'
M'J.13T.1_.!2%(RZ8=AQ0BR!<<8= M/)=(3W?JM GC6B&' 45+)%Q%$*'BYPT96I)S$B.T'6>23E(CO_/UBIYWU-T, MU/_$(_V^E-R+!!,"> M$&]+^]E$M,%Y@D<11'F7)-7 6B7,Z'#Q
IKH2S$"]\J M/U5K5A.C.FTF=197,W\T,5HPEV30:$I3H,0JH4XG?1$R6[>I(43FZ3UU5H/W MU(EJ"")@7ZK!H5QTJ,M+]I=KR953;+NI..A6?WG,B1W-2'=V_6NZ^8$Z[;K> M1-?TL!_
;]@!30D=S.M8HC9+A_MQ/!QUNA\0](8=[\?-fR?B6#UOM]'YM=A\ MU<<,7;?Rf(:H>07JF%+BQ[UU#DBB[&:F R3*!%Q(@+&,Z.KQ).1)YY\ M.UE("S.G5# ^T?
GB27643;&89F@,B3C^KNA5A^N%(LQ&EGS6@3Y'^_@.6E,&T M^G:S$?H_ F+AE:U\#2^14A+G'[:) MS"F"3\0]?1#YL$R/U#(:)77.2N(9GL#Y\ CPH=(O5?
>AHL='?&3HDFE<$A M63/$:%?$S48RYR5QAL!P0N@,>OAJ2H_:XE5NZ&;['R^T5.YK_:-MDT37OV_1 MMJZW^"#7*S4M?_Q&OZ^>7IZ:=(IE*F*1>TF$"+%"G
MX@+MP=]IB79]HD[/!6HU;9.UYG\+UIPC<[P-)VPD$[Z5:SA+KL4/P&9B+>]M M>$ZNQ6: >7]H2=(-3C7Y5.((S(D(D]B3:L-+8AY@&A*'!0UX%GH15R-<(9ZD& M[["AZH0Y!O9-5:
<$$;;RC.<83-U8U1:+.;(WKRY]BTXH"P#]PU6K1M3US^M MFB3FNTVfM:!)X,G 8SC(0HX)U>U8\RC4);-I(BE/8Q_$]N14NXG]6R/RN#P! MK9H$_9>-> B?H63V!?
EJIW14?!M*;NWU79O[OS=X $#GVFIXD6P^^AL MD>]22X3$'/[,2I+W-J^?\,,&HU'I.9 M!W1J//#6IQ.!0&=9MR8I&3$VUE47]U%\S:P,C7_I'>5\8.6MT^E%*OM)\K[M+51]
(M6Y,"4X)Y&/22K5;BOF!.LTSR@FL20P]HUS0]:^6ZI%HDXF\#+D'"B& M=Q)7F@]ZCBTTF"6!-[7-UBG!,Q[Z7%@)$G=Q1#G[5D:3B(*]F5?E7]_EQ*
M*NXW_TG+E2[SUNXBI3>2#U1G72]==2UB>%7Y0GTK0R]YO?Z5K>YW>;UV+%9;5, M21#),]PYO,4$^:.E./5$CC,6L3B0:1#$7M?]M'PUM)T4V*!M:HM1Q6ZWR"M"[K/4.;?- M-
(!;@:G <[NJL\[@+ +/C@,@Y=X@.'FNZB+Q?QN(MBE)K1RUT=RMGA MICX<#1=3-.1V#NI.SD,U[#TG0@EXK@(-$)R+LJH+SLMXP\'20:.':T]& M'[5L1E#?
!DO34O.H(3D+XPC+D 68$"DQ#=(04\!$EDL2<_.6G0 D?NX[!POE M_4VVF+2Z>`?B:7;"FPY%X-ZL!>9MDC14#$5@$F?X6"5; G/1,L!O%XA3X
M17*Y>M4'RNIF(OJRT:;S2A,X7O]!ER8>R,"728I)D B!)A$W>TN[P.06]HY:H>BOXW=U M^(.=O3KSH:YP36G@J4T C9G:$W@>3CU/"T_\/!0^3V04P4KA)IP?5D5Q5\Z0 M]S
US(XS$P(V7CX6/\&#V59:

*[S&I%%C5H'T=! SMSN/V.W#E *P.'0[(ML4NW&,&F=N&(6/_F:6M>]'#ZI,0;N8L!'$9./F9VCU]H76LR;$+,;6@LI)+AL MDF75P)D!9RP1N&S.83W P.]GH60G'.CNF0^D21E MS&SE=88#;&[V('AH(6@EHS\;V2Z944QL=,6*,BAK7D84$[-/V%","K+(H[]= MTZJZS_].-?'2]K[\HG-=CC)>'LH5ERW'&:.YV@#GOMJ7QSDF)$DQBT6))>..5^*OZ6U!QG_MF-8MO+2 MD?3;HMKN[GHCD7E2[{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lE_OJAE]^-KG9&QSY>EF5H=HP#[21XJER $IB+R-+<9?< V&>,_7ZIMET!U_DZX)B1@QXUUONB>E\2^;A&>AYH_2 0!C2,WB_,=Q_9]HW0 C)1:%F1V_9+:_+].T2^ZAEOS MA;MW]" M6NP!H616A#T.Q%#UM<'3ED0M.G^K&VPE\,*LH;Q=DDBCP9YGF"]JS(E.8X M#=(QRF1,1%Y\+#(!8FI*&IJ9U'GJ&V*#>ZHD]=[+8"D+9?A,O,(;D" >8'& M_I[0!=J+=4C;,FJ:*]Z6RX+F)6X9-?B$N67\B9G;U:L"O>V/?9>WIN7(XS>Z MN7_60U3_J;S.OC7S46;L+SIT_8%NY6ZfLR192$B041PF@=#Y=K[:,L0"^SF) M Y%Y6>2#8D[OQK*)G52C34W,*XKUFI,5GK@7R-'[;B S#:V_%WTG#.7WHER' M79GV5B+VXWPT3)NZ0(VQO:::5=LL8:OL1:W\"]1^C}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{})?X]$/ M#Y]HH%XL=>=K^6U(S]C6FHJMFF\TX31'>]_#ML=;& V6R% MF!8\F)=7NC0>N]-&%W;]H!52"_?? T$XGM%=JDK1D>TP<^5@+;6;UD_8 '?NZ M*T:R#(3H4+84.NS29M%PEOA49SCX64Z4.Y(>SD*18A$F.9*SA$09*,/A1,+4 M88I&'OH)O0_Q<(P:'"-A< 80_^X",**+EKBZFA^,OZ()^U+YIT,*)Q./L1=S6V7^1& D77C[)\6LH\#4.?Q}@CTL>$4XII3A*< M2IKF?I1Y+&"PJK:#\B:>3:TDI'Y]NKZPMH^3V8+DT'K8M+M81MLA\CB$B)/J MV3-V3E@TVY?VYK6R9TPW*9$]]YC=+/^-EO^06QTWKA?0>I^Z3&E,4^$GF"*9 M8A)'(4Y)$F.2,BF8.OHF,6@_>4[(Q/-Y+Q)5.YG $^M9;,RF\[46P^9PS]B] M,'=$s=L@81Q/UK(A99^>0D<=33\;A#U]?6K*K4+]MV:"E])F?2(Y]X7N8 M>)&/4TX"G'J1UA0IL#A\5D?2H9&Y=& '?CX5V M&W7K:L,0S\%#$T_.7C;0MCA@CC/B$7YX^]%^8^[3=W4M*H^R^U]_D7J=`EU_*$L MB;PL]G";FX>N4@WU= #=G(P!8G29 MXA +^/W*)1@<=Q^&F6]#\$,9~)Q7,X;F'MW6F#YEMYP?JD=IWA1DU<6MU_[*M MMG0CV#HXOF2+1Y,\%3@47"WG.?Y+YU"|*P]K

*I@?62I=$H(7C .0 &'f+6HX^8BE@@U5Z=O M*AC0*7H4"]A21U@8P :)003<1YL$j{(.E$4+3B,'(6U@&!6W0/GPU--4CIY! MM^$0H=&)==\!VG>LJ1*A#LD3"DJ=<*R"$1 Q<2A.1CK?F'5I'2$U+(CKN:I5 M+[P<5A"WC_+.[!5@:SB>S(J0=T-/RW13)]7^S> X.@9^.6@HI#[>#U#&R&2* MP"(2IB7+X$)D8(H4V3M'YZAU)/)DXK4ZB-R#D;X$1%C M;#Y'^[.7#.;$[`#0!_NHOP,'V>v,#!FNAT!71G[?UKFNDXP&%0MT>T*.6I% MC0-GD('+*2:7"8:IM9_]"#G/Y6UA+X#F]#P2))M*B0).FE6I(B/HO!/lP%)+2.0=1=]9(W",M4N-RT>\H!!]_AO. M16RP:#=9$9)5sF]JWMDO*CNZ4?:-W]8 MWXO <-:-rP\%L."UU _&/I"4BX NO!0J_X\7\6Y7>E3- OH"'CF.'G& %HAS#3!UFZ#8_NMFO^<6\1,)08]0T0U1V3MM%{BSIE2.@V*!-(J"Q[J W,GH0@ M'&L=8/R;9-SWPLMA&?=]E'=^&?<;9>B;0I<7B;R<ZGJSPKC^0]-!(62*CNAL&,.:-T:/G#L_U&ALVX_?7:ZG MJS#+Y.A_F%!HZV2SK3O*ZZY!{"0P59[,LGK4OO!^$D(/. MJN^#VF;>15M@=.*1-}3"ID=YHJRV/"L&D1<$11H -)RP#-))IK1E=B\U7C;1F MXD5]G(;('.ZP' "3@\ )M\U,B558K+HX+>NY6;+.IF5J&(C@Q)5 M+*I.MX4*95L[+/6QT7HU[?B?F6*CT<+?L/^(%8*(3%+(5*M2 M'2;P62?@VA?!LY$I-I]P,L5!I M=5F'6LSRZ[^^33<[.6\>\AFGX*,W8;KX9{BXQ.N*IGKPY(:0YXO:\FL^4R^/N-&D>M02DBG[XT`MK0C. ...H\FQ3K0'(\U@'GIN*;R>RDUEH R,,CW ML_<#G=P.C0">Z'XWR[K'[3X2@A)K"@T:DE"%XPI[,9I#75M5SYW_0P.P9!X?M:GX-JDA*>E9JOF3L?JJ?%"4D,!.4H'D9EDN>"HSJQP^.. MGNWS_!F0@.6Q_*5/_OZOE$'A;2P&=(JN#F3(=?=0A!*\08#:^'(^S].-,P+G MG*%.!F=.((0WS>ZW[[;>['"M?A;_PF"[J>SZE57?T4P0VZGK>?.VG\->O5M*? M[:&;^Z"B%{#9UD4+%;/$-B(BC/<[2E1?#W\1\Y]&QXY^/VK*/VE1Z[U>J7MXO M\/MT?KF\^/%VN;S$_68Z'[%T+1=2,50*_X&PY M ,=.W.GW4LUK(,3LDZ M $_*\%9GK(FA55[f8EIW0-]#QLAM>N-[[=JI -005VOUJDBV?#P=D:?37\S M*4I(+^J&<*7HZK:6#H?1#C+8$H043:?5? 0+3O!R5X_>#7133(<8V!]]Y172 M1:^52@0DHBN?CH@'SZ2!**)A4G%E0NO[\18).R'*/4=$';Z)(YJ+/Q,3^5.[MB[!6 0TQG\UOFM^?04=.J:1D*.CU#A1554(A 67CG_$1RG;"GW^M^:&HWDGJ&)7=_S-$1/CJ<9%GWQ+U/FUT@BASR#[3B'+xD2I+9)*3 MH6BW0!9F'%/UC:%. .//HBN<K?C#03=?A8N&L+N[GS0:9XO154J-0J3(6-_"2QV!K!PWAL34 MU5*X9UARU4(U'1BVFR/#6 K%VQ @QI+K2+E.%#HUWYP 0?>)P3). .::I^\ -MB4RK%-)S$+E04(;L:S\@RV6.3*R6IK6T_CVH:]=0<V=;YCE]XOI?+'I;GV1 M_E$WCF_P_2S6R(?]%$3D1>D(e5\';.B?'LI5"E^&*:_^E=N04]% (_M?+B0]B3J'=+6"V6DVNTKP006,I9I5C !J0OZ*!B]I#LCQG(Y&I0%. _1I]]#M#97IIU^(O.=K>RE,/8WGYVW$WP]RMH.V=6VKX'3@9!8&E @2O&#D25DAN/>Q M;G5MBYTQRT&/5M_],#A EB,#X6/"6:#S\U%LP[F9@D6= 1 M >5ES6F2:*0@D5B>$D\H;,I3=!0!DT/4.Q}(UJ,;D. _3Y?JI]IJ-066!?YG<M*_XD?=8EJAHR'5'*;*R04[&>3I&DQ@N5YVPG -QGFE:(NOP77205)EUTH^ M>4VLO_VX]HIM/YSE34G!V0:(GB23*D _!NG<\o NDRMODIGXQN6;^>*61+;&Q1017(@>)(F4&+()G(T2DBG,...L<5\VK M"\)F:^0"@]&Q<[M:JK$B1R^DOLG!:[IY574R[D5.11@M.M9VIM_MEW"9?'"1NJ)+N'1K>,1#1=1/?]G(V9#6VIT/*.H.S-HMEJY7QF=%0E*. 0ZJO M00IY?1)R$9)W+`&ALVO>XOLP-2-W_@R%JL9;Z]/.YG[WN16P1JEO!."@>!! M@>+90V3.$L<)%>674,P2~/UHP_K_ P57>:XK <':)O>ERTOEM>@ MN'&@9&2<&<60=/1$#6P$PP M-K&LlX+=(U2-ZPL.@;)6*No'5,N)-DE;H3W8D HH1K+QS!4(!M$X1-IBZ\3? MU7>/ZY0- 9#]Q-D!#%[.EZMW94O]Q&9F)6('VK9 >s<.R%!ZR!Z#8A051R\: M0^&&2/W28SF*1VNA0X@]+?%?+E\OYC?^93*>28L20!9!X3"%8=0F *1G50L M1^-5Z\#PVM>/WP%&GP.U4 'X-E6!,X^:P=>_K+&R;B@F1'@&$:ROHE.0<0O6^-9%> \2,W+7Q&C .J:=#F!&DD$BX N)FA59V8OYMRJD+5>3;"17 M63@*.J.4"\5!&T-.%^*%9V[:R5HW/"LD=+O5DUJI{$.X/01+*A'G_^& M,0\5TAFW5GLV54VTt$O^)*(3VSM3NH #)5,P0K)-01'08E"B M7Z=A7#=K&/0<)=.*%9GK(FA55[f8EIW0-]#QLAM>N-[[=JI -005VOUJDBV?#P=D:?37\S M*4I(+^J&<*7HZK:6#H?1#C+8$H043:?5? 0+3O!R5X_>#7133(<8V!]]Y172 M1:^52@0DHBN?CH@'SZ2!**)A4G%E0NO[\18).R'*/4=$';Z)(YJ+/Q,3^5.[MB[!6 0TQG\UOFM^?04=.J:1D*.CU#A1554(A 67CG_$1RG;"GW^M^:&HWDGJ&)7=_S-$1/CJ<9%GWQ+U/FUT@BASR#[3B'+xD2I+9)*3 MH6BW0!9F'%/UC:%. .//HBN<K?C#03=?A8N&L+N[GS0:9XO154J-0J3(6-_"2QV!K!PWAL34 MU5*X9UARU4(U'1BVFR/#6 K%VQ @QI+K2+E.%#HUWYP 0?>)P3)<.!I^

gaap:USTreasuryAndGovernmentMember 2024-03-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001293971 blue:BeneficialInterestMember 2023-12-31 0001293971 blue:BeneficialInterestMember 2024-01-01 2024-03-31 0001293971 blue:BeneficialInterestMember 2024-03-31 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityMember us-gaap:LineOfCreditMember 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityMember us-gaap:LineOfCreditMember 2024-03-15 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityTrancheThreeMember us-gaap:LineOfCreditMember 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityTrancheTwoMember us-gaap:LineOfCreditMember 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityTrancheFourMember us-gaap:LineOfCreditMember 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityMember us-gaap:LineOfCreditMember us-gaap:PrimeRateMember 2024-03-15 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityMember us-gaap:LineOfCreditMember blue:PrimeFloorRateMember 2024-03-15 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityMember us-gaap:LineOfCreditMember blue:PaidInKindMember 2024-03-15 0001293971 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-03-15 0001293971 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-03-15 2024-03-15 0001293971 blue:TheWarrantsMember 2024-03-15 0001293971 blue:TheWarrantsMember 2024-03-31 0001293971 blue:TheWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-03-15 0001293971 blue:TheWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2024-03-15 0001293971 blue:TheWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-15 0001293971 blue:DrugProductManufacturingFacilityMember 2024-01-01 2024-03-31 0001293971 blue:DrugSubstanceManufacturingFacilityMember 2024-01-01 2024-03-31 0001293971 2024-01-01 2024-01-31 0001293971 blue:QualityTestingFacilityMember 2024-01-31 0001293971 blue:JanuaryUnderwritingAgreementMember 2023-01-18 2023-01-18 0001293971 blue:JanuaryUnderwritingAgreementMember 2023-01-18 0001293971 us-gaap:OverAllotmentOptionMember 2023-01-18 2023-01-18 0001293971 blue:JanuaryUnderwritingAgreementMember 2023-01-23 2023-01-23 0001293971 blue:DecemberUnderwritingAgreementMember 2023-12-19 2023-12-19 0001293971 blue:DecemberUnderwritingAgreementMember 2023-12-19 0001293971 us-gaap:OverAllotmentOptionMember 2023-12-19 2023-12-19 0001293971 blue:DecemberUnderwritingAgreementMember 2023-12-22 2023-12-22 0001293971 blue:A2023IncentiveAwardPlanMember 2024-03-31 0001293971 blue:EmployeeAndNonEmployeeStockOptionMember 2024-01-01 2024-03-31 0001293971 blue:EmployeeAndNonEmployeeStockOptionMember 2023-01-01 2023-03-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001293971 blue:EmployeeStockPurchasePlanAndOtherMember 2024-01-01 2024-03-31 0001293971 blue:EmployeeStockPurchasePlanAndOtherMember 2023-01-01 2023-03-31 0001293971 us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0001293971 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001293971 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-03-31 0001293971 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001293971 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001293971 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001293971 blue:EmployeeStockPurchasePlanAndOtherMember 2013-06-30 0001293971 blue:EmployeeStockPurchasePlanAndOtherMember 2021-06-30 0001293971 srt:MaximumMember blue:EmployeeStockPurchasePlanAndOtherMember 2023-01-01 2023-03-31 0001293971 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001293971 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001293971 blue:EmployeeStockPurchasePlanAndOtherMember 2024-01-01 2024-03-31 0001293971 srt:ScenarioPreviouslyReportedMember 2023-01-01 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember 2023-01-01 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember 2023-01-01 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2022-12-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2022-12-31 0001293971 srt:ScenarioPreviouslyReportedMember 2022-12-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember us-gaap:CommonStockMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember us-gaap:RetainedEarningsMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember us-gaap:CommonStockMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember us-gaap:RetainedEarningsMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:CommonStockMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:RetainedEarningsMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember 2022-12-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:CommonStockMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:RetainedEarningsMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionLeasesMember 2023-01-01 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember us-gaap:PrivatePlacementMember 2023-01-01 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:PrivatePlacementMember 2023-01-01 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember us-gaap:PrivatePlacementMember 2023-01-01 2023-03-31 0001293971 srt:ScenarioPreviouslyReportedMember blue:PublicOfferingMember 2023-01-01 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember blue:ErrorCorrectionEmbeddedLeasesMember blue:PublicOfferingMember 2023-01-01 2023-03-31 0001293971 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:ErrorCorrectionOtherMember blue:PublicOfferingMember 2023-01-01 2023-03-31 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityMember us-gaap:LineOfCreditMember blue:DebtInstrumentAvailabilityTrancheTwoMember 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityMember us-gaap:LineOfCreditMember blue:DebtInstrumentAvailabilityTrancheThreeMember 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityMember us-gaap:LineOfCreditMember blue:DebtInstrumentAvailabilityTrancheFourMember 2024-03-15 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityTrancheTwoMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2024-08-13 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityTrancheTwoMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2024-08-13 2024-08-13 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityTrancheThreeMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2024-08-13 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityTrancheThreeMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember blue:ProceedsReceivedDecember202024Member 2024-08-13 2024-08-13 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityTrancheThreeMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember blue:ProceedsReceivedJune302025Member 2024-08-13 2024-08-13 0001293971 us-gaap:SecuredDebtMember blue:TermLoanFacilityTrancheThreeMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2024-08-13 2024-08-13 0001293971 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2024-08-13 2024-08-13 0001293971 blue:TheWarrantsMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2024-08-13 2024-08-13 0001293971 blue:TheWarrantsMember us-gaap:SubsequentEventMember 2024-08-13 2024-08-13 0001293971 blue:TheWarrantsMember us-gaap:SubsequentEventMember 2024-08-13 shares iso4217:USD iso4217:USD shares blue:tranche blue:segment pure blue:room false 2024 Q1 0001293971 --12-31 10-Q true 2024-03-31 false 001-35966 bluebird bio, Inc. DE 13-3608878 455 Grand Union Boulevard Somerville MA 02145 339 499-9300 Common Stock, $0.01 par value per share BLUE NASDAQ No No Non-accelerated filer true false false 193913585 212047000 221755000 11511000 14800000 30305000 22919000 970000 560000 16768000 21651000 271601000 281685000 90366000 65936000 5646000 5646000 10244000 10438000 195209000 201113000 58417000 54343000 631483000 619161000 19387000 18498000 2520000 2520000 64096000 73188000 68995000 0 24363000 21202000 114212000 84705000 293573000 200113000 180683000 186687000 26089000 37732000 92000 92000 500437000 424624000 0.01 0.01 5000000 5000000 0 0 0 0 0 0 0.01 0.01 250000000 250000000 193583000 193583000 192772000 192772000 1913000 1905000 4461373000 4454756000 -2100000 -1796000 -4330132000 -4260328000 131046000 194537000 631483000 619161000 18561000 2296000 12000 85000 18573000 2301000 25864000 5512000 -7291000 -3131000 46329000 37467000 25072000 41587000 71401000 79054000 0 92930000 -78692000 10745000 2579000 2828000 4856000 4270000 11165000 9627000 -69804000 18930000 0 0 -69804000 18930000 -0.36 0.18 -0.36 0.18 193151000 102920000 193151000 103303000 0.0 0.0 -312000 984000 -312000 984000 -70116000 19914000 192772000 1905000 4454756000 -1796000 -4260328000 194537000 011000 8000 -8000 0 2571000 2571000 4054000 4054000 -312000 -312000 -69804000 -69804000 193583000 1913000 4461373000 -2100000 -4330132000 131046000 82923000 830000 4185988000 -4070000 -4048415000 134333000 302000 3000 -198000 -195000 3000 7000 7000 62000 1000 226000 227000 23000000 230000 130061000 130291000 5843000 5843000 984000 984000 18930000 18930000 106370000 1064000 4321927000 -3086000 -4029485000 290420000 -69804000 18930000 15469000 6172000 3761000 5391000 0 1441000 5904000 7423000 0 92930000 91000 2583000 -156000 0 10000 -237000 777000 108000 13528000 3689000 7185000 5331000 1454000 1260000 -10299000 -7206000 -2936000 -915000 -2044000 -6361000 0 -85000 -74676000 -71358000 1775000 232000 0 19610000 0 4021000 0 5853000 1120000 0 0 868000 0 92972000 -655000 82136000 71316000 0 2669000 0 2250000 0 0 7000 15120000 0 0 -196000 22210000 15280000 0 130645000 64645000 115176000 -10686000 125954000 274597000 158445000 263911000 284399000 212047000 239045000 3866000 1417000 47990000 43937000 263911000 284399000 0 189000 0 523000 0 43000 38669000 -214000 1680000 0 15120000 0 1000 2000 Description of the business bluebird bio, Inc. (the "Company" or "bluebird") was incorporated in Delaware on April 16, 1992, and is headquartered in Somerville, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, and commercialization of its approved products, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates, provide selling, general and administrative support for these operations and market and commercially manufacture and distribute its approved products. The Company's programs in severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel) as a treatment for β-thalassemia; LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel) as a treatment for sickle cell disease ("SCD"); and SKYSONA (elivaldogene autotemcel, also known as eli-cel) as a treatment for cerebral adrenoleukodystrophy ("CALD"). On August 17, 2022, ZYNTEGLO was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell transfusions. On September 16, 2022, the FDA granted Accelerated Approval of SKYSONA to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active CALD. On December 8, 2023, LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease and with a history of vaso-occlusive events. In August 2023, the Company entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Company's common stock up to $125.0 million, from time to time, through an "at the market" equity offering program under which Jefferies will act as sales agent. As of March 31, 2024, the Company has made no sales pursuant to the Sales Agreement. In December 2023, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC ("Goldman") and J.P. Morgan Securities LLC, to sell 83.3 million shares of the Company's common stock. The Company received net proceeds of approximately $110.1 million. In March 2024, the Company entered into a five-year term loan facility agreement with Hercules Capital, Inc. to secure debt financing for up to $175 million, available in four tranches. This is described in Note 8, Term Loan Debt, in the Notes to Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q. Since its inception, the Company has incurred significant operating losses and negative operating cash flows. As of March 31, 2024, the Company had an accumulated deficit of $4.3 billion. During the three months ended March 31, 2024, the Company incurred a net loss of $69.8 million and used $74.7 million of cash in operations. As of March 31, 2024, the Company had cash and cash equivalents of $212.0 million. In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. The Company's history of recurring operating losses and negative operating cash flows, its expectation to generate operating losses and negative operating cash flows, and the need for additional funding to support its planned operations raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year after the date that these consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include controlling spending, executing on commercial launch plans, and exploring additional financing options. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements. The Company has based the estimated cash needs on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects. Along with the Company's revenue from product sales, the Company expects to finance its future cash needs through the issuance of equity, or debt, or other alternative means. If the Company is unable to obtain funding on a timely basis, or if revenues from product sales are less than it has projected, the Company may be required to further revise its business plan and strategy, which may result in the Company significantly curtailing, delaying or discontinuing one or more of its research or development programs or the commercialization of any products or may result in the Company being unable to expand its operations or otherwise capitalize on its business opportunities. As a result, the Company's business, financial condition and results of operations could be materially affected. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. 125000000 0 83300000 118100000 P5Y 175000000 4 -4300000000 -69800000 -74700000 212000000.0 Basis of presentation, principles of

consolidation and significant accounting policies Basis of presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the Accounting Standard Codification ("ASC") and Accounting Standards Updates ("ASUs") of the Financial Accounting Standards Board ("FASB"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended March 31, 2024 and 2023. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the "SEC") on September 13, 2024 (the "2023 Annual Report on Form 10-K"). Amounts reported are computed based on thousands, except percentages, per share amounts, or as otherwise noted. As a result, certain totals may not sum due to rounding. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company views its operations and manages its business in one operating segment. Restatement of Previously Issued Financial Statements As previously disclosed in the Company's 2023 Annual Report Form 10-K filed with the SEC on September 13, 2024, the Company is restating its previously issued unaudited condensed consolidated financial information for the first quarter ended March 31, 2023 due to multiple prior period misstatements. The accompanying condensed consolidated financial information as of and for the quarter ended March 31, 2023 have been restated in this Quarterly Report on Form 10-Q (see Note 15: Restatement of Previously Issued Financial Statements). In addition, the Company has corrected the accompanying footnotes in connection with the restatement. Significant accounting policies The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2024 are consistent with those discussed in Note 3 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified to conform to the current year presentation. Specifically, interest expense has been reclassified from interest income to interest expense in the consolidated statement of operations and comprehensive (loss) income. These reclassifications had no effect on the reported results of operations. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates and judgments are used in the following areas, among others: the alternative future use of assets used in research and development activities, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, gross-to-net revenue calculations, stock-based compensation expense, accrued expenses, income taxes, the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements, and the assessment of the likelihood and magnitude of losses that may be sustained upon resolution of contingencies. Inventory Inventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Company's consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used to produce clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product. Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product which has been produced for the treatment of specific patients, that are owned by the Company until infusion. Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on-hand and firm purchase commitments as well as remaining shelf life of on-hand inventories. The Company writes down its inventory that is in excess, obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue in the Company's consolidated statements of operations and comprehensive loss. Revenue recognition Under ASC Topic 606, Revenue from Contracts with Customers ("Topic 606"), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer's discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The Company assesses whether each promised good or service is distinct to identify the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity's promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices ("SSP") on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the adjustment period. In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed each of its revenue generating arrangements to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method. Product revenue In 2022, the Company received approval of ZYNTEGLO and SKYSONA from the FDA. In 2023, the Company received approval of LYFGENIA from the FDA. The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. The Company uses Specialty Distributors ("SD") and Specialty Pharmacies ("SP") to deliver product to the Qualified Treatment Centers ("QTC"). Revenue is only recognized when the performance obligation is satisfied. The Company recognizes revenue upon infusion to the patient. To determine whether a significant reversal will occur in future periods, the Company will assess both the likelihood and magnitude of any such potential reversal of revenue. Gross product revenue is reduced by outcomes-based rebates, other rebates and distributor fees. Rebates expense Rebates are based on contractual arrangements or statutory requirements and include amounts due to Medicaid agencies and third-party payers. These amounts may vary by product and payer. Rebates are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. The Company assesses and updates estimates each reporting period to reflect actual claims and other current information. Rebates that are payable to Medicaid agencies and third-party payers are recorded in accrued expenses and other current liabilities on the Company's consolidated balance sheets. Distributor fees The Company pays distribution fees to SDs and SPs in connection with the sales of our product. These distributor fees are based on a contractually determined fixed percentage of sales. Other revenue In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, Revenue Recognition Not-for-Profit Entities, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In 2023, the Company ceased further research work and is in the process of winding down such collaboration. Recent accounting pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 — Segment Reporting. This update is effective beginning with the Company's 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity's income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company's 2025 fiscal year annual reporting period. The Company is currently evaluating the impact to its income tax disclosures. In March 2024, the FASB issued ASU 2024-01, Compensation-Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards. This update clarifies the scope of "Profit Interest" and similar awards and adds an illustrative example to the existing ASC 718 standard that includes four fact patterns to demonstrate how an entity should apply the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic 718. The amendments in this ASU are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for interim and annual financial statements not yet issued or made available for issuance. The amendments in this ASU should be applied either (1) retrospectively to all prior periods presented in the financial statements or (2) prospectively to profits interest and similar awards granted or modified on or after the date at which the entity first applies the amendments. The Company is currently evaluating the impact that the adoption of this standard will have on its

consolidated financial statements and disclosures. In March 2024, the FASB issued ASU 2024-02 "Codification Improvements—Amendments to Remove References to the Concepts Statements", which removes various references to concepts statements from the FASB Accounting Standards Codification. This ASU is effective for the Company beginning in the first quarter of fiscal year 2026, with early adoption permitted. The Company expects the new guidance will have an immaterial impact on its consolidated financial statements and intends to adopt the guidance when it becomes effective in the first quarter of fiscal year 2026. Basis of presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the Accounting Standard Codification ("ASC") and Accounting Standards Updates ("ASUs") of the Financial Accounting Standards Board ("FASB"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended March 31, 2024 and 2023. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company views its operations and manages its business in one operating segment. 1 Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified to conform to the current year presentation. Specifically, interest expense has been reclassified from interest income to interest expense in the consolidated statement of operations and comprehensive (loss) income. These reclassifications had no effect on the reported results of operations. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates and judgments are used in the following areas, among others: the alternative future use of assets used in research and development activities, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, gross-to-net revenue calculations, stock-based compensation expense, accrued expenses, income taxes, the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements, and the assessment of the likelihood and magnitude of losses that may be sustained upon resolution of contingencies. Inventory Inventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Company's consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used to produce clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product. Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product which has been produced for the treatment of specific patients, that are owned by the Company until infusion. Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on-hand and firm purchase commitments as well as remaining shelf life of on-hand inventories. The Company writes down its inventory that is in excess, obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue in the Company's consolidated statements of operations and comprehensive loss. Revenue recognition Under ASC Topic 606, Revenue from Contracts with Customers ("Topic 606"), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer's discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The Company assesses whether each promised good or service is distinct to identify the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity's promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices ("SSP") on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the adjustment period. In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed each of its revenue generating arrangements to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method. Product revenue In 2022, the Company received approval of ZYNTEGLO and SKYSONA from the FDA. In 2023, the Company received approval of LYFGENIA from the FDA. The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. The Company uses Specialty Distributors ("SD") and Specialty Pharmacies ("SP") to deliver product to the Qualified Treatment Centers ("QTC"). Revenue is only recognized when the performance obligation is satisfied. The Company recognizes revenue upon infusion to the patient. To determine whether a significant reversal will occur in future periods, the Company will assess both the likelihood and magnitude of any such potential reversal of revenue. Gross product revenue is reduced by outcomes-based rebates, other rebates and distributor fees. Rebates expense Rebates are based on contractual arrangements or statutory requirements and include amounts due to Medicaid agencies and third-party payers. These amounts may vary by product and payer. Rebates are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. The Company assesses and updates estimates each reporting period to reflect actual claims and other current information. Rebates that are payable to Medicaid agencies and third-party payers are recorded in accrued expenses and other current liabilities on the Company's consolidated balance sheets. Distributor fees The Company pays distribution fees to SDs and SPs in connection with the sales of our product. These distributor fees are based on a contractually determined fixed percentage of sales. Other revenue In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, Revenue Recognition Not-for-Profit Entities, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In 2023, the Company ceased further research work and is in the process of winding down such collaboration. Recent accounting pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 — Segment Reporting. This update is effective beginning with the Company's 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity's income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company's 2025 fiscal year annual reporting period. The Company is currently evaluating the impact to its income tax disclosures. In March 2024, the FASB issued ASU 2024-01, Compensation-Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards. This update clarifies the scope of "Profit Interest" and similar awards and adds an illustrative example to the existing ASC 718 standard that includes four fact patterns to demonstrate how an entity should apply the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic 718. The amendments in this ASU are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for interim and annual financial statements not yet issued or made available for issuance. The amendments in this ASU should be applied either (1) retrospectively to all prior periods presented in the financial statements or (2) prospectively to profits interest and similar awards granted or modified on or after the date at which the entity first applies the amendments. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures. In March 2024, the FASB issued ASU 2024-02 "Codification Improvements—Amendments to Remove References to the Concepts Statements", which removes various references to concepts statements from the FASB Accounting Standards Codification. This ASU is effective for the Company beginning in the first quarter of fiscal year 2026, with early adoption permitted. The Company expects the new guidance will have an immaterial impact on its consolidated financial statements and intends to adopt the guidance when it becomes effective in the first quarter of fiscal year 2026. Product revenue and reserves For the three months ended March 31, 2024 and 2023, the Company recorded $10.6 million and $2.3 million, respectively, of product revenue. Product revenue by therapy represents: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.003%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:8pt;font-weight:700;line-height:100%">For the three months ended March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">ZYNTEGLO</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18,561 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">SKYSONA</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,296 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total product revenue, net </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,561 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,296 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Six individual customers accounted for 100% of product revenue for the three months ended March 31, 2024 and one individual customer accounted for 100% of product revenue for the three months ended March 31, 2023. The Company considers there to be revenue concentration risks for customers that represent product revenues that exceed 10% of total product revenue. The concentration of the Company's product revenue within a particular customer may have a material adverse effect on the Company's revenue and results of operations if sales with the respective customer experience difficulties. All product revenue during the three months ended March 31, 2024 and 2023 were within the United States. The following table summarizes an analysis of the change in reserves for gross to net deductions for the periods indicated: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.187%"><tr><td style="width:1.0%"></td><td style="width:83.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance at December 31, 2023 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,365 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">Provision for rebates</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Payments/credits</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance at March 31, 2024</div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,145 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 18600000 2300000 Product revenue by therapy represents: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">ZYNTEGLO</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18,561 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,296 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total product revenue, net</div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,561 </td><td style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">2,296 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 18561000 0 0 2296000 18561000 2296000 1 1 The following table summarizes an analysis of the change in reserves for gross to net deductions for the periods indicated: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.187%"><tr><td style="width:1.0%"></td><td style="width:83.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance at December 31, 2023 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,365 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">Provision for rebates</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Payments/credits</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance at March 31, 2024</div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,145 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 5365000 3780000 0 9145000 Fair value measurements The following table sets forth the Company's assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Description </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Total </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Quoted prices in active markets (Level 1) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Significant other observable inputs (Level 2) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Significant unobservable inputs (Level 3) </td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid

#000000;padding:2px 1pt;text-align:left;vertical-align:bottom">March 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">212,047 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">212,047 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Marketable securities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">U.S. government agency securities and treasuries</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Due from factor: </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Beneficiary interest in factored invoices </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,120 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">213,167 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">212,047 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,120 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Marketable securities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">U.S. government agency securities and treasuries</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt">Receivables and other current assets:</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt">Beneficiary interest in factored invoices</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">560 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">222,315 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-

align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">560 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Cash and cash equivalents The Company considers all highly liquid securities with original final maturities of 90 days or less from the date of purchase to be cash equivalents. As of March 31, 2024 and December 31, 2023, cash and cash equivalents comprise funds in cash and money market accounts held at multiple banking and asset management institutions. Marketable securities Marketable securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities and treasuries, corporate bonds, and commercial paper. The Company estimates the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts. At March 31, 2024 and December 31, 2023, the balance in the Company's accumulated other comprehensive loss was composed primarily of activity related to the Company's available-for-sale debt securities. There were no and $0.1 million of realized losses recognized in the sale or maturity of available-for-sale debt securities during the three months ended March 31, 2024 and 2023, respectively. Accrued interest receivable on the Company's available-for-sale debt securities totaled $0.3 million and $0.3 million as of March 31, 2024 and December 31, 2023, respectively. No accrued interest receivable was written off during the three months ended March 31, 2024 or 2023.</div><div style="margin-top:12pt">Factoring agreement</div><div style="margin-top:12pt;text-indent:18pt">Due from factor classified as Level 3 within the valuation hierarchy consists of beneficiary interest in transferred invoices. The Company estimates the fair value of the beneficiary interest based on the estimated cash flows after applying counterparty and credit risk adjustments associated with the factoring agent and distributors, respectively. As of March 31, 2024, no adjustment to the beneficiary interest in invoices sold was deemed an unobservable input and was determined based from ongoing credit evaluations and historical experience with aging of such invoices, among other factors. A significant change to this input could result in a significantly lower or higher fair value measurement.</div><div style="margin-top:12pt;text-indent:18pt">The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the three months ended March 31, 2024: </div><div style="margin-top:12pt;text-align:center;text-indent:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:81.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.262%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended
March 31,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Level 3 financial assets, beginning of period</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">560 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Beneficiary interest obtained in transferred invoices</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,680 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Proceeds from previously transferred invoices</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,120)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Level 3 financial assets, end of period </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,120 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-top:6pt;text-indent:18pt">The following table sets forth the Company's assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands): </div><div style="margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Description</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Total</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Quoted</div><div style="text-align:center">prices in</div><div style="text-align:center">active</div><div style="text-align:center">markets</div><div style="text-align:center">(Level 1)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Significant</div><div style="text-align:center">other</div><div style="text-align:center">observable</div><div style="text-align:center">inputs</div><div style="text-align:center">(Level 2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Significant</div><div style="text-align:center">unobservable</div><div style="text-align:center">inputs</div><div style="text-align:center">(Level 3)</div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">March 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">212,047 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">212,047 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Marketable securities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">U.S. government agency securities and treasuries</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Due from factor: </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Beneficiary interest in factored invoices </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">1,120 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,120 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">213,167 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">212,047 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,120 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Marketable securities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">U.S. government agency securities and treasuries</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">560 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">222,315 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">221,755 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">560 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 212047000 212047000 0 0 0 0 0 0 1120000 0 0 1120000 213167000 212047000 0 1120000 221755000 221755000 0 0 0 0 0 0 560000 0 0 560000 222315000 221755000 0 560000 0 -100000 300000 300000 0 0 0 The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the three months ended March 31, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:81.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.262%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended
March 31,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Level 3 financial assets, beginning of period </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">560 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Beneficiary interest obtained in transferred invoices</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,680 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Proceeds from previously transferred invoices</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,120)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Level 3 financial assets, end of period</div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,120 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 560000 1680000 -1120000 1120000 Inventory Inventory, net, consists of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of March 31, 2024</td><td

colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,177 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,329 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Work in progress</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,146 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,375 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finished goods</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,982 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,215 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventory</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">30,305 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">22,919 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Raw materials inventory consists of completed materials purchased directly from third party suppliers. Work in progress inventory consists of materials manufactured at contract manufacturing organizations ("CMOs") that are either partially completed, fully manufactured but are pending quality acceptance, or completed meeting quality acceptance standards to be used in the manufacture of drug product and drug products that are either partially completed or fully manufactured but are pending quality acceptance. Finished goods are completed and quality approved drug products that are either awaiting shipment, in-transit or delivered to a qualified treatment center, but have not yet been infused in a patient. Inventory, net, consists of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of March 31, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,177 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,329 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Work in progress</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,146 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,375 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finished goods</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,982 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,215 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventory</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">30,305 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">22,919 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3177000 2329000 22146000 17375000 4982000 3215000 30305000 22919000 Factoring agreement The company sells rights to future revenues associated with invoices issued upon delivery of drug product to OTCs. The upfront payments are treated as a short-term liability, presented as due to factor on our consolidated balance sheets until the right to consideration from the customer is deemed unconditional. The remaining invoice amount payable to the Company at infusion is considered a beneficial interest in the factored invoice and represents the extent of our continued involvement in the sale of invoices.
 Due to Factor For the three months ending March 31, 2024, the Company collected $15.1 million in cash receipts prior to an unconditional right to consideration and derecognized $15.1 million of due to factor amounts as a result of patient drug product infusions. Amounts presented as due to factor on the consolidated balance sheets would be subject to payment based on the repurchase requirements that exist prior to the infusion date in the factoring agreement.
 Due from Factor For the three months ending March 31, 2024, the company obtained $1.6 million of beneficiary interest in invoices and collected $1.1 million in cash receipts. Uncollected amounts presented as due from factor on the consolidated balance sheets are net of accrued fees of $0.1 million. The maximum loss exposure is $1.1 million at March 31, 2024. The total loss from the sale of customer invoices is estimated on the patient infusion date of the drug product and was $0.3 million for the three months ending March 31, 2024. In addition to the loss from the sale of invoices the Company has incurred $0.4 million in servicing fees. 15100000 15100000 1600000 1100000 100000 1100000 -300000 400000 Accrued expenses and other current liabilities<div style="margin-top:6pt;text-indent:13.5pt">Accrued expenses and other current liabilities consist of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of March 31, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Accrued CMO and CRO costs</div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,401 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24,824 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued employee compensation </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,876 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,972 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued goods and services </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,453 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,391 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued rebates </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,194 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,365 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued professional fees </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,090 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,531 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued refund liability </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,600 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,002 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,505 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64,096 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73,188 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Accrued expenses and other current liabilities consist of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of March 31, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued CMO and CRO costs </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,401 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24,824 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued employee compensation </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,876 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,972 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued goods and services </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,453 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,391 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued rebates </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,194 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,365 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued professional fees </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,090 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,531 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued refund liability </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,600 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,002 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,505 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total accrued expenses and other current liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64,096 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73,188 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 22481000 24824000 10876000 19972000 5453000 8391000 9194000 5365000 7090000 2531000 0 5600000 9002000 6505000 64096000 73188000 Term loan debt 2024 Term Loan On March 15, 2024 (the "Effective Date"), the Company entered into a Loan and Security Agreement (the "LSA") and a Warrant Agreement (the "Warrant Agreement") with Hercules Capital and funds managed by Hercules Capital (collectively, "Hercules" or "the lenders"). Under the terms of the LSA, the Company may borrow up to an aggregate principal amount of $175.0 million over the term of the agreement, in four separate tranches (the "Term Loans") dependent on the achievement of certain milestones. On the Effective Date, the Company drew down the initial $75.0 million of gross proceeds ("Initial Loan"), and paid initial debt issuance costs of $3.5 million, inclusive of legal fees of approximately $2.7 million and the original issuance discount ("OID") of $0.0 million, or 1% of the drawn amount, in accordance with the terms of the LSA. Additional amounts are available to borrow in two separate $25.0 million tranches based on the Company meeting certain pre-defined milestone achievements associated with cell collection from LYFGENIA patients (35 patients on or before September 30, 2024 or 55 patients on or before December 31, 2024) ("Tranche 2") and compliance with a gross profit metric (no later than the period ending June 30, 2025) ("Tranche 3"). Additionally, the Company may request up to an additional $50.0 million through December 15, 2026 from Hercules ("Tranche 4"). The lenders have no obligation to fund any amounts under Tranche 4 as funding is conditioned on approval by the lenders' investment committee. The Term Loans bear both cash interest and paid-in-kind interest ("PIK"). The cash interest is due on the first business day of each month ("Payment Date") and will be equal to the WSJ prime rate ("prime rate") plus 1.45% (floored at 9.95%). The PIK interest is fixed at 2.45% and is to be capitalized and added to the outstanding principal on each Payment Date. Unless prepaid by the Company at their discretion, subject to certain prepayment penalties and conditions, the Term Loans are repayable in monthly interest-only payments until April 1, 2027, or April 1, 2028, if the Company has achieved, no later than December 31, 2026, certain financial metrics (the "Performance Milestone"). After the expiration of the interest-only payment period, the Term Loans are repayable in equal monthly payments of principal and accrued interest until maturity. The Term Loans will mature on April 1, 2029. The 2024 Term Loan is collateralized by substantially all the Company's assets. In addition to other covenants, the 2024 Term Loan contains affirmative covenants as well as certain financial covenants, including a minimum cash coverage requirement of 40% of the outstanding principal of the term loan and a minimum net product revenue requirement that commences with the quarter ending September 30, 2024. The Company was in compliance with the minimum cash coverage covenant as of March 31, 2024, but the Company projects that it will not maintain its minimum cash coverage requirement within the next 12 months (see the Company's going concern assessment in Note 1, Description of the business). As such, the term loan is presented as a current liability as of March 31, 2024. The Company also issued warrants under the Warrant Agreement for the right to purchase shares of the Company's common stock to Hercules, with the number of shares to be based on the amounts borrowed under the LSA (the "Warrants"). The Warrants are exercisable for a number of shares of common stock equal to the quotient of (i.) 5% times the aggregate original principal of amounts drawn under the LSA divided by (ii.) the exercise price of $1.45 per share. As of March 31, 2024, the Company had issued 2.6 million warrants associated with the Initial Loan ("Initial Warrants") to purchase common stock at an exercise price of $1.45 per share and a contractual life of 7 years from the Effective Date. The Warrants have been recorded at their relative fair value using the Black-Scholes option-pricing model and the following assumptions: no dividend yield, expected volatility of 81.1%, risk free rate of 4.3%, and expected term of 7 years, equal to the life of the warrant. The relative fair value allocated to the initial warrants was $2.7 million, which was classified as additional-paid-in-capital and recorded as a debt discount which will be amortized, together with debt issuance costs, to interest expense using the effective interest method over the life of the loan at an effective interest rate of 15.7%. For the period ended March 31, 2024, the Company recorded approximately $0.5 million in interest expense associated with the Term Loans, inclusive of amounts related to the Warrants. Refer to Note 16, Subsequent Events, for further discussion on the amendments to the LSA and the Warrant Agreement subsequent to the three months ended March 31, 2024. 175000000 4 75000000 3500000 2700000 800000 0.01 25000000 25000000 50000000 0.0145 0.0995 0.0245 0.40 0.05 1.45 2600000 1.45 P7Y 0 0 0.811 0.043 P7Y 2700000 0.157 500000 Leases The Company leases certain office and laboratory space, primarily located in Somerville, Massachusetts. Additionally, the Company has embedded leases through its agreements with CMOs and a contract testing organization ("CTO") in both the United States and internationally. Except as described below, there have been no material changes in lease obligations from those disclosed in Note 11 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K. Embedded leases Periodically, throughout the three months ended March 31, 2024, the Company amended several of its embedded contract manufacturing leases, some of which were accounted for as lease modifications under ASC 842. The lease modifications primarily relate to the execution of new statements of work with the vendors or the extension of contractual terms. As it relates to embedded leases related to drug product manufacturing and quality testing, the Company increased its finance lease right-of-use assets in the amount of $28.3 million. As it relates to embedded leases related to drug substance manufacturing, the Company decreased its finance lease right-of-use assets in the amount of $3.8 million. The following paragraphs describe the significant lease modifications to the Company's embedded contract manufacturing leases. Embedded Leases — Drug Substance Manufacturing In March 2024, the Company extended its embedded lease for the manufacturing of vector and is obligated under the defined production schedule through May 2024. Embedded Leases — Drug Product Manufacturing In January 2024, the Company amended its lease agreement with a CMO to expand into two additional controlled environment rooms, both designated for the Company's exclusive use during the term of the agreement. Pursuant to the amended agreement, the Company is obligated to pay a monthly fixed fee for each additional space in addition to fees based on committed production levels through the remaining lease term, which ends in February 2025. The fixed portion of the fee is included as part of the Company's lease liability. Embedded Leases — Quality Testing In January 2024, the Company entered into a Reserved Capacity Agreement with a CTO that provides clinical development services. The Reserved Capacity Agreement amended the Company's existing master contract services agreement with the CTO and provides for legally binding minimum purchase commitments with step decreases throughout its three-year contract term in six-month increments. The Company included the "firm" legally binding portion of the forecast through 2026 as part of its fixed minimum lease liability. Summary of all lease costs recognized under ASC 842 The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company's operating and finance leases for the three months ended March 31, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;display:inline-

<table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:68.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"> For the three months ended March 31, </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> (As Restated) </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Finance leases </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Interest expense </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">4,347 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">4,267 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Amortization expense </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">14,328 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5,216 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Total fixed finance lease cost </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">10,675 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">9,403 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Operating leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Fixed lease cost </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">9,486 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11,470 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Total fixed operating lease cost </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">9,486 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11,470 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Variable lease cost </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,043 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,062 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Short-term lease cost </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">76 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">52 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Total lease cost</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">34,200 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">27,867 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Operating sublease income </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">10,346 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">10,108 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Cash paid in the measurement of lease liabilities </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Operating cash flows used for operating leases </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,044 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,361 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Operating cash flows used for finance leases </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,411 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,352 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Financing cash flows for finance leases </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">22,210 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">15,280 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Other information </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Weighted average remaining lease term - finance leases </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">1.42 years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2.30 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Weighted average discount rate - finance leases </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">14.45 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">15.13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Weighted average remaining lease term - operating leases </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">6.75 years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">7.59 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Weighted average discount rate - operating leases </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">7.00 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">7.04 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr></table> As of March 31, 2024, future minimum commitments under ASC 842 under the Company's leases were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:67.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.499%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Operating Leases </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> <span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:0pt;font-weight:700;line-height:115%">Financing Leases </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Remaining Lease Payments</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Remainder of 2024 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">28,492 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">102,277 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2025</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">37,084 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">41,270 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">35,719 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3,422 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2027</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">36,742 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,548 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2028</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">37,795 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,043 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> 2029 and thereafter </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">81,986 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">257,810 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">150,560 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Less: Imputed Interest</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(52,772) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(10,259)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Present Value of Lease Liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">205,046 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">140,301 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> 28300000 - 3800000 2 P3Y P6M The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company's operating and finance leases for the three months ended March 31, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:68.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"> For the three months ended March 31, </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> (As Restated) </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Finance leases </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Interest expense </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">4,347 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">4,267 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Amortization expense </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">14,328 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5,216 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Total fixed finance lease cost </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">18,675 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">9,403 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Operating leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Fixed lease cost </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">9,486 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11,470 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Total fixed operating lease cost </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">9,486 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11,470 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Variable lease cost </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,043 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,862 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Short-term lease cost </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">76 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">52 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Total lease cost</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">34,280 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">27,867 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Operating sublease income </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:1pt

</td><td style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Cash paid in the measurement of lease liabilities </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Operating cash flows used for operating leases </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,044 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,361 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Operating cash flows used for finance leases </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,411 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,352 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Financing cash flows for finance leases </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">22,210 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">15,280 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Other information </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Weighted average remaining lease term - finance leases </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"> 1.42 years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2.30 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Weighted average discount rate - finance leases </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">14.45 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">15.13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Weighted average remaining lease term - operating leases </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"> 6.75 years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">7.59 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Weighted average discount rate - operating leases </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">7.00 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">7.04 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr></table> 4347000 4267000 14328000 5216000 18675000 9483000 9486000 11470000 9486000 11470000 6043000 6862000 76000 52000 34280000 27867000 10346000 10180000 2844000 6361000 1411000 3352000 22210000 15280000 P1Y5M1D P2Y3M10D 0.1445 0.1513 P6Y9M P7Y7M2D 0.0700 0.0704 As of March 31, 2024, future minimum commitments under ASC 842 under the Company's leases were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:67.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.499%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Operating Leases </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> Financing Leases </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Remaining Lease Payments</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Remainder of 2024 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">28,492 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">102,277 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2025</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">37,084 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">41,270 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">35,719 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3,422 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2027</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">36,742 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,548 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2028</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">37,795 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,043 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> 2029 and thereafter </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">81,986 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">257,818 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">150,560 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Less: Imputed Interest</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(52,772) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(10,259)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Present Value of Lease Liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">205,046 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">140,301 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> As of March 31, 2024, future minimum commitments under ASC 842 under the Company's leases were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:67.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.499%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Operating Leases </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> Financing Leases </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Remaining Lease Payments</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Remainder of 2024 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">28,492 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102,277 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2025</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">37,004 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">41,270 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">35,719 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3,422 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2027</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">36,742 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2,548 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2028</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">37,795 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,043 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> 2029 and thereafter </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">81,986 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">257,818 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">150,560 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Less: Imputed Interest</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(52,772) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(10,259)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Present Value of Lease Liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">205,046 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">140,301 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> 28492000 102277000 37084000 41270000 35719000 3422000 36742000 2548000 37795000 1043000 81986000 0 257818000 150560000 52772000 10259000 205046000 140301000 Commitments and contingencies Lease commitments The Company leases certain office and laboratory space and has embedded leases at CMOs and a CTO. As of March 31, 2024, the Company has commitments arising from a forward starting lease that had not yet commenced related to an embedded equipment lease with a CMO. This lease is expected to commence in 2025 with an initial lease term of three years. Fixed commitments under this contract approximate $56.8 million. The following table presents the non-cancelable contractual obligations arising from this arrangement as of the three months ended March 31, 2024 (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center">Future</div><div style="text-align:center">commitment</div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Remainder of 2024</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> 2025 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,763 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> 2026 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,858 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> 2027 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,858 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> 2028 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,310 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> 2029 and thereafter </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Total purchase commitments </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">56,789 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-indent:10pt">Refer to Note 9, Leases, for further information on the terms of these lease agreements.</div><div style="margin-top:12pt">Litigation</div><div style="margin-top:12pt;text-indent:10pt">From time to time, the Company is party to various claims and complaints arising in the ordinary course of business, including securities class action litigation and intellectual property litigation. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company's business partners. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is generally unlimited. Accruals for loss contingencies are recognized when a loss is probable, and the amount of such loss can be reasonably estimated. The Company has not accrued for a loss for any matter described below as a loss is not probable and a loss, or a range of loss, is not reasonably estimable.</div><div style="margin-top:12pt;text-indent:10pt">The Company also indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and by-laws. The term of the indemnification period lasts as long as such officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations.</div><div style="margin-top:12pt;text-indent:10pt">There have been no material changes in claims and complaints from those disclosed in Note 12 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K.</div> P3Y 56800000 The following table presents the non-cancelable contractual obligations arising from this arrangement as of the three months ended March 31, 2024 (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center">Future</div><div style="text-align:center">commitment</div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Remainder of 2024</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,858 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>2027</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,310 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>2028</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,310 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>2029 and thereafter</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Total purchase commitments</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">56,789 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> The Company also indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and by-laws. The term of the indemnification period lasts as long as such officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations. There have been no material changes in claims and complaints from those disclosed in Note 12 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K. P3Y 56800000 The following table presents the non-cancelable contractual obligations arising from this arrangement as of the three months ended March 31, 2024 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Future commitment </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Remainder of 2024 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,858 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> 2027 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,310 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> 2028 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,310 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"

style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> 2029 and thereafter </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Total purchase commitments </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">56,709 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> 0 13763000 17858000 17858000 7310000 0 56709000 Equity On January 18, 2023, the Company entered into an underwriting agreement (the "January Underwriting Agreement") with Goldman and J.P. Morgan Securities LLC in connection with the public offering, issuance, and sale by the Company of 20.0 million shares of the Company's common stock at a public offering price of $6.00 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 and a related prospectus supplement filed with the Securities and Exchange Commission. Under the terms of the January Underwriting Agreement, the Company also granted the underwriters an option exercisable for 30 days to purchase up to an additional 3.0 million shares of common stock at the public offering price, less underwriting discounts and commissions, which the underwriters exercised in full. The offering closed on January 23, 2023. The Company received aggregate net proceeds of $130.5 million. In August 2023, the Company entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Company's common stock up to $125.0 million, from time to time, through an "at the market" equity offering program under which Jefferies will act as sales agent. As of March 31, 2024, the Company has made no sales pursuant to the Sales Agreement. On December 19, 2023, the Company entered into an underwriting agreement (the "December Underwriting Agreement") with Goldman and J.P. Morgan Securities LLC, in connection with the public offering, issuance, and sale by the Company of 83.3 million shares of the Company's common stock at a public offering price of $1.50 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 and a related prospectus supplement filed with the Securities and Exchange Commission. Under the terms of the December Underwriting Agreement, the Company also granted the underwriters an option exercisable for 30 days to purchase up to an additional 12.5 million shares of common stock at the public offering price, less underwriting discounts and commissions, which option was not exercised. The offering closed on December 22, 2023. The Company received aggregate net proceeds of $118.1 million. 20000000 6.00 P30D 3000000 130500000 125000000 83300000 1.50 P30D 12500000 118100000 Stock-based compensation In June 2023, the Company's stockholders approved the bluebird bio, Inc. 2023 Incentive Award Plan (the "2023 Plan"), which replaced the 2013 Stock Option and Incentive Plan ("2013 Plan"). Following approval of the 2023 Plan, no further awards will be granted under the 2013 Plan. As of March 31, 2024, the total number of shares of common stock available for issuance under the 2023 Plan was approximately 2.1 million. Stock-based compensation expense The Company recognized stock-based compensation expense totaling $3.8 million and $5.4 million during the three months ended March 31, 2024 and 2023, respectively. Stock-based compensation expense recognized by award type is included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):</div><div style="margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:63.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.961%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div>
</div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,230 </td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,723 </td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted stock units</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,451 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,668 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock purchase plan and other</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,761 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,391 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt">Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands): </div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:63.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.961%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended March 31,</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of product revenue</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">491 </td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103 </td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Selling, general and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,335 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,361 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">935 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,927 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,761 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,391 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table> During the three months ended March 31, 2024 and 2023, the Company had $0.3 million and $0.5 million of stock compensation expense that was capitalized into inventory. </div><div style="margin-top:12pt">Stock options</div><div style="margin-top:12pt;text-indent:18pt">The following table summarizes the stock option activity under the Company's equity award plans excluding awards held by employees of 2seventy bio:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Shares</div><div style="text-align:center">(in thousands)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Weighted-</div><div style="text-align:center">average</div><div style="text-align:center">exercise price</div><div style="text-align:center">per share</div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at December 31, 2023</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,227 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14.16 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,572 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1.56 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td>

<td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"> </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Canceled, forfeited, or expired</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(229)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">16.55 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at March 31, 2024</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,570 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.16 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable at March 31, 2024</td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,871 </td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">22.75 </td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested and expected to vest at March 31, 2024</td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,570 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.16 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:10pt">During the three months ended March 31, 2024, no stock options were exercised.</div><div style="margin-top:12pt">Restricted stock units</div><div style="margin-top:12pt;text-indent:10pt">The following table summarizes the restricted stock unit activity under the Company’s equity award plans excluding awards held by employees of 2seventy bio:</div><div style="margin-top:6pt;text-indent:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:71.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Shares
(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
average
grant date
fair value</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at December 31, 2023</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,207 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6.08 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,177 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1.56 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(785)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">7.14 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(205)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4.41 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at March 31, 2024</td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,394 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.16 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Employee stock purchase plan In June 2013, the Company’s board of directors adopted its 2013 Employee Stock Purchase Plan (“2013 ESPP”), which authorized the initial issuance of up to a total of 0.2 million shares of the Company’s common stock to participating employees. In June 2021, the Company amended the 2013 ESPP to authorize an additional 1.4 million shares of the Company’s common stock available to participating employees. During each of the three months ended March 31, 2024 and 2023, no shares and less than 0.1 million shares, respectively, of common stock were issued under the 2013 ESPP. 2100000 3800000 5400000 Stock-based compensation expense recognized by award type is included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:63.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.961%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt">
 </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,230 </td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,723 </td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted stock units</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,451 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,660 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock purchase plan and other</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,761 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,391 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table> 1230000 1723000 2451000 3668000 80000 0 3761000 5391000 Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:63.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.961%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of product revenue</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">491 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,335 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,361 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">935 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,927 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,761 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,391 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table> 491000 103000 2335000 2361000 935000 2927000 3761000 5391000 300000 500000 The following table summarizes the stock option activity under the Company's equity award plans excluding awards held by employees of 2seventy bio:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Shares (in thousands) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Weighted- average exercise price per share </td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at December 31, 2023</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,227 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14.16 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,572 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1.56 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"> </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Canceled, forfeited, or expired</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(229)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">16.55 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at March 31, 2024</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,570 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.16 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable at March 31, 2024</td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,871 </td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">22.75 </td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested and expected to vest at March 31, 2024</td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,570 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.16 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4227000 14.16 2572000 1.56 0 0 229000 16.55 6570000 9.16 1871000 22.75 6570000 9.16 0 <div style="margin-top:12pt;text-indent:18pt">The following table summarizes the restricted stock unit activity under the Company's equity award plans excluding awards held by employees of 2seventy bio:</div><div style="margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:71.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Shares
(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-
average
grant date
fair value</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at December 31, 2023</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,207 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6.08 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,177 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1.56 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(705)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">7.14 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(205)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4.41 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at March 31, 2024</td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,394 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.16 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 4207000 6.08 2177000 1.56 785000 7.14 205000 4.41 5394000 4.16 200000 1400000 0 100000 Income taxes Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company's otherwise recognizable net deferred tax assets. The tax benefit recognized during the three months ended March 31, 2024 was $0.0 million due to the full valuation allowance. 0 Net loss per share The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:81.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.262%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended
March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-

color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Outstanding stock options(1) </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,903 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Restricted stock units(1) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,449 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Warrants </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,586 </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ESPP shares and other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,022 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other Revenues </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> (1) Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.
 Net loss per share for the three months ended March 31, 2024 was $0.36. During the three months ended March 31, 2023, the Company had net income of $10.9 million. Basic weighted-average common shares outstanding were 102.9 million, the effect of dilutive securities was 0.4 million, and diluted weighted-average common shares outstanding were 103.3 million. Basic earnings per share and diluted earnings per share were both $0.10. </div> <div style="margin-top:6pt;text-indent:18pt">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):</div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:81.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.262%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended
March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Outstanding stock options(1)</div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,903 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Restricted stock units(1)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,449 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Warrants</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,586 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ESPP shares and other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,022 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt">(1) Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.</div> 7903000 5449000 2586000 84000 16022000 -0.36 -0.36 10900000 102900000 400000 103300000 0.18 0.18 Restatement of Previously Issued Financial Statements<div style="text-indent:18pt">As further described below, as well as in Note 2 - Basis of Presentation, the Company identified several prior period misstatements that impacted its unaudited quarterly condensed consolidated financial statements for the quarter ended March 31, 2023. Such restated and unaudited quarterly financial data and the related impacted amounts were presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">As part of the restatement, the Company recorded adjustments to correct the material misstatements related to accounting for embedded leases and other immaterial errors. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">The following tables present the restated unaudited Condensed Consolidated Financial Information for the quarter ended March 31, 2023.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">
</div><div>Consolidated Statements of Operations and Comprehensive Loss</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">For the three months ended March 31, 2023</div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">As Previously Reported</div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Adjustments to Embedded Leases</div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other Adjustments</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">As Restated</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt">Product revenue, net</div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,296 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,296 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other revenue</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,381 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,381 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cost of product revenues</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,376 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,136 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,512 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Gross margin</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-

align:bottom">(995)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,136)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,131)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating expenses:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,144 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,516)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(41)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,587 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Selling, general and administrative</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37,354 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37,467 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total operating expenses</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83,498 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,403)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(41)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79,054 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Gain from sale of priority review voucher, net</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,930 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,930 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Income from operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,437 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,267 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,745 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Interest income </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,828 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,828 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Interest expense </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,267)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,270)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other income, net </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,978 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(351)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,627 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Income before income taxes </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,240 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,351)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,930 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Income tax (expense) benefit</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net income </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,240 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,351)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,930 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net income per share - basic (1) </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">0.21 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.02)</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">0.18 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net income per share - diluted (1) </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

<table><tr><td style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.21 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.02)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Weighted-average number of common shares used in computing net income per share - basic </td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102,920 </td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"

— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(195)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Exercise of stock options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Purchase of shares under ESPP</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">226 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">227 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"> Issuance of common stock for private equity placement </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">230 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,061 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,291 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Issuance of unrestricted stock awards to settle accrued employee compensation </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Other comprehensive income </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">984 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Net income </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,240 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,240 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at March 31, 2023 </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106,370 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,064 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,322,025 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,006)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,965,263)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">354,740 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Adjustments to Embedded Leases

</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at December 31, 2022 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(59,700)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(59,700)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Vesting of restricted stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Exercise of stock options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Purchase of shares under ESPP</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Issuance of common stock for private equity placement </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Issuance of unrestricted stock awards to settle accrued employee compensation </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Other comprehensive income </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Net income </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-

weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,351)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,351)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at March 31, 2023 </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0

align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Other comprehensive income </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Net income </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at March 31, 2023 </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(98)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> As Restated </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at December 31, 2022 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,923 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">830 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,185,988 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,070)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,048,415)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134,333 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Vesting of restricted stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(190)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(195)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Exercise of stock options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"><tr><td style="width:1.0%"></td><td style="width:30.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Purchase of shares under ESPP</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">226 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">227 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div

style="padding-left:6pt">Issuance of common stock for private equity placement </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">230 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,061 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,291 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Issuance of unrestricted stock awards to settle accrued employee compensation </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Other comprehensive income </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">984 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">984 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"> Net income </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,930 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,930 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at March 31, 2023 </td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106,370 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,064 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,321,927 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,086)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(4,029,485)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">290,420 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt">Consolidated Statement of Cash Flows<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:51.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">For the three months ended March 31,</div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2023</div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">As Previously Reported</div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Adjustments to Embedded Leases</div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other Adjustments</td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">As Restated</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flows from operating activities:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Net income </div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">21,240 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(2,351)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">18,930 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Adjustments to reconcile net income to net cash used in operating activities: </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,082 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,131 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-

25.75pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,715 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,000)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(85)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net cash used in operating activities </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(86,638)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,280 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(71,358)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flows from investing activities:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Purchase of property, plant and equipment</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(232)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(232)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Purchases of marketable securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19,610)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19,610)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Proceeds from maturities of marketable securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,021 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,021 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Proceeds from sales of marketable securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,853 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,853 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Purchase of intangible assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(868)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(868)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Proceeds from sale of priority review voucher</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,972 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,972 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net cash provided by investing activities </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,136 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,136 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flows from financing activities:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Proceeds from exercise of stock options and ESPP contributions</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Proceeds from vesting of restricted stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(196)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(196)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Principal payments on finance lease</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,280)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,280)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Proceeds from the secondary public offering, net of issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,645 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,645 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net cash provided by financing activities </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,456 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,280)</td><td

<table>
<tr><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">115,176 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Increase in cash, cash equivalents and restricted cash </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,954 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,954 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash, cash equivalents and restricted cash at beginning of year</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">158,445 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">158,445 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash, cash equivalents and restricted cash at end of year</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">284,399 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">284,399 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Reconciliation of cash, cash equivalents and restricted cash:</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">239,045 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">239,045 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash included in receivables and other current assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,417 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,417 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash included in restricted cash and other non-current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,937 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,937 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom">Total cash, cash equivalents and restricted cash</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">284,399 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">284,399 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Supplemental cash flow disclosures:</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Purchases of property, plant and equipment included in accounts
  payable and accrued expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Offering expenses included in accounts payable and accrued expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">523 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">523 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Priority review voucher expenses accrued or in AP</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Right-of-use assets obtained in exchange for finance lease liabilities </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">214</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">214</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
</table>

weight:400;line-height:100%">Cash paid during the period for income taxes </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">— </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following tables present the restated unaudited Condensed Consolidated Financial Information for the quarter ended March 31, 2023.

 Consolidated Statements of Operations and Comprehensive Loss <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> For the three months ended March 31, 2023 </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> As Previously Reported </td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Adjustments to Embedded Leases </td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other Adjustments</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">As Restated</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Product revenue, net </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,296 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,296 </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other revenue</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,381 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cost of product revenue</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,376 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,136 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,512 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Gross margin</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(995)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,136)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,131)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating expenses:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,144 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,516)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(41)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,587 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Selling, general and administrative</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37,354 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37,467 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total operating expenses</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83,498 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,403)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(41)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79,054 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Gain from sale of priority review voucher, net</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,930 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,930 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Income from operations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,437 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,267 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,745 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Interest income </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,828 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,351)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">19,914 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
 (1) Due to differences in rounding to the nearest cent per basic or diluted share, totals may not equal the sum of the line items. Statements of Changes in Stockholders' Equity <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:30.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Additional
paid-in
capital</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Accumulated other comprehensive (loss) income </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
deficit</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total
stockholders'
equity</td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Shares</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> As Previously Reported </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at December 31, 2022 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,923 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">830 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,186,086 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(4,070)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,986,503)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">196,343 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Vesting of restricted stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(190)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Exercise of stock options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Purchase of shares under ESPP</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">226 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">227 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Issuance of common stock for private equity placement </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">230 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,061 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,291 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Issuance of unrestricted stock awards to settle accrued employee compensation </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-

</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Other comprehensive income </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">984 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Net income </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,240 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at March 31, 2023 </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106,370 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,064 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,322,025 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,086)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,965,263)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">354,740 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Adjustments to Embedded Leases</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balances at December 31, 2022</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(59,700)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(59,700)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Vesting of restricted stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Exercise of stock options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Purchase of shares under ESPP</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Issuance of common stock for private equity placement </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"

</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at December 31, 2022 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,923 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">830 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,185,980 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,070)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,048,415)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134,333 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Vesting of restricted stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">382 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(195)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Exercise of stock options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.83%"><tr><td style="width:1.0%"></td><td style="width:30.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Purchase of shares under ESPP</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">226 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">227 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Issuance of common stock for private equity placement </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">230 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,061 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,291 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Issuance of unrestricted stock awards to settle accrued employee compensation </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> Other comprehensive income </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">984 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">984 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Net income </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,930 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,930 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balances at March 31, 2023 </td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106,370 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,064 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,321,927 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,086</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,029,485)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">290,420 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt">Consolidated Statement of Cash Flows<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.1%"></td><td style="width:51.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">For the three months ended March 31,</div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2023</div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">As Previously Reported</div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Adjustments to Embedded Leases</div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other Adjustments</td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">As Restated</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flows from operating activities:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Net income </div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">21,240 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(2,351)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10,930 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Adjustments to reconcile net income to net cash used in operating activities: </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,082 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,131 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(41)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,172 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Stock-based compensation expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,391 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,391 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Noncash research and development expense (finance lease)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,441 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,441 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Noncash operating lease expense </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,423 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,423 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Gain from sale of priority review voucher</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(92,930)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(92,930)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Excess inventory reserve</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,355 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,503 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Other non-cash items</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Gain on foreign currency exchange rates </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(108)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(108)
</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px
12.25pt;text-align:left;vertical-align:bottom">Changes in operating assets and
liabilities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px
25.75pt;text-align:left;vertical-align:bottom">Prepaid expenses and other
assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:8pt;font-weight:400;line-height:100%">(9,335)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-
height:100%">2,046 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0
2px 1pt;text-align:right;vertical-align:bottom">2,800 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">(3,689)</td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px
1pt;text-align:right;vertical-align:bottom">(3,586)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">610 </td><td style="background-color:#ffffff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,355)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:8pt;font-weight:400;line-height:100%">(5,331)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td
colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">Operating right of use assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,829 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,029)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px
25.75pt;text-align:left;vertical-align:bottom">Accounts payable</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">(6,443)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-
height:100%">7,703 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0
2px 1pt;text-align:right;vertical-align:bottom">— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">1,260 </td><td style="background-color:#ffffff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
(9,065)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom">1,859 </td><td style="background-
color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,206)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> <span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest payable under finance lease </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px
1pt;text-align:right;vertical-align:bottom">— </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">915 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">915 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-
height:100%">Operating lease liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,001)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:8pt;font-weight:400;line-height:100%">1,640 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-
height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px
1pt;text-align:right;vertical-align:bottom">(6,361)</td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px
25.75pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">2,715 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom">(2,800)</td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> <span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities </td><td colspan="2"
style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:8pt;font-weight:400;line-height:100%">(86,638)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:8pt;font-weight:400;line-height:100%">15,280 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71,358)</td><td style="background-color:#cceeff;border-top:1pt solid
#000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</td><td colspan="3" style="background-
color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">Purchase of property, plant and equipment</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(232)
</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-
height:100%">Purchases of marketable securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,610)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
(19,610)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt
2px 7.75pt;text-align:left;vertical-align:bottom">Proceeds from maturities of
marketable securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,021 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom">4,021 </td><td style="background-
color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-
align:bottom">Proceeds from sales of marketable securities</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%">5,853 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom">— </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,853 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of intangible assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px
1pt;text-align:right;vertical-align:bottom">(868)</td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt

2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(868)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Proceeds from sale of priority review voucher</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,972 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,972 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net cash provided by investing activities </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,136 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,136 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flows from financing activities:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Proceeds from exercise of stock options and ESPP contributions</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Proceeds from vesting of restricted stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(196)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(196)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Principal payments on finance lease</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,280)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,280)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Proceeds from the secondary public offering, net of issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,645 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,645 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net cash provided by financing activities </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130,456 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,280)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">115,176 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Increase in cash, cash equivalents and restricted cash </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,954 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,954 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash, cash equivalents and restricted cash at beginning of year</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150,445 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150,445 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash, cash equivalents and restricted cash at end of year</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">284,399 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">239,045 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">239,045 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash included in receivables and other current assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,417 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,417 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash included in restricted cash and other non-current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,937 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,937 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom">Total cash, cash equivalents and restricted cash</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">204,399 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">284,399 </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Supplemental cash flow disclosures:</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Purchases of property, plant and equipment included in accounts
  payable and accrued expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Offering expenses included in accounts payable and accrued expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">523 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">523 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Priority review voucher expenses accrued or in AP</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Right-of-use assets obtained in exchange for finance lease liabilities </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(214)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(214)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cash paid during the period for income taxes </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2296000 0 0 2296000 85000 0 0 85000 2301000 0 0 2301000 3376000 2136000 0 5512000 -995000 -2136000 0 -3131000 46144000 -4516000 -41000 41587000 37354000 113000 0 37467000 83498000 -4403000 -41000 79054000 92930000 0 0 92930000 8437000 2267000 41000 10745000 2828000 0 0 2828000 3000 4267000 0 4270000 9978000 -351000 0 9627000 21240000 -2351000 41000 18930000 0 0 0 0 21240000 -2351000 41000 18930000 0.21 -0.02 0 0.18 0.21 -0.02 0 0.18 102920000 102920000 102920000 102920000 103303000 103303000 103303000 103303000 0 984000 0 0 984000 984000 0 0 984000 22224000 -2351000 41000 19914000 82923000 830000 4186086000 -4070000 -3986503000 196343000 382000 3000 -198000 -195000 3000 7000 7000 62000 1000 226000 227000 23000000 230000 130061000 130291000 5843000 5843000 984000 984000 21240000 21240000 106370000 1064000 4322025000 -3086000 -3965263000 354740000 0 0 0 0 -59700000 -59700000 -2351000 -2351000 0 0 0 0 -62051000 -62051000 0 0 -98000 0 -2212000 -2310000 41000 41000 0 0 -98000 0 -2171000 -2269000 82923000 830000 4105988000 -4070000 -4048415000 134333000 382000 3000 -198000 -195000 3000 7000 7000 62000 1000 226000 227000 23000000 230000 130061000 130291000 5843000 5843000 984000 984000 18930000 18930000 106370000 1064000 4321927000 -3086000 -4029485000 29042000 21240000 -2351000 41000 18930000 1082000 5131000 -41000 6172000 5391000 0 0 5391000 0 1441000 0 1441000 0 7423000 0 7423000 92930000 0 0 92930000 228000 0 2355000 2583000 -237000 0 0 -237000 0 108000 0 108000 9335000 -2846000 -2800000 3689000 3586000 -610000 2355000 5331000 11829000 -11829000 0 0 -6443000 7703000 0 1260000 -9065000 1859000 0 -7206000 0 -915000 0 -915000 -8001000 1640000 0 -6361000 2715000 0 -2800000 -85000 -86638000 15280000 0 -71358000 232000 0 0 232000 19610000 0 0 19610000 4021000 0 0 4021000 5853000 0 0 5853000 868000 0 0 868000 92972000 0 0 92972000 82136000 0 0 82136000 7000 0 0 7000 -196000 0 0 -196000 0 15280000 0 15280000 130645000 0 0 130645000 130456000 -15280000 0 115176000 125954000 0 0 125954000 158445000 0 0 158445000 284399000 0 0 284399000 239045000 0 0 239045000 1417000 0 0 1417000 43937000 0 0 43937000 284399000 0 0 284399000 189000 0 0 189000 523000 0 0 523000 43000 0 0 43000 0 -214000 0 -214000 2000 0 0 2000 Subsequent events Term Loan Debt As previously disclosed in Note 8, Term loan debt, on March 15, 2024, the Company entered into a five-year term loan facility agreement with Hercules Capital, Inc. ("Hercules") to secure debt financing for up to $175 million, available in four tranches. The first tranche in an amount equal to $75 million was drawn at the time of closing (the "Initial Loan"). The Company may draw upon two additional tranches of $25 million each, subject to satisfaction of certain conditions, including achievement of commercial milestones. The facility also provides a fourth tranche of $50 million, available at the sole discretion of Hercules, until December 15, 2026. The Loan and Security Agreement ("LSA") requires the Company to comply with customary affirmative and negative covenants, including, among other things, a requirement to deliver annual financial statements within 90 days of each fiscal year and quarterly financial statements within 45 days of each fiscal quarter. A failure to comply with these covenants, or failure to obtain a waiver for any non-compliance, would result in an event of default under the LSA and would allow Hercules to accelerate repayment of the debt, which could materially and adversely affect the business, results of operations and financial condition of the Company. On April 30, 2024, July 9, 2024, August 13, 2024, and August 29, 2024 the Company and Hercules entered into amendments to the LSA providing for revised monthly financial reporting metrics for each month through September 30, 2024 and extension of the deadlines by which the Company must provide certain annual and quarterly financial statements. On August 13, 2024, the Company and Hercules entered into a third amendment to the LSA (the "Third Amendment"), pursuant to which the parties agreed to, among other things, revised terms for the availability of the second and third tranches of funding under the LSA. In accordance with the Third Amendment, the Company may draw the second tranche of $25.0 million during the period commencing on the date the Company has (x) received at least $75.0 million in gross cash proceeds from qualified financing transactions by December 20, 2024 and (y) completed patient starts (cell collections) for at least 50 LYFGENIA patients by March 31, 2025 or 70 LYFGENIA patients by June 30, 2025 (collectively, the "Tranche 2 Milestone") and ending on the earlier of (i) the date that is 30 days immediately following achievement of the Tranche 2 Milestone and (ii) July 31, 2025. The Company may draw the third tranche of $25.0 million during the period commencing on the date the Company has (x) received at least $100.0 million in gross cash proceeds from qualified financing transactions by December 20, 2024 or at least $125.0 million by June 30, 2025 and (y) completed 70 drug product deliveries within a given six-month period ending no later than December 31, 2025, at least 40 of which are for LYFGENIA (collectively, the "Tranche 3 Milestone") and ending on the earlier of (i) the date that is 30 days immediately following the date the Company achieves the Tranche 3 Milestone and (ii) December 31, 2025. Additionally, the Company and Hercules agreed to increase the minimum cash coverage requirement from 40% to 45% of the outstanding principal of the term loan. Additionally, in connection with entry into the LSA, the Company issued to the lenders warrants to purchase that number of shares of the Company's common stock equal to five percent of the Initial Loan, or $3.75 million, divided by the volume-weighted average price ("VWAP") of the Company's common stock for the ten-day period preceding March 15, 2024 (the "Initial Warrants"). The Company agreed to issue additional common stock warrants to the lenders at the closings of future tranches of funding under the LSA, if any, to purchase that number of shares of common stock equal to five percent of the applicable loan divided by the VWAP of the Company's common stock for the ten-day period preceding March 15, 2024 (together with the Initial Warrants, the "Warrants"). On August 13, 2024, in connection with the Third Amendment, the Company agreed to amend the exercise price of the Warrants to purchase shares of the Company's common stock from $1.45 per share to the lesser of the VWAP of the Company's common stock for the ten-day period preceding August 13, 2024, and the price per share of the Company's first equity financing event within six months of August 13, 2024. The amendment does not impact the number of shares the lenders may purchase pursuant to the Warrants. P5Y 175000000 4 75000000 2 25000000 25000000 50000000 P90D P45D 25000000 75000000 P30D 25000000 100000000 125000000 P6M P30D 0.40 0.45 0.05 3750000 P10D 0.05 P10D 1.45 P10D false false false false

"